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Abstract 
 Cysteine residues are known to perform an array of functional roles in proteins, 
including nucleophilic and redox catalysis, regulation, metal binding, and structural 
stabilization, on proteins across diverse functional classes. These functional cysteine 
residues often display hyperreactivity, and electrophilic chemical probes can be utilized 
to modify reactive cysteines and modulate their protein functions. A particular focus was 
placed on three peptide-based cysteine-reactive chemical probes (NJP2, NJP14. and 
NJP15) and their particular biological applications. NJP2 was discovered to be an 
apoptotic cell-selective inhibitor of glutathione S-transferase omega 1 and shows 
additional utility as an imaging agent of apoptosis. NJP14 aided in the development of a 
chemical-proteomic platform to detect Zn2+-cysteine complexes. This platform identified 
both known and unknown Zn2+-cysteine complexes across diverse protein classes and 
should serve as a valuable complement to existing methods to characterize functional 
Zn2+-cysteine complexes. Finally, NJP15 was part of a panel of site-selective cysteine-
reactive inhibitors of protein disulfide isomerase A1 (PDIA1). These inhibitors show 
promise in clarifying the unique and redundant properties of PDIA1’s dual active-sites, as 
well as interrogating the protein’s role in cancer. Together, these case studies illustrate 
the potential of cysteine-reactive chemical probes to modulate protein activities, 
interrogate biological systems, and aid in the development of powerful therapeutic drugs.  
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Chapter 1 
Introduction 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A significant portion of the work described in this chapter has been published in: 
 
Pace, N. J.; Weerapana, E. Diverse Functional Roles of Reactive Cysteines. ACS Chem. 
Biol. 2013, 8, 283-296.  
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This thesis focuses on the continued annotation and characterization of 
functionally important cysteine residues. Cysteine residues are known to contribute to 
protein structure, catalysis, redox activity, regulation, and metal binding. Increased 
cysteine reactivity has been found to correlate with functionality; consequently, 
experimental approaches have been designed to detect these hyperreactive cysteines.1  
These methods typically rely on chemical probes possessing a cysteine-reactive 
electrophile to covalently bind nucleophilic (reactive) cysteines within the proteome for 
enrichment and subsequent identification by mass spectrometry. Cysteine-reactive probes 
have been designed to target diverse cysteine-mediated protein activities including 
proteases, kinases and oxidoreductases.2 We sought to exploit the inherent diversity of 
peptide-based scaffolds to expand the protein classes amenable to covalent modification 
using cysteine-reactive probes. Herein, we provide a detailed account of three cysteine-
reactive peptide-based probes (NJP2, NJP14 and NJP15) as tools to study different 
biological applications.    
 This thesis is divided into four chapters. Chapter 1 introduces the relevant roles of 
functional cysteines within proteins and provides classical examples of each. The 
remaining three chapters concentrate on individual probes that modulate a particular 
cysteine function and their biological consequences.  Chapter 2 focuses on NJP2 and its 
application as an apoptotic cell-selective inhibitor of a catalytic cysteine within 
glutathione S-transferase omega 1 (GSTO1). Chapter 3 centers on NJP14 and the 
development of a chemical proteomic technology to identify cysteines with high affinity 
for Zn2+ within a complex proteome. Finally, Chapter 4 details a panel of cysteine-
reactive inhibitors, including NJP15, selective for the redox-catalytic cysteines within 
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protein disulfide isomerase (PDIA1) to interrogate the role of this protein in cancer 
progression.  
  
Cellular roles of reactive cysteines 
Although cysteine is one of the least abundant amino acids incorporated into 
proteins (1.9% abundance), it concentrates at functionally important locations within 
protein scaffolds.3, 4 Cysteine was a late evolutionary addition to the genetic code but has 
since accrued at a high frequency, hinting at the preferential incorporation of cysteines at 
functional loci.5 Additionally, mutations of cysteine residues contribute to genetic 
diseases significantly more than mutations to any other amino acid.6  
Cysteine residues possess unique physiochemical properties that allow them to 
facilitate diverse protein functions. Importantly, cysteine is the only amino acid that 
contains a thiol functional group. The large atomic radius of sulfur and the low 
dissociation energy of the S-H bond allow cysteine to perform both nucleophilic and 
redox-active functions that are unfeasible for other natural amino acids. The pKa of the 
thiol group of cysteine (~8.0) is typically close to physiological pH (7.4) for a solvent 
exposed residue (Figure 1-1).7 However, the ionization state is highly sensitive to slight 
changes within the local protein microenvironment, and in extreme cases, the pKa of a 
specific cysteine thiol can drop as low as 2.0.8  
 
Figure 1-1. The thiol group of cysteine is readily ionized to a thiolate anion.  
 
4 
 
As a result, the thiol ionization state governs cysteine nucleophilicity and redox 
susceptibility, thereby facilitating the unique functions of cysteine: nucleophilic and 
redox catalysis, regulation, metal binding, and structural stabilization, on proteins across 
diverse functional classes (Figure 1-2).9, 10 The proteins that are discussed in Chapters 2 - 
4 contain cysteines that act in several of these functional roles. As an introduction to 
these diverse functions of cysteine, here we provide prototypical examples of proteins 
that utilize cysteines for redox catalysis, nucleophilic catalysis, metal binding and 
regulation. Furthermore, we highlight covalent inhibitors that have been developed to 
target these functional cysteines to demonstrate the potential of cysteine-reactive small 
molecules to modulate diverse protein activities. 
 
Figure 1-2. Functional roles performed by cysteine residues.  
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Redox catalytic cysteine residues 
 One of the most common functions of cysteines is their ability to catalyze redox-
reactions, including substrate oxidation/reduction, disulfide bond 
formation/isomerization, and detoxification of reactive oxygen species.11 The majority of 
these proteins belongs to the thiol oxidoreductase family and includes isoforms of 
thioredoxin, glutaredoxin, peroxiredoxin, and protein disulfide isomerase. Notably, many 
of these proteins contain a conserved CXXC motif,12 and approximately half contain 
thioredoxin folds.13 Herein, we will focus on thioredoxin, a prototypical member of the 
thiol oxidoreductase family.  
 The thioredoxin system is composed of the proteins thioredoxin (Trx) and 
thioredoxin reductase (TrxR), and together with NADPH14 constitutes one of the major 
cellular redox-control systems. Trx1 and TrxR1 comprise the cytoplasmic system, 
whereas Trx2 and TrxR2 are localized to the mitochondria. The active site of human Trx 
contains a pair of highly conserved cysteine residues (Cys32 and Cys35), which serve as 
the center for redox catalysis. The active, dithiol version of Trx reduces a disulfide bond 
within the protein substrate and is concomitantly oxidized, forming an intramolecular 
disulfide bond. TrxR shuttles reducing equivalents from NADPH to Trx to recycle the 
enzyme back to its reduced, active form (Figure 1-3). Interestingly, TrxR is a 
selenoprotein, which utilizes a Cys/Sec sequence within its active-site to shuttle reducing 
equivalents from NAPDH to Trx.15 The thioredoxin system was originally discovered as 
the essential reducing mechanism for the regeneration of ribonucleotide reductase 
activity, but since then the functions of Trx have expanded to numerous other cellular 
pathways. Among the multitude of functions attributed to the Trx/TrxR system are the 
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defense against oxidative stress, scavenging of reactive oxygen species, and regulation of 
redox signaling by messengers such as hydrogen peroxide and nitric oxide.16, 17   
 
Figure 1-3. The thioredoxin system catalyzes disulfide bond reduction within its protein 
substrates.  
 
 The thioredoxin system is known to play a crucial role in both promoting cellular 
growth and inhibiting apoptosis, both of which are hallmarks of cancer progression. 
Toward this end, many inhibitors of Trx have been developed in recent years as a 
potential therapeutic pathway. One promising candidate, PX-12, is a covalent inhibitor 
that acts by binding to a cysteine proximal to the active-site (Cys73) of Trx1  through its 
disulfide moiety (Figure 1-4).18 PX-12-modified Trx is no longer able to be recycled back 
to its reduced, active state by TrxR, leading to suppression of the entire thioredoxin 
system and the induction of apoptosis. This compound underwent phase II clinical trials 
for cancer treatment but is awaiting further development beyond this stage.19, 20 PX-12 
was shown to be a potent inducer of apoptosis in HL-60 cells, and patients treated with 
PX-12 demonstrated decreased expression of vascular endothelial growth factor (VEGF), 
an essential mediator of angiogenesis and cancer metastasis.21 The continued 
development and clinical evaluation of PX-12 holds promise for inhibitors directed at Trx 
and supports the future exploration of covalent inhibitors targeting the redox catalytic 
cysteines of other thiol oxidoreductases for cancer therapy. Chapter 4 of this thesis 
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focuses on a panel of chemical probes that targets redox-catalytic cysteine residues within 
protein disulfide isomerase.   
 
Figure 1-4. Structure of the thioredoxin inhibitor PX-12, with its reactive group 
highlighted in red.  
 
Cysteine residues as catalytic nucleophiles 
 Unlike redox-catalytic cysteines, cysteine residues that serve as catalytic 
nucleophiles do not undergo a change of oxidation state during their catalytic cycle. 
These enzymatic reactions often rely on a catalytic dyad, consisting of a cysteine residue 
and an adjacent basic residue to stabilize the thiolate anion within the active-site. Most of 
these cysteines are highly conserved and are found on proteins across diverse enzyme 
classes. Common examples include the active-site cysteine residue of cysteine proteases 
(e.g. caspases),22 ubiquitin ligases and hydrolases,23 phosphatases,24 metabolic enzymes 
(e.g glyceraldehyde phosphate dehydrogenase),25 and protein arginine deiminases.26 
Herein, we will highlight the roles of catalytic cysteines within the ubiquitin degradation 
system.  
 The ubiquitin degradation system employs cysteine residues acting as catalytic 
nucleophiles. Proteins are post-translationally tagged with ubiquitin as a cellular 
mechanism to signal for their degradation. The ubiquitin-mediated degradation system 
consists of the conserved 76-amino-acid protein ubiquitin, a series of ubiquitin ligases 
(E1, E2, and E3), deubiquitinases (DUBs), and the 26S-proteosome (Figure 1-5). The 
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ubiquitin ligases conjugate the C-terminus of ubiquitin to the ε-amino group of a lysine 
residue within the substrate protein, and those substrates tagged with a polyubiquitin 
chain are subsequently directed to the proteasome for degradation. DUBs modulate this 
process by removing ubiquitin from tagged proteins. Both ubiquitin ligases (E1, E2 and 
HECT E3) and DUBs act through cysteine residues acting as catalytic nucleophiles.  
 
Figure 1-5. Ubiquitin-mediated protein degradation is comprised of a series of ubiquitin 
ligases (E1s, E2s, and HECT E3s) and deubiquitinating enzymes (DUBs) that possess 
catalytic cysteine residues.  
 
 A series of three ubiquitin ligases (E1, E2, an E3) act sequentially to conjugate 
ubiquitin to its substrate protein. First, a single ubiquitin is coupled to the ubiquitin-
activating enzyme E1 through an ATP-dependent reaction. ATP binds first, followed by 
ubiquitin, resulting in an ubiquitin adenylate intermediate that is susceptible to 
nucleophilic attack by the proximal catalytic cysteine to generate a thioester.27, 28 After 
activation, the ubiquitin is transferred to the cysteine nucleophile of an ubiquitin-
conjugating enzyme E2 to produce another thioester intermediate.27 Notably, unlike other 
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cysteine nucleophiles, the catalytic cysteine in the E2 active site does not contain a 
nearby basic residue (within 6 Ǻ) to stabilize the nucleophilic thiolate anion.29 One theory 
is the binding of E1 or E3 assembles a complex that provides the correct positioning of 
the necessary charged residues to facilitate ubiquitin transfer.27 The organization of the 
ubiquitin ligation system is hierarchical: a single E1 couples with a limited number of 
E2s that interact with a larger subset of E3s specific for a diverse panel of substrate 
proteins. The E3s are grouped into 4 classes based on common structural and biological 
features, but only the Homologue of E6-AP C Terminus (HECT) E3s utilize a catalytic 
cysteine for its function. The HECT E3s form a complex with both an E2 and a substrate, 
after which the ubiquitin is sequentially transferred to the cysteine in the HECT E3 and 
finally to the lysine side chain on the substrate protein. Ubiquitination is a tightly 
regulated process mediated primarily by an intricate network of protein-protein 
interactions between the E1, E2, and E3 proteins and their substrate proteins.  
 Deubiquitinases (DUBs) further modulate ubiquitin-mediated protein degradation. 
Of the 5 known classes of DUBs, 4 are papain-like cysteine proteases and contain a 
canonical catalytic triad consisting of a nucleophilic cysteine residue adjacent to two 
histidines.23 These proteases facilitate a variety of functions, including the activation of 
ubiquitin proproteins, the rescue of ubiquitin trapped by endogenous electrophiles, and 
the removal of ubiquitin from modified proteins. Because ubiquitin-mediated protein 
degradation governs many essential cellular functions, the activity of DUBs must be 
tightly regulated to ensure these processes are carried out definitively. Known 
mechanisms to regulate DUB activity include posttranslational modifications, 
transcriptional regulation, conformational changes, and cellular sequestration.30 
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 Ubiquitin-mediated protein degradation is critical for maintaining protein 
homeostasis and thereby governs numerous cellular processes, including cell growth and 
apoptosis.31, 32 As a result, a tremendous focus has been placed on the development of 
chemical regulators of ubiquitin-mediated protein degradation as therapeutics for disease 
pathways such as cancer.33 Toward this end, the design of cysteine-reactive inhibitors for 
E1, E2, HECT E3s, and DUBs represents one promising approach.34 A pyrozone 
derivative, PYR41, represents a successful example of a cysteine-reactive covalent 
inhibitor of E1 (Figure 1-6).35 PYR41 has been shown to be cysteine-reactive, but 
unfortunately the structure of the resulting covalent adduct is poorly defined. This 
compound was shown to stabilize p53 in cells, and a related compound demonstrated 
anti-leukemic activity in a mouse cancer model.36 Although these data are still 
preliminary, it provides promising support for the application of cysteine-reactive small 
molecules to target other proteins within the ubiquitin-mediated degradation pathway. 
Within this thesis, a chemical probe that targets the catalytic cysteine within GSTO1 will 
be detailed within Chapter 2.   
 
Figure 1-6. Structure of the cysteine-reactive E1 ubiquitin ligase inhibitor, PYR-41. 
 
Metal-binding cysteine residues 
  A significant number of proteins bind metal ions to serve diverse functional roles 
including structural stabilization, catalysis, and regulation of protein activity. Cysteine is 
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one of the most common metal-binding residues within protein scaffolds, along with 
histidine, aspartate, and glutamate. Due to the multiple oxidation states available to the 
sulfur atom, cysteine is able to accommodate a large number of bonds and geometries 
resulting in a myriad of possible metal complexes. Because the cysteine thiolate is a 
“soft” ligand, it preferentially binds strongly to “soft” metals including Fe2+/3+, Zn2+, 
Cd2+, and Cu+.9, 37 Because of the large diversity of putative metal-cysteine complexes, 
they facilitate a wide-range of protein functions, including structure, catalysis, and 
regulation. Herein, we will highlight the metal binding cysteine residue within protein 
farnesyltransferases (FTase) and its contribution to catalysis. 
 FTase is part of the prenyltransferase protein family and catalyzes the post-
translational addition of the 15-carbon farnesyl isoprenoid to cysteine residues on 
proteins such as Ras, Rho, and Rab.38, 39 The isoprenoid is attached through a thioether 
linkage to a cysteine residue within a C-terminal CaaX peptide and is required for proper 
protein function by mediating membrane association and protein-protein interactions.40 A 
Zn2+ is coordinated to Asp297, Cys299, and His362 within the active-sit of the β-subunit 
of FTase (Figure 1-7a).41 The cysteine residue of the protein substrate coordinates to the 
Zn2+, displacing either a water or Asp ligand. The adjacently bound farnesyl diphosphate 
is now vulnerable to nucleophilic attack by the Zn2+-activated thiol, resulting in the 
release of inorganic phosphate and the farnesylated protein (Figure 1-7b).42, 43  
As discussed in Chapter 3, global methods to identify metal-binding cysteines, 
especially those with transient binding and low affinity, are lacking., Chapter 3 of this 
thesis illustrates a novel chemical proteomic platform utilizing cysteine-reactive probes to 
identify metal-binding cysteine residues, in particular, those that chelate Zn2+. 
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Figure 1-7. (a) The active-site of FTase contains a Zn2+ (purple) coordinated to Asp297 
(orange), Cys299 (red), His362 (blue), and the thiol-containing target peptide (yellow) 
adjacent to the farnesyl diphosphate (cyan) (PDB ID: 1JCQ). (b) The cysteine of the 
target peptide is able to displace either an Asp297 or water ligand. The now-activated 
thiol forms a thioether linkage to the farnesyl diphosphate and is released by ligand 
exchange with Asp297 or water. Figure adapted from Pace et al.44 and Ramos et al.43  
  
Cysteine residues as regulators of protein functions 
 Regulatory cysteines do not directly act in catalysis; however, due to their 
proximity to either the active-site or surfaces involved in essential protein-protein 
interactions, these cysteines are key modulators of protein activities. Modification of 
these cysteine residues by reactive oxygen species or endogenous or exogenous 
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electrophiles regulates protein activity. A key example of proteins utilizing regulatory 
cysteines is the kinase family. 
 
Protein kinase activity is regulated by cysteine residues 
 Sequencing the human genome, coupled with detailed structural information, has 
provided significant insight into structural and functional homology between the 518 
human protein kinases. Numerous bioinformatics and inhibitor screening efforts revealed 
the presence of cysteine residues within the ATP-binding pocket of a large number of 
protein kinases (~200 out of the 518). These cysteines have recently been reviewed and 
were classified into five groups based upon the structural location of the each cysteine.45 
Group 1 kinases contain a cysteine within the glycine-rich or P-loop (e.g., FGFR); group 
2 kinases are those with cysteines positioned at the roof of the ATP-binding pocket (e.g., 
RSK); group 3 kinases present a cysteine in the hinge region and front pocket (e.g., 
EGFR); group 4 kinases are the most common and contain a cysteine adjacent to the 
DFG-motif (e.g., ERK2); and group 6 cysteines have a cysteine located in the activation 
loop (e.g., IKKα) (Figure 1-8).46-49 Several of these cysteines were identified by isoTOP-
ABPP,1 hinting at their reactive nature.   
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Figure 1-8. Human protein kinases with reactive cysteine residues were divided into five 
groups based on structural location: Group 1B (green), Group 2B (blue), Group 3F 
(black), Group 4 (red), and Group 5 (orange).  
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Protein kinases, many of which possess regulatory cysteine residues, play an 
important role in the progression of cancer.46 In particular, epidermal growth factor 
receptor (EGFR), a receptor tyrosine kinase, is overexpressed in several cancer types, 
including breast, lung, esophageal, and head and neck.50 Through phosphorylation-
mediated signaling cascades, EGFR and its family members modulate growth, signaling, 
differentiation, adhesion, migration, and survival of cancer cells.50, 51 Notably, Cys797 of 
EGFR is found close to the hinge region and was found to be sulfenylated in EGF-
stimulated cells. Oxidation of Cys797 enhances tyrosine kinase activity, exemplifying its 
role as a regulatory residue: one that is not involved in catalysis but modulates protein 
activity.52 Furthermore, the identification of this regulatory residue sparked the 
development of cysteine-reactive covalent inhibitors of EGFR. Four of these (HKI-272, 
CI-1033, EKB-569, and PF-00299804) are currently undergoing clinical trial, and one 
(Afatinib) has been approved in the United states as a first-line treatment for metastatic 
non-small cell lung carcinoma (Figure 1-9).53, 54 An acrylamide electrophile was 
incorporated into all these inhibitors and undergoes a Michael addition with the reactive 
cysteine to form a covalent adduct.55 
 
Figure 1-9. Structure of the EGFR inhibitor, Afatinib.  
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 In addition to EGFR, cysteine-reactive small molecule inhibitors have been 
developed for both ribosomal s6 kinase (RSK) and extracellular signal-related kinase 
(ERK), although these have not yet advanced to clinical trials. Selective RSK inhibitors 
have been developed through incorporation of a cysteine-reactive fluoromethyl ketone 
electrophile into a scaffold of a pan-kinase inhibitor.48 These compounds have been 
recently altered to produce slow dissociating, covalent inhibitors that may help 
circumvent toxicity issues typically encountered through irreversible inhibition.56  
Natural products of the resorcylic acid lactone family contain a cis-enone that forms a 
Michael adduct with the reactive cysteine within the ERK family.47 Together, these 
studies demonstrate that reactive cysteines located at diverse positions within the ATP-
binding pocket of kinases may be exploited in the development of covalent inhibitors. 
Traditional kinase inhibitors typically encounter high chemical resistance due to 
mutations within the ATP-binding site. This new approach displays potential to overcome 
any evolved resistance, as evidenced by the covalent EGFR inhibitors ability to still 
inhibit the protein with a mutation of the gatekeeper threonine (T790M).57 
 
Conclusion 
Cysteine residues are able to facilitate diverse protein functions that contribute to 
essential cellular processes. Electrophilic small molecules can be utilized to characterize 
and modulate cysteine-mediated protein activities across diverse protein classes. The 
expansion of new cysteine-reactive probes for other protein classes is essential to the 
continued annotation of functional cysteines. This thesis will focus on a cysteine-reactive 
inhibitor of the catalytic cysteine of GSTO1 that selectively targets apoptotic cell 
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populations (Chapter 2), a chemical-proteomic platform to identify Zn2+-binding cysteine 
residues (Chapter 3), and use of a panel of cysteine-reactive inhibitors of the redox-
catalytic cysteines in protein disulfide isomerase to interrogate the role of this protein in 
cancer progression (Chapter 4).    
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Chapter 2 
A peptide-based inhibitor of GSTO1 that selectively targets apoptotic cells 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A significant portion of the work described in this chapter has been published in: 
Pace, N. J.; Pimental, D. R.; Weerapana, E. An Inhibitor of Glutathione S-Transferase 
Omega 1 that Selectively Targets Apoptotic Cells. Angew. Chem. Int. Ed. 2012, 51, 8365-
8368. 
 
Daniel Pimental synthesized a portion of the peptide probe library.  
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Introduction 
 Since the mid-1800s, many observations have indicated that cell death plays a 
considerable role within physiological processes and the development of multicellular 
organisms. In 1964 the term programmed cell death was introduced, proposing that cell 
death during development is not accidental, but rather follows a sequence of controlled 
steps leading to locally and temporally defined self-destruction.1 Kerr, Wyllie, and Currie 
first coined the term apoptosis in 1972 to describe the morphological processes leading to 
controlled cellular self-destruction.2 Since this time, apoptosis has been distinguished as 
an active and defined process that plays an essential role in the development of 
multicellular organisms and in the regulation and maintenance of cell populations in 
tissues upon physiological and pathological conditions.3 While apoptosis is possibly the 
most frequent form of programmed cell death, it should be noted that other non-apoptotic 
forms of controlled cell death, such as autophagy and programmed necrosis do exist.4 
Because apoptosis is such an important biological process, tightly regulated 
intrinsic and extrinsic signaling cascades have evolved to facilitate its induction. 
Regardless of the initiating death stimulus or cell type, apoptosis always culminates in the 
fragmentation of several hundred proteins and DNA. Caspases (Cysteine-dependent 
aspartate-directed proteases) largely mediate this proteolysis and also activate CAD 
(caspase-activated DNase) by cleaving its chaperone/inhibitor ICAD (inhibitor of CAD) 
and allow CAD to fragment chromatin.5 These caspases have been categorized into two 
groups based on their function: initiator caspases (caspase-2, 8, 9, 10) and executioner 
caspases (caspase-3, 6, 7).6 The executioner caspases perform nearly all the proteolysis, 
including activation of CAD. To regulate their activity, executioner caspases are 
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synthesized as inactive zymogens and rely on proteolytic cleavage into a large and small 
subunit by the initiator caspases to assemble the constitutively active hetero-tetramer. The 
initiator caspases have long prodomains that, following an apoptotic signal, target them to 
specific scaffold proteins (Fas-associated protein with death domain (FADD) for caspase-
8 & Apoptotic protease activity factor 1 (Apaf-1) for caspase-9) where conformational 
changes provoke their activation.5 
While both ultimately converge upon executioner caspase activation, vertebrates 
possess two distinct apoptosis signaling cascades: an extrinsic death receptor pathway 
and an intrinsic mitochondrial pathway (Figure 2-1). The death receptor (extrinsic) 
pathway is triggered by ligand binding to the tumor necrosis factor receptor (TNF-R) 
superfamily, which contain intracellular “death domains” such as Fas, TNF-related 
apoptosis-inducing ligand receptor 1 (TRAIL-R1), and TNF-R1. Upon ligand binding, 
these receptors assemble the DISC (death-inducing signaling complex), within which the 
FADD adapter protein recruits and activates caspase-8.7 In certain death receptors, 
FADD/caspase-8 binding is assisted by the adaptor protein Tumor necrosis factor type 1-
associated Death Domain protein (TRADD). Once activated, caspase-8 cleaves the 
executioner caspases to initiate apoptosis. In the case of the mitochondrial (intrinsic) 
pathway, internal apoptotic stimuli (growth factor deprivation, exposure to DNA damage, 
or cancer therapeutics) trigger release of apoptogenic factors, such as cytochrome c, from 
the mitochondrial intermembrane space to the cytosol. This release induces the binding of 
Apaf-1 and caspase-9 and assembly of the apoptosome; after which, the now activated 
caspase-9 cleaves the executioner caspases to initiate apoptosis.5  
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Figure 2-1. The two major apoptotic signaling pathways: the intrinsic or mitochondrial 
pathway (left) and the extrinsic or death receptor pathway (right). Figure adapted from 
Strasser et al.5   
 
Upon triggering apoptosis, cells experience a variety of characteristic 
morphological changes, many of which can serve as biomarkers. First, the cell shrinks 
and becomes deformed, losing contact to its neighboring cells. The cell’s chromatin 
condenses and marginates at the nuclear membrane, the plasma membrane undergoes 
blebbing or budding, and finally the cell is fragmented into compact membrane-enclosed 
structures termed apoptotic bodies, which contain cytosol, condensed chromatin, and 
organelles (Figure 2-2). These apoptotic bodies are engulfed by macrophages and 
removed from the tissue without eliciting an immune response. These morphological 
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changes are a consequence of characteristic molecular and biochemical events occurring 
within the apoptotic cell, including proteolysis and degradation of DNA as well as a 
change in lipid composition of the plasma membrane.3 Anionic phosphatidylserines (PS), 
which are typically found within the inner leaflet of the plasma membrane,8 are exposed 
to the outer surface of the cell and ultimately signal for the cell’s clearance by 
macrophages.9, 10 PS exposure is a near-universal event during apoptosis and occurs 
within a few hours of the apoptotic stimulus.11 Importantly, apoptosis differs from the 
necrotic mode of cell-death, where the cells suffer a major insult resulting in loss of 
membrane integrity, swelling, and rupture of the cells. (Figure 2-2) The cellular contents 
are released uncontrollably into its surround environment and results in a strong 
inflammatory response in the corresponding tissue.12   
 
Figure 2-2. Hallmarks of apoptotic and necrotic cell death. Figure modified from Van 
Cruchten et al.13 
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Dysregulation of apoptotic signaling cascades plays a critical role in disease 
pathways, especially cancer progression.14 Thus, cytotoxic cancer agents function by 
inducing apoptosis, and chemotherapeutic resistance is tightly coupled to defective 
progression of apoptotic signaling.15 To identify proteins implicated in maintaining or 
accelerating apoptosis, it would be advantageous to develop apoptotic cell-selective 
inhibitors with no effect on healthy cells. Additionally, the use of a covalent inhibitor 
would allow for subsequent biochemical analysis due to their ability to stably tag a 
specific protein. Such context-dependent covalent inhibitors would serve as valuable 
tools to deconvolute protein activities implicated in chemotherapeutic resistance and 
accelerate apoptosis within a specific cell population.  
Furthermore, apoptotic cell-selective covalent modifiers could also be employed 
as valuable imaging agents of cell death. Because the progression of many diseases 
functions through an imbalance of apoptosis, the ability to image and assess the degree of 
apoptosis allows for spatial recognition of a disease, evaluation of the efficacy of 
treatments, and correlates directly to patient prognosis. For these reasons, protein, 
peptide, and small molecule-derived imaging agents of apoptosis have been developed. 
These imaging agents typically function through detection of PS and caspase activity 
(Table 2-1). Annexin V, a 36 kD protein with strong affinity for PS, conjugated to either 
fluorophores or radionucleotides is the most highly studied imaging agent for apoptosis 
within both animal16 and human models.17 In addition to its high specificity for apoptotic 
cells, Annexin V also lacks immunogenicity and in vivo toxicity; however, several issues 
still limit its clinical use. Annexin V suffers from high cost, large size, slow clearance, 
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moderate stability, and requires micromolar concentrations of Ca2+ for optimal binding.18, 
19 In addition to Annexin V, peptide-based PS sensing agents have been developed in the 
form of cLac peptides20. These agents help circumvent some of the limitations of 
Annexin V but still require further optimization of their PS-affinity and fluorescence. As 
a whole, these current PS-targeting imaging agents are less than ideal because the binding 
interactions are non-covalent. Due to their lack of stability, these non-covalent adducts 
are limited by the types of systems chosen and analytical techniques. Additionally, 
necrotic cells also expose PS at the cell-surface and distinguishing between necrotic and 
apoptotic cells can therefore be problematic.  
Name Type Interaction Mechanism 
Annexin-V Protein Non-covalent PS exposure 
cLac peptide Peptide Non-covalent PS exposure 
AB50-Cy5 Peptide Covalent Caspase activity 
LE22-Cy5 Peptide Covalent Caspase activity 
ApoSense Small molecule Non-covalent Membrane Integrity 
YO-PRO1 Small molecule Non-covalent Membrane Integrity 
GSAO Peptide Non-covalent Membrane Integrity 
Table 2-1. Apoptotic cell-selective imaging agents.  
 
Another common strategy to image apoptosis is through detection of caspase 
activity. Assessing caspase activity provides several inherent advantages over PS-
exposure as a biomarker. Since caspase activity is unique to apoptotic cells, off-target 
signals by healthy or necrotic cells are of no concern. In addition, active caspases possess 
a hyperreactive cysteine residue that can be exploited as a handle for covalent 
modification. This covalent modification would allow for subsequent target detection 
through biochemical assays, which is not available for those agents that bind through 
non-covalent interactions. Cysteine-reactive acyloxymethyl ketone (AOMK) 
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electrophiles have been conjugated to caspase-directed peptide sequences to afford 
selective probes for caspase activity.21 These initial covalent inhibitors have been further 
optimized to produce AB50-Cy5 and LE22-Cy5 (Figure 2-3), both of which are effective 
imaging agents of apoptosis in vivo.19, 22 AB50-Cy5 was utilized to evaluate the degree of 
apoptosis within a tumor treated with the apoptosis-inducing monoclonal antibody, 
Apomab.19 Through use of LE22-Cy5, the signaling pathway that triggers caspase-6 
activity was further deconvoluted.22 Together, these peptide-based inhibitors show the 
capacity to evaluate apoptosis in vitro and in vivo and show promise as imaging agents, 
evaluators of potential drugs, and as tools to deconvolute apoptotic signaling pathways. 
While these peptides represent a major achievement, their off-target reactivity with other 
potent cysteine proteases, such as legumain, must still be addressed.  
 
Figure 2-3. Structures of AB50-Cy5 and LE22-Cy5, probes from caspase activity.  
 
We sought to expand the available apoptotic-cell selective covalent inhibitors for 
proteins beyond caspases to serve as tools to interrogate a protein’s role within apoptosis.  
We also hoped to improve upon the properties of these covalent inhibitors in hopes of 
applying them as imaging agents. In order to achieve apoptotic-cell selectivity, we sought 
to exploit the characteristic changes in plasma membranes composition during apoptosis. 
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In a healthy cell, phosphatidylcholine and sphingomyelin are mainly present in the outer 
leaflet of the plasma membrane, whereas PS is restricted to the inner leaflet.8 Cell 
membranes also contain phosphatidylinositol and phosphatidylethanolamine, which can 
be found distributed within both the inner and outer leaflet.8 Upon induction of apoptosis, 
a calcium-dependent lipid scramblase, Xk-Related Protein 8 (Xkr8), is activated and 
randomly re-distributes lipids throughout the inner and outer leaflets, resulting in the 
traditionally observed PS exposure.9, 11, 23 Proteins such as careticulin, annexin I, and 
intercellular adhesion molecule 3 (ICAM3) also translocate to the surface of the cell and 
are thought to serve as receptors.24 Many membrane proteins also experience altered 
glycosylation patterns that are thought to play in role in extracellular signaling of 
macrophages to clear apoptotic debris.25 Additionally, specific triggers during apoptosis 
disrupt the ion gradient and results in a depolarization of the plasma membrane 
potential.26 Together, these changes result in a loss of membrane integrity and permits 
distinct small molecules to now be internalized.27 This phenomenon has been exploited in 
the development of dyes to selectively detect apoptotic cells, such ApoSense,28 YO-
PRO1,29 and GSAO.30 The green fluorescent YO-PRO1 dye was found to preferentially 
accumulate in apoptotic cells (Figure 2-4).29, 31 Similarly, an organoarsenic peptide-based 
agent, GSAO, was shown to be internalized into apoptotic cells at the stage at which 
plasma membrane integrity is compromised (Figure 2-4).30 The mechanism of 
internalization of these molecules has yet to be determined, but future studies should aim 
to determine whether selectively permeable molecules enter by passive diffusion or 
active transport and which specific changes to the plasma membrane permit their 
internalization.  
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Figure 2-4. Structures of selectively permeable YO-PRO-1 and GSAO. 
 
Although a correlation between molecular structure and apoptotic cell-
permeability has yet to be achieved, the tri-peptide backbone of the organoarsenic agent 
suggested that small peptides could serve as a vehicle for internalization. Since many 
cysteine-mediated protein activities are known to be hyperactivated in apoptotic cells (e. 
g. caspases), we hypothesized that combining tri/tetrapeptide-based motifs with cysteine-
reactive electrophiles will afford us chemical probes that covalently target proteins in 
apoptotic cell populations. In an effort to test this hypothesis, we aimed to synthesize a 
library of tri/tetrapeptides conjugated to cysteine-reactive electrophiles and screen the 
library to identify apoptotic cell-selective inhibitors of cysteine-mediated protein 
activities (Figure 2-5). Previously, a peptide-based library of chloroacetamides was 
shown to demonstrate intriguing proteome-labeling patterns, although these peptides 
were not evaluated in whole cells.32 This work would expand upon this previous study by 
exploring protein labeling by cysteine-reactive peptides within both healthy and apoptotic 
cells, with the aim of developing an apoptotic-cell selective inhibitor.  
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Figure 2-5. Proposed strategy for an apoptotic cell-selective inhibitor based on a peptide 
scaffold.  
 
Results and Discussion 
 
Synthesis of cysteine-reactive peptide library 
 The peptides were synthesized on solid-support using standard Fmoc-based solid-
phase peptide synthesis (SPPS), and the acrylamide and sulfonate ester electrophiles were 
subsequently installed on resin (Figure 2-6).  
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Figure 2-6. Synthetic route to cysteine-reactive peptide probes NJP1 – NJP10.a 
aReagents and conditions: (a) acrylic acid, PyBOP, DIPEA, DMF, rt; (b) 3-
(trityloxy)propanoic acid, PyBOP, DIPEA, DMF, rt; (c) 1% TFA, 2% TIS, DCM, rt; 
benzene sulfonyl chloride, NEt3, DCM, rt; (d) 90% TFA, 5% water, 2.5% DCM, 2.5% 
TIS.   
 
A synthesized 3-(trityloxy)propanoic acid linker, upon deprotection, provided an 
alcohol for the addition of the sulfonate ester. This route generated the peptide-based 
chemical probes NJP1 – NJP10, each containing a variable peptide sequence to exploit 
the inherent structural diversity of commercially amino acids. An alkyne handle was 
incorporated in the form of a propargylglycine residue within the peptide for subsequent 
enrichment and visualization through click chemistry. The peptide scaffolds were 
conjugated to either an acrylamide or sulfonate-ester electrophile (Figure 2-7), both of 
which have been shown to be highly reactive towards cysteine residues.33 Yields of 
peptides range from 6 – 40%.  
 
Figure 2-7. Library of sulfuonate ester (NJP1-5) and acrylamide (NJP6-10) electrophile-
bearing peptides utilized in a screen for apoptotic-cell selective inhibitors.  
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Evaluation of the peptide inhibitor library 
NJP1 – NJP10 were evaluated for apoptosis-specific labeling events in HeLa 
cells. Cells were first incubated with DMSO as a control or staurosporine (STS), a broad-
spectrum kinase inhibitor34 that is thought to induce apoptosis through caspase-3 
activation,35 and were subsequently treated with the peptides by adding each directly to 
the media. The cells were lysed, subjected to click chemistry to conjugate a fluorophore 
in the form of rhodamine azide (Rh-N3), and analyzed by in-gel fluorescence (Figure 2-
8).36 
 
Figure 2-8. In-gel fluorescence analysis of control and apoptotic HeLa lysates treated 
with peptide-based probes NJP1 - 10.  
 
Our aim was to identify a peptide from the initial 10-member library that 
demonstrated labeling of a single protein exclusively within apoptotic cells. Initially, 
three of our peptides (NJP2, NJP4, and NJP10) appeared to be of interest. In the case of 
NJP4, significant labeling of multiple proteins within the apoptotic cells was less than 
desirable, as we wanted our inhibitor to be selective for a specific protein. On the other 
hand, NJP10 did display labeling of a single protein within the STS-treated cells, but 
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unfortunately a significant signal was also observed within the untreated cells.  
Fortunately, NJP2 (Figure 2-9a) satisfied both of these criteria, displaying significant 
labeling of a single 28 kD protein in apoptotic cells with no significant signal within 
healthy cells (Figure 2-9b). To further characterize this unique labeling profile, we 
performed a time-course analysis of STS treatment while monitoring the extent of 
apoptosis by DNA fragmentation (Figure 2-9c). The intensity of protein labeling by NJP2 
increased proportionally with the progression of apoptosis.  
 
Figure 2-9. (a) The structure of NJP2. (b) In-gel fluorescence analysis of control and 
apoptotic HeLa cells treated with NJP2. (c) Time-course treatment of HeLa cells with 
STS. Cells were subjected to DNA fragmentation and in-gel fluorescence from NJP2 
labeling at each time point. 
 
To further substantiate this apoptotic cell-selective labeling, we extended this 
platform across different cell lines and apoptosis-inducing drugs. Control and STS-
treated Jurkat cells were subjected to in-gel fluorescence after NJP2-treatment, and 
displayed the same differential labeling pattern (Figure 2-10a). Moreover, STS was 
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replaced with camptothecin (CPT), a DNA-topoisomerase inhibitor that triggers 
apoptosis through the resulting DNA damage,37 and confirmed that the labeling event still 
occurs under other chemically induced models of apoptosis (Figure 2-10b).  
 
Figure 2-10. (a) In-gel fluorescence analysis of probe labeling by NJP2 in Jurkat cells. 
(b) Probe labeling by NJP2 within HeLa cells incubated at various concentrations of 
CPT. 
 
Identification of the protein target of NJP2 
Next, we sought to identify the major 28 kD target of NJP2. NJP2-labeled lysates 
underwent click chemistry to conjugate biotin-azide, followed by purification on 
streptavidin beads, on-bead trypsin digestion, and LC/LC-MS/MS analysis.38 The 
proteins identified in NJP2-treated lysates were compared to a DMSO-treated control. 
This analysis revealed glutathione S-transferase omega 1 (GSTO1) as the major protein 
target of NJP2, since high spectral counts (142 and 155) were observed in duplicate 
NJP2-labeled samples, with no spectral counts in the DMSO-treated samples (Table 2-2). 
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The molecular weight of GSTO1 (27,566 Da) also coincides with the observed band 
migration during in-gel fluorescence analysis (Figure 2-9b).  
 
Table 2-2. All proteins in the 25 – 30 kD molecular weight range with spectral counts >5 
in the NJP2-treated runs. The data are sorted by greatest-fold change in spectral counts in 
the NJP2 samples vs the DMSO samples.  
 
Glutathione S-transferases (GSTs) catalyze nucleophilic attack by reduced 
glutathione (GSH) on nonpolar compounds that contain an electrophilic carbon, nitrogen, 
or sulfur atom. Their substrates include halogenated nitrobenzenes, arene oxides, 
quinones, and α,β-unsaturated carbonyls.39 The conjugation of GSH to endogenous and 
exogenous electrophiles functions as a mechanism of cellular defense against 
carcinogens, therapeutic drugs, and oxidative stress.40 GSTs encompass 3 major families 
of proteins: 1) cytosolic, 2) mitochondrial, and 3) microsomal, with the cytosolic GSTs 
accounting for the largest of the families. On the basis of amino acid sequence 
similarities, substrate specificity, and immunological cross-reactivity, seven classes of 
cytosolic GSTs have been identified in mammals. Most GST classes show a high degree 
of polymorphism and include several subunits (Table 2-3).41 Each subunit (22 – 29 kD) 
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contains an amino-terminal GSH-binding site (G-site) and a carboxy-terminal 
hydrophobic substrate-binding domain (H-site).42 The exact catalytic mechanisms for 
each class of GST are still largely unknown; however, they all encompass binding of 
GSH and stabilization of the thiolate anion within the G-site, followed by conjugation to 
a substrate bound within the H-site. This results in GST’s ability to facilitate conjugation, 
isomerization, reduction, and thiolysis activities among others.  
Class Enzyme Designation Subunits 
Alpha GSTA 1,2,3,4,5 
Mu GSTM 1,2,3,4,5 
Omega GSTO 1,2 
Pi GSTP 1,2 
Sigma GSTS 1 
Theta GSTT 1,2 
Zeta GSTZ 1 
Table 2-3. Classes of cytosolic GSTs. 
 
The omega class of GSTs was recently discovered through a sequence database.43 
Structurally, GSTO1 is very similar except that it contains a 19-20 residue N-terminal 
extension, and, while it contains high sequence and structural similarities to the other 
GST classes, GSTO1 behaves rather uniquely.44 It possesses glutathione-dependent thiol 
transferase activity along with glutathione-dependent dehydroascorbate reductase 
activity, both of which are not observed within the other classes of GSTs and are more 
similar to that of glutaredoxins.43, 45 GSTO1 displays only minimal activity with 
chloronitrobenzenes, which are generally good substrates for other classes of GSTs. 
Mechanistically, GSTO1 is also thought to be unique from other GSTs. GSH binding is 
analogous to what has been observed in other GSTs, except that GSTO1  possesses a 
catalytic cysteine residue (Cys32) in place of the canonical tyrosine or serine residue.43 
42 
 
Traditionally within GSTs, the catalytic tyrosine/serine residue stabilizes the thiolate 
anion within GSH; however, Cys32 of GSTO1 acts as a nucleophile to form a mixed 
disulfide with GSH. The H-site of GSTO1 also contains a larger pocket and Trp222 
points its indole nitrogen into the pocket.43, 44 This would allow GSTO1 to accommodate 
larger substrates that are not entirely hydrophobic, such as the peptides we employ here.  
GSTO1 overexpression has been observed in highly aggressive human cancers,46 
and other studies have implicated GSTO1 in chemotherapeutic resistance.47 Further 
interrogation revealed that GSTO1 overexpression averts cisplatin-induced toxicity and 
RNAi knockdown of GSTO1 sensitizes cancer cells to cytotoxic effects of cisplatin.48 
The mechanism of resistance is thought to be through GSTO1-modulation of apoptotic 
signaling cascades;  in particular, GSTO1 overexpression appears to be associated with 
activation of proteins essential to survival pathways (Protein kinase B (AKT) and 
Extracellular-signal-related kinases (ERK1/2)) and inhibition of proteins contributing to 
apoptotic pathways (Mitogen-activated protein kinase 8 (JNK1)).48 Despite its potential 
role in cancer, only a few inhibitors have been developed for GSTO1. A commercially 
available fluorescent protein tag from Invitrogen, CellTracker Green (5-
chloromethylfluorescein diacetate, Figure 2-11), inhibits GSTO1 with good potency (IC50 
= 51 nM) and selectivity.49 Unfortunately, while this inhibitor may be useful in certain 
applications, it readily undergoes hydrolysis by endogenous esterases, rendering the 
active compound membrane-impermeable. More recently, a chloroacetamide-containing 
inhibitor, KT53 (Figure 2-11), was identified through a high-throughput screen as a 
GSTO1 inhibitor with improved potency (IC50 ~30-40 nM), selectivity, and cellular 
activity.50 KT53 was shown to sensitize cancer cells to the cytotoxic effects of cisplatin, 
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providing the first pharmacologic evidence that GSTO1 contributes to chemotherapeutic 
resistance in cancer.50 Notably, KT53 functions by covalently modifying the GSH-
binding catalytic Cys32 through its cysteine-reactive chloroacetamide electrophile, which 
led us to believe our apoptotic-cell selective inhibitor of GSTO1 functioned in the same 
manner.  
 
Figure 2-11. Structures of GSTO1 inhibitors CellTracker Green and KT53. 
 
In order to confirm GSTO1 as the target protein and evaluate the mechanism of 
action of NJP2, we overexpressed the WT and C32A mutant of GSTO1 in HEK293T 
cells by transient transfection. These cells were then treated with NJP2 and subjected to 
in-gel fluorescence analysis revealing an extensive fluorescent signal of the WT 
overexpressed GSTO1 (Figure 2-12). This signal was absent for the C32A mutant, 
indicating that covalent modification of GSTO1 by NJP2 occurs at the catalytic Cys32 
residue. 
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Figure 2-12. Mock-transfected, GSTO1 WT, and GSTO1 C32A mutant overexpressing 
cells labeled with NJP2 and analyzed by in-gel fluorescence (top panel). Western blots of 
an anti-myc antibody confirmed overexpression (bottom panel). The overexpressed 
GSTO runs higher on the gel than the endogenous GSTO1 (*) due to the additional mass 
of the linker sequence and C-terminal myc/His tag. 
 
Application of NJP2 as an apoptotic cell-selective inhibitor and imaging agent 
 Once GSTO1 was identified as the target of NJP2, we investigated the mechanism 
of apoptotic-cell selectivity. To confirm our initial hypothesis that the peptide scaffold 
would be selectively internalized by compromised cell membranes, we had to eliminate 
any possibility of an increase in GSTO1 abundance or activity occurring during 
apoptosis. A previous proteomic study into proteolysis events during apoptosis revealed 
no change in GSTO1 abundance;51 however, the possibility of post-translational 
activation of GSTO1 still existed. In order to refute this notion, we employed a non-
specific sulfonate ester ABP, PS-alkyne (undec-10-yn-1-yl benzenesulfonate, Figure 2-
13a). This more promiscuous cysteine-reactive inhibitor is known to be membrane 
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permeable in both healthy and apoptotic cells and labels GSTO1, amongst other targets.52 
Because its labeling can easily be competed with GSH, PS-alkyne is believed to bind 
within the G-site of GSTO1 and modifies Cys32 in the same manner as NJP2.53, 54  Due 
to its binding mode, PS-alkyne binding should be indicative of GSTO1 activity since 
Cys32 is required for catalysis. In vitro (lysates) treatment of control and apoptotic HeLa 
lysates with PS-alkyne and subsequent in-gel fluorescence analysis indicated no change 
in GSTO1 activity during apoptosis (Figure 2-13b). Additionally, in-gel fluorescence 
analysis of in situ (whole-cell) PS-alkyne treated samples also detected no change in 
GSTO1 activity when employing an equally membrane permeable inhibitor. These data 
suggest that NJP2 is selectively internalized by apoptotic cells due to the compromised 
integrity of their cell membranes (Figure 2-13b).   
 
Figure 2-13. (a) Structure of cell permeable PS-alkyne. (b) PS-alkyne was administered 
to control and apoptotic HeLa cells in vitro and in situ and analyzed by in-gel 
fluorescence analysis.  
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To further interrogate the selective internalization of NJP2 by apoptotic cells and 
to demonstrate its utility as an imaging agent, a fluorescent analog, NJP13, was 
synthesized by appending a rhodamine fluorophore through click chemistry (Figure 2-
14a). Both control and apoptotic HeLa cells were administered NJP13 and visualized by 
fluorescence microscopy. Apoptotic cells, upon exposure to NJP13, exhibited a 
significant fluorescent signal over background levels, and this increase in fluorescent 
intensity coincided with the characteristic morphological changes in cellular structure 
observed during apoptosis (Figure 2-14b). No fluorescence was detected in NJP13-
treated control cells. This dramatic increase in cellular uptake upon inducing apoptosis 
confirms our hypothesis that the increased cell permeability during apoptosis can be 
exploited to selectively deliver peptide-based probes to apoptotic cells. Moreover, since 
only low concentrations of STS (1 μM) and short incubation times (30 mins) yielded a 
considerable fluorescent signal, these peptides may represent a valuable class of covalent 
imaging agents for early-stage apoptotic cells.  
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Figure 2-14. (a) Structure of fluorescent-functionalized apoptotic cell-selective probe, 
NJP13. (b) Fluorescence microscopy images of HeLa cells incubated with DMSO 
(control) or STS (1 μM) for 30 mins, 1 h, or 2 h, followed by NJP13-treatment.  
 
 In order to quantitatively evaluate the potency and cell-selectivity of GSTO1 
inhibition by NJP2, we performed a dose-dependent labeling experiment in conjunction 
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with a competitive activity-based protein profiling (ABPP) experiment. The competitive 
ABPP experiment measured residual GSTO1 activity through use of a fluorescently-
tagged phenyl sulfonate inhibitor (PS-Rh) after treatment with NJP2.50 Previous research 
has determined that the degree of PS-Rh labeling of Cys32 correlates to GSTO1 activity, 
and thereby a loss of PS-Rh labeling signifies inhibition of GSTO1 activity.50 Both 
control and apoptotic HeLa cells were treated with increasing concentrations of NJP2 (1 
– 60 μM), and the resulting lysates were either subjected to click chemistry with Rh-N3 or 
administered PS-Rh. Both sets of lysates were then analyzed by in-gel fluorescence. The 
Rh-N3 gels illustrate the increase in labeling of GSTO1 by NJP2 in apoptotic cells, with 
only a minimal increase observed in the control (Figure 2-15a). As for the PS-Rh gel, a 
decrease in PS-Rh labeling, and thus GSTO1 activity, was only observed in apoptotic 
cells upon increasing concentrations of NJP2 (Figure 2-15b). These gel bands were 
integrated at each concentration to quantify the residual GSTO1 activity, and a plot of 
these demonstrates the remarkable selectivity of NJP2 towards GSTO1-inhibition solely 
within apoptotic cells (Figure 2-15c). In combination, the labeling of GSTO1 by NJP2 
determined after click chemistry correlated with the loss of residual GSTO1 activity 
observed through the competitive ABPP assay as quantified by gel-band integration 
(Figure 2-15d). The quantified bands were plotted using Prism software and the IC50 
value for NJP2 within apoptotic cells was calculated as 13 μM. Together, these data 
illustrate the specificity and potency of NJP2 as an inhibitor of GSTO1 solely within 
apoptotic cells.  
49 
 
 
Figure 2-15. Control and apoptotic cells administered increasing concentrations of NJP2 
were (a) subjected to click chemistry with Rh-N3 or (b) treated with PS-Rh and analyzed 
by in-gel fluorescence. (c) Residual GSTO1 activity within control and apoptotic cells 
was quantified through gel-band integration. (d) Within apoptotic cells, quantification 
through gel-band integration demonstrated that the labeling of GSTO1 by NJP2 
correlated with a loss of residual GSTO1 activity. (e) The quantified bands were plotted 
on Prism to determine the IC50 value for NJP2 within apoptotic cell populations.  
 
Conclusions 
 Through the use of a library of cysteine-reactive peptides, we developed an 
apoptotic-cell selective inhibitor of GSTO1 that functions through covalent modification 
of its catalytic cysteine residue. Because of its importance in cancer progression and 
chemotherapeutic resistance, the discovery of selective inhibitors of GSTO1 is 
paramount. Other more potent GSTO1 inhibitors (IC50 of NJP2 for GSTO1 ≈ 13 μM) 
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have been described previously,50, 55 but these existing inhibitors are equipotent for 
GSTO1 in both healthy and apoptotic cells. NJP2 should serve as a valuable complement 
to existing inhibitors because of its high specificity for GSTO1 over other protein targets 
along with its unique ability to solely target cells undergoing apoptosis. This context-
dependent inhibitor could help elucidate the role of GSTO1 in apoptosis or be used to 
accelerate apoptosis within a distinct population of cells. We demonstrated that the 
characteristic loss of plasma membrane integrity in apoptotic cells can be exploited in the 
development of cell-selective inhibitors. Towards this end, other members of our peptide 
library, particularly NJP4, displayed labeling of other protein targets through in-gel 
fluorescence. This suggests that the peptide-based scaffold can be expanded upon to 
develop context-dependent inhibitors of diverse protein classes other than GSTO1. The 
visualization of NJP13 internalization using fluorescence microscopy also implies that 
these peptides can be added to the repertoire of selective imaging agents for apoptotic 
cells.56 These covalent inhibitors targeting compromised membranes appear to provide an 
inherent advantage over PS-targeting agents (non-covalent, cannot distinguish from 
necrotic cells) and current caspase-targeting agents (off-target binding); however, the 
precise chemical changes occurring to plasma membranes during apoptosis must be 
better understood.     
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Experimental procedures 
 
General procedures and materials 
 All materials were purchased from Sigma Aldrich or Fisher Scientific unless 
otherwise noted. Fmoc-propargyl glycine (Fmoc-Pra-OH) was purchased from BaCHEM. 
All other Fmoc-protected amino acids, PyBOP, and resin were purchased from 
Novabiochem. PBS buffer, DMEM/High glucose media, RPMI 1640 media, and 
penicillin streptomycin (Pen/Strep) were purchased from Thermal Scientific. Trypsin-
EDTA and RPMI 1640 media (no phenol red) were purchased from Invitrogen. STS was 
purchased from Cell Signaling. CPT was purchased from MP Biomedicals LLC. The α-
myc tag antibody and the α-rabbit IgG HRP-linker antibody were purchased from Cell 
Signaling. X-tremeGENE 9 DNA transfection reagent was purchased from Roche. 
Analytical TLC was performed on Sorbent Technologies Silica G TLC Plates w/UV354 
(0.25 mm). All compounds were visualized on TLC by cerium sulfate-ammonium 
molybdate staining. Column chromatography was carried out using forced flow of 
indicated solvent on Sorbent Technology Standard grade silica gel (40 – 63 μm particle 
size, 60 Ǻ pore size). Proton and Carbon NMR spectra were recorded on a Varian 
INOVA 500 NMR Spectrometer (500 MHz). Chemical shifts (δ) are reported in ppm 
with chemical shifts referenced to internal standards: CDCl3 (7.26 ppm for 1H, 77.0 ppm 
for 13C). Coupling constants (J) are reported in Hz and multiplicities are abbreviated as 
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singlet (s), doublet (d), triplet (t), multiplet (m), doublet of doublets (dd), and doublet of 
triplets (dt). High resolution Mass Spectra (HRMS) were obtained at the Mass 
Spectrometry Facility at Boston College unless otherwise noted.  
 
General procedures for solid-phase peptide synthesis 
 All peptides were synthesized by manual solid-phase methods on Rink Amide 
MBHA Resin using Fmoc as the protecting group for α-amino functionalities. Amino 
acids were coupled using PyBOP as the activating reagent. The following side-chain 
protecting groups were used: Asp(t-Bu), Lys(Boc), and Trp(Boc). The success of each 
Fmoc-deprotection and coupling reaction was qualitatively tested using the standard 
procedure for the Kaiser test. After the addition of the electrophile, cleavage from the 
resin was performed in TFA: DCM: TIS: water (90: 5: 2.5: 2.5) solution for 2 hrs. All 
peptides were purified by preparative HPLC with a gradient of increasing acetonitrile-
0.1% TFA (solvent B) in water-0.1% TFA (solvent A). All peptides were analyzed by a 
Micromass LCT TOF mass spectrometer coupled to a Waters 2975 HPLC and a Waters 
2996 photodiode array UV-vis detector.  
 
Synthesis of BsO-(propanamide)-Phe-Phe-Pra-Lys-NH2 (NJP1) 
Rink Amide MBHA resin was used and Fmoc-Lys(Boc)-OH, Fmoc-Pra-OH, 
Fmoc-Phe-OH, and Fmoc-Phe-OH residues were added under standard conditions. After 
Fmoc-deprotection, 3-(trityloxy)propanoic acid (NJP12) (2 eq) and PyBOP (2 eq) were 
dissolved in DMF and this solution was added to the resin. DIPEA (4 eq) was added to 
the resin, and the reaction was shaken at room temperature for 2 hrs. The solvent was 
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removed by vacuum and the resin was washed with DMF (5 x 3 mL) and DCM (3 x 3 
mL). The resin was shaken in a 1% TFA, 2% TIS in DCM solution to remove the trityl 
group (3 x 5 mins). Dry DCM was added to the resin and N2 gas was bubbled through the 
reaction vessel. NEt3 in large excess (~100 eq) followed by benzene sulfonylchloride in 
large excess (~100 eq) were added to the resin. N2 gas was bubbled through the reaction 
mixture for 1 hr, and any solvent lost was replaced. The reaction vessel was capped, 
sealed with parafilm, and shaken for 15 hrs. The solvent was removed and the resin was 
washed with DCM (5 x 3 mL). The peptide was cleaved using the conditions described 
above and purified by HPLC to give the pure peptide NJP1 (8.6%). HPLC tR = 20.00 min 
(C18, 5-95% B in 30 mins); HRMS for NJP1 (C38H46N6O8S + Na+): m/z calcd 769.2996; 
obsd [M + Na+] 769.4025 (MALDI+).  
 
Synthesis of BsO-(propanamide)-Ile-Gly-Pra-NH2 (NJP2) 
 The standard procedure outlined above for NJP1 was used, except the lysine was 
not added and the Fmoc-Phe-OH and Fmoc-Phe-OH were replaced with Fmoc-Gly-OH 
and Fmoc-Ile-OH respectively. The peptide was cleaved and purified by HPLC as 
described above to give the pure peptide NJP2 (8.3%). HPLC tR = 18.67 min (C18, 5-95% 
B in 30 mins); HRMS for NJP2 (C22H30N4O7S + Na+): m/z calcd 517.1733; obsd [M + 
Na+] 517.1737 (MALDI+). 
 
Synthesis of BsO-(propanamide)-Val-Phe-Pra-NH2 (NJP3) 
 The standard procedure outlined for NJP2 was used except the Fmoc-Gly-OH and 
Fmoc-Ile-OH were replaced with Fmoc-Phe-OH and Fmoc-Val-OH respectively. The 
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peptide was cleaved and purified by HPLC using the conditions described above to give 
the pure peptide NJP3 (7.1%). HPLC tR = 19.90 min (C18, 5-95% B in 30 mins); HRMS 
for NJP3 (C28H34N4O7S + Na+): m/z calcd 593.2046; obsd [M + Na+] 593.2056 (ESI+). 
 
Synthesis of BsO-(propanamide)-Leu-Asn-Pra-NH2 (NJP4) 
 The standard procedure outlined for NJP2 was used except the Fmoc-Gly-OH and 
Fmoc-Ile-OH were replaced with Fmoc-Asn(t-Bu)-OH and Fmoc-Leu-OH respectively. 
The peptide was cleaved and purified by HPLC using the conditions described above to 
give the pure peptide NJP4 (12%). HPLC tR = 18.05 min (C18, 5-95% B in 30 mins); 
HRMS for NJP4 (C24H33N5O8S + Na+): m/z calcd 574.1948; obsd [M + Na+] 574.1931 
(ESI+). 
 
Synthesis of BsO-(propanamide)-Ala-Trp-Pra-NH2 (NJP5) 
 The standard procedure outlined for NJP2 was used except the Fmoc-Gly-OH and 
Fmoc-Ile-OH were replaced with Fmoc-Trp(Boc)-OH and Fmoc-Ala-OH respectively. 
The peptide was cleaved and purified by HPLC using the conditions described above to 
give the pure peptide NJP5 (12%). HPLC tR = 19.14 min (C18, 5-95% B in 30 mins); 
HRMS for NJP5 (C28H31N5O7S + Na+): m/z calcd 604.1842; obsd [M + Na+] 604.1887 
(ESI+). 
 
Synthesis of Acrylamide-Phe-Phe-Pra-Lys-NH2 (NJP6) 
 The Rink Amide MBHA resin was used and Fmoc-Lys(Boc)-OH, Fmoc-Pra-OH, 
Fmoc-Phe-OH, and Fmoc-Phe-OH residues were added under standard conditions. After 
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Fmoc-deprotection, acrylic acid (2 eq) and PyBOP (2 eq) were dissolved in DMF and 
were added to the resin. DIPEA (4 eq) was added to the resin and the reaction was shaken 
at room temperature for 2 hrs. The solvent was removed by vacuum and the resin was 
washed with DMF (5 x 3 mL) and DCM (3 x 3 mL). The peptide was cleaved and 
purified by HPLC as described above to give the pure peptide NJP6 (5.9%). HPLC tR = 
17.53 min (C18, 5-95% B in 30 mins); HRMS for NJP6 (C32H40N6O5 + Na+): m/z calcd 
611.2958; obsd [M + Na+] 611.2975 (ESI+). 
 
Synthesis of Acrylamide-Ile-Gly-Pra-NH2 (NJP7) 
 The standard procedure outlined above for NJP6 was used, except the lysine was 
not added and the Fmoc-Phe-OH and Fmoc-Phe-OH were replaced with Fmoc-Gly-OH 
and Fmoc-Ile-OH respectively. The peptide was cleaved and purified by HPLC as 
described above to give the pure peptide NJP7 (13%). HPLC tR = 14.27 min (C18, 5-95% 
B in 30 mins); HRMS for NJP7 (C16H24N4O4 + Na+): m/z calcd 359.1696; obsd [M + 
Na+] 359.1678 (ESI+). 
 
Synthesis of Acrylamide-Val-Phe-Pra-NH2 (NJP8) 
 The standard procedure outlined above for NJP7 was used except the Fmoc-Gly-
OH and Fmoc-Ile-OH were replaced with Fmoc-Phe-OH and Fmoc-Val-OH respectively. 
The peptide was cleaved and purified by HPLC as described above to give the pure 
peptide NJP8 (7.7%). HPLC tR = 16.39 min (C18, 5-95% B in 30 mins); HRMS for NJP8 
(C22H28N4O4 + Na+): m/z calcd 435.2009; obsd [M + Na+] 435.2010 (ESI+). 
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Synthesis of Acrylamide-Leu-Asn-Pra-NH2 (NJP9) 
 The standard procedure outlined above for NJP7 was used except the Fmoc-Gly-
OH and Fmoc-Ile-OH were replaced with Fmoc-Asn(t-Bu)-OH and Fmoc-Leu-OH 
respectively. The peptide was cleaved and purified by HPLC as described above to give 
the pure peptide NJP9 (40%). HPLC tR = 15.07 min (C18, 5-95% B in 30 mins); HRMS 
for NJP9 (C18H27N5O5 + Na+): m/z calcd 416.1910; obsd [M + Na+] 416.1901 (ESI+). 
 
Synthesis of Acrylamide-Ala-Trp-Pra-NH2 (NJP10) 
 The standard procedure outlined above for NJP7 was used except the Fmoc-Gly-
OH and Fmoc-Ile-OH were replaced with Fmoc-Trp(Boc)-OH and Fmoc-Ala-OH 
respectively. The peptide was cleaved and purified by HPLC as described above to give 
the pure peptide NJP10 (21%). HPLC tR = 16.53 min (C18, 5-95% B in 30 mins); HRMS 
for NJP10 (C22H25N5O4 + Na+): m/z calcd 446.1805; obsd [M + Na+] 446.1801 (ESI+). 
 
Synthesis of 3-(trityloxy)propan-1-ol (NJP11) 
OHO
NJP11
 
A round bottom flask was flushed with N2 gas. 1,3-propanediol (6.0 mL, 83.0 
mmol) and pyridine (30 mL) were added to the flask. The solution was stirred and cooled 
on ice to 0 °C. Trityl chloride (23.3 g, 83.8 mmol) and pyridine (20 mL) were combined 
in a flask. This solution was added to the diol solution on ice. The reaction was left on ice 
and slowly warmed to room temperature overnight (15 hrs). The reaction mixture was 
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evaporated to dryness. The residue was dissolved in ethyl acetate (150 mL) and water 
(200 mL). The organic layer was separated from the aqueous layer. The organic layer was 
washed with 1 M HCl (3 x 100 mL), saturated sodium bicarbonate (3 x 100 mL), and 
brine (6 x 100 mL). The organic layer was dried with sodium sulfate, filtered, and 
evaporated to dryness to give the crude product. The crude product was dissolved in a 
small amount of DCM and purified by silica column chromatography using 5:1 hexane: 
ethyl acetate and 3:1 hexane: ethyl acetate. The fractions were analyzed by TLC in 1:1 
hexane: ethyl acetate. This process resulted in the monotritylated product, NJP11 (10.1 g, 
36.4%), a white powder. Rf 0.65 (1:1 hexane: ethyl acetate); 1H NMR (500 MHz, CDCl3): 
δ 7.18 – 7.37 (m, 15H), 3.70 (dt, J = 5.5Hz, 2H), 3.21 (t, J = 6.0 Hz, 2H), 1.79 (tt, J = 6.0 
Hz, 2H); 13C NMR (125 MHz, CDCl3): 143.9, 128.4, 127.9, 127.1, 87.1, 62.2, 61.8, 32.3. 
 
Synthesis of 3-(trityloxy)propanoic acid (NJP12) 
OHO
O
NJP12  
A round bottom flask was flushed with N2 gas. Oxalyl chloride (485 μL, 5.6 
mmol) was added to the reaction vessel and was dissolved in dry DCM (10 mL). The 
solution was stirred in a dry ice/acetone bath under N2. DMSO (935 μL, 13.2 mmol) and 
dry DCM (10 mL) were mixed in a N2 flushed round bottom flask. This solution was 
added dropwise to the reaction vessel over 10 mins. The monotrityl-protected alcohol 
NJP11 (1.2 g, 3.8 mmol) was dissolved in dry DCM (7 mL) in a N2 flushed round bottom 
flask. This solution was added to the reaction vessel dropwise. The reaction was stirred in 
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the dry ice/acetone bath for 10 mins under N2 gas. NEt3 (2 mL, 14.3 mmol) was added to 
the reaction dropwise. The reaction was stirred for 20 mins, then removed from the dry 
ice/acetone bath and stirred for 1 hour. The reaction was monitored by TLC in 1:1 
hexane/ethyl acetate. The reaction mixture was washed with water (3 x 50 mL), and the 
organic and aqueous layers were collected and combined. The aqueous layer was 
extracted with DCM (3 x 50 mL). The organic layers were combined, dried with sodium 
sulfate, filtered, and evaporated to dryness. The crude product (766.8 mg) was 
recrystallized in warm hexane. The crude product underwent subsequent oxidation. A 
round bottom flask containing the crude product (766.8 mg) was flushed with N2 gas. The 
crystals were dissolved in an acetone/water mixture (20 mL / 8 mL). KMnO4 (385.8 mg, 
2.4 mmol) was added to the stirring solution. The reaction was stirred under N2 for 2 hrs 
15 mins. The pH of the reaction mixture was adjusted to ~5 by the addition of 3 M HCl. 
A 40% sodium bisulfate solution was added until the reaction mixture turned colorless. 
The mixture was stirred for 45 mins. The mixture was acidified to a pH of 2 using 3 M 
HCl. The mixture was extracted with ethyl acetate (3 x 40 mL). The organic layers were 
collected, combined, and washed with water (3 x 70 mL). The organic layers were dried 
with sodium sulfate, filtered, and evaporated to dryness to form the crude product. The 
crude product was dissolved in a small amount of ethyl acetate and was purified by silica 
column chromatography using 3:2 hexane: ethyl acetate. The fraction was analyzed by 
TLC in 1:1 hexane: ethyl acetate. This process resulted in the pure monotritylprotected 
acid, NJP12 (314.4 mg, 25.1% over 2 steps), a white powder. Rf 0.25 (1:1 hexane: ethyl 
acetate); 1H NMR (500 MHz, CDCl3, TMS = 0.00 ppm): δ 11.1 (s, 1H, COOH), 7.23 – 
59 
 
7.47 (m, 15H), 3.41 (t, J = 6.5 Hz, 2H), 2.62 (t, J = 6.0 Hz, 2H); 13C NMR (125 MHz, 
CDCl3): 175.8, 142.8, 128.4, 127.9, 127.1, 87.1, 58.9, 35.0. 
 
Probe labeling and preparation of cell lysates 
 STS and DMSO-treated cells were treated with NJP1 – 10 by adding directly to 
the media from a 10 mM probe stock in DMSO to give a final probe concentration of 50 
μM. The plates were placed in the cell incubator at 37 °C under 5% CO2 for 1 hr. The 
cells were washed 3 times with PBS, harvested by scraping, and resuspended in an 
appropriate amount of PBS. Cells were sonicated to lyse, and these lysates were 
separated by centrifugation (45 mins, 45,000 rpm) at 4 °C under high vacuum to yield the 
soluble and membrane proteomes. The supernatant was collected as the soluble protein 
fraction and the pellet was discarded. Protein concentrations of these soluble lysates were 
determined using the Bio-Rad DC Protein Assay (Bio-Rad).  
 
In-gel fluorescent analysis 
 Protein samples (50 μL, 2 mg/mL) were subjected to click chemistry. Synthesized 
Rh-N357 (20 μM), TCEP (1 mM, from 50x fresh stock in water), TBTA ligand (100 μM, 
from 17x stock in DMSO : t-butanol 1:4), and copper(II) sulfate (1 mM, from 50x stock 
in water) were added in this order to the protein. The samples were vortexed after every 
addition, except TCEP, and allowed to react at room temperature for 1 hr, while being 
vortexed periodically. SDS-PAGE loading buffer 2x (reducing, 50 μL) was added to the 
samples and 25 μL of each protein solution was separated by SDS-PAGE for 217 V hrs 
on a 10% polyacrylamide gel. Gels were visualized for fluorescence on a Hitachi FMBIO 
60 
 
II multiview flatbed laser-induced fluorescent scanner. After analysis, gels underwent a 
typical procedure for coomassie staining. Stained gels were visualized on a Stratagene 
Eagle Eye apparatus by a COHU High performance CCD camera.  
 
HeLa cell culture and DNA fragmentation assay to monitor apoptosis 
 HeLa cells were grown at 37 °C under 5% CO2 in DMEM media supplemented 
with 10% FCS, 2 mM glutamine, and 1% Pen/Strep. HeLa cells grown to 100% 
confluency were treated with STS (4 μM from 1 mM stock) or the corresponding amount 
of DMSO. These cells were incubated for various time points at 37 °C under 5% CO2. 
The cells were washed 3 times with PBS, harvested by scraping, and lysed in 400 μL of 
lysis buffer (100 mM Tris pH 8.0, 5 mM EDTA, 0.2% SDS, 200 mM NaCl). Cells were 
incubated with RNase A (0.1 mg/mL) for 0.5 hr at 37 °C. Proteinase K was added to a 
concentration of 0.3 mg/mL and samples were incubated overnight at 55 °C. Genomic 
DNA was precipitated with isopropanol (1 volume) and resuspended in dH2O (100 μL). 
The DNA (10 μL) and bromophenol blue were combined and visualized on a 1% agarose 
gel with ethidium bromide.  
 
Jurkat cell culture, induction of apoptosis, probe labeling 
 Jurkat cells were grown at 37 °C under 5% CO2 in RPMI 1640 media 
supplemented with 10% FCS, 2 mM glutamine, and 1% Pen/Strep. STS (4 μM from 1 
mM stock) or the corresponding amount of DMSO was added to the media, and the cells 
were incubated at various time points at 37 °C under 5% CO2. NJP1-10 (50 μM from 10 
mM stocks) were added and the cells were incubated at 37 °C under 5% CO2 for 1 hr. 
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Induction of apoptosis was monitored by DNA fragmentation in the same manner as 
described above. Fluorescent gel analysis was also performed in the same manner as 
described above.  
 
Induction of apoptosis with CPT and fluorescent gel analysis 
 HeLa cells were grown at 37 °C under 5% CO2 in DMEM media supplemented 
with 10% FCS, 2 mM glutamine, and 1% Pen/Strep and allowed to reach 100% 
confluency. CPT (5, 10, 20 μM from 50x stock in DMSO) or DMSO was added to the 
cells and they were incubated for 4 hrs at 37 °C under 5% CO2. NJP2 (50 μM from 10 
mM stock in DMSO) was added and the cells were incubated at 37 °C under 5% CO2 for 
another hour. These CPT-treated cells were harvested and underwent fluorescent gel 
analysis as described above. STS-treated lysates were used as a control.  
 
Click chemistry and streptavidin enrichment of probe-labeled proteins for mass 
spectrometry 
 HeLa soluble protein lysates treated with STS and subsequently administered 
NJP2 or DMSO were prepared as described above. These protein samples (500 μL, 2 
mg/mL) were aliquoted to undergo click chemistry. Biotin azide38 (200 μM from 5 mM 
DMSO stock), TCEP (1 mM, from fresh 50x stock in water), ligand (100 μM, from 17x 
stock of DMSO : t-butanol 1:4), and copper(II) sulfate (1 mM, from 50x stock in water) 
were added to the protein samples. The samples were allowed to react at room 
temperature for 1 hr and were vortexed periodically. Tubes were centrifuged (10 mins, 4 
°C) to pellet the precipitated proteins. The pellets were resuspended in cold MeOH (500 
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μL) by sonication, centrifuged (10 mins, 4 °C), and the supernatants were removed. 
Following a second MeOH wash, the pelleted protein was solubilized in a 1.2% SDS in 
PBS solution (1 mL) by sonication and heating (5 mins, 80 °C). These solubilized 
samples were diluted with PBS (5 mL) to give a final SDS concentration of 0.2%. The 
solutions were incubated with streptavidin-agarose beads (100 μL, Thermo Scientific) at 
4 °C for 16 hrs and then at room temperature for 2.5 hrs. The beads were washed with 
0.2% SDS in PBS (5 mL), PBS (3 x 5 mL), and water (3 x 5 mL). The beads were 
pelleted by centrifugation (3 mins, 1400 x g) between washes.  
 
On-bead trypsin digestion 
 The washed beads were suspended in a 6 M urea in PBS solution (500 μL). DTT 
(10 mM, from 20x stock in water) was added to the samples and they were reduced by 
heating to 65 °C for 15 mins. Iodoacetamide (20 mM, from 50x stock in water) was 
added and the samples were placed in the dark so alkylation could proceed at room 
temperature for 30 mins. Following reduction and alkylation, the beads were pelleted by 
centrifugation (2 mins, 1400 x g) and resuspended in 2 mM of urea (200 μL), CaCl2 (1 
mM, from 100x stock in water), and trypsin (2 μg, from a 20 μg in 40 μL of trypsin 
buffer) in PBS. The digestion was then allowed to proceed overnight at 37 °C. The 
digestion was separated from the beads using a Micro Bio-Spin column (Bio-Rad). The 
beads were washed with water (2 x 50 μL) and the washes were combined with the eluted 
peptides. Formic acid (15 μL) was added to the samples, and they were stored at -20 °C 
until analyzed by mass spectrometry.  
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Liquid chromatography/mass spectrometry (LC/MS) analysis 
 LC/MS analysis was performed on an LTQ Orbitrap Discovery mass spectrometer 
(ThermoFisher) coupled to an Agilent 1200 series HPLC. Digests were pressure loaded 
onto a 250 μm fused silica desalting column packed with 4 cm of Aqua C18 reverse 
phase resin (Phenomenex). The peptides were eluted onto a biphasic column (100 μm 
fused silica with a 5 μm tip, packed with 10 cm C18 and 3 cm Partisphere SCX 
(Whatman) using a gradient of 5-100% Buffer B in Buffer A (Buffer A: 95% water, 5 % 
acetonitrile, 0.1% formic acid; Buffer B: 20% water, 80% acetonitrile, 0.1% formic acid). 
The peptides were eluted from the SCX onto the C18 resin and into the mass 
spectrometer following the four salt steps outlined previously.38 The flow rate through the 
column was set to ~0.25 μL/min and the spray voltage was set to 2.75 kV. One full MS 
scan (400-1800 MW) was followed by 8 data dependent scans of the nth most intense ions 
with dynamic exclusion enabled.  
 
MS Data Analysis 
 The generated tandem MS data were searched using the SEQUEST algorithm58 
against the human IPI database. A static modification of +57 on cysteine was specified to 
account for iodoacetamide alkylation. The SEQUEST output files generated from the 
digests were filtered using DTASelect 2.0.59 The data were then sorted by protein 
molecular weight to yield those between 25-30 kD, and all proteins in this range with 
detected average-spectral counts >5 in the NJP2-treated samples are disclosed. The data 
are ordered by fold-change, which is the ratio of average spectral counts in the NJP2-
treated sample, relative to those treated with DMSO. GSTO1 is the top hit in this table.  
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HEK 293T cell culture, recombinant expression of GSTO1-WT and GSTO1-C32A, 
and probe labeling 
 The cDNA for GSTO1-WT was subcloned into pcDNA3.1-myc-His mammalian 
expression vector. Site-directed mutagenesis was performed to obtain the C32A mutant 
(Quick-change, Stratagene), and all constructs were verified by sequencing (Genewiz, 
Cambridge, MA). HEK 293T cells were grown at 37 °C under 5% CO2 in DMEM media 
supplemented with 10% FCS, 2 mM glutamine, and 1% Pen/Strep. Transfections were 
performed on 10 cm cell plates of ~50% confluency. DMEM serum free media (600 μL) 
and X-tremeGENE DNA transfection reagent (20 μL) were combined in an Eppendorf 
tube. Plasmids of GSTO1 WT or C32A (6 μg) were added and the sample was vortexed 
and remained at room temperature for 15 mins. This plasmid solution was added 
dropwise to HEK 293T cells. The plate was incubated at 37 °C under 5% CO2 for 48 hrs. 
NJP2 (50 μM from 10 mM stock in DMSO) was added and the cells were incubated for 
another hour. HEK 293T cells transfected with the pcDNA3.1-myc/His plasmid were 
used as a mock negative control. The lysates were prepared as described above and 
underwent fluorescent gel analysis.  
 
Western blot analysis 
The SDS-PAGE gels from above were transferred by electroblotting into 
nitrocellulose membranes for 150 volt hours. The membranes were blocked with TBS-T 
and 5% (w/v) non-fat dry milk at room temperature for 2 hrs. The blot was washed with 
TBS-T three times (5 mins/wash), then treated with α-myc tag rabbit antibody (1:1000) 
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overnight at 4 °C. The blots were washed with TBS-T three times (5 mins/wash). The 
blots were treated with α-rabbit-HRP conjugated secondary antibody (1:10,000) for 2 hrs 
at room temperature. The blots were washed three times with TBS-T (5 mins/wash), 
treated with HRP super signal chemiluminescence reagents (Thermo) and exposed to film 
for 1 min before development. Development took place using a Kodak X-OMAT 2000A 
processor.  
 
In vitro and in situ labeling with non-specific PS-alkyne 
OS
O
O
PS-alkyne  
 The PS-alkyne probe was synthesized according to a previous protocol.33 HeLa 
cells were cultured as described above. Once the plates were grown to 100% confluency, 
STS (4 μM, from 1 mM stock in DMSO) or DMSO were added to the media and the cells 
were incubated for 4 hrs at 37 °C under 5% CO2. The PS-alkyne probe (50 μM from 10 
mM DMSO stock) was added and the cells were incubated for another hour. The lysates 
were prepared as described above. For the in vitro samples, unlabeled STS or DMSO-
control HeLa cell lysates were aliquoted (50 μL, 2 mg/mL). The samples were vortexed 
and allowed to sit at room temperature for 1 hr. Click chemistry and fluorescent gel 
analysis was performed on the in vitro and in situ labeled samples as described above.  
 
Synthesis of NJP13, a fluorescent version of NJP2 
 NJP2 (1.1 mg, 0.0022 mmol) and Rh-N3 (0.8 mg, 0.002 mmol) were dissolved in 
a mixture of MeOH (300 μL) and water (70 μL). A fresh solution of sodium ascorbate in 
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water (10 μL, 200 mg/mL) and copper(II) sulfate in water (3 μL, 85 mg/mL) were added 
to the solution. The sample was vortexed for 1.5 hrs. The solvent was evaporated off to 
leave a crude pink solid. The fluorescent peptide was purified by HPLC to yield NJP13 
(11.3%). HPLC tR = 20.07 min (C18, 5-95% B in 30 mins); HRMS for NJP13 
(C50H59N10O11S+): m/z calcd 1007.4080; obsd  [M]+ 1007.4087 (ESI+). The HRMS was 
performed on an LTQ Orbitrap Discovery mass spectrometer.  
 
Fluorescence microscopy 
 HeLa cells were plated on each well of a Lab-Tek Chamber Slide System 4-well 
Permanox slide and the cells were incubated overnight at 37 °C under 5% CO2. The cells 
were allowed to achieve ~50% confluency. All washes/media were removed gently with 
a pipet. The DMEM media was removed from each well and the wells washed with PBS 
(500 μL). RPMI 1640 media no phenol red supplemented with 10% FCS, 2 mM 
glutamine, and 1% Pen/Strep containing either DMSO (1 well per slide) or STS (1 μM 
from 1 mM stock in DMSO) was added to each well and the slides were incubated under 
the same conditions for the appropriate time course (30 mins, 1 hr, 2 hr – 1 well of each 
timepoint per slide). The media was removed from each well and the wells were washed 
with PBS (500 μL). RPMI 1640 media no phenol red containing NJP13 (1 μM) was 
added to each well. The slides were incubated for 1 hr. The media was removed from 
each well and the cells were washed with fresh RPMI 1640 clear media for 30 mins. The 
media was removed and each well was washed with PBS (3 x 500 μL) and cold MeOH (2 
x 500 μL). The dividers were removed and the slide was fixed with a couple of drops of 
MeOH and 3 coverslips (Fisherfinest premium, 18 mm x 18 mm) were added. Images 
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were taken on a Zeiss Axioplan 2 microscope equipped with a filter that allowed 
detection of rhodamine (546 excitation, 580-640 emission). A dry 40x objective (Plan-
NeoFluar, Zeiss) was used. Phase contrast images were taken by using the channel with 
polarized halogen light. All images were captured (time of exposure 527 msec), colored, 
and processed in OpenLab 5.5.2 following the same protocol.  
 
 
In situ labeling with NJP2 and evaluation of inhibitor potency using PS-Rh 
OS
O
O
N
H
O H
N
O
O
N+
PS-Rh  
STS and DMSO control-treated HeLa cells were administered NJP2 (from 10 mM 
stock in DMSO) to give final NJP2 concentrations of 1, 5, 10, 20, 40, 50, and 60 μM. 
Cells were harvested and lysates prepared as described above. PS-Rh (10 μM, from 500 
μM stock in DMSO), as synthesized according to previous method,54 was added to each 
protein aliquot (50 μL, 2 mg/mL). The samples were vortexed and allowed to sit at room 
temperature for 1 hr. The samples underwent fluorescent gel analysis as described above. 
Another set of these NJP2-treated protein samples (50 μL, 2 mg/mL) underwent click 
chemistry and fluorescent gel analysis as described above. The intensity of the bands 
from the PS-Rh-treated gel was quantified by ImageJ and the IC50 value for NJP2 
inhibition of GSTO1 in apoptotic cells was calculated from two trials at each inhibitor 
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concentration (1 – 60 μM). An example of each gel for the apoptotic samples is presented 
in Appendix III (Figure 2A-1).  
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Chapter 3 
A chemical-proteomic platform to identify zinc-binding cysteine residues 
 
 
 
 
 
 
 
 
 
 
 
 
A significant portion of the work described in this chapter has been published in: 
 
Pace, N. J.; Weerapana, E. A Competitive Chemical-Proteomic Platform to Identify Zinc-
Binding Cysteines. ACS Chem. Biol. 2014, 9, 258-265. 
Pace, N. J.; Weerapana, E. Zinc-Binding Cysteines: Diverse Functions and Structural 
Motifs. Biomolecules 2014, 4, 419-434.  
Qian, Y.; Martell, J.; Pace, N. J.; Ballard, T. E.; Johnson, D. S.; Weerapana, E. An 
Isotopically Tagged Azobenzene-Based Cleavable Linker for Quantitative Proteomics. 
ChemBioChem 2013 14, 1410-1414. 
78 
 
Introduction 
 
Overview 
 Of the biologically relevant transition metals, zinc is the second most abundant 
found within cells, behind only iron. Zinc ions (Zn2+) facilitate diverse protein functions 
that are essential for life. Common Zn2+ ligands within proteins include cysteine (S), 
histidine, (N), aspartate (O), and glutamate (O) residues. In particular, cysteine residues 
are very often observed as ligands at Zn2+-binding sites. The ionization state of the thiol 
group of cysteine governs its ability to bind metals such as Zn2+. Because the ionization 
state of cysteine is highly sensitive to small changes within the local protein 
environment,1 the affinity of cysteine for Zn2+ varies accordingly for each individual 
cysteine within a protein scaffold. These resulting Zn2+-cysteine complexes can be 
categorized by function: those that contribute to protein structure, catalysis, or regulation 
(Figure 3-1).2, 3 Additionally, the cysteine-rich metallothioneins tightly regulate cellular 
Zn2+ levels by storing and properly redistributing Zn2+ throughout the cell.4 Due to these 
diverse functional roles of Zn2+-cysteine complexes, the development of both 
experimental and theoretical approaches has been paramount in the identification and 
characterization of Zn2+-binding cysteines. Herein, we summarize key examples of 
functional cysteine complexes and discuss recent advances in methodologies to study 
them.   
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Figure 3-1. The diverse functional roles of Zn2+-cysteine complexes. Figure adapted 
from Pace et al.5 
 
Structural Zn2+-cysteine complexes   
 Since zinc is a d10 transition metal, it exclusively forms a Zn2+ ion and lacks 
redox activity within cells. Zn2+ typically is found to assemble coordination complexes 
with four ligands in a tetrahedral geometry. Recent studies estimate the human proteome 
consists of approximately 3000 Zn2+-proteins.6 Out of all the potential Zn2+ ligands 
within proteins (cysteine, histidine, aspartate, or glutamate), the sulfur atom of cysteine 
transfers the most charge over to Zn2+.  As cysteine occupies more ligand sites, it often 
quenches the ability of Zn2+ to act as a Lewis acid, rendering these complexes relatively 
inert.7 Consequently, Zn2+-cysteine complexes traditionally perform structural roles 
within proteins with the most abundant and extensively studied of these being the zinc-
finger motif.8  
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Figure 3-2. Three zinc-finger motifs bound within the major groove of a DNA strand 
with a single zinc-finger being highlighted (PDB ID: 1A1J). Figure adapted from Pace et 
al.5 
 
Zinc-finger motifs are canonically comprised of Cys4 or Cys2His2 coordination 
environments.6 The classical Cys2His2 zinc finger chelates a single Zn2+ within an α-helix 
and antiparallel β-sheet (Figure 3-2).9 Zinc-finger domains are typically found in clusters 
of four or more within a single protein, and often structurally stabilize the protein to 
promote interactions with other proteins and biomolecules, such as DNA and RNA. 
Although the functional roles of most zinc-finger proteins are poorly understand, most 
annotated proteins act as transcriptional activators or suppressors.10 A single zinc finger 
possesses four amino acids at the -1, 2, 3, and 6 positions  of the α-helix (Figure 3-2, 
highlighted in yellow) that participate in hydrogen-bond interactions with 3-4 nucleic 
acids within the major groove of DNA.11 Differential sequences at these four positions 
preferentially bind to distinct nucleic acid sequences with high affinity and selectivity.11 
Consequently, this motif has been exploited in the development of zinc-finger 
endonucleases for genetic engineering. By conjugating specific arrays of zinc-fingers to a 
promiscuous FokI endonuclease, DNA can be cut at an indicated sequence to disrupt, 
add, or correct the gene of interest.12 The development of a conserved linker sequence 
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was vital to the construction of polymeric zinc-finger endonucleases, requiring DNA 
sequences of up to 18 bp for recognition.13 This advance provided enough specificity to 
target single genes within the human genome,14, 15 and has extended genetic engineering 
to diverse gene families.12    
 
Catalytic Zn2+-cysteine complexes 
 Beyond their structural roles, cysteines bind Zn2+ to directly facilitate enzymatic 
transformations. Cysteines are less commonly observed ligands in catalytic Zn2+ 
complexes due to the steric bulk of the sulfur and greater charge transfer compared to 
histidine or water ligands.7 However, catalytic Zn2+-cysteine complexes have been 
observed across diverse enzyme classes, such as oxidoreductases, hydrolases, and 
transferases (Table 3-1). The exact mechanism varies within each individual enzyme, but 
typically is comprised of either substrate coordination or activation by the Zn2+.  
Protein Enzyme Class Function Mechanism 
Alcohol dehydrogenase Oxidoreductase Interconverts alcohols to aldehyde and ketones 
Zn2+-coordination of 
substrate16 
Sorbitol dehydrogenase Oxidoreductase Interconverts sorbitol to fructose 
Zn2+-activation of 
nucleophilic water 
molecule17 
Cytidine deaminase Hydrolase 
Irreversible hydrolytic 
deamination of cytidine to 
uridine 
Zn2+-activation of 
nucleophilic water 
molecule18, 19 
GTP cyclohydrolase Hydrolase Converts GTP to dihydroneopterin 
Zn2+-activation of 
nucleophilic water 
molecule20 
Betaine-homocysteine 
methyltransferase Transferase 
Transfers methyl group 
from betaine to 
homocysteine, forming 
dimethyl glycine and 
methionine 
Zn2+-activation of 
thiol of homocysteine 
substrate21 
Protein farnesyltransferase Transferase 
Post-translational addition 
of farnesyl to cysteine 
residues within proteins 
Zn2+-activation of 
thiol on target 
protein22, 23 
Table 3-1. Representative human proteins containing catalytic Zn2+-cysteine complexes.  
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Alcohol dehydrogenases (ADHs) constitute a well-studied class of enzymes that 
were first discovered to require a Zn2+ for catalysis over 50 years ago.24 These 
evolutionarily conserved enzymes facilitate the interconversion between alcohols and 
ketones or aldehydes. Humans possess six distinct classes of ADH enzymes (Figure 3-
3a), each utilizing a catalytic mechanism dependent on a cysteine residue binding Zn2+.25 
The active enzyme is a dimer, with each 40 kD monomer possessing a catalytic complex 
comprised of a Zn2+ bound to cysteine and an NAD+ cofactor.16, 26 In the case of ADH5, 
the Zn2+ is bound to Cys46 and Cys 174 (red), His66 (blue) and coordinates the alcohol 
substrate (cyan) adjacent to the NAD+ (yellow). The bound Zn2+ coordinates the substrate 
in the correct geometry for the sequential proton transfer to Ser48, NAD+, and His51, 
while also properly positioning the alcohol for hydride transfer to NAD+ (Figure 3-3b). 
Although they do not directly interact with the substrate, these cysteine residues are 
essential for ADH activity and are highly conserved through human ADH enzyme 
classes.25 
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Figure 3-3. (a) The active-site of ADH5 contains a Zn2+ (purple) bound to two cysteines 
(Cys46, Cys174, red), a histidine (His66, blue), and S-hydroxymethyl glutathione as the 
alcohol substrate (cyan). This positions the alcohol in the correct geometry to the adjacent 
NAD+ cofactor (yellow) (PDB ID: 1MC5). (b) The bound Zn2+ facilitates sequential 
proton transfers from the alcohol substrate to Ser48, NAD+, and His51, while also 
properly positioning the alcohol for a hydride transfer to NAD+. Figures adapted from 
Pace et al.5    
 
Regulatory Zn2+-cysteine complexes 
 Additionally, cysteine residues have also been observed to bind Zn2+ to modulate 
protein activities. In these cases, Zn2+-binding must be weaker and more transient in 
nature to allow for the interchange between bound and apo-forms. As a result, these 
cysteines are often more challenging to identify. Characterized regulatory mechanisms 
range in complexity, and include inhibitory, redox-switches, and protein interface Zn2+-
84 
 
cysteine complexes (Table 3-2).  Herein, we will detail each class and provide a well-
characterized example.  
Protein Enzyme Class Function Mechanism 
Dimethylarginine 
dimethylaminohydrolase Hydrolase 
Converts N-omega,N-omega-
methyl-L-arginine to dimethylamine 
and L-citrulline 
Inhibitory27 
Ornithine 
transcarbamoylase Transferase 
Converts carbamoyl phosphate and 
ornithine to citrulline and phosphate Inhibitory
28 
Cathepsin S Protease Lysosomal cysteine protease Inhibitory29, 30 
Caspase 3 Protease Cysteine protease Inhibitory31, 32 
Caspase 6 Protease Cysteine protease Inhibitory33 
Caspase 9 Protease Cysteine protease Inhibitory34 
Aconitase 2 Isomerase Converts citrate to iso-citrate Inhibitory35 
Glutathione S-transferase 
omega 1 Transferase 
Conjugates glutathione to a variety 
of electrophiles Inhibitory
36 
Betaine-homocysteine 
methyltransferase Transferase 
Transfers methyl group from betaine 
to homocysteine, forming dimethyl 
glycine and methionine 
Redox-switch37 
Protein kinase C Kinase Phosphorylates serines and threonines Redox-switch
38 
Nitric oxide synthase Oxidoreductase Produces nitric oxide and arginine 
Protein 
interface39; 
Redox-switch40 
Apo2L/TRAIL Cytokine Induces signaling pathways to trigger apoptosis Protein interface
41 
Table 3-2. Representative human proteins containing regulatory Zn2+-cysteine 
complexes.  
 
Inhibitory Zn2+-cysteine complexes 
 Cysteine residues have been found to bind Zn2+ as a means of inhibiting 
enzymatic activities.29 Inhibition usually occurs by chelation of Zn2+ to the catalytic 
cysteine residue (e.g. dimethylarginine dimethylaminohydrlase), but allosteric inhibition 
attributed to Zn2+-binding at a cysteine distal to the active-site has also been described 
(e.g. caspase 9) (Table 3-2). 
   Dimethylarginine dimethylaminohydrolase (DDAH-1) is a metabolic enzyme 
responsible for the conversion of dimethylarginine to dimethylamine and citrulline. 
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Dimethylarginine is known to inhibit nitric oxide synthases to mitigate the production of 
nitric oxide, an important cell-signaling molecule.42 The best studied DDAH-1 is from 
bovine; however, the human homologue retains 94% sequence homology. Zn2+ inhibits 
DDAH-1 activity with a Ki of 4.2 nM at pH 7.4.27  This value is rather high when 
considering the physiological range of available Zn2+ concentrations and is suggestive of 
a weaker, more transient binding mode that is indicative of a regulatory role for Zn2+ 
within DDAH-1. The enzyme functions through a nucleophilic cysteine residue (Cys274) 
conserved in both the human and bovine forms.43 Structural studies reveal a Zn2+ (purple) 
bound to the catalytic Cys274 (red) and His173 (blue) within the active-site of the 
enzyme (Figure 3-4).44 The remaining two ligands are comprised of water molecules 
(white) stabilized by hydrogen-bonding to adjacent Asp79 and Glu78 (orange). DDAH-1 
only possesses two Zn2+ ligands instead of the typical three or four, which may contribute 
to the weaker, more transient Zn2+ binding.  
 
Figure 3-4. Zn2+ bound within the active-site of DDAH-1 (PDB ID: 2CI7).44 Figure 
adapted from Pace et al.5 
 
Although most inhibitory Zn2+-cysteine complexes are found to bind directly to 
the nucleophilic cysteine residue, the potential for allosteric inhibition has been realized 
86 
 
in the case of caspase-9. Caspases are cysteine-dependent aspartate-directed proteases 
that play a prevalent role in signaling cascades culminating in apoptosis.45 Zn2+ has been 
implicated as a strict mediator of apoptosis, where small fluctuations in concentration can 
strongly dictate cell survival and death.46 Caspase-9 is an initiator caspase that goes on to 
cleave executioner caspases-3 and -7 to trigger apoptosis. When attempting to decipher 
the mechanism of Zn2+-mediated inhibition of capase-9, two distinct Zn2+ binding sites 
were uncovered. The first, comprised of the catalytic dyad, His237 and Cys239 (red), 
along with the adjacent Cys287 (red), was primarily responsible for the Zn2+-mediated 
inhibition.34 The second binding site, which comprised Cys272, Cys230, and His224 
(orange), was found distal to the active-site (Figure 3-5). Subsequent assays suggested 
that this distal site may have the potential for Zn2+-mediated allosteric inhibition of 
caspase-9 activity.34 To give precedence to this notion, Zn2+-mediated allosteric 
inhibition has been observed in Caspase-6; however, cysteines are not Zn2+ ligands in this 
instance.33 
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Figure 3-5. Caspase-9 structure highlighting possible Zn2+-cysteine inhibitory sites. 
Figure adapted from Pace et al.5  
 
Redox-switch Zn2+-cysteine complexes 
 Cysteine residues are susceptible to a myriad of post-translational modifications 
including oxidation, nitrosation, and disulfide formation.47-49 The ability of cysteine to 
bind Zn2+ is predicated upon the presence of a fully reduced, unmodified thiol. Cellular 
redox metabolism can therefore be coupled to Zn2+-binding, giving rise to a “redox-
switch” regulatory mechanism, where increase in oxidants of sulfur release Zn2+ and 
reductants restore the Zn2+-binding capacity of the thiol.50 Regulatory Zn2+-cysteine 
complexes that function through a redox-switch mechanism have been found to modulate 
diverse enzymatic activities (Table 3-2). Betaine-homocysteine methyltransferase 
(BHMT) is an essential metabolic enzyme that contributes to the biosynthesis of glycine, 
serine, threonine, and methionine.51 This transformation relies on a Zn2+-cysteine 
complex to activate the homocysteine substrate (cyan). Under reducing conditions, 
Cys217, Cys299, and Cys300 (red) chelate Zn2+ (purple) to assemble the active form of 
the enzyme (Figure 3-6, left). Upon exposure to oxidative conditions, Cys217 and 
Cys299 (red) form a disulfide bond resulting in the release of Zn2+ and inactivation of the 
enzyme (Figure 3-6, right).37 This interplay between Zn2+-binding and disulfide 
formation couples the intracellular redox state to BHMT activity.  
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Figure 3-6. A Zn2+-cysteine redox-switch regulates BHMT activity. Figure adapted from 
Pace et al.5 
 
Protein interface Zn2+-cysteine complexes 
 Zn2+-cysteine complexes can also stabilize interactions between two proteins or 
protein-subunits. The dependence of these protein-protein interactions on available Zn2+ 
levels establishes a novel mechanism to modulate protein supramolecular assembly and 
subsequent enzymatic activities (Table 3-2). Nitric oxide synthases (NOS) catalyze the 
formation of nitric oxide and citrulline from arginine through a complex mechanism 
consisting of five single-electron transfers.52 Proper dimer formation is essential for 
oxidoreductase activity. Structures of the endothelial NOS isoform (NOS3) revealed a 
Zn2+ bound to Cys94 and Cys99 from each monomer (Figure 3-7).39 The Zn2+-cysteine 
complex assists in proper dimer formation, a prerequisite for binding of the substrates and 
cofactors. Additionally, these Zn2+-binding cysteines appeared susceptible to redox-
modifications, particularly by peroxynitrite. A recent study speculates that peroxynitrite 
facilitates disulfide-bond formation between Cys94 and Cys99 in each monomer, 
allowing for subsequent release of Zn2+, release of free monomers, and disruption of 
enzyme activity.40 This Zn2+-cysteine complex, employing both protein interface and 
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redox-switch mechanisms, illustrates the potential for multifaceted protein regulation by 
Zn2+-binding cysteines.   
 
Figure 3-7. The α-subunit (green) and β-subunit (blue) of NOS3 are dependent on Zn2+-
binding cysteines for dimerization. Cys94 and Cys99 (red) from each subunit chelate a 
Zn2+ (purple) to stabilize dimer formation, allowing for proper binding of the heme 
cofactor (orange), tetrahydrobiopferin cofactor (yellow), and the homo-arginine substrate 
(magenta) within each active-site (PDB ID: 3NOS). Figure adapted from Pace et al.5  
 
Zn2+-cysteine complexes for Zn2+ transfer and cellular redistribution 
 Zn2+ readily forms stable coordination complexes, resulting in extremely low 
concentrations of free Zn2+ within cells.53, 54 On the contrary, total cellular Zn2+ 
concentrations have been estimated on the order of 100 micromolar with Zn2+ being 
strongly buffered through a protein storage system.55 Metallothioneins are a superfamily 
of low molecular weight proteins (6 – 7 kD) that possess 20 cysteine residues capable of 
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binding up to 7 Zn2+ within Zn4Cys11 and Zn3Cys9 clusters with unique geometries. These 
clusters have been evaluated as thermodynamically stabile, yet kinetically labile.56 As a 
result, metallothionein and the apo-form, thionein, are able to rapidly donate/accept Zn2+ 
through ligand exchange.57 This rapid exchange allows metallothioneins to increase the 
pool of available Zn2+, providing an adequate source of Zn2+ for proteins.58 Interestingly, 
while Zn2+-binding to metallothioneins has not been found to be cooperative, the 
cysteines of the Zn4Cys11 bind slightly tighter than the Zn3Cys9 cluster, producing a more 
fluid buffering mechanism.54 Zn2+-complexes regulated by metallothioneins/thioneins 
modulate diverse protein activities such as gene expression and DNA repair.59  
 
Methods of identification of Zn2+-cysteine complexes 
 Because of the importance of Zn2+-cysteine complexes to protein structure and 
function, strategies to identify them have been thoroughly explored. The most common 
methods combine experimental strategies, including structural genomics and NMR-based 
platforms, with computational approaches, consisting of homology searches of sequence 
databases.60-62 Despite advances in both these fields, they frequently encounter a number 
of limitations. These structure-based approaches are reliant on a high resolution structure 
being available for the protein of interest or a close homologue, and the Zn2+-cysteine 
complex must be stable to the conditions required to produce the structure. Similarly, 
computational methods have been successful in identifying Zn2+-cysteine complexes with 
recognized sequence conservation, but are ineffective at predicting Zn2+-cysteine 
complexes in which the defining structural features are unknown. For both cases, 
differentiation between protein-bound Zn2+ and other metal ions remains challenging, 
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thereby complicating the identification of the physiologically relevant metal species. 
Together, these methods prove to be well-suited to distinguish Zn2+-cysteine complexes 
within motifs where structural features have been well-defined, such as zinc-finger 
domains; however, regulatory Zn2+-cysteine complexes are more difficult to identify due 
to their necessary transient binding. By nature, these complexes must be more labile to 
allow for interchange between the Zn2+-bound and apo-protein forms. The employment 
of fewer protein-based ligands (one or two instead of three or four) and the use of ligands 
from multiple proteins or subunits at binding interfaces contribute to this transient 
binding ability. As a result, regulatory Zn2+-cysteine complexes are difficult to predict, 
and structures and homology searches fail to sufficiently detect them.  
Due to their importance and the limitations of current technologies, the 
development of new platforms to characterize functional Zn2+-cysteine complexes is vital 
for their expanded annotation across the entire proteome. Herein, we propose an 
alternative strategy for identifying Zn2+-cysteine complexes within the human proteome, 
especially transient, regulatory complexes. Functionally important cysteine residues, 
including metal-binding cysteines, typically exhibit hyper-reactivity63 and are therefore 
susceptible to covalent modification by small molecules containing cysteine-reactive 
electrophiles.64 Our hypothesis is predicated upon the mitigated nucleophilicity of the 
metal-bound thiol of cysteine as compared to the free thiol; thus, Zn2+-binding cysteines 
would show a decreased reactivity with cysteine-reactive chemical probes upon 
pretreatment with Zn2+ ions. These reactivity changes could be visualized by in-gel 
fluorescence and quantified using mass spectrometry (Figure 3-8).  
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Figure 3-8. Proposed chemical-proteomic platform coupled to in-gel fluorescence or 
mass spectrometry for identification of Zn2+-cysteine complexes and quantification of 
their relative affinities.  
 
Results and Discussion 
 
Cysteine-reactive probes can identify Zn2+-cysteine complexes 
 Of the many cysteine-reactive probes utilized within the lab, two were selected to 
validate our proposed strategy based on their contrasting reactivities. The commonly used 
IA-alkyne (N-(hex-5-yn-1-yl)-2-iodoacetamide), a highly reactive, promiscuous probe for 
cysteines, was first employed for an initial gel-based evaluation (Figure 3-9a). Soluble 
HeLa lysates were first treated with a panel of biologically relevant divalent metal ions: 
Zn2+, Ca2+, Mg2+, or Mn2+. After pre-treatment, the lysates were administered IA-alkyne, 
fractionated on a size exclusion column to eliminate any unbound metal or probe, and 
visualized by in-gel fluorescence after incorporation of rhodamine azide (Rh-N3) through 
click chemistry (Figure 3-9b). Although a few proteins experienced an observable 
reduction in fluorescence signal upon Zn2+-treatment, the IA-alkyne’s high reactivity 
resulted in conjugation to a large amount of proteins, which made distinguishing Zn2+-
sensitivity rather difficult.    
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Figure 3-9. (a) Structure of IA-alkyne. (b) In-gel fluorescence analysis of HeLa lysates 
treated with Zn2+, Ca2+, Mg2+, or Mn2+ and subsequently administered IA-alkyne.  
 
NJP14 was also chosen to evaluate the proposed strategy. When evaluating our 
peptide-based library of cysteine-reactive probes, NJP14 was found to label a distinct 
subset of reactive cysteines from diverse protein classes as identified by LC/LC-MS/MS 
and detailed in Appendix II (Table 3A-1).36 NJP14 consists of a Ser-Pro-Pra-Phe-Phe 
pentapeptide scaffold conjugated to a moderately-cysteine reactive chloroacetamide 
electrophile (Figure 3-10a). Because of its moderate-reactivity towards only a subset of 
reactive cysteines within the proteome, NJP14 appeared more adept to visualize potential 
Zn2+-sensitive cysteines by in-gel fluorescence. After subjecting HeLa lysates to the same 
in-gel fluorescence protocol, two particular gel bands, one at ~38 kD and the other at ~28 
kD, displayed a complete loss of fluorescence signal solely within the Zn2+-treated 
samples. These bands have been arbitrarily labeled as band A and band B (Figure 3-10b).  
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Figure 3-10. (a) Structure of NJP14. (b) In-gel fluorescence analysis of HeLa lysates 
treated with Zn2+, Ca2+, Mg2+, or Mn2+ and subsequently administered NJP14. 
 
 Because Zn2+-induced precipitation of protein has been previously observed,65 we 
sought to eliminate this possibility by demonstrating the fluorescent signal for these 
proteins could be recovered with the addition of a Zn2+-chelator, EDTA, to Zn2+-treated 
samples (Figure 3-11a). This supports our hypothesis that reversible Zn2+-binding to a 
reactive cysteine accounts for the mitigated fluorescent signal, as opposed to irreversible 
Zn2+-inducted protein precipitation. Additionally, treatment with only EDTA also 
resulted in an increase in fluorescent signal (especially for band A), suggesting that 
EDTA is able to remove prebound metal ions to enhance cysteine reactivity (Figure 3-
11a). This provides further support of our hypothesis that this competitive platform is 
selecting for endogenous Zn2+-cysteine complexes.  
To further demonstrate the utility of our platform, we sought to quantitatively 
compare the relative Zn2+-affinities for band A and band B.  The in-gel fluorescence 
platform was carried out on lysates exposed to increasing Zn2+ concentrations (100 nM – 
10 μM). The fluorescent intensities of each band was integrated from three trials, and 
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plotted to calculate relative EC50 values (Figure 3-11b). These values ranged from 365 
nM for band A to 2.1 μM for band B, illustrating the differential affinities of each 
cysteine residue for Zn2+.  
 
Figure 3-11. (a) The effects of Zn2+ (10 μM) and EDTA (1 mM) on in-gel fluorescent 
signals from band A and band B. (b) Integrated fluorescent signals of band A and band B 
from three trials were plotted to quantify relative affinities for Zn2+.  
 
We next sought to identify the proteins represented by band A and band B by 
adapting our platform to mass spectrometry. HeLa lysates were preincubated with Zn2+, 
Mg2+, or DMSO as a control and subsequently labeled with NJP14. The probe-labeled 
proteins were tagged with biotin-azide through click chemistry, enriched on streptavidin 
beads, and subjected to on-bead tryptic digestion, and LC/LC-MS/MS analysis.66  
Proteins identified with high spectral counts in the vehicle and Mg2+-treated samples with 
significantly decreased spectral counts within the Zn2+-treated samples were designated 
as putative Zn2+-chelating proteins. Spectral counts refer to the total fragmentation 
spectra for peptides identified from a particular protein and provide a semi-quantitative 
measure of protein abundance across numerous proteomic samples. To best sort our 
dataset, for each of the proteins a % change in spectral counts was calculated for both 
Zn2+ / Mg2+ treatments, and the data were ranked by those that showed the largest 
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decrease in spectral counts (largest negative % change) in the Zn2+ 20 μM samples 
relative to the Ctrl samples (Table 3-3, Figure 3-12). The full dataset is presented in 
Appendix II (Table 3A-2). The majority of the proteins displayed no reduction in spectral 
counts due to Zn2+-treatment, such as bleomycin hydrolase (BLMH); however, this 
analysis identified the two Zn2+-sensitive proteins as visualized by gel as sorbitol 
dehydrogenase (SORD, band A, red point in Figure 3-12) and glutathione S-transferase 
omega 1 (GSTO1, band B, blue point in Figure 3-12) (Figure 3-13). These two proteins 
displayed the largest negative % change in the Zn2+ 20 μM samples and the molecular 
weights coincided with band migration during in-gel fluorescence.  Interestingly, a few 
proteins displayed a large % decrease in spectral counts upon treatment with Mg2+, with 
low sensitivity to Zn2+ (yellow points, Figure 3-12). While cysteine is not typically found 
as a ligand for Mg2+, these could represent cysteines that are allosterically modulated by 
Mg2+ and could present interesting case studies for the future.67   
 
 
Figure 3-12. Mass spectrometry data of each protein represented as a % Change of the 
Zn2+ and Mg2+-treated samples relative to the Ctrl sample. 
 
97 
 
Protein Molecular 
Weight 
Spectral Counts % 
Change 
Zn2+    
(20 μM) Ctrl Zn
2+ 
(10μM) 
Zn2+ 
(20μM) 
Mg2+ 
(20μM) 
SORD similar to sorbitol dehydrogenase 38687 250 12 3 262 -98.8 
GSTO1 Glutathione transferase omega-1 27566 324 269 24 267 -92.5926 
TXNRD1 thioredoxin reductase 1 isoform 3 71153 535 86 42 464 -92.1495 
RRM1 Ribonucleoside-diphosphate 
reductase large subunit 90070 136 114 26 124 -80.8824 
RPS3 40S ribosomal protein S3 26688 40 21 13 38 -67.5 
EEF1A2 Elongation factor 1-alpha 2 50470 68 45 25 15 -63.2353 
TUBB4 Tubulin beta-4 chain 49586 351 246 171 357 -51.2821 
TGM2 Isoform 1 of Protein-glutamine 
gamma-glutamyltransferase 2 77329 53 27 26 63 -50.9434 
Table 3-3. Mass spectrometry data using NJP14 reveals proteins containing Zn2+-
sensitive cysteine residues. The data were sorted by % change in spectral counts when 
comparing the control sample to Zn2+ (20 μM)-treated sample.  
 
To corroborate our mass-spectrometry data, gel-based studies were performed to 
confirm the observed Zn2+-sensitivity of SORD and GSTO1 and corresponding Zn2+-
insensitivity for BLMH (Figure 3-13). The three proteins were each overexpressed with 
C-terminal myc/His tags through transient transfection in HEK293T cells, and the 
overexpressed lysates were subjected to our in-gel fluorescence platform. As predicted by 
our mass spectrometry data, a reduced fluorescent signal was observed in both SORD and 
GSTO1 lysates upon Zn2+ treatment, but BLMH fluorescence was unaffected. 
Overexpression of SORD and GSTO1 was confirmed using an α-myc antibody, while an 
α-BLMH antibody had to be employed to confirm expression of BLMH because of auto-
cleavage of its C-terminal tag (Figure 3-13).   
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Figure 3-13. Spectral counts from mass spectrometry analysis of SORD, GSTO1, and 
BLMH upon Zn2+ or Mg2+ treatment. In-gel fluorescence analysis of overexpressed 
protein lysates confirms SORD and GSTO1 as Zn2+-sensitive and BLMH as Zn2+-
insensitive. Overexpression was confirmed by either α-myc or α-BLMH antibody.  
 
NJP14 modifies the catalytic Zn2+-chelating cysteine of SORD 
SORD is a metabolic enzyme within the polyol pathway that functions to reduce 
aberrantly high glucose levels. A major consequence of glucose metabolism by the polyol 
pathway is the production of reactive oxygen species (ROS), and this polyol pathway-
induced oxidative stress is most likely an important contributing factor to diabetes 
mellitus (Figure 3-14). Under homeostatic conditions, glycolysis mediates the conversion 
of glycose to pyruvate to generate ATP and facilitate other metabolic pathways such as 
the tricarboxylic acid cycle. Under a state of hyperglycemia, aldose reductase first 
converts glucose to sorbitol, utilizing NADPH as a cofactor. As a result, the cytosolic 
ratio of NADP+/NADPH drastically increases, preventing reduction of GSSG to GSH by 
99 
 
glutathione reductase, which leads to increased ROS.68, 69 Next, sorbitol is converted to 
fructose by SORD, utilizing NAD+ as a cofactor. This reaction has multiple consequences 
that contribute to oxidative stress. First, fructose can be converted to fructose-3-
phosphate and 3-deoxyglucosone and results in an increase in advanced glycation end 
products (AGEs) that contribute to generation of ROS.69 Additionally, activity by SORD 
produces a drastic decrease in the cytosolic NAD+/NADH ratio. Under homeostatic 
conditions, the conversion of NAD+ to NADH by SORD is balanced by the reduction of 
pyruvate to lactate by lactate dehydrogenase. Under hyperglycemic conditions,  
glyceraldehyde phosphate dehydrogenase (GAPDH) cannot convert glyceraldehyde-3-
phophate to 1,3-bisphosphoglycerate because the transformation requires NAD+.69, 70 
Instead, accumulating glyceraldehyde-3-phosphate enters alternative metabolic pathways 
to generate more AGEs that also contribute ROS production. Because of its impact on 
ROS production that likely contributes to disease pathways such as diabetes mellitus, 
SORD structure and enzymatic activity has been extensively studied 
Structural studies have concluded that SORD is active as a tetramer, each 
containing a single catalytic Zn2+-cysteine complex (Figure 3-15a). SORD has long been 
accepted to utilize a catalytic Zn2+-cysteine complex within its enzymatic mechanism.71, 
72 Moreover, a recent crystal structure determined that each subunit of the tetrameric 
protein coordinates the Zn2+ to Cys44, His69, Glu70, and an activated water molecule 
(Figure 3-15b).17 The mechanism has been hypothesized to occur through nucleophilic 
attack by this activated water molecule on sorbitol with concomitant hydride transfer to 
NAD+, similar to that of ADH.17 Importantly, this reaction is reversible; and, although to 
a lesser degree, SORD shows the capacity to also convert fructose back to sorbitol.  
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Figure 3-14. The polyol pathways functions to reduced aberrantly high glucose levels, 
but consequently generates significant oxidative stress. Sorbitol dehydrogenase (blue 
box) is a main component of this pathway and facilitates the reversible conversion of 
sorbitol to fructose 
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Figure 3-15. (a) Structure of SORD tetramer, each containing an active-site with a single 
bound Zn2+. (b) The active-site of SORD contains a Zn2+ (purple) bound to Cys44 (red), 
His69 (blue), Glu70 (orange) and an activated water molecule (white). The substrate is 
anticipated to bind the activated water molecule and be position in the proper geometry 
for hydride transfer to NAD+ (yellow).  
 
Because of its drastic increases on ROS production observed upon SORD activity, 
the development of SORD inhibitors are crucial to evaluate the effect of SORD activity 
on contributions to cellular functions and diabetes. Inhibitor development will also allow 
for the assessment of SORD inhibition as a therapeutic strategy for diabetic patients. 
Toward this end, a very limited number of SORD inhibitors have been developed in 
recent years (Figure 3-16a). The first, and most well-studied, of these inhibitors is SDI-
158, which has been found to inhibit  SORD activity with an IC50 of 250 nM and Ki for 
SORD of 154 nM.73 Crystal structures dosed with SDI-158 revealed that the inhibitor acts 
by chelating the active-site Zn2+ through both a pyrimidine nitrogen and the 
hydroxymethyl oxygen, displacing the activated water molecule and preventing 
nucleophilic attack on the substrate (Figure 3-16b).17 Notably, SDI-158 is uncompetitive 
in respect to NAD+, NADH, and sorbitol, meaning that the assembled enzyme-substrate 
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complex is required for SDI-158 binding. SDI-158 underwent stringent SAR analysis, 
resulting in the optimized SORD inhibitor, Compound 20, with an IC50 value of 4 nM 
and improved pharmacological properties.74 Through the use of these inhibitors, recent 
attention has been directed to SORD’s involvement in diabetic complications, although 
its role to date is still unclear. Additionally, the therapeutic potential of SORD inhibition 
has not been confirmed or refuted, producing conflicting results that either support or 
reject this strategy.69 
 
Figure 3-16. (a) Structures of SORD inhibitors SDI-158 and Compound 20. (b) SORD 
active-site with Zn2+ (purple) bound to Cys44 (red), His69 (blue), and SDI-158 
(magenta). This displaces Zn2+-chelation of the required water molecule (not shown) and 
Glu70 (orange) and prevents substrate binding. Inhibition has no effect on NAD+ binding 
(yellow). 
  
We aimed to examine the binding mode of NJP14. We hypothesized that NJP14 
covalently modified this Cys44 within this predicted catalytic Zn2+-cysteine complex; 
however, a previous proteomic study identified another cysteine within SORD (Cys179) 
as being hyper-reactive.63 In order to determine the site of labeling of NJP14, SORD WT, 
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C44A, and C179A mutants were overexpressed by transient transfection in HEK293T 
cells, and these lysates were subjected to our in-gel fluorescence analysis. A complete 
loss of labeling was observed in the C44A sample, confirming that NJP14 does indeed 
target this Zn2+-binding cysteine of SORD (Figure 3-17). The identification of a known 
Zn2+-binding cysteine through our platform serves to validate our competitive cysteine-
labeling strategy to identify putative Zn2+-binding cysteines in the human proteome.  
 
Figure 3-17. In-gel fluorescence analysis and corresponding western blots of 
overexpressing SORD WT, C44A, and C179 lysates compared to the mock. 
 
 To fully assess the effects of Zn2+, EDTA, and NJP14 on SORD function, SORD 
activity assays were performed using SORD-overexpressing HEK293T lysates. We 
employed previously reported oxidative and reductive activity assays, in an effort to 
evaluate both reactions catalyzed by SORD.75, 76 The oxidative activity assay assesses the 
primary conversion of sorbitol to fructose by measuring the increase in absorbance at 340 
nm as the required cofactor, NAD+, is concomitantly reduced to NADH. The reductive 
activity assay measures the reverse reaction, whereby fructose is converted back to 
sorbitol and the activity is measured by monitoring the decrease in absorbance at 340 nm 
as NADH is oxidized back to NAD+.  
First, lysates overexpressing SORD WT, C44A, and C179A were assessed for 
enzymatic activity. As expected, the C44A lysates experienced a complete loss of 
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oxidative and reductive activity compared to the WT and C179A lysates, confirming this 
Zn2+-binding cysteine is required for enzymatic activity (Figure 3-18a). Upon treatment 
with EDTA, both oxidative and reductive SORD activities were completely abolished, 
corroborating the presence of the intact Zn2+-cysteine complex is essential for function 
(Figure 3-18b). Interestingly, subsequent treatment with Zn2+ restored oxidative and 
reductive activity; however, this recovery was partial (~60%), likely due to residual 
EDTA remaining in the buffer (Figure 3-18b). Unlike EDTA treatment, NJP14 only 
partially inhibited both oxidative and reductive activity (~50%), suggesting that NJP14 
can only bind the Zn2+-free population of SORD and is unable to displace bound Zn2+ 
ions from the active-site (Figure 3-18b). Pretreatment with Zn2+ completely abolished the 
inhibitory effect of NJP14, confirming that saturation of the SORD active-site with Zn2+ 
prevents NJP14 binding (Figure 3-18b). Finally, SORD lysates were administered EDTA 
to remove the catalytic Zn2+, followed by treatment with NJP14 to covalently modify the 
now accessible Cys44. These labeled lysates were then assayed for oxidative and 
reductive activities upon treatment with Zn2+, revealing complete inhibition of SORD 
activity  due to the covalently bound NJP14 preventing the reformation of the Zn2+-
cysteine complex (Figure 3-18b). Together, these experiments verify that NJP14 
covalently modifies Cys44 of Zn2+-free SORD and inhibits its activity. This inhibition is 
mitigated by pre-treatment with Zn2+ and enhanced with EDTA. Importantly, the 
observed labeling of SORD in non-overexpressing HeLa lysates (Figure 3-10b, Figure 3-
11a) implies that a certain population of SORD endogenously exists in the Zn2+-free state 
and is susceptible to inhibition by cysteine-reactive agents. Therefore, depending on the 
relative cellular concentrations of the Zn2+-bound versus unbound protein, cysteine-
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reactive small molecules could be utilized as potential inhibitors of SORD as well as 
other enzymes that rely on Zn2+-cysteine complexes for activity.  
 
Figure 3-18. (a) SORD WT, C44A, and C179 overexpressing lysates were analyzed for  
oxidative (light gray) and reductive (dark gray) activities. (b) EDTA, Zn2+, and NJP14 
can be used in combination to regulate SORD oxidative (light gray) and reductive (dark 
gray) activities.   
 
A Zn2+-cysteine complex regulates GSTO1 activity 
 In contrast to SORD, GSTO1 has not been previously annotated as a Zn2+-
chelating protein. Because of the significant decrease in NJP14-labeling of GSTO1 we 
observed due to Zn2+-treatment, we decided to further investigate the effect of Zn2+ on 
GSTO1 activity. As described in Chapter 2, GSTO1 is part of the GST superfamily that 
catalyzes the conjugation of GSH to endogenous and exogenous electrophiles as a 
mechanism of cellular defense against carcinogens, therapeutic drugs, and oxidative 
stress.77 GSTO1 is unique from other GSTs in that it possesses a catalytic cysteine 
residue (Cys32) in place of the canonical tyrosine residue.78 Although Cys32 has long 
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been characterized as the catalytic nucleophile for GSTO1 activity, its ability to bind Zn2+ 
and the functional role of this resulting Zn2+-cysteine complex have never been defined. 
To address the role of Zn2+ in regulating GSTO1 function, GSTO1 WT and the C32A 
mutant were recombinantly expressed in E. coli and purified over a Ni-NTA column. A 
dose-dependent decrease in labeling by NJP14 was observed by in-gel fluorescence when 
treating GSTO1 WT with increasing Zn2+ concentrations (Figure 3-19). Additionally, the 
absence of NJP14-labeling within the GSTO1 C32A protein sample indicates that NJP14 
covalently binds selectively to the catalytic cysteine (C32) of GSTO1.  
 
Figure 3-19. In-gel fluorescence of purified recombinant GSTO1 exposed to increasing 
concentrations of Zn2+ and labeled by NJP14. 
 
Recombinant GSTO1 was also subjected to a previously reported activity assay 
that couples thioltransferase activity of GSTO1 to the oxidation of NADPH by 
glutathione reductase (GSR) (Figure 3-20a).78, 79 A symmetrical disulfide, in this case 2-
hydroxyethyl disulfide, must first undergo a disulfide exchange reaction with one 
equivalent of reduced glutathione (GSH) to form the mixed disulfide (HRS-SG). GSTO1 
subsequently catalyzes another round of thioltransferase on the mixed disulfide to 
produce one equivalent of GS-SG. The GS-SG can now be reduced by GSR, requiring 
one equivalent of NADPH, and this reaction can be monitored by the absorbance of 
NADPH at 340 nm. At saturating concentrations of GSR, the reaction is a direct measure 
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of GS-SG formation and thus allows for quantification of GSTO1 activity. Importantly, 
the GSTO1 activity assessed here is a combination of both reactions 1 and 2 and these 
individual reaction rates cannot be discerned from the assay. Increasing Zn2+ 
concentrations resulted in a decrease in GSTO1 activity (Figure 3-20b) suggesting that, at 
least in vitro, GSTO1 activity is regulated by an inhibitory Zn2+-cysteine complex. 
However, since high concentrations were necessary for complete inhibition (>10 μM), 
the physiological relevance of Zn2+-inhibition of GSTO1 is still in question.     
 
 Figure 3-20. (a) Scheme of assay employed to measure GSTO1 thioltransferase activity. 
The first two steps were catalyzed by GSTO1 to produce GS-SG, which can subsequently 
be reduced by GSR. This activity can be monitored by the absorbance of NADPH at 340 
nm. (b) Purified recombinant GSTO1 was treated with increasing Zn2+ concentrations 
and assayed for enzyme activity.   
 
 Quantitative mass spectrometry can globally identify Zn2+-cysteine 
complexes 
 Since the previous studies conducted with NJP14 only target a subset of cysteines 
within the proteome, we decided to modify our platform in an effort to globally and 
quantitatively characterize reactive, and functional, cysteines that bind Zn2+. To achieve 
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this, we revisited the highly promiscuous IA-alkyne probe known to react with hundreds 
of functional cysteines within the proteome. Although more difficult to distinguish, the 
gel-based studies indicated that several proteins were sensitive to Zn2+-treatment (Figure 
3-9b). Because the high reactivity of IA-alkyne often results in labeling of multiple 
cysteines within the same protein, we also needed to employ a mass spectrometry 
platform that specifically identifies each IA-targeted cysteine within a protein. 
Furthermore, we envisioned a platform that provides a more quantitative read-out relative 
to the semiquantitative method of spectral counting described previously. A recently 
developed mass-spectrometry method by our lab was modified to facilitate the 
identification and accurate quantification of sites of IA-alkyne labeling between two 
proteomes.80 IA-alkyne labeled proteins are tagged with a linker that contains (a) an azide 
for click-chemistry-based conjugation to labeled proteins, (b) a biotin for enrichment on 
streptavidin beads, (c) an azobenzene-based cleavable moiety for release of tagged 
peptides upon sodium dithionite treatment, and (d) an isotopically tagged valine (light: 
Azo-L; heavy: Azo-H) for quantification of IA-alkyne labeled peptides across two 
proteomes (Figure 3-21). The Azo-L/H tags were synthesized on resin containing a PEG-
linker attached to a biotin moiety under standard Fmoc-peptide coupling conditions 
utilizing a synthesized Fmoc-Azo-OH amino acid, an isotopic valine, and 5-azido-
pentanoic acid.80  
 
Figure 3-21. Isotopic cleavable linker for identification of site of labeling and 
quantitative proteomics. 
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In order to identify Zn2+-binding cysteines and further elucidate those that 
endogenously bind Zn2+, we performed two quantitative mass-spectrometry analyses with 
the IA-alkyne probe.  The first compared untreated control lysates (conjugated to the 
Azo-H tag) to those treated with either Zn2+ or Mg2+ (conjugated to the Azo-L tag) 
(Figure 3-22a). A light : heavy ratio (R) was calculated for each IA-alkyne-labeled 
peptide. A cysteine with a R value of 1.00 is unaffected by metal-ion treatment, whereas 
a cysteine with R < 0.66 signifies a residue that demonstrated at least 1.50-fold decrease 
in reactivity in the presence of the metal ion. Similar to the studies using NJP14, most 
cysteines in the Mg2+-treated sample showed ratios of ~1.00, while several cysteines in 
the Zn2+-treated sample showed significantly reduced R values. The full dataset is 
presented in Appendix II (Table 3A-3). These cysteines represent those displaying 
affinity towards Zn2+. To further filter our dataset, we employed a second round of mass 
spectrometry comparing untreated control lysates (conjugated to the Azo-H tag) to those 
treated with EDTA (conjugated to the Azo-L tag) (Figure 3-22b). In this experiment, an 
R value of 1.00 signifies a cysteine that is unaffected by EDTA treatment, whereas a 
cysteine with R > 1.50 possess at least 1.5-fold increase in cysteine reactivity upon 
EDTA treatment, implying that the innate reactivity of these cysteines is quenched by a 
bound-metal ion. These cysteines would represent those endogenously chelating a metal 
ion.  
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Figure 3-22. Quantitative mass spectrometry analysis of untreated control HeLa lysates 
compared to those pre-treated with (a) Zn2+ or (b) EDTA.  
 
We therefore hypothesized that refining the data from these two mass-
spectrometry analyses by focusing our attention on those cysteines that showed a ratio R 
< 0.66 upon Zn2+-treatment and R > 1.50 upon EDTA-treatment would likely indicate a 
cysteine that is endogenously chelated to Zn2+ in these HeLa cells lysates (Figure 3-23a). 
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These are cysteines that show rescued reactivity upon EDTA-mediated metal removal 
and decreased reactivity upon addition of Zn2+. The proteins that fulfilled these criteria 
represent diverse functional classes including oxidoreductases, metabolic enzymes, 
ribosomal proteins, and microtubule assembly proteins (Table 3-4). Many of these 
proteins have been previously annotated to bind Zn2+, which helps validate our workflow. 
For example, our platform identified Cys174 from alcohol dehydrogenase class-3 
(ADH5), which is known to bind Zn2+ to facilitate catalysis as described in the 
introduction (Figure 3-23b).81 Additionally, bacterial ribosomal proteins are known to 
possess the capacity to bind up to 11 equivalents of Zn2+ within a single ribosome, and 
these interactions can account for up to 65% of the total cellular Zn2+.82 After stringent 
filtering of our data, 10 unique ribosomal cysteine residues were detected by our 
platform, confirming that this Zn2+ affinity extends to human ribosomes as well. The 
mass spectrometry platform also identified numerous cysteines in both alpha and beta-
isoforms of tubulin as Zn2+-binding. Tubulin-Zn2+ interactions have been well 
documented, and these interactions have proven essential for the formation of 
protofilament sheets and subsequent polymerization.83, 84  
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Figure 3-23. (a) Mass spectrometry data analyses filters to prioritize those putative Zn2+-
binding cysteines. (b) Structure of the active-site of ADH5, highlighting the identified 
Cys174 (red) that binds the catalytic Zn2+ (purple) (PDB 1MC5).  
 
Protein Peptide Sequence 
Ratio (light: heavy) 
Cellular Role 
Zn2+ 20uM EDTA 
ACO2 Aconitase 2, 
mitochondrial R.VGLIGSC*TNSSYEDMGR.S 0.12 1.58 Metabolic 
RPS27 40S ribosomal 
protein S27 R.LTEGC*SFR.R 0.39 4.55 
Ribosomal 
protein 
RPS3 40S ribosomal 
protein S3 K.GC*EVVVSGK.L 0.44 8.83 
Ribosomal 
protein 
TUBB2C, TUBB, 
TUBB4, TUBB2B, 
TUBB8, TUBB6, Tubulin 
β chain 
K.NMMAAC*DPR.H 0.44 1.95 Tubulin protein 
TUBA4A, TUBA1B, 
TUBA1A, TUBA1C, 
Tubulin α/β chain 
K.AYHEQLSVAEITNAC*FEPANQMV
K.C 0.46 1.98 
Tubulin 
protein 
ADH5 Alcohol 
dehydrogenase class-3 K.VCLLGC*GISTGYGAAVNTAK.L 0.57 3.92 Metabolic 
RPS11 40S ribosomal 
protein S11 R.DVQIGDIVTVGEC*RPLSK.T 0.57 4.98 
Ribosomal 
protein 
RPL23 60S ribosomal 
protein L23 R.ISLGLPVGAVINC*ADNTGAK.N 0.61 1.72 
Ribosomal 
protein 
USP22 Ubiquitin 
carboxyl-terminal 
hydrolase 22 
K.C*DDAIITK.A 0.64 1.52 Protein Degradation 
MRPS12 28S ribosomal 
protein S12, mitochondrial K.GVVLC*TFTR.K 0.66 1.50 
Ribosomal 
protein 
 Table 3-4. Cysteine residues identified by mass spectrometry to endogenously bind Zn2+ 
in HeLa cell lysates.  
 
In addition to these previously characterized Zn2+-binding cysteines, we identified 
several other putative Zn2+-binding cysteines with unknown function for future 
exploration. For example, Cys494 of Ubiquitin carboxyl-terminal hydrolase 22 (USP22) 
was identified to be Zn2+-binding. USP22 is the histone deubiquitinating component of 
the transcription regulatory histone acetylation complex SAGA (Spt-Ada-Gcn5-Acetyl 
transferase).85, 86 USP22 is a putative cancer stem cell marker and was found to be highly 
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expressed in malignant tumor samples.87 High levels of USP22 in tumor tissues are 
associated with poor clinical outcome, including high risk of recurrence, metastasis, and 
resistance to chemotherapy.88-90 USP22 has another cysteine (Cys185) that acts as a 
catalytic nucleophile and is also thought to possess two others that assemble a structural 
zinc finger (Cys61 and Cys121). The role of Cys494 and its Zn2+-bound complex within 
USP22 is currently undefined, and future studies into this cysteine residue could shed 
light on USP22’s role in cancer progression. As a whole, these data suggest that diverse 
cellular pathways could potentially be modulated by fluxes in localized Zn2+ 
concentrations resulting from cellular damage or dysregulation of Zn2+ homeostasis. 
It is also of interest to note that a small number of cysteines demonstrated an 
increase in reactivity upon treatment with Zn2+. These cysteines were found on proteins 
such as ribonuclease inhibitor and inorganic pyrophosphatase (Table 3A-3). Although the 
relevance of these increases in cysteine reactivity is still unclear, we hypothesize that 
these are likely cysteines that do not directly chelate Zn2+ but instead are located 
allosteric to a Zn2+-binding site, such that the metal-binding event perturbs the local 
environment of the cysteine and thereby affects reactivity. Future studies into such 
proteins are still necessary to examine the functional relevance of such cases of metal-
induced increases in cysteine reactivity.     
 
Conclusions 
 In summary, we report a competitive platform to identify cysteine residues that 
are susceptible to Zn2+-binding within a complex proteome. This platform relies on 
monitoring a loss in cysteine nucleophilicity induced by direct chelation of Zn2+ to the 
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thiol group, as well as an increase in reactivity resulting from the removal of prebound 
Zn2+ from endogenous chelation sites in proteins. Using a mildly reactive cysteine probe, 
NJP14, we identified the known Zn2+-binding cysteine in SORD, thereby validating the 
reliability of this platform. Furthermore, we also identified and characterized a cysteine 
disposed to Zn2+-binding in GSTO1 and demonstrated the effect of Zn2+ in inhibiting 
GSTO1 activity. We then expanded our platform to apply a highly promiscuous cysteine-
reactive probe, IA-alkyne, which enabled identification of potential Zn2+-chelating 
cysteines among ~900 reactive cysteines in the human proteome. These novel Zn2+-
binding proteins allude to the potential regulation of a variety of cellular functions 
through transient fluctuations in intracellular Zn2+ concentrations. Since the 
concentrations of Zn2+ used in our study are significantly higher than endogenous 
concentrations, the physiological significance of the putative Zn2+-binding sites that we 
identified is still unclear. However, we hypothesize that the combined identification of 
cysteines displaying Zn2+-sensitivity (lower R value) that also show an EDTA-mediated 
increase in reactivity (higher R value) suggests that (1) the cysteine has high affinity to 
chelate to Zn2+, and (2) a certain population of the protein is found to be endogenously 
bound to a metal ion. Therefore, combining these two analyses gives added confidence in 
the assignment of these cysteines as physiologically relevant Zn2+ binders.  
Importantly, from a technological standpoint, our competitive platform can be 
easily expanded to examine other biologically relevant metals across diverse proteomes, 
thereby providing an experimental method to complement available structural and 
computational studies to identify both stable and transient metal-binding sites in 
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proteomes. Future studies should extend this platform to other metals, such as Fe2+/3+, 
Cd2+, and Cu+, that utilize cysteine-based ligands.  
 
Acknowledgements 
I would like to acknowledge Alex Shannon for his continued help maintaining the 
Orbitrap mass spectrometer and also for his assistance in data analysis.  
 
Experimental procedures 
 
General procedures and materials 
 All materials were purchased from Sigma Aldrich or Fisher Scientific unless 
otherwise noted. Fmoc-propargylglycine (Fmoc-Pra-OH) was purchased from BaCHEM. 
All other Fmoc-protected amino acids, PyBOP, peptide-synthesis resin were purchased 
from Novabiochem. PBS buffer, DMEM/High glucose media, and penicillin 
streptomycin (Pen/Strep) were purchased from Thermal Scientific. Trypsin-EDTA was 
purchased from Invitrogen. The α-myc-tag antibody, α-mouse IgG HRP-linked antibody, 
and the α-rabbit IgG HRP-linked antibody were purchased from Cell Signaling. The α-
BLMH antibody was purchased from Abcam. X-tremeGENE 9 DNA transfection reagent 
was purchased from Roche. High resolution Mass Spectra (HRMS) were obtained at the 
Mass Spectrometry Facility at Boston College unless otherwise noted. All metal ion 
solutions were composed of the appropriate concentration of MCl2 in water. A Molecular 
Devices Spectramax M5 plate reader was used to read the absorbance of all activity 
assays. All silver staining was carried out using a ProteoSilver Silver Stain kit from 
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Sigma. All chemical probes were added to samples at the indicated concentration from a 
50x stock in DMSO unless otherwise noted.   
 
Synthesis of BsO-(propanamide)-Ser-Pro-Pra-Phe-Phe-NH2 (NJP14)  
The peptide was synthesized by manual solid-phase methods on Rink Amide 
MBHA Resin using Fmoc as the protecting group for α-amino functionalities. Amino 
acids were coupled using PyBOP as the activating reagent. The success of each Fmoc-
deprotection and coupling reaction was qualitatively tested using the standard procedure 
for the Kaiser test. Fmoc-Phe-OH, Fmoc-Phe-OH, Fmoc-Pra-OH, Fmoc-Pro-OH, and 
Fmoc-Ser(tBu)-OH residues were added under standard coupling conditions. After Fmoc-
deprotection, dry DCM was added to the resin and N2 gas was bubbled through the 
reaction vessel. NEt3 (3 eq) followed by chloroacetyl chloride (3 eq) were added 
dropwise to the vessel. N2 gas was bubbled through the reaction mixture for 1 hr. Any 
solvent lost to evaporation was replaced. The reaction vessel was capped, sealed, and 
shaken for 15 hrs. The solvent was removed and the resin was washed with DCM (5 x 3 
mL). After the addition of the electrophile, cleavage from the resin was performed in 
TFA: DCM: TIS: water (90: 5: 2.5: 2.5) solution for 2 hrs. The peptide was purified by 
preparative HPLC with a gradient of increasing acetonitrile-0.1% TFA (solvent) in water-
0.1% TFA (solvent A) and analyzed by a Micromass LCT TOF mass spectrometer 
coupled to a Waters 2975 HPLC and a Waters 2996 photodiode array UV-vis detector to 
give the pure peptide NJP14 (23.2%). HPLC tR = 18.60 min (C18, 5-195% B in 30 mins); 
HRMS for NJP14 (C33H39ClN6O7 + H+): m/z calcd 667.26; obsd [M + H+] 667.95 (ESI+). 
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Cell culture and gel-based experiments 
 
General cell culture preparation of lysates 
 HeLa cells were grown at 37°C under 5% CO2 in DMEM media supplemented 
with 10% FCS, 2 mM glutamine, and 1% Pen/Strep. The plates were allowed to grow to 
100% confluence, the cells were harvested by scraping, and the pellets were washed with 
PBS. The pellets were resuspended in an appropriate amount of PBS and sonicated to 
lyse to give whole-cell lysates. These lysates were separated by centrifugation (45 mins, 
45,000 rpm) at 4°C under high vacuum to separate the soluble and membrane proteomes. 
The supernatant was collected as the soluble fraction and the pellet was discarded. The 
protein concentrations were determined using the Bio-Rad DC Protein Assay kit (Bio-
Rad).  
 
General click chemistry and fluorescent gel analysis 
 Protein samples (50 μL, 2 mg/mL) were subjected to click chemistry. TAMRA-
N3 (Lumiprobe, 25 μM from 50x stock in DMSO), TCEP (1 mM, from 50x fresh stock in 
water), TBTA ligand (100 μM, from 17x stock in DMSO: t-butanol 1:4), and copper(II) 
sulfate (1 mM, from 50x stock in water) were added in this order to the protein. The 
samples were vortexed after every addition, except TCEP, and allowed to react at room 
temperature for 1 hr, while being vortexed periodically. SDS-PAGE loading buffer 2x 
(reducing, 50 μL) was added to the samples and 25 μL of each protein solution was 
separated by SDS-PAGE for 217 V hrs on a 10% polyacrylamide gel. Gels were 
visualized for fluorescence on a Hitachi FMBIO II multiview flatbed laser-induced 
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fluorescent scanner. After analysis, gels underwent a typical procedure for Coomassie 
staining. Stained gels were visualized on a Stratagene Eagle Eye apparatus by a COHU 
High performance CCD camera.  
 
Competitive metal-binding fluorescent-gel analysis: IA-alkyne 
 HeLa soluble protein lysates (50 μL, 2 mg/mL) were treated with either Zn2+, 
Ca2+, Mg2+, Mn2+ (10 and 20 μM) or water as a control. The samples were allowed to sit 
at room temperature for 1 hr. Then IA-alkyne (1 μM) was added to the samples and they 
were allowed to incubate at room temperature for 1 hr. The protein samples were purified 
by Bio-Spin Micro-P6 size exclusion columns (Bio-Rad) according to the standard 
protocol. These samples were then subjected click chemistry and in-gel fluorescence 
analysis. 
 
Competitive metal-binding fluorescent-gel analysis: NJP14 
 HeLa soluble protein lysates (50 μL, 2 mg mL-1) were treated with either Zn2+, 
Ca2+, Mg2+, Mn2+ (10 and 20 μM) or water as a control. The samples were allowed to sit 
at room temperature for 1 hr. Then NJP14 (50 μM) was added to the samples and they 
were allowed to incubate at room temperature for 1 hr. The protein samples were purified 
by Bio-Spin Micro-P6 size exclusion columns (Bio-Rad) according to the standard 
protocol. These samples were then subjected click chemistry and in-gel fluorescence 
analysis 
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EDTA treatments for gel-based analysis 
 HeLa soluble protein lysates underwent the competitive metal-binding fluorescent 
gel analysis as described above with Zn2+ (10 μM). Lysates were sequentially treated 
with EDTA (1 mM) from a 50x stock in water and NJP15 (50 μM) and were allowed to 
incubate at room temperature for 1 hr each time. The samples were purified by Bio-Spin 
Micro-P6 size exclusions columns and underwent click chemistry and in-gel fluorescence 
analysis as described above.  
 
In-gel fluorescence analysis to determine Zn2+-binding constants 
 HeLa soluble protein lysates (50 μL, 2 mg/mL) underwent the competitive metal-
binding fluorescent gel analysis as described above with increasing Zn2+ concentrations 
(0, 100 nM, 250 nM, 500 nM, 1 μM, 2 μM, 3 μM, 5 μM, 10 μM). Three trials were 
performed and the band intensities were quantified by ImageJ and averaged from the 
trials. EC50 values were generated using prims software. The full gels are presented 
within Appendix III (Figure 3A-1).  
 
Overexpression of SORD, GSTO1, and BLMH in HEK293T cells 
 The cDNA constructs for each protein were purchased as full-length expressed 
sequence tags (Open Biosystems) and subcloned into a pcDNA3.1-myc/His mammalian 
expression vector. HEK293T cells were grown at 37 °C under 5% CO2 in DMEM media 
supplemented with 10% FCS, 2 mM glutamine, and 1% Pen/Strep. Transfections were 
performed on 15 cm plates of ~50% confluence. DMEM media serum free (600 μL) and 
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X-tremeGENE DNA transfection reagent (20 μL) were combined and vortexed. Plasmids 
for each protein (6 μg) were added and the samples were vortexed and remained at room 
temperature for 15 mins. This plasmid solution was added dropwise to a plate of 
HEK293T cells. The plate was incubated at 37 °C under 5% CO2 for 48 hrs. HEK293T 
cells transfected with the pcDNA3.1-myc/His plasmid was used as a mock negative 
control. The lysates were prepared as before and underwent competitive metal-binding 
fluorescent-gel analysis with Zn2+ and Mg2+ as described above. 
 
Western blot analysis 
 The SDS-PAGE gels from above were transferred by electroblotting onto 
nitrocellulose membranes for 150 volt hours. The membranes were blocked in TBS-T 
and 5% (w/v) non-fat dry milk at room temperature for 2 hrs. The blot was washed with 
TBS-T three times (5 min per wash), and the SORD and GSTO1 blots were treated with 
α-myc tag rabbit antibody (1:1000) overnight at 4 °C. The BLMH blot was treated with 
α-BLMH mouse antibody (1:1000), since self-processing of the enzyme results in the 
removal of the C-terminal myc tag. The blots were washed with TBS-T three times (5 
mins per wash). The blots were treated with the appropriate secondary antibody (α-rabbit 
or α-mouse, 1:3333) for 2 hrs at room temperature. The blots were washed three times 
with TBS-T (5 mins per wash), treated with HRP super signal chemiluminescence 
reagents and exposed to film for 1-10 mins before development. Development took place 
using a Kodak X-OMAT 2000A processor.  
 
Site-directed mutagenesis and fluorescent gel analysis of SORD mutants 
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 The SORD C44A and C179A mutants were generated using the Quickchange kit 
(Stratagene) using the following primers: 
SORD-C44A  Sense: 5’-GAAAAGCTTATGCTGCGCCGC-3’ 
   Antisense: 5’-GCATCTAGACAGTTCATCTTTCACAGCTT-3’ 
SORD-C179A  Sense: 5’-GAAAAGCTTATGAGGGAAATCGTGCACAT-3’ 
   Antisense: 5’-GAACTCGAGGGCCTCCTCTTC-3’ 
The mutant cDNA was sequenced and found to contain only the desired mutation. The 
SORD WT, C44A, and C179A mutants were overexpressed in HEK293T cells and 
lysates were collected as described above. The lysates were subjected to in-gel 
fluorescence studies after labeling with NJP14 and subsequently underwent western 
blotting as described above to confirm the site of labeling of NJP14.  
 
General mass spectrometry experiments 
 
Click chemistry and streptavidin enrichment of protein for mass spectrometry 
 HeLa soluble protein lysates treated were prepared as described above. These 
protein samples (500 μL, 2 mg/mL) were aliquoted to undergo click chemistry. Biotin 
azide66 (200 μM from 5 mM DMSO stock), TCEP (1 mM, from fresh 50x stock in 
water), ligand (100 μM, from 17x stock of DMSO: t-butanol 1:4), and copper(II) sulfate 
(1 mM, from 50x stock in water) were added to the protein samples. The samples were 
allowed to react at room temperature for 1 hr and were vortexed periodically. Tubes were 
centrifuged (10 mins, 4 °C) to pellet the precipitated proteins. The pellets were 
resuspended in cold MeOH (500 μL) by sonication, centrifuged (10 mins, 4 °C), and the 
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supernatants were removed. Following a second MeOH wash, the pelleted protein was 
solubilized in a 1.2% SDS in PBS solution (1 mL) by sonication and heating (5 mins, 80 
°C). These solubilized samples were diluted with PBS (5 mL) to give a final SDS 
concentration of 0.2%. The solutions were incubated with streptavidin-agarose beads 
(100 μL, Thermo Scientific) at 4 °C for 16 hrs and then at room temperature for 2.5 hrs. 
The beads were washed with 0.2% SDS in PBS (5 mL), PBS (3 x 5 mL), and water (3 x 5 
mL). The beads were pelleted by centrifugation (3 mins, 1400 x g) between washes.  
 
On-bead trypsin digestion 
 The washed beads were suspended in a 6 M urea in PBS solution (500 μL). DTT 
(10 mM, from 20x stock in water) was added to the samples and they were reduced by 
heating to 65 °C for 15 mins. Iodoacetamide (20 mM, from 50x stock in water) was 
added and the samples were placed in the dark and alkylation was allowed to proceed at 
room temperature for 30 mins. Following reduction and alkylation, the beads were 
pelleted by centrifugation (2 mins, 1400 x g) and resuspended in 200 μL of urea (2 mM), 
CaCl2 (1 mM, from 100x stock in water), and trypsin (2 μg, from a 20 μg in 40 μL of 
trypsin buffer) in PBS. The digestion was allowed to proceed overnight at 37 °C. The 
digestion was separated from the beads using a Micro Bio-Spin column (Bio-Rad). The 
beads were washed with water (2 x 50 μL) and the washes were combined with the eluted 
peptides. Formic acid (15 μL) was added to the samples, and they were stored at -20 °C 
until analyzed by mass spectrometry.  
 
Liquid chromatography/mass spectrometry (LC/MS) analysis 
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 LC/MS analysis was performed on an LTQ Orbitrap Discovery mass spectrometer 
(ThermoFisher) coupled to an Agilent 1200 series HPLC. Digest were pressure loaded 
onto a 250 μm fused silica desalting column packed with 4 cm of Aqua C18 reverse 
phase resin (Phenomenex). The peptides were eluted onto a biphasic column (100 μm 
fused silica with a 5 μm tip, packed with 10 cm C18 and 3 cm Partisphere SCX 
(Whatman)). Using a gradient 5-100% Buffer B in Buffer A (Buffer A: 95% water, 5 % 
acetonitrile, 0.1% formic acid; Buffer B: 20% water, 80% acetonitrile, 0.1% formic acid). 
The peptides were eluted from the SCX onto the C18 resin and into the mass 
spectrometer following the four salt steps outlined previously.66 The flow rate through the 
column was set to ~0.25 μL/min and the spray voltage was set to 2.75 kV. One full MS 
scan (400-1800 MW) was followed by 8 data dependent scans of the nth most intense ions 
with dynamic exclusion enabled.  
 
NJP14 mass spectrometry experiments 
 
Mass spectrometry Data Analysis: +/- NJP14 
 HeLa soluble protein lysates (2 x 500 μL, 2 mg/mL) in PBS were aliquoted as 6 
samples (three neg. ctrl, three +NJP14). NJP14 (25 μM) was added to the appropriate 
samples and the corresponding volume of DMSO was added to the negative controls. 
These samples were subjected to click chemistry, streptavidin enrichment, on-bead 
trypsin digestion, and LC/LC-MS/MS as described above. The generated tandem MS 
data were searched using SEQUEST91 algorithm against the human IPI database. A static 
modification of +57 on Cys was specified to account for iodoacetamide alkylation. The 
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SEQUEST output files generated from the digests were filtered using DTASelect 2.092 to 
generate a list of protein hits with a peptide false-discovery rate of <5%. The resulting 
identified peptides were further filtered to display proteins identified in all three NJP14 
samples with spectral counts >25. For each of these proteins, a % change in spectral 
counts was calculated and the data were ranked by those proteins displaying the highest 
% change in spectral counts in the NJP14 samples relative to the Ctrl samples. All 
proteins with a 50% change in spectral counts (2-fold increase in NJP14 vs Ctrl) are 
displayed within the Table 3A-1 of Appendix II.  
 
Mass spectrometry analysis: Zn2+/Mg2+ + NJP14 
 HeLa soluble protein lysates (1 x 500 μL, 4 mg/mL) in PBS were aliquoted as 8 
samples (two neg. ctrl, two 10 μM Zn2+, two 20 μM Zn2+, and two 20 μM Mg2+). 
Zn2+/Mg2+ were added to the appropriate samples at the designated concentration, and an 
equal volume of water was added to the control samples. The samples were allowed to sit 
at room temperature for 1 hr. NJP14 (100 μM) was added to all the samples, and they 
were allowed to sit at room temperature for 1 hr. Each sample was passed through a Nap-
5 column (GE Healthcare) according to standard protocol, and eluents (2 x 500 μL, 2 
mg/mL protein for each sample) were collected. These samples were subjected to click 
chemistry, streptavidin enrichment, on-bead trypsin digestion, and LC/LC-MS/MS as 
described above. The generated tandem MS data were searched using the SEQUEST91 
algorithm against the human IPI database. A static modification of +57 on Cys was 
specified to account for iodoacetamide alkylation. The SEQUEST output files were 
filtered using DTASelect 2.092 to generate a list of protein hits with a peptide false-
125 
 
discovery rate of <5%. The resulting peptides were further filtered to display proteins 
identified in both the Ctrl samples with spectral counts > 25. For each of these proteins, a 
% change in spectral counts was calculated for both Zn2+/Mg2+ samples, and the data 
were ranked by those that showed the highest decrease in spectral counts (large negative 
% change) in the Zn2+ 20 μM samples relative to the Ctrl samples. A partial dataset is 
presented as Table 3-1, and the full dataset in Appendix II as Table 3A-2.  
 
SORD activity assays 
 
Generalized procedure for the SORD oxidative activity assay 
 An oxidative assay buffer (OAB) stock consisted of glycine (50 mM) and the pH 
was adjusted to 9.9. OAB, sorbitol (10 mM), NAD+ (18.0 μM), and HEK293T SORD 
soluble protein lysates (15 μg, prepared as described above) were combined and aliquoted 
into a clear 96-well plate at 100 μL per well. The increase in absorbance at 340 nm was 
monitored and activities were calculated as the initial change in absorbance.  
 
Generalized procedure for SORD reductive activity assay 
 A reductive assay buffer (RAB) stock consisted of sodium phosphate (10 mM) 
and the pH was adjusted to 7.0. RAB, fructose (100 mM), NADH (46 μM), and 
HEK293T SORD soluble protein lysates (15 μg, prepared as described above) were 
combined and aliquoted into a clear 96-well plate, 100 μL per well. The decrease in 
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absorbance at 340 nm was read and activities were calculated as the initial change in 
absorbance.  
 
SORD WT vs Mutants 
 HEK293T mock and SORD WT, C44A, and C179A lysates were subjected to 
both the SORD oxidative and reductive activity assays. The activities were determined as 
replicates of 3 separate trails.  
 
Effect of Zn2+, and NJP14 competition on SORD activity 
 SORD WT overexpressed HEK293T lysates (75 μL, 2 mg/mL) in PBS were 
aliquoted (4 aliquots). Zn2+ (5 μM) was added to two of the aliquots and water added to 
the other two as a control. The samples were incubated at room temperature for 1 hr. 
NJP14 (50 μM) was added to a + and – Zn2+ sample, while DMSO as a control was added 
to the remaining two samples. The samples were incubated at room temperature for 1 hr. 
These samples were subjected to both SORD oxidative and reductive activity assays. 
Activities were determined as replicates of 3 separate trials and normalized relative to the 
untreated Ctrl sample. 
 
Effect of EDTA, NJP14, and Zn2+ on SORD activity 
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 SORD WT overexpressed HEK293T lysates (50 μL, 2 mg/mL) in PBS were 
aliquoted (4 samples) and designated as follows: SORD; SORD-EDTA; SORD-EDTA-
Zn2+; SORD-EDTA-NJP14-Zn2+.  EDTA (1 mM) was added to the appropriate samples 
and they were allowed to incubate at room temperature for 1 hr. All samples underwent 
size exclusion chromatography as described previously. NJP14 (100 μM) or DMSO 
vehicle were added to the appropriate samples and they were allowed to incubate at room 
temperature for 1 additional hour. Zn2+ (1 mM) was added to the appropriate samples and 
they were allowed to incubate at room temperature for 1 hr. These samples underwent 
both the oxidative and reductive SORD activity assays as described above. Activities 
were determined as replicates of 3 separate trials and normalized relative to the untreated 
Ctrl sample.    
 
GSTO1 WT and C32A recombinant expression, activity, and binding assays 
 
Recombinant expression 
 The cDNA for both the GSTO1 WT and C32A mutant were amplified by PCR 
(sense primer 5’-TATGGATCCGCCATGTCCGGGGGAGTCA-3’, antisense primer 5’-
GCACTCGAGGAGCCCATAGTCACAGGC-3’), added between the BamHI and XhoI 
sites of a bacterial pET-23a(+) expression vector, and transformed into BL21 cells. 
Overnight cultures were seeded, scaled up, and grown to OD600 of 0.8. The cultures were 
induced with isopropyl β-D-1-thiogalactopyranoside (IPGT, 1 mM) and grown for 4 hrs 
further. The soluble protein fractions for each protein were collected and purified on 
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nickel agarose resin (Thermo). The resin was washed with 50 mM imidazole in PBS and 
protein was eluted with 500 mM imidazole in PBS. The purity of the fractions was 
judged by silver-stained SDS-PAGE gels and the fractions containing purified enzyme 
were combined. The imidazole was removed by running the protein through a NAP-5 
size exclusion column according to the standard protocol. The protein was subsequently 
used for the assays and stored on ice.  
 
NJP14 labeling of recombinant GSTO1 in the presence of Zn2+ 
 The recombinant purified GSTO1 WT or C32A mutant was diluted (2 : 3; protein 
: PBS) and 50 μL aliquots were made. Zn2+ was added to the samples at 0, 1, 10, 50, or 
100 μM. The samples were incubated at room temperature for 30 mins. NJP14 (1 μM) 
was added to all the samples and they were vortexed and allowed to sit at room 
temperature for an additional hour. Bio-Spin Micro-6 columns (Bio-Rad) were 
equilibrated and each sample was passed through a column. The eluents underwent click 
chemistry and in-gel fluorescence as described previously and were subsequently silver-
stained according to the standard protocol. The fluorescent signals were integrated using 
ImageJ software and these values were plotted.  
 
General procedures for assay of GSTO1 activity 
 The procedure for a previously described thioltransferase activity assay was 
employed.78 Tris (100 mM) pH 8.0, bovine serum albumin (0.1 mg/mL), GSH (1 mM), 
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glutathione reductase (~2 units), and NADPH (0.3 mM) were combined for each sample. 
Hydroxyethyl disulfide (HEDS, 0.75 mM) was added to each sample and they were 
allowed to sit at room temperature for about 2 mins in order for the disulfides to 
equilibrate. The protein was added to each sample and they were subsequently aliquoted 
into a clear 96-well plate, 100 μL per well. The plate was read for absorbance at 340 nm 
and activities were calculated as the initial change in absorbance.  
 
Effect of increasing [Zn2+] on GSTO1 activity 
 Aliquots of PBS, recombinant purified GSTO1 WT or C32A protein were treated 
with Zn2+ at 0, 1, 10, 20, 50, or 100 μM. The protein samples were allowed to incubate at 
room temperature for 30 mins. The protein was then utilized in the previously described 
GSTO1 activity assay and the activities were determined as an average from 3 trials.  
 
Quantitative mass spectrometry with IA-alkyne and azo-tags 
 
Synthesis of light and heavy azobenzene tags (Azo-L and Azo-H) 
FmocHN
OH
N
N
OH
O
Fmoc-Azo-OH  
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 Azo-L and Azo-H tags were synthesized by manual solid-phase methods on 
Biotin-PEG NovaTag resin using Fmoc as the protecting group for the α-amino 
functionalities. All reactions were performed in the dark. Amino acids were coupled 
using PyBOP (2 eq) as the activating agent and DIPEA (4 eq). Fmoc-Azo-OH ((E)-4-((5-
(Fmoc-2-aminoethyl)-2-hydroxyphenyl)diazenyl)benzoic acid, synthesized accord to 
Qian et al),80 valine, and 5-azido-pentanoic acid (2 eq each) were added under standard 
coupling conditions. Cleavage from the resin was performed in TFA : DCM : TIS : water 
(90 : 5 : 2.5 : 2.5) solution for 2 hrs. All peptides were purified by preparative HPLC with  
a gradient of increasing acetonitrile-0.1% TFA (solvent B) in water -0.1% TFA (solvent 
A). All peptides were analyzed by a Micromass LCT TOF mass spectrometer coupled to 
a Waters 2975 HPLC and a Waters 2996 photodiode array UV-vis detector and HRMS 
were determined using an LTQ Orbitrap Discovery mass spectrometer (ThermoFisher) 
coupled to an Agilent 1200 series HPLC. Azo-L (48.49%), HPLC tR = 28.50 min (C18, 
5-100% B in 30 mins); HRMS (C45H67N11O9S): m/z calcd 937.48; obsd [M + H]+ 938.49 
(ESI+); Azo-H (38.23%), HPLC tR = 28.50 min (C18, 5-100% B in 30 mins); HRMS 
(C45H67N11O9S): m/z calcd 943.88; obsd [M + H]+ 944.51 (ESI+).  
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Quantitative mass spectrometry using Azo-tags: Zn2+ + IA-alkyne 
 HeLa soluble protein lysates (500 μL, 2 x 4 mg/mL) in PBS for each proteome 
were aliquoted. One set underwent treatment with Zn2+ 10 μM / Zn2+ 20 μM / Mg2+ 20 
μM while the other set was treated with an equal volume of water for 1 hr. All samples 
were then treated with IA-alkyne (100 μM from 100x stock in DMSO) and allowed to sit 
at room temperature for 1 hr. After purification by size exclusion chromatography, the 
Azo-L tag (100 μM) was added to the variable samples, while the Azo-H tag (100 μM) 
was conjugated to the control samples through standard procedure for click chemistry. 
The samples were combined pairwise and washed with MeOH as described above. 
Streptavidin enrichment and trypsin digestion was also performed as described above. 
The beads were washed with PBS (3 x 600 μL) and water (3 x 600 μL) and subsequently 
transferred to Eppendorf tubes. The azobenzene cleavage was carried out by incubating 
the beads with fresh 25 mM sodium dithionite in PBS (25 mM) for 1 hr at room 
temperature on a rotator. After centrifugation, the supernatant was transferred to new 
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eppendorf tubes. The cleavage process was repeated twice more with dithionite solution 
(75 μL, 25 mM; 75 μL, 50 mM) to ensure completion and the supernatants were 
combined each time in the eppendorf. The beads were additionally washed twice with 
water (75 μL). Formic acid (15 μL) was added to the samples, and they were stored at -20 
°C until mass spectrometry analysis. Mass spectrometry analysis was performed as 
described previously using a biphasic chromatography column. The peptides were eluted 
from the strong cation exchange (SCX) onto the C18 resin and into the mass spectrometer 
following the four salt steps outline in Weerapana et al for the TEV samples.66 The flow 
rate through the column was set to ~0.25 μL/min and the spray voltage was set to 2.75 
kV. One full MS scan (400-1800 MW) was followed by 18 data dependent scans of the 
nth most intense ions with dynamic exclusion disabled.   
 
Quantitative mass spectrometry using Azo-tags: EDTA + IA-alkyne 
 Protein samples underwent the same procedure described above, except metal 
ions were substituted with EDTA (100 mM).  
 
Combined data analysis 
 The generated tandem MS data from each sample were searched using the 
SEQUEST91 algorithm against the human IPI database. A static modification of +57 on 
Cys was specified to account for iodoacetamide alkylation and differential modifications 
of +456.2849 (Azo-L) and +462.2987 (Azo-H) were specified on cysteine to account for 
probe modifications. The SEQUEST output files generated from the digests were filtered 
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using DTASelect 2.0.92 Reported peptides were required to be fully tryptic and contain 
the desired probe modification and discriminant analyses were performed to achieve a 
peptide false-discovery rate below 5%. Quantification of light/heavy ratios “R” was 
performed using the CIMAGE quantification package as described previously.63 Data 
from the Zn2+-treated samples were sorted to identify peptides with R < 0.66 (149 hits), 
while data from the EDTA-treated samples were sorted to identify peptides with R > 1.50 
(118 hits). These full datasets are presented in the Appendix as Table 3A-3 and Table 3A-
4 respectively. These datasets were combined and sorted to obtain peptides that fit both 
criteria (48 hits) and these are presented in Table 3-2.  
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Chapter 4 
Selective covalent inhibitors to interrogate the role of protein disulfide isomerase in 
cancer progression 
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Introduction 
 
Overview 
 Protein disulfide isomerase A1 (PDIA1), a 57-kD dithiol-disulfide oxidoreductase 
and molecular chaperone, is one of the most abundant soluble proteins in the endoplasmic 
reticulum (ER) and accounts for up to 0.8% of total cellular protein.1, 2 PDIA1 was the 
first endogenous protein-folding catalyst discovered in 1963,3, 4 and was given its name 
the following decade.5 At least 21 other members have been subsequently identified, 
giving rise to the PDI protein family (Table 4-1).6 While many vary in size, structure, and 
function, the majority of PDIs possess at least one, but often multiple, conserved 
thioredoxin-like domains (CXXC) that facilitate catalysis and have thus been 
characterized as members of the thioredoxin super family. Thioredoxin domains are 
recognized by a canonical protein fold and are often comprised of a pair of redox-
catalytic cysteines (CXXC) that catalyzes oxidative protein folding and the formation of 
native disulfide bonds.7 It’s this structural similarity that defines the PDI protein family; 
however, only about half of PDIs possess the CXXC active-site domain, suggesting that 
the others likely do not have catalytic activity. These 21 isoforms have been studied in 
varying detail, but the majority of this thesis will focus on protein disulfide isomerase A1 
(PDIA1) henceforward.  
Name Length Domain composition 
# a-type 
domains Active-site sequence 
PDIA1 (PDI) 508 a-b-b’-a’ 2 CGHC, CGHC 
PDIA2 (PDIp) 525 a-b-b’-a’ 2 CGHC, CTHC 
PDIA3 (ERp57) 505 a-b-b’-a’ 2 CGHC, CGHC 
PDIA4 (ERp72) 645 a°-a-b-b’-a’ 3 CGHC, CGHC, CGHC 
PDIA5 (PDIr) 519 b-a°-a-a’ 3 CSMC, CGHC, CPHC 
PDIA6 (P5) 440 a°-a-b 2 CGHC, CGHC 
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PDIA7 (PDILT) 584 a-b-b’-a’ 2 SKQS, SKKC 
PDIA8 (ERp27) 273 b-b’ 0 N/A 
PDIA9 (ERp28) 261 b-D 0 N/A 
PDIA10 (ERp44) 406 a-b-b’ 1 CRFS 
PDIA11 (TMX1) 280 a 1 CPAC 
PDIA12 (TMX2) 296 a 1 SNDC 
PDIA13 (TMX3) 454 a-b-b’ 1 CGHC 
PDIA14 (TMX4) 349 a 1 CPSC 
PDIA15 (ERp46) 432 a°-a-a’ 3 CGHC, CGHC, CGHC 
PDIA16 (ERp18) 172 a 1 CGAC 
PDIA17 (HAG-2) 175 a 1 CPHS 
PDIA18 (HAG-3) 165 a 1 CQYS 
PDIA19 (ERdj5) 793 J-a’’-b-a°-a-a’ 4 CSHC, CPPC, CHPC, CGPC 
PDIB1 (CASQ1) 396 Unknown N/A N/A 
PDIB2 (CASQ2) 399 Unknown N/A N/A 
Table 4-1. PDI protein family consists of 21 members with varying structures.  
  
Cellular functions of PDIA1 
PDIA1 primarily mediates oxidative protein folding within the ER as a dithiol-
disulfide reductase, oxidase, and isomerase, and also displays general molecular 
chaperone activity. Disulfide-bond formation occurs in approximately 30% of all proteins 
and is essential for assembly of native structures required for bioactivity.2 In addition, 
PDIA1 performs other diverse and essential cellular functions. It binds and stabilizes the 
major histocompatibility complex (MHC) class I peptide-loading complex that mediates 
MHC class I folding and peptide loading.8 PDIA1 also binds NAD(P)H oxidase subunits 
and regulates NAD(P)H oxidase activity in vascular smooth muscle cells.9 Finally, 
PDIA1 has also been observed to be a subunit of prolyl-4 hydroxylase,10 an essential 
enzyme for the synthesis of collagens and microsomal triglyceride transfer protein, a 
central enzyme for the assembly of apoliprotein B-containing lipoproteins.11  
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Besides its primary location in the ER as a soluble oxidoreductase, PDIA1 is also 
present on the extracellular side of the plasma membrane.12, 13 Although the mechanism 
of PDIA1 secretion or translocation to the cell surface is unresolved, some evidence 
suggests that it interacts with the cell membrane via electrostatic charges.14 PDIA1 
mainly functions as a reductase15 or an isomerase16 at the cell surface and has been shown 
to regulate multiple important biological processes, including coagulation,17 injury 
response,18 platelet activation19-21 and thrombus formation,22-24 T cell migration,15 glioma 
cell migration,25 gamete fusion,26 and nitric oxide internalization from extracellular S-
nitrosothiols.27 PDIA1 has also been shown to facilitate viral infection,28 as exemplified 
by its involvement in HIV-1 fusogenic events. Cell surface PDIA1 catalyzes the 
reduction of at least two disulfide bonds in an HIV-1 envelope glycoprotein, gp120, 
resulting in a conformation change that enhances binding to chemokine (C-X-C motif) 
receptor 4 (CXCR4) and C-C chemokine receptor type 5 (CCR5).29-31 Besides the ER and 
cell surface, PDIA1 has also been speculated to reside within other organelles, such as the 
mitochondria and nucleus; however, no conclusive evidence confirms the presence of 
PDIA1 within these subcellular locations and potential biological functions of PDIA1 
within these organelles remain unclear.32, 33  
  
Structural properties of PDIA1 
 The full-length PDIA1 contains 508 amino acids, including a 17-amino-acid N-
terminal signal peptide that undergoes cleavage upon maturation. PDIA1 is organized 
into four thioredoxin-like domains: a, b, b’, a’, and a highly acidic C-terminal extension 
c domain (Figure 4-1). The a-type domains each contain a thioredoxin-like active-site 
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motif (CGHC) to facilitate thiol-disulfide oxidoreductase activity. These cysteines 
typically convert between reduced dithiols and an oxidized disulfide. In contrast, the b-
type domains exhibit no catalytic activity and solely contribute to substrate binding. The 
c domain possesses a canonical ER signaling sequence (KDEL) at the C-terminus, which 
sequesters the protein to the lumen of the ER, an oxidizing environment that promotes 
disulfide-bond formation. 
 
Figure 4-1. Domain organization of PDIA1.  
 
Although the structure of full-length human PDIA1 has not yet been resolved, a 
high resolution structure of human PDIA1 a-b-b’-a’ within both its reduced and oxidized 
states revealed that the a-b-b’-a’ domains arrange in a horseshoe-like shape with the 
active-sites of the a-type domains facing each other (Figure 4-2).34 Importantly, PDIA1 is 
found to undergo significant conformational changes upon reduction/oxidation. In the 
reduced PDIA1, the open side of the cleft formed by the a-b-b’-a’ domains for 
accommodating a substrate is narrow (~15 Ǻ) and the volume of the cleft is smaller 
(~6,816 Ǻ3), which is estimated to be sufficient to accommodate a small folded protein of 
~50 residues. However, in the oxidized PDIA1, the open side of the cleft becomes wider 
(~30 Ǻ), and the volume of the cleft becomes much larger (~14,453 Ǻ3) allowing for 
accommodation of larger proteins of ~100 residues.34 These conformational changes are 
thought to help facilitate the oxidoreductase activity of PDIA1. 
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Figure 4-2. Crystal structures of the oxidized (PDB ID 4EL1) and reduced (PDB ID 
4EKZ) a-b-b’-a’ domains of PDIA1 show conformational changes.   
 
 PDIA1 is a structurally unique enzyme, as it contains two functional active-sites, 
each relying on a pair of redox-catalytic cysteine residues (Cys53 and Cys56 within a; 
Cys397 and Cys400 within a’) for activity (Figure 4-1). The cysteines nearer the N-
terminus (Cys53 & Cys397) have a pKa-value in the range of 4.5-5.6 and are readily 
deprotonated at physiological pH.35, 36 These nucleophilic cysteines are exposed to 
solvent and able to react with substrates, while the more C-terminal cysteines (Cys56, 
Cys400) possess a higher pKa, calculated to be about 12.8,37 and are found to be buried 
within the active-sites.38 Some studies have suggested that during certain chemical 
transformations, the a-type domains undergo conformational changes that cause a shift in 
the pKa of the C-terminal cysteine from 12.8 to 6.1.37, 39 The interplay between these 
cysteine residues facilitates disulfide bond reduction, oxidation, and isomerization.  
While each retain the highly conserved CGHC domains that are required for 
activity, the a and a’ domains of PDIA1 share only 33.6% sequence homology and have 
been observed to be functionally nonequivalent. A detailed analysis of the oxidase 
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activity of PDIA1 WT and mutants of the redox-catalytic cysteines within the a and a’ 
site revealed that while both sites contribute to the overall enzyme kinetics, the two sites 
may play complementary rather than identical roles. The a site was found to contribute 
more to catalysis (higher kcat) within the enzyme-substrate complex, while the a’ site 
improves the binding interactions between the enzyme and substrate (lower Km).40 The a 
and a’ site are also found to possess different structural characteristics. Almost no 
interactions exists between the a and b site, which renders these domains as structurally 
rigid. Alternatively, the a’ and b’ exhibit extensive interactions, which are thought to be 
facilitated by a “x linker” located between these domains. This bestows an increased 
flexibility to the a’ site and allows for a very elastic structure.34 Upon 
oxidation/reduction, the a and a’ site also experience distinct conformational changes. 
Within the reduced state, the a, b, and b’ domains are found to be within the same plane, 
whereas the a’ domain is twisted ~45° out of this plane and is found to be 27.6 Ǻ from 
the a site. Upon oxidation, the a’ site arranges in the same plane as the a-b-b’ domains, 
and the distance between the two active sites increases to 40.3 Ǻ.34 Together, it’s clear 
that the a and a’ sites display functional nonequivalence, and we believe that site-
selective inhibitors would help uncover the specific contribution from each active-site to 
PDIA1 function.  
 In contrast, the b and b’ domains do not possess catalytically-active sites and 
instead contribute to substrate binding. Within PDIA1, the b and b’ domains only share 
16.5% sequence identity, and vary greatly amongst other PDI family members. For 
PDIA1, the b’ domain has been shown to be especially important, as it constitutes the 
principal substrate-binding site and displays high affinity and broad specificity.41 The b’ 
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domain is essential for sufficient binding of smaller peptides through hydrophobic 
interactions,42 but not for binding of larger peptides or proteins.41 Additionally, substrate 
binding for general chaperone activity,43 as well as the interactions with the α-subunit of 
prolyl-4-hydroxylase also occur at the b’ site.44   
 
Thiol-exchange reactions of PDIA1 
PDIA1 possesses two pairs of redox-catalytic cysteines that facilitate oxidation, 
reduction, and isomerization of disulfide bonds within proteins. During transfer of 
oxidizing or reducing equivalents to substrates, the cysteine pairs within PDIA1 cycle 
between the oxidized (disulfide) and reduced (dithiol) states. Sequence characteristics, 
especially the traversing XX within the CXXC motif, influence the relative stabilities of 
these two states and dictate how easily the active-site disulfide can be formed or reduced. 
Active-sites that are good oxidants possess a disulfide that is less stable, more difficult to 
assemble, and is more easily transferred to the substrate. On the contrary, active sites that 
are good reductants possess a disulfide that is more stable, easier to assemble, and is 
difficult to transfer to substrates.45 Notably, PDIA1 is one of the best oxidants of the 
entire PDI family,46 and therefore primarily functions in the formation of disulfide bonds. 
This oxidase activity of PDIA1 inserts disulfides into protein substrates, while 
consequently reducing the disulfide within the PDIA1 active-site (Figure 4-3a). 
Mechanistically, a thiolate from the dithiol substrate will attack a disulfide bond of 
PDIA1, forming an intermolecular disulfide bond. Subsequent nucleophilic attack by the 
remaining thiolate generates the desired disulfide bond within the substrate and generates 
a reduced dithiol within PDIA1 (Figure 4-3b). Subsequently, oxidants, such as 
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glutathione disulfide (GSSG) and H2O2 act as terminal electron acceptors to oxidize the 
dithiol back to the disulfide state and complete the catalytic cycle. Additionally, 
enzymatic regeneration of disulfide bonds in PDIA1 has been observed by endoplasmic 
reticulum oxidoreductin 1 (Ero1). During this reaction, Ero1 transfers electrons to O2, 
producing one equivalent of H2O2 per disulfide bond.47  
 
Figure 4-3.  (a) PDIA1 oxidase activity promotes the formation of disulfide bonds. (b) 
Mechanistically, a nucleophilic cysteine within the substrate attacks the disulfide bond of 
PDIA1, resulting in an intermolecular disulfide. An adjacent cysteine within the substrate 
is then activated, and assembles the intramolecular disulfide bond, breaking the 
intermolecular disulfide and generating the dithiols within PDIA1.  
 
 A less common activity of PDIA1, compared to its other family members, is its 
ability to act as a reductase. Contrary to oxidation, PDIA1 within its reduced state utilizes 
its dithiols to reduce disulfides within protein substrates (Figure 4-4a). These thiol-
disulfide reactions proceed through the formation of a transient mixed disulfide between 
the N-terminal cysteine residue of either pair (Cys53 or Cys397) of PDIA1 and the 
substrate (Figure 4-4b).  Upon activation, the C-terminal cysteine residue within PDIA1 
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(Cys56 or Cys400) will cleave the intermolecular disulfide generating the reduced 
substrate and oxidized PDIA1. The resulting intramolecular disulfides within PDIA1 are 
reduced by terminal electron donors, such as reduced glutathione (GSH) and NADPH 
back to the dithiol state to complete the catalytic cycle. Interestingly, since reduction 
requires the C-terminal cysteine to resolve the mixed disulfide with the substrate, 
mutation of this residue leads to the accumulation of covalent substrate-enzyme 
complexes through an intermolecular disulfide.38, 48  
 
Figure 4-4. (a) PDIA1 reductase activity promotes cleavage of disulfide bonds. (b) 
Mechanistically, a nucleophilic cysteine (Cys53 or Cys397) within PDIA1 attacks the 
disulfide bond of substrate, resulting in an intermolecular disulfide. The adjacent cysteine 
(Cys56 or Cys400) within PDIA1 is then activated, and forms the intramolecular 
disulfide bond, breaking the intermolecular disulfide and generating the dithiols within 
the substrate. 
 
Additionally, PDIA1 has the ability to isomerize wrongly formed disulfide 
bonds,49 an activity unique to only a few protein disulfide isomerases (Figure 4-5a). Non-
native disulfides that assemble during folding prevent the formation of the native 
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structure for proper function and necessitate isomerization activity by PDIA1 to promote 
conventional folding.49 First, the N-terminal nucleophilic cysteine attacks a mismatched 
disulfide bond, forming a covalent complex between the substrate and PDIA1 (Figure 4-
5b). At this point, a “mechanistic decision” must occur: either the original substrate 
cysteine will attack the intermolecular disulfide releasing the substrate without 
isomerization (dashed black line) or another cysteine and assemble the native protein 
structure (solid black line).45 Importantly, the C-terminal cysteine within the PDIA1 
active site can react with its adjacent cysteine to reduce the intermolecular disulfide bond 
(dashed red line) (Figure 4-5b). This mechanism instills a set amount of time the 
substrate has to succeed in an intramolecular isomerization, which increases the 
likelihood of attaining the native protein structure.48 In addition, if the PDIA1 escapes 
and reduces the substrate, subsequent reoxidation may achieve the desired isomerization. 
PDIA1 does not experience any net reduction/oxidation upon isomerization, and can 
readily participate in additional catalytic cycles. Together, these PDIA1 thioltransferase 
activities assist in promoting proper disulfide-bond formation and native protein 
structures. 
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Figure 4-5. (a) PDIA1 isomerase activity assembles native protein structures. (b) 
Mechanistically, a nucleophilic cysteine (Cys53 or Cys397) within PDIA1 attacks the 
misfolded disulfide bond of substrate, breaking this bond and assembling an 
intermolecular disulfide. At this point, either the correct substrate disulfide can form 
(solid black arrows), the substrate can reassemble the incorrect disulfide (dashed black 
arrows), or the adjacent cysteine in PDIA1 (Cys56 or Cys400) can break the 
intermolecular disulfide and release the unfolded substrate (dashed red arrows).  
   
Regulation of PDIA1 activity 
 Because proper protein folding is necessary for virtually all cellular functions, 
mechanisms have evolved to regulate activities of proteins such as PDIA1 (Figure 4-6). 
To mediate oxidative protein folding, PDIA1 exhibits oxidase activity to assemble 
disulfide bonds in nascent proteins, but the required active-site disulfides within PDIA1 
are simultaneously reduced. At this point, these reduced disulfides can function in 
isomerization reactions within the ER, but these cysteines need to be reoxidized back to a 
disulfide bond in order to participate in multiple rounds oxidase activity. Small 
molecules, such as GSSG and H2O2, have long been known to carry out this process, but 
recently an enzyme, Ero1, was found to preferentially interact with and oxidize PDIA1.50, 
51 In particular, Ero1 was found to possess high affinity for the cysteines within the a’ 
site.52 Other mechanisms of PDIA1 reoxidation, such as those utilizing peroxiredoxin 4 
(Prdx4), docosahexaenoic acid (DHA) and vitamin K, have also been described but are 
less common.53  
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Figure 4-6. Regulatory mechanisms of PDIA1 activity within the ER. PDIA1 primarily 
acts as an oxidase to assemble disulfide bonds within its protein substrates. This results in 
dithiol formation in the active-site of PDIA1, which can be used to facilitate disulfide 
bond isomerizations or be oxidized back to the requisite disulfide to perform multiple 
rounds of oxidase activity. Reduced PDIA1 can also be post-translationally modified and 
rendered inactive, which results in an accumulation of misfolded and unfolded proteins 
that contribute to significant ER stress. To account for this ER stress, the cell activates an 
Unfolded Protein Response (UPR). ER transmembrane proteins ATF6, IRE1, and PERK 
translocate to the cytosol to suppress protein translation and upregulate expression of 
protein chaperones and UPR machinery.   
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 Beyond, oxidation, the reduced redox-catalytic cysteines of PDIA1 are also 
susceptible to post-translational modifications, with the N-terminal cysteines (Cys53 and 
Cys397) being especially vulnerable (Figure 4-6). A reduced, nucleophilic thiol is 
preferential for post-translational modifications; thus, once PDIA1 performs a disulfide 
bond oxidation, modifications to the resulting dithiols are able to “trap” and inactivate 
PDIA1, preventing the reoxidation of its redox-catalytic cysteine pairs back to the 
required disulfides. These cysteines have been observed to undergo S-
glutathionylation,54-56 S-nitrosation,57 and carbonylation by 4-hydroxynonenal (HNE),58 
which results in disruption of enzymatic activity, activation of the unfolded protein 
response, and induction of ER stress that can ultimately lead to apoptosis. 
 Because PDIA1 serves as one of the most abundant and essential enzymes in 
disulfide-bond formation and protein folding, its dysfunction results in rapid 
accumulation of unfolded and misfolded proteins in the lumen of the ER. These proteins 
typically expose hydrophobic residues at their surface and aggregate, which triggers 
significant ER stress. To account for this ER stress, cells have evolved a stress responsive 
signaling pathway termed the Unfolded Protein Response (UPR) to maintain ER 
proteostasis (Figure 4-6).59, 60 UPR signaling emanates from three ER transmembrane 
proteins, activating transcription factor 6 (ATF6), Inositol-requiring protein 1 (IRE1), and 
protein kinase RNA-like endoplasmic reticulum kinase (PERK).59 Once activated, PERK 
migrates to the cytosol and phosphorylates E74-like factor 2 (eIF2), a regulator of 
initiator mRNA translation, which results in cessation of protein translation, decreasing 
protein influx to the ER.61 Activated IRE1, a site-specific endonuclease, removes an 
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intron from X-box binding protein 1 (XBP1) mRNA, which results in mRNA 
stabilization and an increase in XBP1 levels.62 ATF6 translocates to the Golgi and is 
cleaved to form the activated subunit, ATF6 p50.63 XBP1 and ATF6 p50 subsequently 
translocate to the nucleus and bind to promoters that upregulate expression of general 
protein chaperones and UPR machinery. The combined increase in protein folding 
machinery signaled by XBP1 and ATF6 with the decreased influx of proteins to the ER 
accomplished by PERK provides a mechanism to rescue the cell from ER stress; 
however, if this pro-survival mechanism does not restore ER homeostasis, the cell will 
enter apoptosis.  
 
PDIA1 as a potential drug target for cancer treatment 
 Although PDIA1 has been studied extensively, its role in cancer has not yet been 
established. Gene expression microarray studies have observed an increase in PDIA1 
expression in a variety of cancer types, including brain and central nervous system 
cancers,64-69 lymphoma,70-72 kidney,73-75 ovarian,76, 77 prostate,78, 79 lung,80 and male germ 
cell tumors.81 Additionally, upregulation of PDIA1 has also been shown in MALDI/TOF 
proteome analyses of human cancers.82, 83 Increased PDIA1 levels have also been shown 
to correlate with cancer metastasis and invasion, as evidenced by significantly higher 
PDIA1 protein levels observed in axillary lymph node metastatic breast tumor compared 
to primary breast tumor.84 Lower PDIA1 expression levels have also been associated with 
higher survival rates of patients with glioblastoma and breast cancer.66, 67, 85 These 
combined studies indicate PDIA1 has the potential to be a biomarker of cancer and could 
be used to assess patient prognosis. Monitoring PDIA1 levels as a biomarker for clinical 
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detection of cancers has the potential to be a powerful and noninvasive strategy because 
PDIA1 is both abundant and secreted into the extracellular environment.  
 Additionally, chemotherapeutic resistance is a major obstacle in cancer treatment, 
and PDIA1 has been recently thought to play a role in resistance mechanisms. A recent 
study evaluated the levels of PDIA1 in HeLa cells resistant to aplidin, a cyclic 
depsipeptide currently in clinical trials for anti-tumor activity. Compared to aplidin-
sensitive HeLa cells, aplidin-resistant HeLa cells expressed significantly higher levels of 
PDIA1, and inhibition of PDIA1 by bacitracin sensitized aplidin-resistant HeLa cells to 
the drug.86 Similarly, a class of PDIA1 inhibitors was found to sensitize cancer cells 
towards etoposide-induced apoptosis at subtoxic concentrations.87 These data suggest that 
combining PDIA1 inhibitors with traditional anticancer therapies could achieve 
synergistic effects and overcome chemotherapeutic resistance.   
 
Inhibitors of PDIA1 show promise as therapeutic drugs 
 Towards this end, inhibitors of PDIA1 have been designed with various efficacies 
(Table 4-2).2 It is important to note that different activity assays have been designed to 
assess oxidase, reductase, isomerase, and general chaperone activity, and many of the 
described PDIA1 inhibitors have only been evaluated to inhibit a single PDIA1 function, 
most often reductase activity. These inhibitors are both reversible and irreversible (often 
covalently binding the redox-catalytic cysteines) and display a wide-range of potencies 
and specificities.  
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Name IC50 
(μM) 
PDIA1 
Activity Selectivity Reversibility 
Membrane 
Permeable? 
Juniferdin94 0.156 Reductase Nonspecific Reversible Unknown 
P191 1.7 Reductase Moderate selectivity Irreversible (Cys397) Yes 
Quercetin-3-
rutinoside 6.1 Reductase 
Selective for PDIA1 
over other family 
members 
Reversible No 
NEM93 8 Reductase Nonspecific Irreversible Yes 
Iodoacetamide93 8*** Reductase Nonspecific Irreversible Yes 
PACMA 3188 10 Reductase 
Selective for PDIA1 
over other proteins such 
as BSA and Grp78 
Irreversible 
(Cys397) Yes 
Acrolein93 10 Reductase Nonspecific Irreversible Yes 
JP04-4287 15 Reductase Moderate selectivity Reversible Yes 
Thiomuscimol15 23 Reductase Nonspecific Irreversible Yes 
RB-11-ca90 40 Reductase N/A Irreversible (Cys53) Yes 
16F1689 63 Reductase N/A Irreversible Yes 
Cystamine53 66 Reductase Nonspecific Irreversible Yes 
PS8987 78 Reductase Moderate selectivity Reversible Yes 
PAO88* 85 Reductase Reacts readily with CxxC motif Irreversible Yes 
Bacitracin95 90 Reductase Nonspecific Irreversible No 
DTNB92** 100 Reductase Nonspecific Irreversible No 
Ribostamycin96 N/A**** Chaperone Nonspecific Reversible Yes 
Table 4-2. Previously reported PDIA1 inhibitors sorted by potency. Table adapted from 
Xu et al.2 First generation PDIA1 inhibitors are shaded white; second generation PDIA1 
inhibitors are shaded gray. (*PAO: phenylarsine oxide **DTNB: 5′5-dithio-bis(2-
nitrobenzoic acid); ***At pH 6; ****Sufficient inhibition at 100:1 molar ratio of 
ribostamycin to PDIA1.)   
 
 The first inhibitor of PDIA1, bacitracin, was first reported in 1981 and was found 
to inhibit PDI activities in a variety of cellular processes.95 However bacitracin required 
high micromolar concentrations for inhibition of reductase activity, displayed minimal 
inhibition of oxidase or isomerase activity, possessed low specificity for PDIA1, and was 
membrane impermeable, making it a fairly weak and ineffective inhibitor of PDIA1.42 
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Similarly, the majority of these initial PDIA1 inhibitors lacked specificity for PDIA1, 
failed to inhibit PDIA1 oxidase activity, and possessed poor pharmacological properties, 
rendering them relatively ineffective as tools to deconvolute the role of PDIA1 in cancer 
or in the development of potential drug candidates. Towards this end, a second-
generation of potent and selective PDIA1 inhibitors has been developed in recent years: 
PACMA 31, 16F16, Juniferdin, JP04-42 and PS89, P1, and RB-11-ca (Figure 4-7).  
 
Figure 4-7. Structures of second-generation PDIA1 inhibitors. 
  
16F16 was discovered through a high-throughput screen of 68,887 compounds as 
an irreversible inhibitor of PDIA1.89 16F16 contains a cysteine-reactive chloroacetamide 
electrophile, but the specific site (a or a’) and cysteine it binds are not currently known. 
Through the use of an alkyne handle, 16F16 was found to bind PDIA1 and PDIA3, but 
also displayed cytotoxicity in cells at concentrations above 12 μM, hinting at significant 
off-target binding.  While 16F16 was never tested in a cancer model, it showed the ability 
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to rescue cells from apoptosis in an in vitro PC12 cell-based model of Huntington’s 
disease.89 
Juniferdin was discovered as a PDIA1 inhibitor through a high-throughput screen 
of natural product libraries.94 Juniferdin was found to be a noncovalent inhibitor of 
PDIA1, but the binding mode has not been described. Although Juniferdin was never 
studied in cancer models, it was found to block PDIA1-catalyzed reduction of disulfide 
bonds in the HIV-1 envelope glycoprotein gp120, thereby inhibiting the entry of HIV-1 
virus into cells.94 Although it was found to be a potent inhibitor of PDIA1 reductase 
activity, which is the primary activity of extracellular PDIA1, Juniferdin displayed little 
inhibition of PDIA1 oxidase activity, the primary activity of PDIA1 within the ER. 
Furthermore, because studies with Juniferdin have been on extracellular PDIA1, its cell 
permeability and stability within cells is still unclear.94 
 A previous member within the Weerapana lab synthesized a library of cysteine-
reactive covalent inhibitors from a trifunctionalized 1,3,5-triazine scaffold. Each library 
member was evaluated in HeLa cells, and one inhibitor, RB-11-ca, was determined to 
selectively bind PDIA1.90 Interestingly, RB-11-ca was shown to exhibit high specificity 
for Cys53 of the a site, with virtually no binding observed to Cys56 or either redox-
catalytic cysteine within the a’ site. The ability of RB-11-ca to inhibit PDIA1 reductase 
activity was determined to be comparable to that of 16F16, and mitigated HeLa cell 
proliferation with an EC50 value of 23.9 μM.90 
 Because the most effective PDIA1 inhibitors possess cysteine-reactive 
electrophiles, recent efforts have focused on screening libraries of compounds comprised 
of similar moieties, including vinyl sulfones and sulfonates. The screen resulted in the 
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discovery of P1, a phenyl vinyl sulfonate-containing small molecule.91 This vinyl 
sulfonate electrophile was found to covalently bind Cys397 within the a’ site to inhibit 
PDIA1 activity at potencies not yet achieved by this new generation of selective PDIA1 
inhibitors (1.7 μM). P1 represents one of the more potent, cell-permeable small molecule 
PDIA1 inhibitors discovered to date.91  
PACMA 31 was recently reported as an irreversible inhibitor of PDIA1 with 
potency in both in vitro and in vivo models of ovarian cancer.88 The molecule contains a 
cysteine-reactive electrophile in the form of the terminal propionic group and inhibits 
PDIA1 through covalent modification of a cysteine residue. Mass spectrometry and 
modeling studies predict binding of PACMA 31 to the nucleophilic Cys397 within the a’ 
site. Importantly, PACMA 31 showed tumor targeting ability and significantly 
suppressed ovarian tumor growth without causing toxicity to normal tissues, implicating 
PDIA1 as a potential target for cancer therapeutics.88  
 Because most of the second-generation PDIA1 inhibitors are covalent modifiers, 
recent efforts have sought to develop inhibitors that function through noncovalent 
interactions, which are thought to be more pharmacologically desirable. Through a screen 
of a commercial compound library and upon further structure-activity relationship (SAR) 
optimization, JP04-42 and PS89 were identified through proteomic analyses to be potent 
reversible inhibitors of PDIA1 reductase activity.87 These inhibitors were shown to 
sensitize cancer cells to etoposide treatment at subtoxic concentrations, providing further 
evidence that PDIA1 plays a role in chemotherapeutic resistance.87  
 This second-generation of PDIA1 inhibitors represents a significant improvement; 
however, these inhibitors are limited by their potency, selectivity, and poor 
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pharmacological properties. We aimed to utilize cysteine-reactive electrophiles and 
proteomic analyses to access improved second-generation inhibitors of PDIA1 to be 
employed as tools to better understand the role of PDIA1 in cancer progression and 
chemotherapeutic resistance. Importantly, we believe that the current strategies employed 
to evaluate PDIA1 inhibitors as tools to interrogate the enzyme’s role in cancer are 
flawed. PDIA1 is an extremely unique and complex enzyme, since it possesses two non-
equivalent active sites, is localized within the ER and at the cell surface, and is 
multifunctional, performing oxidase, reductase, isomerase, and general chaperone 
activities. Increased PDIA1 oxidase and isomerase activities within the ER are thought to 
be essential for cancer cells to produce the elevated levels of protein to facilitate the 
biological activities that promote their rapid growth. Because healthy cells do not require 
the higher levels of PDIA1 activity, cancerous cells should display an increased 
sensitivity to PDIA1 inhibition. To date, all of the second-generation PDIA1 inhibitors 
described have only been tested against PDIA1 reductase activity, which is thought to be 
of little importance to PDIA1’s role cancer. When evaluating PDIA1 inhibitors as cancer 
therapeutics, activity assays to assess PDIA1’s oxidase and isomerase activity, which 
appear to be most important to cancer progression, should be employed.  
Furthermore, we sought to evaluate the binding affinities of each PDIA1 inhibitor 
for both the a and a’ site, as inhibitors may display differential affinities for each site. 
The endogenous functions of each active-site (a or a’) are still unknown, but we believe 
that site-selective inhibitors may help clarify the redundancy and unique properties of 
each active-site. Additionally, site-selective inhibitors are likely to display a better 
therapeutic index because they are not completely shutting down all PDIA1 activity, but 
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only those activities attributed to a single active-site. PDIA1 is essential for normal cell 
growth and maintenance, so complete abolition of PDIA1 activity is likely to be 
detrimental. Inhibition of a single active site will likely have a larger effect on cancer 
cells due to their increased reliance on PDIA1 activity, while still allowing for enough 
activity in healthy cells to prevent cytotoxicity.  
In conclusion, we believe that the expansion of cysteine-reactive inhibitors and 
the revised methodologies taken to evaluate them will lead to 1) a potent and selective 
inhibitor of the a site of PDIA1, 2) a potent and selective inhibitor of the a’ site of PDI, 
and 3) a potent and selective pan-inhibitor for both the a and a’ site of PDIA1. These 
optimized second-generation inhibitors will deconvolute the function of each individual 
active site, including their substrate scopes and contribution to various cellular PDIA1 
activities. Successful inhibitors will then be evaluated for inhibition of PDIA1 oxidase 
and isomerase activity, and for cytotoxicity in cancer cells. We hope that these inhibitors 
aid in uncovering the role of PDIA1 in cancer progression and may serve as a starting 
point for PDIA1-based cancer therapeutics. 
 
Results and Discussion 
 
Validation of PDIA1 as a potential target for cancer therapeutics 
 We first sought to assess PDIA1 as a therapeutic target for cancer, and chose a 
well-characterized ovarian cancer cell line, SKOV3, as a model system. We aimed to 
engineer stable cell lines through lentiviral transduction containing a PDIA1 knockdown 
or a PDIA1 overexpression and perform cancer phenotypic assays on these cell lines to 
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measure the effect of PDIA1 on the capacity of cancer cells for proliferation, survival, 
migration, and invasion. For the knockdown, a PDIA1 shRNA within a pLKO.1 vector 
was purchased (Figure 4-8a). For the overexpression, the PDIA1 sequence within a 
pDONR2233 vector was subcloned into a pLenti CMV Puro DEST viral overexpression 
vector through an LR Clonase reaction standard to Gateway cloning (Figure 4-8b). 
HEK293T cells were first transfected with vsvg and pspax2 viral constructs and either the 
shRNA-pLKO.1 viral knockdown plasmid, the PDIA1-pLenti CMV Puro DEST viral 
overexpression plasmid, or a shGFP-pLKO.1 control. The shGFP-pLKO.1 contains an 
shGFP sequence that will result in no proteomic effect (since the SKVO3 cells do not 
synthesize GFP) and will therefore serve as a control for PDIA1 mRNA and protein 
levels.  
 
Figure 4-8. Vector maps for (a) pLKO.1-Puro (Figure from Sigma Aldrich) and (b) 
pLenti CMV Puro Dest (Figure from Eric Campeau).  
 
168 
 
After two days, the presence of virus was confirmed and harvested within the 
media. This media was utilized to infect SKOV3 cells to incorporate either the PDIA1 
shRNA or overexpression sequence stably within the genome. After a round of 
puromycin selection, the PDIA1 knockdown (SKOV3-PDIA1-) and overexpression 
(SKOV3-PDIA1+) were confirmed using RT-PCR (Figure 4-9a/b) and western blot 
(Figure 4-9c) by comparing to the GFP knockdown (SKOV3-Ctrl). RT-PCR revealed a 
~75% decrease in mRNA levels for the PDIA1 knockdown, while the overexpression 
saw an increase of ~75%. The gel band intensities were integrated and averaged from an 
n = 2 from two biological replicates (Figure 4-9b). The western blot confirmed that this 
decrease in RNA extends to PDIA1 protein levels as well. Interestingly, a higher band 
also appeared on the western blot, and we hypothesize this band is the nascent PDIA1, 
containing the additional N-terminal 18 amino acid sequence to account for the additional 
molecular weight.  
 
Figure 4-9.  (a) Confirmation of PDIA1 knockdown by RT-PCR. (b) Gel bands were 
integrated with an n = 2 from two biological replicates. (c) Western blot with a α-PDIA1 
antibody confirms almost complete PDIA1 knockdown at protein levels.  
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 The SKOV3-Ctrl and SKOV3-PDIA1+ cell lines could be cultured over multiple 
passages, but the PDIA1 knockdown was found to be lethal after approximately one week 
post-selection, likely due to the inability to support protein folding and homeostasis upon 
complete PDIA1 knockdown. Consequently, the SKOV3-PDIA1- cells underwent the 
cancer phenotypic assays immediately after coming off selection. The cell lines were first 
assessed for SKOV3 cell proliferation and survival by comparing the PDIA1- and 
PDIA1+ to the Ctrl. Proliferation assays necessitate serum-containing media that 
promotes rapid growth. These conditions allow for assessment of the cell viability of 
readily propagating cells compared to the SKOV3-Ctrl. Survival assays require serum-
free media, which generates environmental stress and prevents cellular growth. These 
conditions allow for the evaluation of solely the plated cells’ ability to survive compared 
to the SKOV3-Ctrl. The three cell lines were suspended in both media and plated into 
four 96-well plates. To evaluate cell viability, cells were treated with WST-1. WST-1 is 
cleaved to form formazan by a complex cellular mechanism that occurs primarily at the 
cell surface via plasma membrane electron transport.97 Consequently, this bioreduction is 
largely dependent on the glycolytic production of NAD(P)H in viable cells.97 Therefore, 
the amount of formazan dye formed directly correlates to the number of metabolically 
active cells in the culture. The transition from WST-1 to formazan generates a sharp 
increase in absorbance at 450 nm and directly correlates to cell viability (Figure 4-10).97  
170 
 
 
Figure 4-10. WST-1 salt is reduced to formazan by plasma membrane reductases and 
provides a direct correlation to cell viability.  
 
 One of the four plates is immediately treated with WST-1 after plating to assess 
initial cell viability at Time 0. After the appropriate time points, the other plates of cells 
were also administered WST-1 and the changes in cell viabilities were compared to the 
initial measurements at Time 0. The relative changes in proliferation/survival for 
SKOV3-PDIA1- and SKOV3-PDIA+ were compared relative to the SKOV3-Ctrl. After 
72 hrs, the rate of proliferation had decreased by ~50%, and after 120 hrs the cells had all 
but completely stopped growing (Figure 4-11a). These observations all extended to 
cancer cell survival, as the cells were almost completely dead at 120 hrs (Figure 4-11b). 
We anticipated no significant change in the SKOV3-PDIA+ because PDIA1 is already a 
highly abundant enzyme, and further increasing the levels are unlikely to be beneficial. 
Notably, the SKOV3-PDIA1+ did display a slight decrease, although this decrease 
remained stable throughout the timeframe of the experiment, in both cell proliferation 
and survival compared to SKOV3-Ctrl and could make for an interesting future case 
study. 
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Figure 4-11. SKOV3-PDIA1- and SKOV3-PDIA1+ cell lines (a) proliferation and (b) 
survival were compared to that of the SKOV3-Ctrl. Data are presented  as a mean of n = 
5 replicates from two biological samples +/- SEM with significance expressed as * p < 
0.01.   
 
 The SKOV3-Ctrl, SKOV3-PDIA1-, and SKOV3-PDIA1+ cell lines were also 
assessed for their migration and invasion capacities, both essential phenotypes of 
aggressive metastatic cancers. Metastasis is defined as the dissemination of cancer cells 
from the primary tumor to a distant organ and is often the leading cause of death among 
patients with cancer.98 The particular molecular mechanisms of metastasis are poorly 
understood as a result of their inherent complexity. Cancer cell migration and invasion in 
adjacent tissues and intravasation into blood/lymphatic vessels are required for metastasis 
in most human cancers.99, 100 Cancer cell migration and invasion are typically 
complementary to each other. Invasive cancer cells acquire a migratory phenotype that 
involves increased expression of several genes that contribute to cell motility.101, 102 Once 
moving, this allows cancer cells to respond to cues from the tumor microenvironment and 
trigger invasion. 
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 Migration is often used as a general term in cell biology to describe any directed 
cell movement throughout the body. This phenotype was assessed using a transwell assay 
to measure a cell movement through a 2D porous surface without any obstructive fiber 
network (in this case, a collagen I network was employed).103 Invasion is defined as the 
penetration of tissue barriers and is increasingly more complex than migration.103 
Invasion requires adhesion, proteolysis of extracellular matrix components, and 
migration.104 A similar transwell assay to measure cell movement was employed; 
however the transwell will be coated with a 3D extracellular matrix environment.103 For 
both assays, the transwells will be stained and measured by cell counting.  
At 24 hrs post-selection, the SKOV3-PDIA1- cells underwent both migration and 
invasion assays and were compared to SKOV3-Ctrl and SKOV3-PDIA1+. The SKOV3-
PDIA1- cell line displayed an approximately 20% decrease in migration (Figure 4-12a) 
and 45% decrease in invasion phenotypes (Figure 4-12b), both of which were found to be 
statistically significant. Alternatively, SKOV3-PDIA1+ showed no significant change in 
migration and invasion phenotypes, which was expected since PDIA1+ is already a 
highly abundant protein. Importantly, these assays were carried out at a point when the 
cells are still living according to the proliferation and survival assays, so cell viability 
should only have minimal effect on these phenotypes. This effect of the PDIA1 
knockdown provides continued support that PDIA1 plays a role in cancer progression and 
aggressiveness.  
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Figure 4-12. SKOV3-PDIA1- and SKOV3-PDIA1+ cell lines (a) migration and (b) 
invasion phenotypes were compared to that of the SKOV3-Ctrl. Data are presented  as a 
mean of n = 3 replicates from two biological samples +/- SEM with significance 
expressed as * p < 0.01. A representative image from each sample is included. 
 
Evaluation of PDIA1 oxidase activity 
 Of the many cellular functions PDIA1 performs, its oxidative protein folding 
within the ER is of most significant interest when developing PDIA1 inhibitors as cancer 
therapeutics. In order to assess PDIA1 oxidase activity, we employed a previously 
reported ribonuclease (RNase) oxidation assay on recombinantly expressed and purified 
PDIA1.40, 107 RNase catalyzes the hydrolysis of phosphodiester bonds within RNA. In 
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this assay, PDIA1 catalyzes the oxidative renaturation of active RNase from its inactive 
reduced form. The active RNase subsequently catalyzes the hydrolysis of cyclic cytidine 
monophosphate (cCMP), leading to an increase in absorbance at 296 nm. This rate of 
cCMP hydrolysis correlates to the oxidase activity of PDIA1 (Figure 4-13). PDIA1 
oxidase activity was determined by subtracting each measurement from a corresponding 
sample without PDIA1 to account for spontaneous regeneration of active RNase. Lags 
are common observations in both the catalyzed and  uncatalyzed regeneration of RNase 
A and have been attributed to the prerequisite formation of RNase redox isomers that can 
be converted to the native protein.107 
 
Figure 4-13. PDIA1 oxidase activity is measured by the rate of oxidation of reduced 
RNase to active RNase by coupling this oxidase reaction to the hydrolysis of cCMP by 
activated RNase.    
 
 We wanted to evaluate the effect of each cysteine residue on PDIA1 oxidase 
activity. Previous studies have reported the contribution of each active-site (a and a’) to 
reoxidation of RNase by comparing PDIA1 WT to PDI C53/56A and PDIA1 C397/400A. 
At saturating concentrations of reduced RNase, the PDIA1 C397/400A mutant (kcat ~ 
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0.72 min-1) was found to retain activity near that of the PDIA1 WT (kcat ~0.76 min-1), 
while the PDIA1 C53/56A exhibited a significantly lower kcat (~0.24 min-1). The Km for 
reduced RNase is elevated for PDIA1 C397/400A mutant (Km ~29 μM), while the PDI 
53/56A mutant (Km ~ 7.1 μM) exhibits a near PDIA1 WT Km (~6.9 μM). The larger Km 
for the PDIA1 C397/400A mutant (4.2x of PDIA1 WT) and the lower kcat of PDIA1 
C53/56A (one third that of PDIA1 WT) suggest that the a’ site contributes more to 
apparent steady-state substrate binding, and the a site contributes more to catalysis at 
saturating concentrations of substrate.40  
While these data adequately illustrate the contribution of each active-site to 
oxidase activity, we looked to perform the assay on our single cysteine mutants (PDIA1 
C53A, C56A, C397A, C400A) in order to examine the contribution of each cysteine 
residue within the redox-catalytic pairs to oxidase activity. Recombinant PDIA1 WT and 
cysteine mutants were assayed for oxidase activity (Figure 4-14a). These data suggest 
that the N-terminal cysteine within each pair (Cys53 and Cys397) contributes 
significantly more to activity than the C-terminal cysteine (Cys56 and Cys400). Both 
PDIA1 C53A and PDIA1 C397A displayed a ~50% drop in Vmax and kcat compared to the 
WT, indicating that mutation of these residues completely abolishes activity at these sites 
(Figure 4-14b). Additionally, a double-mutant of both N-terminal cysteines (PDIA1 
C53/397A) displayed only minimal activity, confirming our claim. The PDIA1 C56A and 
C400A mutants exhibited a slight decrease in activity as compared to the WT; however, 
oxidase activity still occurs in each active-site even without these cysteines present, 
indicating that they may be non-essential for activity. The assay requires glutathione, and 
it’s possible that the nucleophilic cysteines (Cys53 and Cys397) could assemble the 
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necessary disulfide bond for oxidation intermolecularly. Together, we conclude that 
under our assay conditions both active-sites display near equal affinities for RNase and 
similar oxidative activity as indicate by their comparable kcat/Km values. 
 
Figure 4-14. (a) PDIA1 WT and cysteine mutants were assayed for oxidase activity to 
compare Vmax, kcat, Km and kcat/Km. (b) Vmax values revealed loss of activity within each 
active-site upon mutation to nucleophilic cysteine residue (Cys53 or Cys397), with only 
minimal activity observed in double-mutant.  
 
Evaluation of inhibitor affinities for each active-site within PDIA1 
 From previous work within our lab, RB-11-ca was identified as a cysteine-
reactive probe that appeared to target Cys53 of PDIA1,90 and SMC-9 was also found to 
target PDIA1 through a screen of a 4-aminopiperidine library.105 Additionally, NJP15, a 
peptide-based cysteine-reactive small molecule, was also found to bind PDIA1. We 
decided to take RB-11-ca, SMC-9, and NJP15 along with the 16F16, since it’s 
commercially available, and assess their affinities for each active-site cysteine residue 
(Cys53 or Cys397) within PDIA1 (Figure 4-15).  
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Figure 4-15. Structures of the panel of potential site-selective PDIA1 inhibitors: RB-11-
ca, NJP15, SMC-9, and 16F16.  
 
 In order to individually assess each active site, the nucleophilic cysteines within 
each redox-catalytic pair from the a and a’ site (Cys53 and Cys397) were mutated to 
alanine through site-directed mutagenesis. As a result, PDIA1 C53A will allow us to 
assess affinity for Cys397 in the a’ site and vice versa (Figure 4-16).  
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Figure 4-16. PDIA1 WT, C53A, and C397A structures allow for isolation of each active-
site to determine differential affinities of each potential inhibitor for the a and a’ site.  
 
 We employed a competitive in-gel fluorescence platform on each PDIA1 mutant 
to assess the potential inhibitors’ affinities for each active-site. Since all of these potential 
inhibitors function through a covalent, irreversible mechanism, we employed a 
chloroacetamide rhodamine (CA-Rh) to measure residual cysteine reactivity upon 
inhibitor competition (Figure 4-17). CA-Rh can be easily synthesized and displays near-
equal affinities for Cys53 and Cys397.106 Those potential inhibitors that mitigate CA-Rh 
binding within either the a or a’ site, represent strong binders to that particular active-site.  
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Figure 4-17. Structure of CA-Rh used to measure residual PDIA1 binding.  
 
 HeLa lysates spiked with recombinantly expressed and purified PDIA1 C53A or 
C397A were exposed to increasing concentrations of each of the four potential inhibitors 
(Figure 4-18). Notably, no binding occurs to solely purified PDIA1 unless additional 
protein (HeLa lysates) is added. This additional protein may be required for proper 
PDIA1 folding or to prevent aggregation; however, the exact reasoning is still unclear. 
RB-11-ca and 16F16 displayed similar potencies, with complete inhibition of the a site 
requiring less than 100 μM. SMC-9 and NJP15 were significantly less potent, requiring 
higher concentrations (upwards of 1,000 μM) to achieve near complete inhibition. For 
each inhibitor/active-site combination, at least two trials were performed. Gel band 
intensities were integrated, subtracted away from a PDIA1 C53/397A sample that served 
to measure the background fluorescence of the protein in the absence of CA-Rh binding 
to Cys53 or Cys397, normalized to the vehicle-treated sample, and pEC50 values were 
generated through non-linear regression (Figure 4-19). While the potencies of these 
inhibitors are suboptimal, we were much more interested in their selectivities for each 
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active-site. RB-11-ca remarkably displays 10-fold selectivity for the a site (EC50 = 47.4 
μM) over the a’ site (EC50 = 560.2 μM). 16F16, while displaying similar potency as RB-
11-ca for the a site (35.4 μM), only produced 2-fold selectivity over the a’ site (65.4 μM). 
For SMC-9, similar affinities for both the a (172.2 μM) and a’ sites (258.1 μM) were 
observed. NJP15 displayed almost 10-fold selectivity for the a’ site (396.4 μM) over the 
a site (3,172.0 μM). From these data, we believe we have an inhibitor toolbox that, upon 
optimization, could lead to an inhibitor selective for the a site (RB-11-ca), an inhibitor 
selective for the a’ site (NJP15), and a pan-active-site inhibitor (SMC-9) (Figure 4-19, 
corner circles). Notably, because this approach is competitive, these EC50 values are 
dependent on the potency of CA-Rh and should be recognized as relative to the assay.  
 
Figure 4-18. Affinity for each of the PDIA1 inhibitors for each active-site (a or a’). 
Concentrations for RB-11-ca and 16F16 ranged from 10 – 200 μM while those for SMC-
9 and NJP15 ranged from 100 μM  – 1,000  μM. 
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Figure 4-19. pEC50 values for each active-site of PDIA1 were calculated for each of the 
four inhibitors. The colored circles represent the optimal potencies/selectivities for our 
inhibitors 
 
Evaluation of the effect of cysteine-reactive inhibitors on PDIA1 oxidase activity 
Next, we looked to assess the effect of our PDIA1 inhibitors on oxidase activity. 
Enzyme kinetics for covalent inhibitors is assumed to be a two-step process (Figure 4-
20). Inhibitor must first bind and associate within the enzyme noncovalently, and this rate 
of association is represented as kon. This first-step is reversible, with the rate of 
dissociation represented as koff. KI, which represents the overall binding affinity for the 
inhibitor for the enzyme, is calculated by comparing the relative rates of association (kon) 
and dissociation (koff). Once the transient enzyme-inhibitor complex is generated, the 
electrophilic warhead can covalently bind to the enzyme. This irreversible reaction 
produces the permanently inactivated enzyme-inhibitor complex, and this rate of enzyme 
inactivation is measured as kinact. For covalent inhibition, the electrophilic warhead alone 
is not the sole determinant of potency; covalent inhibitors must possess a balance 
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between binding and reactivity. To account for both properties, covalent inhibitors are 
typically evaluated by their kinact/KI. Notably, a certain population of inhibitor may 
covalently bind to other nucleophilic species in the system and be inactivated, lowering 
the effective inhibitor concentration.  
 
Figure 4-20. Enzyme kinetics of covalent inhibition is a two-step process. The first step 
is reversible and involves inhibitor binding to the enzyme. Once bound, the inhibitor can 
covalently bind and permanently inactivate the enzyme. 
 
The majority of existing PDIA1 inhibitors have only been assessed for PDIA1 
reductase activity, including 16F1689 and RB-11-ca.90 Aliquots of PDIA1 WT and casein 
(excess protein required for inhibitor binding) in PBS were treated with inhibitor at 
increasing concentrations (10, 25, 50, 75, 100, 200 μM) for various time points (5, 15, 30, 
45 and 60 mins). These inhibitor-treated PDIA1 samples were assayed for oxidase 
activity of the reduced RNase substrate (25 μM). Data were analyzed to generate kinact/KI 
values for 16F16 and RB-11-ca (Figure 4-21). RB-11-ca and 16F16 both displayed 
similar kinact/KI values, which was consistent with data from the in-gel fluorescence 
platform and affinity for each site. Furthermore, the ability of 16F16 to bind both active-
sites with similar potencies likely accounts for its higher kinact value, since RB-11-ca is 
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only binding the a site and will eventually reach a limit of inactivation rate. The 
combined potency of 16F16 renders it a better inhibitor of overall PDIA1 WT oxidase 
activity. Because these PDIA1 inhibitors mitigate PDIA1 oxidase activity, they show 
promise as starting points in the development of cancer therapeutic agents.   
 
Figure 4-21. PDIA1 oxidase activity upon treatment with RB-11-ca and 16F16.  
 
Effects of PDIA1 inhibition on cancer cell survival and proliferation 
  
 Next, we wanted to evaluate the effect of PDIA1 inhibitor treatment on cell 
proliferation. SKOV3 cells were dosed with increasing concentrations of RB-11-ca or 
16F16 and assayed for cell proliferation after 24 hrs (Figure 4-22). This produced IC50 
values of 32.97 and 9.98 μM respectively. Importantly, IC50 (32.97 and 9.98 μM 
respectively) are close to the concentrations required for inhibitor binding to PDIA1 (47.4 
μM for RB-11-ca binding to the a site; 35.4 μM for 16F16 binding to the a site; 65.4 μM 
for 16F16 binding to the a’ site) and in the range of those used to inhibit oxidase activity, 
hinting that inhibition of PDIA1 oxidase activity is triggering cellular death. 
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Figure 4-22. RB-11-ca and 16F16 show dose-dependent inhibition of SKOV3 
proliferation.  
 
As described earlier, PDIA1 inhibition causes a great deal of ER stress, which 
results in the activation of the unfolded protein response (UPR) (Figure 4-6). To 
corroborate that cytotoxicity is due to PDIA1 inhibition, we hypothesized that an 
upregulated UPR should provide a certain degree of protection to cells treated with 
PDIA1 inhibitors. A HEK293DAX cell line was engineered to stably overexpress ATF6 
and XBP1 within an inducible expression system.108 Tetracycline (tet)-repressor 
technology was applied to allow doxycycline(dox)-dependent control of XBP1 levels 
within a physiological range.109 Additional tet-repressor regulation of ATF6 activity 
produced non-physiological levels of ATF6 expression and significant off-target effects 
including strong upregulation of established XBP1 target genes. Instead, a destabilized 
domain technology was employed as a dosable and orthogonal system to tet-repressor 
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technology.110, 111 A destabilized variant of E. coli dihydrofolate reductase (DHFR) was 
fused to the N-terminus of ATF6 via a short Gly-Ser linker. The poorly folded DHFR 
domain directs the entirely constitutively expressed DHFR-ATF6 fusion protein towards 
rapid proteasomal degradation. Administration of the DHFR-specific chaperone, 
trimethoprim (TMP), stabilizes the folded DHFR conformation, increasing the initially 
poorly populated folded DHFR population, attenuating proteomsomal degradation and 
inducing the ATF6 transcriptional program.108 Recent studies on the HEK293DAX cell line 
demonstrated that activation of XBP1 and ATF6 influences folding, trafficking, and 
degradation of destabilized ER proteins without globally effecting the endogenous 
proteome.108 HEK293DAX cells appear to be the perfect system to confirm that ER stress 
arising from PDIA1 inhibition is the cause of cellular death.  
HEK293DAX were grown within selection media and both dox and TMP were 
added to media to induce expression of XBP1 and ATF6 and activate UPR. After 12 
hours, both the UPR-activated HEK293DAX cells and inactivated controls were treated 
with increasing concentrations of RB-11-ca or 16F16 and assayed for cell proliferation 
after 24 hrs (Figure 4-23). For each inhibitor, three biological replicates were performed 
at an n = 3. Importantly, RB-11-ca showed in increase in inhibitor tolerance of 1.91-fold 
upon activation of UPR, while 16F16 only showed an increase in inhibitor tolerance of 
1.35-fold. In both cases, the chemotherapeutic resistance achieved upon UPR activations 
signals that these inhibitors function, at least partially, by cytotoxicity induced by ER 
stress arising from PDIA1 inhibition. However, the lower degree of tolerance achieved by 
16F16 compared to RB-11-ca signifies that 16F16 may suffer from off-target binding that 
also contributes to cytotoxicity.  
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Figure 4-23. UPR activation provides cytoprotection from cytotoxicity resulting from 
PDIA1 inhibition by RB-11-ca and 16F16.  
 
Conclusions 
 We believe that our novel approach will ultimately lead to the development of a 
PDIA1 inhibitor toolbox to help deconvolute the role of PDIA1 in cellular functions and 
disease pathways. First, an engineered PDIA1 knockdown into an ovarian cancer cell line 
(SKOV3) significantly diminished cell proliferation, survival, migration and invasion, 
which validates PDIA1 inhibition as a therapeutic pathway for cancer treatment. We 
sought to examine a panel of PDIA1 inhibitors, and enact our new approach to assess 
their effectiveness as anticancer agents. This strategy first employed a competitive in-gel 
fluorescence assay to evaluate inhibitor binding affinities for each individual active-site 
(a vs a’). At this point, we have designed PDIA1 inhibitors with potential of being 1) 
selective for the a site (RB-11-ca), 2) selective for the a’ site (NJP15), and 3) a pan-
PDIA1 inhibitor (SMC-9). These site-selective inhibitors should help uncover the roles of 
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each active-site in PDIA1 function. Site-selective inhibitors could be extremely important 
for PDIA1-based anticancer therapies. Because PDIA1 function is essential for healthy 
and cancer cells, only inhibiting a single active-site may result in cytotoxicity solely to 
cancer cells due to their increased reliance on PDIA1. Furthermore, inhibitors that 
displayed successful binding to PDIA1 underwent an activity assay to determine their 
ability to inhibit PDIA1 oxidase activity, since that activity is thought to be most 
important to cancer progression. While inhibition of PDIA1 oxidase activity was 
observed upon RB-11-ca and 16F16 treatment, these inhibitors all unfortunately lacked 
sufficient potencies. Currently, other members of the Weerapana lab are examining SAR 
of all PDIA1 inhibitors for each active-site in the hopes of developing more potent 
derivatives that maintain site-selectivity. Furthermore, other PDIA1 family members, in 
particular PDIA3, PDIA4, and PDIA6, should be examined for a role in cancer 
pathogenesis. The design of selective inhibitors for other members of the PDIA1 family 
should continue to aid efforts to deconvolute their cellular roles and contribution to 
disease.   
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Experimental procedures 
 
General procedures and materials 
 All materials were purchased from Sigma Aldrich or Fisher Scientific unless 
otherwise noted. Fmoc-propargylglycine (Fmoc-Pra-OH) was purchased from BaCHEM. 
All other Fmoc-protected amino acids, PyBOP, peptide-synthesis resin were purchased 
from Novabiochem. PBS buffer, DMEM/High glucose media, and penicillin 
streptomycin (Pen/Strep) were purchased from Thermal Scientific. Trypsin-EDTA was 
purchased from Invitrogen. X-tremeGENE 9 DNA transfection reagent was purchased 
from Roche. High resolution Mass Spectra (HRMS) were obtained at the Mass 
Spectrometry Facility at Boston College unless otherwise noted. A Molecular Devices 
Spectramax M5 plate reader was used to read the absorbance of all activity assays. All 
silver staining was carried out using a ProteoSilver Silver Stain kit from Sigma. The α-
PDI antibody was purchased from cell signaling. All work with RNA was performed 
under RNase free conditions (filtered pipet tips and decontaminating with RNase away). 
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DEPC-water and pLenti Go-Stix were purchased from ClonTech. All sequencing was 
performed by Genewiz with the appropriate primers.  
 
Synthesis of BsO-(propanamide)-Glu-Pro-Pra-Phe-Phe-NH2 (NJP15) 
The peptide was synthesized by manual solid-phase methods on Rink Amide 
MBHA Resin using Fmoc as the protecting group for α-amino functionalities. Amino 
acids were coupled using PyBOP as the activating reagent. The success of each Fmoc-
deprotection and coupling reaction was qualitatively tested using the standard procedure 
for the Kaiser test. Fmoc-Phe-OH, Fmoc-Phe-OH, Fmoc-Pra-OH, Fmoc-Pro-OH, and 
Fmoc-Glu(OtBu)-OH residues were added under standard coupling conditions. After 
Fmoc-deprotection, 3-(trityloxy)propanoic acid (NJP12, synthesis detailed in Chapter 2) 
(2 eq) and PyBOP (2 eq) were dissolved in DMF and this solution was added to the resin. 
DIPEA (4 eq) was added to the resin, and the reaction was shaken at room temperature 
for 2 hrs. The solvent was removed by vacuum and the resin was washed with DMF (5 x 
3 mL) and DCM (3 x 3 mL). The resin was shaken in a 1% TFA, 2% TIS in DCM 
solution to remove the trityl group (3 x 5 mins). Dry DCM was added to the resin and N2 
gas was bubbled through the reaction vessel. NEt3 in large excess (~100 eq) followed by 
benzene sulfonylchloride in large excess (~100 eq) were added to the resin. N2 gas was 
bubbled through the reaction mixture for 1 hr, and any solvent lost was replaced. The 
reaction vessel was capped, sealed with parafilm, and shaken for 15 hrs. The solvent was 
removed and the resin was washed with DCM (5 x 3 mL). After the addition of the 
electrophile, cleavage from the resin was performed in TFA: DCM: TIS: water (90: 5: 
2.5: 2.5) solution for 2 hrs. The peptide was purified by preparative HPLC with a gradient 
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of increasing acetonitrile-0.1% TFA (solvent) in water-0.1% TFA (solvent A) and 
analyzed by a Micromass LCT TOF mass spectrometer coupled to a Waters 2975 HPLC 
and a Waters 2996 photodiode array UV-vis detector to give the pure peptide NJP15 
(5.71%). HPLC tR = 20.48 min (C18, 5-195% B in 30 mins); HRMS for NJP14 
(C42H48N6O11S + Na+): m/z calcd 844.31; obsd [M + Na+] 867.3 (ESI+). 
 
Generation of stable cell lines 
 
General cell culture and preparation of protein lysates 
 All SKOV3 cell lines were grown in the cell incubator at 37°C under 5% CO2 in 
RPMI media supplemented with 10% FCS, 2 mM glutamine, and 1% Pen/Strep 
(RPMI+FBS). HEK293T and HeLa cells were grown in the cell incubator at 37°C under 
5% CO2 in DMEM media supplemented with 10% FCS, 2 mM glutamine, and 1% 
Pen/Strep (DMEM+FCS). The plates were allowed to grow to 100% confluence, the cells 
were harvested by scraping, and the pellets were washed with PBS. The pellets were 
resuspended in an appropriate amount of PBS and sonicated to lyse to give whole-cell 
lysates. These lysates were separated by centrifugation (45 mins, 45,000 rpm) at 4°C 
under high vacuum to separate the soluble and membrane proteomes. The supernatant 
was collected as the soluble fraction and the pellet was discarded. The protein 
concentrations were determined using the Bio-Rad DC Protein Assay kit (Bio-Rad). In 
some cases serum free RPMI or DMEM media supplemented with 2 mM glutamine and 
1% Pen//Strep are utilized (RPMI-SF or DMEM-SF).  
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Heat Inactivated Serum 
 An aliquot of FCS (50 mL) was removed from the -20 °C freezer and was thawed. 
The FCS was heated in a 55 °C water bath for at least 30 mins, and was then added to 
either RPMI media supplemented with 2 mM glutamine and 1% Pen/Strep (RPMI+HIS) 
or DMEM media supplemented with 2 mM glutamine and 1% Pen/Strep (DMEM+HIS).    
 
Gateway cloning of PDIA1 sequence into viral expression vector 
 PDIA1-pDONR2233 plasmid (1.0 μL, 100 ng/μL = 100 ng; GE Healthcare) and 
the destination pLenti CMV Puro Dest expression vector (1.0 μL, 150 ng/μL), TE buffer 
pH 8.0 (6.0 μL, purchased from Fisher) were combined in an eppendorf tube. LR clonase 
II enzyme mix (Life Technologies) was thawed on ice and briefly vortexed. This solution 
(2.0 μL) was added to the eppendorf. The reaction was vortexed and allowed to proceed 
at room temperature for 1 hr. Proteinase K (1.0 μL; Life Technologies) was added to the 
reaction and it was vortexed and allowed to proceed at room temperature for an addition 
10 mins. The reaction mixture was transformed into DH5α chemically competent cells, 
colonies were cultured, and plasmid was isolated and confirmed by sequencing.  
 
Lentiviral transduction of shGFP, shPDIA1, and PDIA1 overexpression sequence 
 The following procedure is for one 10 cm plate HEK293T cells to produce one 10 
cm plate of infected SKOV3 cells. (If performing in a 15 cm plate, multiply all amounts 
by 4). DMEM-SF (1.160 mL) and X-tremeGENE 9 DNA transfection reagent (40 μL) 
were combined and briefly shaken. VSVG-pCMV (1 μg), pspax2-pCMV (1 μg), and the 
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shRNA or viral overexpression construct (2 μg) were added to the solution. The sample 
was briefly shaken and allowed to sit at room temperature for about 15-20 mins. A 10 cm 
plate of HEK293T cells at ~75% confluence, grown in DMEM-HIS were removed from 
the cell incubator, and the plasmid solution was added dropwise to the plate. The plate 
returned to the cell incubator for approximately 16-24 hrs. The media was removed by 
vacuum, and fresh DMEM-HIS (5 mL) was added to the transfected plate to concentrate 
the virus, and the plate was returned to the cell incubator for an additional 16-24 hrs. The 
presence of virus was confirmed using Lenti-X GoStix. For each sample, RPMI+HIS (5 
mL) and polybrene in water (10 μL, 10 mg/mL) were combined in a 15 mL conical tube. 
The virus-containing DMEM+HIS (5 mL) was removed from the HEK293T cells and 
was filtered through a 0.4 μm filter into the 15 mL conical tubes. In addition, a negative 
control was made by using DMEM+HIS. SKOV3 cells at ~50% confluence grown in 
RPMI+HIS were removed from the cell incubator and the media was removed by 
vacuum. Each of the virus containing media solutions (~10 mL) was added to the plates, 
and the plates were returned to the cell incubator for 16-24 hrs. The plates were removed 
from the cell incubator and the media was removed by vacuum. RPMI+FBS (10 mL) and 
puromycin (10.0 μL, 1 mg/mL) were added to the plates and they were returned to the 
cell incubator. The selection was carried out until all the cells were dead within the 
negative control (approx. 72 hrs for SKOV3 cells). The media was removed from all the 
plates by vacuum and replaced with fresh RPMI+FBS.  
 
Evaluation of mRNA levels of SKOV3-Ctrl, SKOV3-PDIA1-, SKOV3-PDIA1+ 
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RNA extraction 
 TRIzol reagent (1.00 mL; Life Technologies) was added to a 10 cm plates of 
100% confluent SKOV3 cells and allowed to incubate at room temperature for 5 mins. 
The TRIzol solution was transferred to an eppendorf tube and chloroform (200 μL) was 
added to the tube. The tube was briefly shaken and centrifuged (12 mins, 4 °C). The top 
layer was carefully transferred to another eppendorf tube. Isopropanol (400 μL) was 
added, the tube was vortexed, and it was allowed to sit at room temperature for ~5-10 
mins. The samples were centrifuged (10 mins, 4 °C) and the supernatants were carefully 
discarded. A 75% EtOH in DEPC-water solution (400 μL) was added to wash the pellets. 
The sample was vortexed rigorously, centrifuged (5 mins, 4 °C), and the supernatant was 
carefully removed. The sample was allowed to briefly air dry and was resuspended in 
DEPC-water (25-35 μL). The RNA can be stored at -80 °C and concentrations can be 
taken using the Nanodrop.  
 
cDNA formation 
 RNA stocks were diluted to 500 ng/μL. DEPC-water (9.5 μL), RNA (1.0 μL, 500 
ng/μL = 500 ng), and Oligo-dT’s (2.0 μL, 100 μM) were combined in a PCR tube. The 
tube was incubated in at 65 °C for 2 mins and was then chilled on ice for 1 min. M 
MuLV Reverse Transcriptase 10x Reaction Buffer (2.0 μL; New England Biolabs), dNTP 
mix (2.0 μL, 10 mM), DTT (2.0 μL, 100 mM), RNase Inhibitor (0.5 μL; New England 
Biolabs), and M MuLV Reverse Transcriptase (1.0 μL; New England Biolabs) were 
added to the sample to give a total volume of 20.0 μL. The tubes were briefly mixed and 
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were incubated at 37 °C for 60 mins, then 85 °C for 5 mins to terminate the reaction. The 
tubes were allowed to sit on ice for 1 min, and can be stored at -80 °C.  
 
RT-PCR 
  The following primers were designed to evaluate PDIA1 mRNA levels and 
GAPDH levels. GAPDH was used as a housekeeper gene. For each gene, the primers 
were prepared as a mixture of both forward and reverse (10 μM each) in DEPC-water. 
The primers were evaluated for the capacity to dimerize.  
 PDIA1_Forward: 5’-TTTGGAGGTGAAATCAAGACTCA-3’ 
 PDIA1_Reverse: 5’-GAAAGAACTTGAGTGTGGGG-3’ 
 GAPDH_Forward: 5’-GATTTGGTCGTATTGGGCGC-3’ 
 GAPDH_Reverse: 5’-AGTGATGGCATGGACTGTGG-3’ 
 For each sample, DEPC-water (16.8 μL), 5x HF Buffer (5.0 μL; Finnzyme), primer mix 
(1.50 μL), cDNA (1.00 μL), dNTPs (0.50 μL, 10 mM), and Phusion polymerase (0.25 
μL; Finnzyme). The following PCR conditions were used:  
 30 cycles   
Initial Denature Anneal Elongation Final 
95 °C 95 °C 55 °C 68 °C 72 °C 4 °C 
2 mins 15 sec 30 sec 30 sec 10 mins End 
 
Xylene cyanol (5.0 μL) was added to the samples and each sample (5.0 μL) and a Tri-
Dye 100 bp DNA ladder (New England Biolabs) ware loaded onto a 2% agarose gel. The 
gel was run at 155 volts for 15 mins and visualized under UV light. Band quantification 
was performed using ImageJ software, and values were calculated from two technical 
replicates of two biological replicates.  
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Western blot 
 Protein lysates were collected for the SKOV3-Ctrl, SKOV3-PDIA1-, and 
SKOV3-PDIA1+ cell lines. The protein lysates (15 μL) and 2x gel loading dye (15 μL) 
were combined and loaded onto a 10% polyacrylamide gel. The gel was run for 217 volt 
hrs. These SDS-PAGE gels were transferred by electroblotting onto nitrocellulose 
membranes for 150 volt hours. The membranes were blocked in TBS-T and 5% (w/v) 
non-fat dry milk at room temperature for 2 hrs. The blot was washed with TBS-T three 
times (5 min per wash), and the blot was treated with α-PDIA1 rabbit antibody (1:1000) 
overnight at 4 °C. The blots were washed with TBS-T three times (5 mins per wash). The 
blots were treated with the appropriate secondary antibody (α-rabbit, 1:3333) for 2 hrs at 
room temperature. The blots were washed three times with TBS-T (5 mins per wash), 
treated with HRP super signal chemiluminescence reagents and exposed to film for 1-10 
mins before development. Development took place using a Kodak X-OMAT 2000A 
processor.  
 
Cancer phenotypic assays 
 
Proliferation and survival 
 A 10 cm plate of each cell type (SKOV3-Ctrl, SKOV3-PDIA1-, SKOV3-
PDIA1+) was removed from the cell incubator and the media was removed. The plates 
were washed with PBS (5 mL). RPMI-SF (5 mL) was added to the plates and they were 
returned to the cell incubator for ~2 hrs to serum starve cells. 
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 The serum-starved plates were removed and the media was removed. The plates 
were washed with PBS (5 mL). The cells were incubated in Trypsin-EDTA (1.25 mL) for 
an appropriate time point. The suspension were diluted 10x with RPMI-SF (12.5 mL), 
transferred to 15 mL conical tubes, centrifuged (5 mins, 3500 rpm, 4°C), and the 
supernatants were removed. The pellets were resuspended in RPMI-SF and were counted 
using a hemocytometer.  
 Four, clear, 96-well plates were designated as Day 0, Day 1, Day 3, Day 5. For 
proliferation, SKOV3 cells (10,000 cells/well) in RPMI+FBS (150 μL total volume) were 
added to five wells of each of the four plates. For survival, SKOV3 cells (20,000 
cells/well) in RPMI-SF (150 μL total volume) were added to five wells of each of the 
four plates. WST-1 proliferation agent (10.0 μL; Roche) was immediately added to each 
well of the Day 0 plates. The plates were placed in the cell incubator for 1 hr and the 
absorbance at 450 nm was recorded for each well. After the appropriate time points (24, 
72, and 120 hrs), WST-1 proliferation agent (10 μL) was added to plate and the process 
was repeated. Data were subtracted from a media blank and taken as n = 5 from two 
biological replicates.  
 
Migration 
 A 10 cm plate of each cell type (SKOV3-Ctrl, SKOV3-PDIA1-, SKOV3-
PDIA1+) was removed from the cell incubator and the media was removed. The plates 
were washed with PBS (5 mL). RPMI-SF (5 mL) was added to the plates and they were 
returned to the cell incubator for ~2 hrs to serum starve cells. PBS (13 mL) and collagen 
from rat tail (35 μL; Life Technologies) were combined and this solution (750 μL) was 
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added to 12 wells of a Corning Transwell Permeable Support (24-well plate with 12 
inserts). The inserts were placed in these collagen filled wells, and the plate was placed in 
the cell incubator for ~2 hrs.  
 The serum-starved plates were removed and the media was removed. The plates 
were washed with PBS (5 mL). The cells were incubated in Trypsin-EDTA (1.25 mL) for 
an appropriate time point. The suspension were diluted 10x with RPMI-SF (12.5 mL), 
transferred to 15 mL conical tubes, centrifuged (5 mins, 3500 rpm, 4°C), and the 
supernatants were removed. The pellets were resuspended in RPMI-SF and were counted 
using a hemocytometer.  
 The migration chamber was removed from the cell incubator and RPMI-SF (750 
μL) was added to the remaining 12 wells. The inserts were moved to these wells, and 
SKOV3 cells (50,000 cells/well) in RPMI-SF (200 μL) were added to these inserts. The 
migration chamber was placed in the cell incubator for 5 hrs. The migration chamber was 
removed and the inserted wells were removed, dried, and stained using Diff-Quik Stain 
Set (Siemens). Images were captured for each well under a 20x and 40x optical 
microscope. The amount of cells on the 40x images were counted, and the results were 
displayed as an average and SEM from n = 3 from two biological samples. The data were 
displayed relative to the SKOV3-Ctrl cell line.  
 
Invasion 
  A 10 cm plate of each cell type (SKOV3-Ctrl, SKOV3-PDIA1-, SKOV3-
PDIA1+) was removed from the cell incubator and the media was removed. The plates 
were washed with PBS (5 mL). RPMI-SF (5 mL) was added to the plates and they were 
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returned to the cell incubator for ~2 hrs to serum starve cells. RPMI-SF (750 μL) was 
added to 12 wells of a Corning BioCoat Matrigel Invasion Chamber (24-well plate with 
12 inserts). The inserts were placed in these media filled wells for re-hydration, and the 
plate was placed in the cell incubator for ~2 hrs.  
 The serum-starved plates were removed and the media was removed. The plates 
were washed with PBS (5 mL). The cells were incubated in Trypsin-EDTA (1.25 mL) for 
an appropriate time point. The suspension were diluted 10x with RPMI-SF (12.5 mL), 
transferred to 15 mL conical tubes, centrifuged (5 mins, 3500 rpm, 4°C), and the 
supernatants were removed. The pellets were resuspended in RPMI-SF and were counted 
using a hemocytometer.  
 The invasion chamber was removed from the cell incubator and RPMI-SF (750 
μL) was added to the remaining 12 wells. The inserts were moved to these wells, and 
SKOV3 cells (50,000 cells/well) in RPMI-SF (500 μL) were added to these inserts. The 
migration chamber was placed in the cell incubator for 24 hrs. The invasion chamber was 
removed and the inserted wells were removed, dried, and stained using Diff-Quik Stain 
Set (Siemens). Images were captured for each well under a 20x and 40x optical 
microscope. The amount of cells on the 40x images were counted, and the results were 
displayed as an average and SEM from n = 3 from two biological samples. The data were 
displayed relative to the SKOV3-Ctrl cell line.  
 
PDIA1 recombinant protein expression 
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Cloning of PDIA1 WT and cysteine mutants into mammalian overexpression vector 
pcDNA3.1+(myc/His) bacterial expression vector (pET) 
 The PDIA1 WT cDNA was initially subcloned into pcDNA3.1+(myc/His) 
mammalian expression vector through the HindIII and XbaI restriction sites. The PDIA1 
C53A, C56A, C397A, C400A, and C53/397A mutants were generated through site-
directed mutagenesis (Quik-Change, Stratagene) using the following primers: 
 PDIA1 C53A-For: 5’-CATGCCCCCTGGGCTGGCCACTGCAAG-3’ 
 PDIA1 C53A-Rev: 5’- CTTGCAGTGGCCAGCCCAGGGGGCATG-3’ 
 PDIA1 C56A-For: 5’- GGTGTGGCCACGCCAAGGCTCTGGC-3’ 
 PDIA1 C56A-For: 5’- GCCAGAGCCTTGGCGTGGCCACACC-3’ 
 PDIA1 C397A-For: 5’- CTATGCCCCATGGGCTGGTCACTGCAAAC-3’ 
 PDIA1 C397A-Rev: 5’- GTTTGCAGTGACCAGCCCATGGGGCATAG-3’ 
 PDIA1 C400A-For: 5’- CATGGTGTGGTCACGCCAAACAGTTGGCTC-3’ 
 PDIA1 C400A-Rev: 5’- GAGCCAACTGTTTGGCGTGACCACACCATG-3’ 
The PDIA1 C53/397A was made through two rounds of mutagenesis. All constructs were 
verified by sequencing.  
 
Cloning of PDIA1 WT and cysteine mutants into bacterial expression vector (pET-
a-d(+)) 
 The PDIA1 WT, C53A, C56A, C397A, C400A, C53/397A constructs were 
subcloned into pET-a-d(+) through the BamHI and HindIII restriction sites. For all 
constructs, the first 51 bases were removed and replaced by an ATG sequence in the 
forward primer to account for the loss of the 18 amino acid signaling sequence that is 
200 
 
cleaved upon PDIA1 maturation. Constructs were verified by sequencing and contained a 
His-tag for purification.  
 
Bacterial protein expression 
 Starting from a 5 mL overnight BL21 E. coli culture, PDIA1 WT, C53A, C56A, 
C397A, C400A, and C53/397A were grown at 37°C in LB broth (500 mL) to an OD600 of 
~0.8. The cultures were induced with IPTG (0.4 mM) and were shaken at 37°C for 4 
additional hours. The cells were harvested by centrifugation (5 mins, 5000 rpm) and 
pellets were frozen at -80°C until needed.  
 
Protein purification 
 E. coli pellets were thawed on ice and resuspended in PBS (10 mL). The 
suspensions were sonicated to lyse to form whole cell lysates. These lysates were 
separated by centrifuging at 45,000 rpm for 45 mins at 4 °C to yield soluble and 
membrane proteomes. The supernatant was collected as the soluble crude fraction and the 
pellet was discarded. The crude lysates were loaded onto a Ni-NTA column equilibrated 
with PBS. The column was washed with 3 - 6 column volumes of a 25 mM imidazole in 
PBS solution, and the purified protein was eluted with 2 column volumes of 500 mM 
imidazole in PBS solution. Each fraction was analyzed by SDS-PAGE and silver stain, 
and purified fractions were combined and further purified by a PD-10 size exclusion 
column (GE Life Sciences) to remove imidazole. The protein concentrations were 
determined using the Bio-Rad DC Protein Concentration Assay, and the lysates were 
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stored on ice in GSH (1 mM) and GSSG (0.2 mM) in PBS. The protein retained activity 
for approximately 2 – 4 weeks. 
 
Competitive in-gel fluorescence to assay affinity to the a and a’ site of PDIA1 
 Recombinant PDIA1 C53A, C397A, or C53/397A (1.25 μg) and HeLa lysates 
(1.00 mg/mL) were combined and diluted with PBS to a total volume of 25 μL. DMSO or 
inhibitor (from a 50x stock in DMSO) was added to each of the protein samples to give 
the following concentrations: 
 RB-11-ca/16F16: 10, 25, 50, 100, 200 (μM) 
 SMC-9/NJP15: 100, 200, 400, 600, 800, 1,000 (μM)  
Additionally, a PDIA1 C53/397A sample plus DMSO was added as a negative control. 
The samples were vortexed and allowed to sit at room temperature for 1 hr. CA-Rh (8 
μM, from a 50x stock in DMSO) was added to all the samples, they were vortexed and 
incubated at room temperature for an additional hour. Loading dye 2x (25 μL) was added 
to the samples, and each sample (25 μL) was loaded onto a 10% polyacrylamide gel. The 
gel was run for 217 volt hrs, fluorescent scanned, and coomassie stained. The gel band 
intensities were integrated using ImageJ from at least three trials. For each sample, the 
band intensity was subtracted from the PDIA1 C53/397A sample, which served to 
measure background protein fluorescence. The full gels are presented within Appendix 
III (Figure 4A-1, Figure 4A-2, Figure 4A-3, ,and Figure 4A-3).   
 
PDIA1 oxidative activity assays 
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General assay protocol 
 To prepare the reduced RNase substrate (rRNase), guanidine HCl (6 M), DTT 
(1.4 mM from 100x stock), and RNase A (10 mg/mL) were combined and shaken at 37°C 
overnight. The rRNase was purified on a Nap-5 size exclusion column (GE Life 
Sciences) immediately before use. GSH (1 mM, from 100x stock), GSSG (0.2 mM from 
100x stock), and cytidine 2’3’-cyclic monophosphate (4.5 mM from 100x stock; cCMP) 
were combined in a 100 mM Tris-acetic acid, 2 mM EDTA, pH 8.0 buffer (PDIA1 
buffer) to form an assay stock solution. Recombinant PDIA1 (1.4 μM) was added to the 
stock solution and aliquoted to wells of a UV-capable 96-well plate (Greiner). rRNase (1, 
5, 10, 25, or 50 μM) was added and the absorbance at 296 nm was recorded every 30 
seconds for 15-30 mins to measure the amount of product, activated RNase (aRNase).  
 
Oxidative activity assays of PDIA1 WT and cysteine mutants 
 The rRNase substrate was prepared as described above. A stock solution of 
PDIA1 buffer, GSH, GSSG, cCMP, and PDIA1 was prepared as described above and 
aliquoted (86.4 μL) to each well. Purified rRNase solution (13.6 μL, 1, 5, 10, 25, 50 μM 
from a 0.1 mg/mL, 0.5 mg/mL, 1.0 mg/mL, 2.5 mg/mL, and 5.0 mg/mL stock 
respectively) was added to each well, and the absorbance at 296 nm was recorded every 
30 seconds for 15 mins. Data analysis was performed to generate curves of [Product] 
formed / Time vs. [Substrate]. The derivative of each A vs. Time plot gave dA vs. Time, 
which was converted to [aRNase] vs. Time (769 A = 1 μM aRNase). Linear regression 
for each [rRNase] was performed to give a final plot of [aRNase]/Time vs. [rRNase].  
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Oxidative activity assays of PDIA1 WT treated with 16F16 or RB-11-ca 
 PDIA1 WT (0.29 mg/mL, 5.09 μM), casein in PBS (0.057 mg/mL), GSH (100 
mM), GSSG (0.2 mM) and PBS were combined and aliquoted as 30.0 μL samples. 
Inhibitor in DMSO (1.00 μL at the appropriate 30x concentration) was added to each 
sample for either 10, 20, 30, 40, or 50 mins. The samples were briefly vortexed and spun 
down. PDIA1 buffer, GSH (1 mM), GSSG (0.2 mM) and cCMP (will be 4.5 mM once 
diluted) were combined as a substrate stock solution. This solution (65.8 μL) was added 
to each well of a 96-well plate. Each inhibitor-treated protein sample (27.4 μL) was 
added to the appropriate wells. A sample without PDIA1 was used as a blank control. 
Purified rRNase (6.9 μL, 5 mg/mL) was added to the samples. This gives final 
concentrations of PDIA1 WT (1.4 μM), GSH (1 mM), GSSG (0.2 mM), cCMP (4.5 
mM), and rRNase (25 μM). The plate was read for absorbance at 296 every 30 seconds 
for 30 mins. For data analysis, each well was subtracted from the average of the –PDIA1 
samples at each respective time point. The derivatives (dA) of each concentration at each 
precincubation time were calculated as dA vs Time. The dA vs Time plots were 
converted to [aRNase] vs Time (769 A = 1 μM aRNase). Linear regressions for each 
preincubation time point at each [Inhibitor] were performed to give 5 slopes (5 
preincubation times) for each [Inhibitor]. For each [Inhibitor], the Rate of Activity 
([aRNase] / Time) vs Preincubation time was plotted. These were all normalized to the 
samples without Inhibitor, to give % Rate of Ctrl vs Preincubation time. One phase 
nonlinear regression was performed for each [Inhibitor] to produce a rate constant for 
inhibition. These rate constants were plotted as kobs vs [I], and another nonlinear 
regression was performed to calculate KI and kinact.  
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PDIA1 cytotoxicity assays 
 
Proliferation assay: SKOV3 + PDIA1 inhibitors 
 A 10 cm plate of SKOV3 cells was removed from the cell incubator and the 
media was removed. The plates were washed with PBS (5 mL). RPMI-SF (5 mL) was 
added to the plates and they were returned to the cell incubator for ~2 hrs to serum starve 
cells. 
 The serum-starved plates were removed and the media was removed. The plates 
were washed with PBS (5 mL). The cells were incubated in Trypsin-EDTA (1.25 mL) for 
an appropriate time point. The suspension were diluted 10x with RPMI-SF (12.5 mL), 
transferred to 15 mL conical tubes, centrifuged (5 mins, 3500 rpm, 4°C), and the 
supernatants were removed. The pellets were resuspended in RPMI-SF and were counted 
using a hemocytometer.  
 Two, clear, 96-well plates were designated as Day 0 and Day 1. SKOV3 cells 
(10,000 cells/well) and inhibitor (0, 0.5 1.0, 5.0, 10.0, 25.0, 50.0, 100.0 μM) in 
RPMI+FCS (150 μL total volume) stocks (6x) were made and each solution (150 μL) 
added to three wells of each of the two plates. WST-1 proliferation agent (10.0 μL; 
Roche) was immediately added to each well of the Day 0 plates. The plates were placed 
in the cell incubator for 1 hr and the absorbance at 450 nm was recorded for each well. 
After 24 hrs, WST-1 proliferation agent (10 μL) was added to the Day 1 plate and the 
process was repeated. Data were taken as n = 3 from 3 biological replicates.  
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Proliferation assay: HEK293DAX + PDIA1 inhibitors 
 Two 10 cm plates of HEK293DAX cells at ~80% confluence were removed from 
the cell incubator and the media was replaced with fresh DMEM+FBS (10 mL). Dox in 
water (1.00 μL, 10 mg/mL = 1.0 μg/mL) and TMP in DMSO (1.00 μL, 10 mg/mL = 10 
μM) were added to one of the plates to activate UPR. DMSO (1.00 μL) and water (1.00 
μL) was added to the other plate as a control. The plates were returned to the cell 
incubator for 12 hours.  
The plates were removed from the cell incubator and the media was removed. The 
plates were washed with PBS (5 mL). The cells were incubated in Trypsin-EDTA (1.25 
mL) for an appropriate time point. The suspension were diluted 10x with DMEM-SF 
(12.5 mL), transferred to 15 mL conical tubes, centrifuged (5 mins, 3500 rpm, 4°C), and 
the supernatants were removed. UPR-Media was made by combining DMEM+FBS (15.0 
mL), dox in water (1.00 μL, 10 mg/mL = 1 μg/mL), and TMP in DMSO (1.00 μL, 100 
mM = 10 μM) in a conical tube. Ctrl-Media was made by combining DMEM+FBS (15.0 
mL), water (1.00 μL), and DMSO (1.00 μL) in a conical tube. The HEK293DAX pellets 
were resuspended in the appropriate media (Ctrl or UPR) and were counted using a 
hemocytometer.  
 For both Ctrl and UPR HEK293DAX cells, 7x stocks were made by combining 
cells (20,000 cells/well) and inhibitor (0, 0.5, 1.0, 5.0, 10.0, 50.0, 100.0 μM from 100x 
stock in DMSO) in the appropriate media (Ctrl or UPR). Each suspension was aliquoted 
to three wells of two 96-well plates (150 μl/well) designated as Day 0 and Day 1. WST-1 
proliferation agent (10.0 μL; Roche) was immediately added to each well of the Day 0 
plates. The plates were placed in the cell incubator for 1 hr and the absorbance at 450 nm 
206 
 
was recorded for each well. After 24 hrs, WST-1 proliferation agent (10 μL) was added to 
the Day 1 plate and the process was repeated. Data were taken as n = 3 from 3 biological 
replicates.  
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Table 3A-1. Tryptic digests of HeLa lysates treated +/- NJP14.  
Protein Mol Weight (Da) 
Average Spectral 
counts % Change 
Ctrl NJP14 
IPI00793953 -  Gene_Symbol=TUBA8 Putative uncharacterized protein 
DKFZp686L04275 (Fragment)  53969 0.00 146.33 100.00 
IPI00787158 -  Gene_Symbol=SORD similar to sorbitol dehydrogenase 38687 0.00 126.00 100.00 
IPI00023598 -  Gene_Symbol=TUBB4 Tubulin beta-4 chain 49586 0.00 124.00 100.00 
IPI00019755 -  Gene_Symbol=GSTO1 Glutathione transferase omega-1  27566 0.00 76.00 100.00 
IPI00013871 -  Gene_Symbol=RRM1 Ribonucleoside-diphosphate reductase 
large subunit  90070 0.00 43.00 100.00 
IPI00303568 -  Gene_Symbol=PTGES2 Prostaglandin E synthase 2  41943 0.00 39.00 100.00 
IPI00009904 -  Gene_Symbol=PDIA4 Protein disulfide-isomerase A4 
precursor 72933 0.00 28.00 100.00 
IPI00219575 -  Gene_Symbol=BLMH Bleomycin hydrolase  52562 0.67 164.67 99.60 
IPI00010796 -  Gene_Symbol=P4HB Protein disulfide-isomerase precursor 57116 4.67 453.67 98.97 
IPI00025252 -  Gene_Symbol=PDIA3 Protein disulfide-isomerase A3 
precursor  56782 3.00 118.67 97.47 
IPI00022977 -  Gene_Symbol=CKB Creatine kinase B-type  42644 1.67 38.00 95.61 
IPI00783641 -  Gene_Symbol=TXNRD1 thioredoxin reductase 1 isoform 3  71153 7.67 145.67 94.74 
IPI00299571 -  Gene_Symbol=PDIA6 Isoform 2 of Protein disulfide-
isomerase A6 precursor 53901 3.67 57.00 93.57 
IPI00218343 -  Gene_Symbol=TUBA1C Tubulin alpha-1C chain 49895 13.33 171.33 92.22 
IPI00171438 -  Gene_Symbol=TXNDC5;MUTED Thioredoxin domain-
containing protein 5 precursor 47629 3.67 46.33 92.09 
IPI00180675 -  Gene_Symbol=TUBA1A Tubulin alpha-1A chain 50136 15.67 194.00 91.92 
IPI00477531 -  Gene_Symbol=DYNC1H1 532 kDa protein 532371 5.00 40.00 87.50 
IPI00031370 -  Gene_Symbol=TUBB2B Tubulin beta-2B chain  49953 25.67 184.00 86.05 
IPI00007750 -  Gene_Symbol=TUBA4A Tubulin alpha-4A chain  49924 27.67 189.67 85.41 
IPI00646779 -  Gene_Symbol=TUBB6 TUBB6 protein 50090 24.67 164.67 85.02 
IPI00387144 -  Gene_Symbol=TUBA1B Tubulin alpha-1B chain  50152 32.00 202.00 84.16 
IPI00011654 -  Gene_Symbol=TUBB Tubulin beta chain 49671 74.33 460.33 83.85 
IPI00007752 -  Gene_Symbol=TUBB2C Tubulin beta-2C chain 49831 39.33 241.33 83.70 
IPI00296337 -  Gene_Symbol=PRKDC Isoform 1 of DNA-dependent 
protein kinase catalytic subunit  469093 10.67 59.67 82.12 
IPI00152453 -  Gene_Symbol=TUBB3 Tubulin, beta, 4 88382 29.00 155.33 81.33 
IPI00026781 -  Gene_Symbol=FASN Fatty acid synthase 273397 15.33 65.67 76.65 
IPI00186711 -  Gene_Symbol=PLEC1 plectin 1 isoform 6  531796 9.00 35.00 74.29 
IPI00472102 -  Gene_Symbol=HSPD1 61 kDa protein 61213 22.67 72.00 68.52 
IPI00021290 -  Gene_Symbol=ACLY ATP-citrate synthase 120839 14.00 44.00 68.18 
IPI00186290 -  Gene_Symbol=EEF2 Elongation factor 2 95338 18.33 56.67 67.65 
IPI00643920 -  Gene_Symbol=TKT Transketolase 67878 16.00 49.00 67.35 
IPI00480131 -  Gene_Symbol=FLNB Uncharacterized protein FLNB 278188 28.00 68.00 58.82 
IPI00019502 -  Gene_Symbol=MYH9 Myosin-9 226530 47.33 114.67 58.72 
IPI00396485 -  Gene_Symbol=EEF1A1 Elongation factor 1-alpha 1 50141 30.33 68.00 55.39 
IPI00472724 -  Gene_Symbol=- Elongation factor 1-alpha 50185 30.33 68.00 55.39 
IPI00009342 -  Gene_Symbol=IQGAP1 Ras GTPase-activating-like protein 
IQGAP1 189251 13.00 28.00 53.57 
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IPI00024067 -  Gene_Symbol=CLTC Isoform 1 of Clathrin heavy chain 1 191613 24.00 51.00 52.94 
IPI00333541 -  Gene_Symbol=FLNA Filamin-A 280737 92.00 192.33 52.17 
IPI00465248 -  Gene_Symbol=ENO1 Isoform alpha-enolase of Alpha-
enolase 47169 22.00 44.67 50.75 
IPI00848058 -  Gene_Symbol=ACTB Actin, cytoplasmic 2 45086 93.33 188.67 50.53 
IPI00294578 -  Gene_Symbol=TGM2 Isoform 1 of Protein-glutamine 
gamma-glutamyltransferase 2 77329 17.33 34.67 50.00 
  
Table 3A-2. Tryptic digests of HeLa lysates treated with +/- Zn2+/Mg2+ followed by 
NJP14. 
Protein 
Average Spectral Counts % 
Change 
Zn 
% 
Change 
Mg Ctrl 
Zn2+ 
10μM 
Zn2+ 
20μM 
Mg2+ 
20μM 
IPI00787158 -  Gene_Symbol=SORD similar to sorbitol 
dehydrogenase ENSG00000140263 IPI00216057 
IPI00791243 IPI00787158 xxxxx 
250 11.5 2.5 261.5 -99.00 4.40 
IPI00019755 -  Gene_Symbol=GSTO1 Glutathione 
transferase omega-1 ENSG00000148834 IPI00513927 
IPI00019755 IPI00642936 xxxxx 
324 268.5 23.5 266.5 -92.75 -17.75 
IPI00783641 -  Gene_Symbol=TXNRD1 thioredoxin 
reductase 1 isoform 3 ENSG00000198431 IPI00783641 
IPI00743646 IPI00554786 IPI00847482 IPI00796750 
IPI00797831 IPI00816732 xxxxx 
535 86 42 463.5 -92.15 -13.36 
IPI00013871 -  Gene_Symbol=RRM1 Ribonucleoside-
diphosphate reductase large subunit ENSG00000167325 
IPI00013871 xxxxx 
135.5 114 26 124 -80.81 -8.49 
IPI00011253 -  Gene_Symbol=RPS3 40S ribosomal protein 
S3 ENSG00000149273 IPI00011253 xxxxx 40 21 13 37.5 -67.50 -6.25 
IPI00014424 -  Gene_Symbol=EEF1A2 Elongation factor 1-
alpha 2 ENSG00000101210 IPI00014424 xxxxx 68 44.5 25 15 -63.24 -77.94 
IPI00023598 -  Gene_Symbol=TUBB4 Tubulin beta-4 chain 
ENSG00000104833 IPI00023598 xxxxx 351 245.5 171 357.5 -51.28 1.82 
IPI00294578 -  Gene_Symbol=TGM2 Isoform 1 of Protein-
glutamine gamma-glutamyltransferase 2 ENSG00000198959 
IPI00218252 IPI00218251 IPI00294578 xxxxx 
52.5 26.5 26 62.5 -50.48 16.00 
IPI00396485 -  Gene_Symbol=EEF1A1 Elongation factor 1-
alpha 1 ENSG00000156508 IPI00853600 IPI00396485 
IPI00641459 IPI00847435 IPI00431701 IPI00431441 
IPI00382804 IPI00025447 xxxxx 
219.5 180 132.5 123 -39.64 -43.96 
IPI00472724 -  Gene_Symbol=- Elongation factor 1-alpha 
ENSG00000185637 IPI00472724 xxxxx 219.5 180 132.5 123 -39.64 -43.96 
IPI00010796 -  Gene_Symbol=P4HB Protein disulfide-
isomerase precursor ENSG00000185624 IPI00010796 
IPI00386460 xxxxx 
677 376.5 433.5 723 -35.97 6.36 
IPI00329633 -  Gene_Symbol=TARS Threonyl-tRNA 
synthetase, cytoplasmic ENSG00000113407 IPI00329633 
xxxxx 
37 31.5 25 28 -32.43 -24.32 
IPI00026328 -  Gene_Symbol=TXNDC12 Thioredoxin 
domain-containing protein 12 precursor ENSG00000117862 
IPI00026328 xxxxx 
35 39.5 24 32 -31.43 -8.57 
IPI00025252 -  Gene_Symbol=PDIA3 Protein disulfide-
isomerase A3 precursor ENSG00000167004 IPI00657680 
IPI00025252 IPI00796177 IPI00796736 IPI00790740 
IPI00791418 xxxxx 
321 263.5 239.5 308 -25.39 -4.05 
IPI00171438 -  Gene_Symbol=TXNDC5;MUTED 
Thioredoxin domain-containing protein 5 precursor 
ENSG00000188428 IPI00154778 IPI00395646 IPI00171438 
IPI00646720 xxxxx 
85.5 59 64 82.5 -25.15 -3.51 
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IPI00000875 -  Gene_Symbol=EEF1G Elongation factor 1-
gamma ENSG00000186676 IPI00000875 IPI00747497 
IPI00738381 xxxxx 
27 24.5 20.5 26 -24.07 -3.70 
IPI00303568 -  Gene_Symbol=PTGES2 Prostaglandin E 
synthase 2 ENSG00000148334 IPI00472496 IPI00303568 
IPI00395565 IPI00514138 xxxxx 
106 99 82.5 105 -22.17 -0.94 
IPI00180730 -  Gene_Symbol=- Uncharacterized protein 
ENSP00000333488 ENSG00000183920 IPI00180730 xxxxx 36.5 42 29 24 -20.55 -34.25 
IPI00478758 -  Gene_Symbol=C10orf119 Uncharacterized 
protein C10orf119 ENSG00000197771 IPI00478758 
IPI00414458 IPI00552546 xxxxx 
44.5 44.5 35.5 43.5 -20.22 -2.25 
IPI00007750 -  Gene_Symbol=TUBA4A Tubulin alpha-4A 
chain ENSG00000127824 IPI00335314 IPI00007750 
IPI00794663 IPI00797717 IPI00794009 xxxxx 
554 393 446.5 572.5 -19.40 3.23 
IPI00216694 -  Gene_Symbol=PLS3 plastin 3 
ENSG00000102024 IPI00848312 IPI00216694 xxxxx 27.5 32 23 29 -16.36 5.17 
IPI00013723 -  Gene_Symbol=PIN1 Peptidyl-prolyl cis-trans 
isomerase NIMA-interacting 1 ENSG00000127445 
IPI00013723 IPI00644298 IPI00446477 xxxxx 
52 49 44 54.5 -15.38 4.59 
IPI00301263 -  Gene_Symbol=CAD CAD protein 
ENSG00000084774 IPI00301263 xxxxx 38.5 43 33.5 52 -12.99 25.96 
IPI00477531 -  Gene_Symbol=DYNC1H1 532 kDa protein 
ENSG00000197102 IPI00456969 IPI00477531 IPI00440177 
xxxxx 
76.5 83.5 67.5 93.5 -11.76 18.18 
IPI00169383 -  Gene_Symbol=PGK1 Phosphoglycerate 
kinase 1 ENSG00000102144 IPI00169383 xxxxx 35 32.5 31 34 -11.43 -2.86 
IPI00793953 -  Gene_Symbol=TUBA8 Putative 
uncharacterized protein DKFZp686L04275 (Fragment) 
ENSG00000183785 IPI00646909 IPI00743964 IPI00816098 
IPI00792478 IPI00791613 IPI00853556 IPI00793953 xxxxx 
346 248.5 311 402.5 -10.12 14.04 
IPI00796333 -  Gene_Symbol=ALDOA 45 kDa protein 
ENSG00000149925 IPI00465439 IPI00640568 IPI00642546 
IPI00796333 xxxxx 
28.5 35 26 23 -8.77 -19.30 
IPI00784459 -  Gene_Symbol=CFL1 Uncharacterized 
protein CFL1 ENSG00000172757 IPI00784459 IPI00012011 
xxxxx 
38 38 36.5 28.5 -3.95 -25.00 
IPI00180675 -  Gene_Symbol=TUBA1A Tubulin alpha-1A 
chain ENSG00000167552 IPI00180675 xxxxx 588 389 565.5 585 -3.83 -0.51 
IPI00643920 -  Gene_Symbol=TKT Transketolase 
ENSG00000163931 IPI00643920 IPI00793119 IPI00792641 
IPI00789310 IPI00788802 xxxxx 
110 105 107.5 88 -2.27 -20.00 
IPI00011062 -  Gene_Symbol=CPS1 Isoform 1 of 
Carbamoyl-phosphate synthase [ammonia], mitochondrial 
precursor ENSG00000021826 IPI00011062 IPI00397498 
IPI00447499 xxxxx 
60.5 61 59.5 60.5 -1.65 0.00 
IPI00387144 -  Gene_Symbol=TUBA1B Tubulin alpha-1B 
chain ENSG00000123416 IPI00387144 IPI00792677 
IPI00793930 xxxxx 
613.5 437 608 635.5 -0.90 3.46 
IPI00418169 -  Gene_Symbol=ANXA2 annexin A2 isoform 
1 ENSG00000182718 IPI00418169 IPI00455315 
IPI00795925 IPI00797556 IPI00798111 IPI00797581 
IPI00790111 xxxxx 
64 74 63.5 65.5 -0.78 2.29 
IPI00019502 -  Gene_Symbol=MYH9 Myosin-9 
ENSG00000100345 IPI00019502 IPI00395772 IPI00556012 
IPI00742780 xxxxx 
231.5 267.5 235 191.5 1.49 -17.28 
IPI00031370 -  Gene_Symbol=TUBB2B Tubulin beta-2B 
chain ENSG00000137285 IPI00031370 IPI00748943 xxxxx 314.5 232.5 322.5 332.5 2.48 5.41 
IPI00024067 -  Gene_Symbol=CLTC Isoform 1 of Clathrin 
heavy chain 1 ENSG00000141367 IPI00024067 
IPI00455383 xxxxx 
68 92 71 77 4.23 11.69 
IPI00645078 -  Gene_Symbol=UBE1 Ubiquitin-activating 
enzyme E1 ENSG00000130985 IPI00645078 IPI00026119 
IPI00641319 IPI00644183 IPI00647463 IPI00646990 
IPI00552452 IPI00383182 xxxxx 
41 46 43 38.5 4.65 -6.10 
IPI00333541 -  Gene_Symbol=FLNA Filamin-A 
ENSG00000196924 IPI00553169 IPI00302592 IPI00644576 
IPI00333541 IPI00552858 IPI00552416 xxxxx 
442.5 436.5 466.5 363 5.14 -17.97 
IPI00480131 -  Gene_Symbol=FLNB Uncharacterized 
protein FLNB ENSG00000136068 IPI00480131 85.5 112.5 91 101.5 6.04 15.76 
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IPI00382697 IPI00289334 IPI00382698 IPI00477536 
IPI00382696 IPI00382699 IPI00382700 IPI00798140 
IPI00797598 IPI00794125 IPI00798186 IPI00816637 xxxxx 
IPI00186711 -  Gene_Symbol=PLEC1 plectin 1 isoform 6 
ENSG00000178209 IPI00186711 IPI00398779 IPI00398777 
IPI00420096 IPI00398775 IPI00398002 IPI00398778 
IPI00398776 IPI00014898 xxxxx 
44 44.5 47 54.5 6.38 19.27 
IPI00218343 -  Gene_Symbol=TUBA1C Tubulin alpha-1C 
chain ENSG00000167553 IPI00478908 IPI00218343 
IPI00166768 IPI00795002 xxxxx 
488.5 320.5 524.5 506.5 6.86 3.55 
IPI00007752 -  Gene_Symbol=TUBB2C Tubulin beta-2C 
chain ENSG00000188229 IPI00007752 xxxxx 470.5 333.5 529 506 11.06 7.02 
IPI00329200 -  Gene_Symbol=RANBP5 127 kDa protein 
ENSG00000065150 IPI00329200 IPI00793443 IPI00514205 
IPI00639960 xxxxx 
39.5 58.5 45.5 46.5 13.19 15.05 
IPI00334775 -  Gene_Symbol=HSP90AB1 85 kDa protein 
ENSG00000096384 IPI00414676 IPI00334775 IPI00411633 
IPI00640129 IPI00515119 IPI00746291 IPI00514659 
IPI00514027 xxxxx 
103 105 119 103 13.45 0.00 
IPI00419585 -  Gene_Symbol=PPIA;LOC654188;PPIAL3 
Peptidyl-prolyl cis-trans isomerase A ENSG00000196262 
IPI00472718 IPI00419585 Tax_Id=9606 
Gene_Symbol=PPIA;LOC654188;PPIAL3 Peptidyl-prolyl 
cis-trans isomerase A ENSG00000198618 IPI00419585 
xxxxx 
31.5 30 36.5 21.5 13.70 -31.75 
IPI00219575 -  Gene_Symbol=BLMH Bleomycin hydrolase 
ENSG00000108578 IPI00219575 IPI00794082 xxxxx 483 455 560 455 13.75 -5.80 
IPI00006510 -  Gene_Symbol=TUBB1 Tubulin beta-1 chain 
ENSG00000101162 IPI00006510 xxxxx 33.5 0 39 15 14.10 -55.22 
IPI00011654 -  Gene_Symbol=TUBB Tubulin beta chain 
ENSG00000183311 IPI00011654 Tax_Id=9606 
Gene_Symbol=TUBB Tubulin beta chain 
ENSG00000137379 IPI00011654 Tax_Id=9606 
Gene_Symbol=TUBB Tubulin beta chain 
ENSG00000196230 IPI00647896 IPI00011654 IPI00645452 
xxxxx 
839.5 627 980.5 916 14.38 8.35 
IPI00298994 -  Gene_Symbol=TLN1 Uncharacterized 
protein TLN1 ENSG00000137076 IPI00298994 
IPI00385946 IPI00642355 IPI00784273 xxxxx 
58 64 68 50.5 14.71 -12.93 
IPI00026781 -  Gene_Symbol=FASN Fatty acid synthase 
ENSG00000169710 IPI00026781 IPI00847250 IPI00792768 
IPI00793768 IPI00795589 IPI00795588 xxxxx 
220 211 260.5 197 15.55 -10.45 
IPI00848058 -  Gene_Symbol=ACTB Actin, cytoplasmic 2 
ENSG00000075624 IPI00021439 IPI00848058 IPI00844533 
xxxxx 
259 216 307 218 15.64 -15.83 
IPI00001159 -  Gene_Symbol=GCN1L1 GCN1-like protein 
1 ENSG00000089154 IPI00001159 IPI00789420 
IPI00788818 xxxxx 
47.5 63 56.5 57.5 15.93 17.39 
IPI00646779 -  Gene_Symbol=TUBB6 TUBB6 protein 
ENSG00000176014 IPI00646779 IPI00641706 IPI00643158 
IPI00647682 IPI00646972 xxxxx 
229 190.5 274 270 16.42 15.19 
IPI00186290 -  Gene_Symbol=EEF2 Elongation factor 2 
ENSG00000167658 IPI00186290 xxxxx 117 108 143 101.5 18.18 -13.25 
IPI00009342 -  Gene_Symbol=IQGAP1 Ras GTPase-
activating-like protein IQGAP1 ENSG00000140575 
IPI00009342 xxxxx 
38.5 57.5 48.5 43.5 20.62 11.49 
IPI00296337 -  Gene_Symbol=PRKDC Isoform 1 of DNA-
dependent protein kinase catalytic subunit 
ENSG00000121031 IPI00296337 IPI00376215 xxxxx 
62 78.5 79 86.5 21.52 28.32 
IPI00465248 -  Gene_Symbol=ENO1 Isoform alpha-enolase 
of Alpha-enolase ENSG00000074800 IPI00465248 
IPI00759806 xxxxx 
38.5 51 50 32.5 23.00 -15.58 
IPI00013452 -  Gene_Symbol=EPRS glutamyl-prolyl tRNA 
synthetase ENSG00000136628 IPI00013452 xxxxx 35.5 40 47.5 41.5 25.26 14.46 
IPI00178352 -  Gene_Symbol=FLNC Isoform 1 of Filamin-
C ENSG00000128591 IPI00178352 IPI00413958 
IPI00783128 xxxxx 
41.5 55 58.5 57 29.06 27.19 
IPI00009865 -  Gene_Symbol=KRT10 Keratin, type I 
cytoskeletal 10 ENSG00000186395 IPI00383111 51.5 50 73 27 29.45 -47.57 
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IPI00009865 xxxxx 
IPI00013808 -  Gene_Symbol=ACTN4 Alpha-actinin-4 
ENSG00000130402 IPI00013808 IPI00793285 xxxxx 31 29.5 45 25.5 31.11 -17.74 
IPI00219757 -  Gene_Symbol=GSTP1 Glutathione S-
transferase P ENSG00000084207 IPI00219757 IPI00793319 
xxxxx 
53.5 45 79 44.5 32.28 -16.82 
IPI00382470 -  Gene_Symbol=HSP90AA1 heat shock 
protein 90kDa alpha (cytosolic), class A member 1 isoform 1 
ENSG00000080824 IPI00784295 IPI00382470 IPI00604607 
IPI00795108 IPI00796865 IPI00796844 IPI00796258 xxxxx 
57 66 85.5 54.5 33.33 -4.39 
IPI00011200 -  Gene_Symbol=PHGDH D-3-
phosphoglycerate dehydrogenase ENSG00000092621 
IPI00642548 IPI00011200 xxxxx 
33 35.5 50.5 36 34.65 8.33 
IPI00026216 -  Gene_Symbol=NPEPPS Puromycin-sensitive 
aminopeptidase ENSG00000141279 IPI00026216 xxxxx 52.5 53 81.5 50.5 35.58 -3.81 
IPI00783061 -  Gene_Symbol=PKM2 Uncharacterized 
protein PKM2 ENSG00000067225 IPI00783061 
IPI00784179 IPI00607698 IPI00604528 IPI00479186 
IPI00220644 IPI00847989 IPI00788663 IPI00789727 
IPI00792817 IPI00797668 IPI00798295 xxxxx 
143.5 145 223 144 35.65 0.35 
IPI00024580 -  Gene_Symbol=MCCC1 Methylcrotonoyl-
CoA carboxylase subunit alpha, mitochondrial precursor 
ENSG00000078070 IPI00024580 IPI00792499 IPI00792968 
IPI00789136 xxxxx 
102.5 128.5 160 116.5 35.94 12.02 
IPI00009904 -  Gene_Symbol=PDIA4 Protein disulfide-
isomerase A4 precursor ENSG00000155660 IPI00009904 
IPI00852730 IPI00852792 xxxxx 
86.5 105 139 117.5 37.77 26.38 
IPI00396015 -  Gene_Symbol=ACACA Isoform 4 of Acetyl-
CoA carboxylase 1 ENSG00000132142 IPI00745874 
IPI00396015 IPI00847501 IPI00011569 IPI00396018 
IPI00472339 IPI00796495 IPI00798329 IPI00796157 
IPI00793409 IPI00816085 IPI00396017 xxxxx 
701.5 664 1159 653.5 39.47 -6.84 
IPI00022977 -  Gene_Symbol=CKB Creatine kinase B-type 
ENSG00000166165 IPI00022977 IPI00794730 IPI00789218 
xxxxx 
174 131 294.5 134.5 40.92 -22.70 
IPI00021290 -  Gene_Symbol=ACLY ATP-citrate synthase 
ENSG00000131473 IPI00021290 IPI00394838 xxxxx 170.5 190 289.5 158.5 41.11 -7.04 
IPI00788737 -  Gene_Symbol=GAPDH 39 kDa protein 
ENSG00000111640 IPI00789134 IPI00219018 IPI00788737 
IPI00796735 IPI00797221 IPI00795622 IPI00796111 
IPI00794508 IPI00794991 IPI00793922 IPI00794605 
IPI00795257 xxxxx 
56 53.5 95.5 54.5 41.36 -2.68 
IPI00220327 -  Gene_Symbol=KRT1 Keratin, type II 
cytoskeletal 1 ENSG00000167768 IPI00220327 xxxxx 57 48.5 98.5 47 42.13 -17.54 
IPI00152453 -  Gene_Symbol=TUBB3 Tubulin, beta, 4 
ENSG00000198211 IPI00152453 IPI00013683 IPI00640115 
IPI00644620 xxxxx 
209.5 148 368 253 43.07 17.19 
IPI00472102 -  Gene_Symbol=HSPD1 61 kDa protein 
ENSG00000144381 IPI00472102 IPI00784154 IPI00795445 
IPI00790763 IPI00794769 xxxxx 
52.5 71.5 102.5 69.5 48.78 24.46 
IPI00796978 -  Gene_Symbol=PCCA 80 kDa protein 
ENSG00000175198 IPI00749503 IPI00553145 IPI00553241 
IPI00552419 IPI00744115 IPI00796978 IPI00552081 
IPI00647500 IPI00383473 xxxxx 
95 126.5 192 102.5 50.52 7.32 
IPI00008603 -  Gene_Symbol=ACTA2 Actin, aortic smooth 
muscle ENSG00000107796 IPI00008603 IPI00645534 
IPI00816229 xxxxx 
52.5 69.5 107.5 52 51.16 -0.95 
IPI00023006 -  Gene_Symbol=ACTC1 Actin, alpha cardiac 
muscle 1 ENSG00000159251 IPI00023006 xxxxx 52.5 69.5 107.5 52 51.16 -0.95 
IPI00021304 -  Gene_Symbol=KRT2 Keratin, type II 
cytoskeletal 2 epidermal ENSG00000172867 IPI00021304 
IPI00791653 IPI00792970 xxxxx 
26.5 26 56.5 15.5 53.10 -41.51 
IPI00299402 -  Gene_Symbol=PC Pyruvate carboxylase, 
mitochondrial precursor ENSG00000173599 IPI00299402 
xxxxx 
505.5 787 1087.5 475.5 53.52 -5.93 
IPI00299571 -  Gene_Symbol=PDIA6 Isoform 2 of Protein 
disulfide-isomerase A6 precursor ENSG00000143870 
IPI00644989 IPI00299571 xxxxx 
94 77.5 208 98.5 54.81 4.57 
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IPI00009790 -  Gene_Symbol=PFKP 6-phosphofructokinase 
type C ENSG00000067057 IPI00642664 IPI00643196 
IPI00552617 IPI00009790 IPI00552290 IPI00645848 
IPI00646468 IPI00639981 xxxxx 
33 41.5 75.5 34 56.29 2.94 
IPI00027223 -  Gene_Symbol=IDH1 Isocitrate 
dehydrogenase [NADP] cytoplasmic ENSG00000138413 
IPI00027223 IPI00023029 xxxxx 
26.5 39.5 62 42 57.26 36.90 
 
Table 3A-3. Mass-spectrometry results of global competitive zinc-binding treatment of 
HeLa cell with zinc and IA-alkyne utilizing the quantitative isotopic Azo-tags. Two 
replicates of each metal ion concentration were performed and if the peptide was found in 
both runs it is represented as an average of the two R ratios. Data were sorted to present 
those with the lowest R ratio within the Zn2+ 20μM runs (i.e. largest decrease in IA-
labeling upon zinc treatment). A ‘0’ indicates that the peptide was not identified in those 
samples. Peptides with a R < 0.66 for the Zn2+ 20μM runs are highlighted in grey and 
represent cysteines that are most sensitive to Zn2+ (show a 1.5-fold decrease in labeling 
upon zinc treatment). 
ipi description symbol sequence 
Reactivity Ratios (R) 
Zn2+ 
10μM 
Zn2+ 
20μM 
Mg2+ 
20μM 
IPI00017799.5 TXN2 Thioredoxin, mitochondrial precursor ENSG0000 TXN2 
R.VVNSETPVVVDF
HAQWC*GPCK.I 0.605 0.05 1.045 
IPI00216298.6 
TXN Thioredoxin 
ENSG00000136810 IPI00552768 
IPI002 
TXN K.LVVVDFSATWC*GPCK.M 0.695 0.085 1.03 
IPI00790739.1 ACO2 Aconitase 2, mitochondrial ENSG00000100412 IP ACO2 
R.VGLIGSC*TNSSY
EDMGR.S 0.46 0.115 1.03 
IPI00007102.3 GLOD4 Uncharacterized protein C17orf25 ENSG0000016 
GLOD
4 
K.AAC*NGPYDGK.
W 0.68 0.13 0.92 
IPI00641743.2 HCFC1 Uncharacterized protein HCFC1 ENSG0000017253 
HCFC
1 R.VAGINAC*GR.G 0.84 0.165 0.975 
IPI00163085.2 AMOT Isoform 1 of Angiomotin ENSG00000126016 IPI00 AMOT 
R.QGNC*QPTNVSE
YNAAALMELLR.E 0.875 0.19 1.08 
IPI00430812.4 CNBP Zinc finger protein 9 ENSG00000169714 IPI0043 CNBP R.C*GESGHLAK.D 0.1 0.19 0.125 
IPI00041127.6 ASF1B Histone chaperone ASF1B ENSG00000105011 IPI0 ASF1B 
K.GLGLPGC*IPGLL
PENSMDCI.- 0.965 0.2 1.035 
IPI00844388.1 HELLS 103 kDa protein ENSG00000119969 IPI00012073  
HELL
S 
K.ILENSEDSSPEC*L
F.- 0.855 0.21 0.45 
IPI00797038.1 PCK2 mitochondrial phosphoenolpyruvate carboxykina PCK2 
R.YVAAAFPSAC*G
K.T 0.81 0.22 1.245 
IPI00014589.1 CLTB Isoform Brain of Clathrin light chain B ENSG0 CLTB K.VAQLC*DFNPK.S 0.74 0.24 1.005 
IPI00299214.6 TK1 thymidine kinase 1, soluble ENSG00000167900 IP TK1 R.YSSSFC*THDR.N 0.51 0.25 1.035 
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Reverse_IPI00376
429.3 
LOC391370 Uncharacterized 
protein ENSP00000352557  
LOC39
1370 K.C*LGVWEGLK.K 0.905 0.26 0.985 
IPI00032900.1 BOLA1 BolA-like protein 1 ENSG00000178096 IPI00032 
BOLA
1 
R.VCLC*QGSAGSG
AIGPVEAAIR.T 0.655 0.275 0.975 
IPI00183626.8 PTBP1 polypyrimidine tract-binding protein 1 isofo PTBP1 
K.LSLDGQNIYNAC*
CTLR.I 0 0.28 0.73 
IPI00016610.2 PCBP1 Poly(rC)-binding protein 1 ENSG00000169564 I PCBP1 
R.VMTIPYQPMPASS
PVIC*AGGQDR.C 0.54 0.28 0.945 
IPI00013847.4 UQCRC1 Ubiquinol-cytochrome-c reductase complex co 
UQCR
C1 
R.NALVSHLDGTTP
VC*EDIGR.S 0.73 0.28 1.005 
IPI00797038.1 PCK2 mitochondrial phosphoenolpyruvate carboxykina PCK2 
R.QC*PIMDPAWEAP
EGVPIDAIIFGGR.R 0.66 0.29 1.06 
IPI00216230.3 TMPO Lamina-associated polypeptide 2 isoform alpha TMPO K.SGIQPLC*PER.S 0.945 0.29 1.02 
IPI00376429.3 LOC391370 Uncharacterized protein ENSP00000352557  
LOC39
1370 K.LGEWVGLC*K.T 0.885 0.29 0.995 
IPI00024623.3 ACADSB Short/branched chain specific acyl-CoA dehy 
ACAD
SB 
R.ASSTC*PLTFENV
K.V 0.69 0.3 1.01 
IPI00008982.1 ALDH18A1 Isoform Long of Delta-1-pyrroline-5-carbo 
ALDH
18A1 
K.CEYPAAC*NALET
LLIHR.D 0.94 0.31 1.095 
IPI00742905.1 
DHX9 146 kDa protein 
ENSG00000135829 IPI00742905 
I 
DHX9 K.SSVNC*PFSSQDMK.Y 0.75 0.31 0.895 
IPI00103994.4 LARS Leucyl-tRNA synthetase, cytoplasmic ENSG00000 LARS 
R.NFEATLGWLQEH
AC*SR.T 0 0.31 0 
IPI00377005.2 _ Uncharacterized protein ENSP00000340627 ENSG0000 _ K.EEHLC*TQR.M 0.815 0.31 0.95 
IPI00025273.1 GART Isoform Long of Trifunctional purine biosynth GART 
R.FGDPEC*QVILPLL
K.S 0.74 0.315 1.055 
IPI00021277.1 NUBP1 Nucleotide-binding protein 1 ENSG00000103274 
NUBP
1 
R.LC*ASGAGATPDT
AIEEIKEK.M 0.875 0.32 1.12 
IPI00030702.1 IDH3A Isoform 1 of Isocitrate dehydrogenase [NAD]  IDH3A K.C*SDFTEEICR.R 0 0.32 1.16 
IPI00217952.6 GFPT1 Isoform 1 of Glucosamine--fructose-6-phospha GFPT1 
R.VDSTTC*LFPVEE
K.A 0.82 0.33 1.08 
IPI00217952.6 GFPT1 Isoform 1 of Glucosamine--fructose-6-phospha GFPT1 
K.C*QNALQQVVAR.
Q 0.575 0.335 1.015 
IPI00026781.2 FASN Fatty acid synthase ENSG00000169710 IPI000267 FASN 
R.LGMLSPEGTC*K.
A 0.7 0.34 1 
IPI00015262.10 
CNN2 Calponin-2 
ENSG00000064666 IPI00015262 
IPI003 
CNN2 K.AGQC*VIGLQMGTNK.C 0.875 0.34 1.12 
IPI00220503.9 
DCTN2 dynactin 2 
ENSG00000175203 IPI00220503 
IPI00 
DCTN
2 
R.C*DQDAQNPLSA
GLQGAC*LMETVEL
LQAK.V 
0.77 0.34 1.155 
IPI00641950.3 GNB2L1 Lung cancer oncogene 7 ENSG00000204628 IPI0 
GNB2
L1 K.VWNLANC*K.L 0.7 0.345 0.87 
IPI00150269.1 PRPF4 Isoform 1 of U4/U6 small nuclear ribonucleop PRPF4 
K.DVNLASC*AADG
SVK.L 0.51 0.35 0.965 
IPI00306301.2 PDHA1 Mitochondrial PDHA1 ENSG00000131828 IPI00642 
PDHA
1 
R.GFC*HLCDGQEA
CCVGLEAGINPTDH
LITAYR.A 
1.39 0.35 0 
IPI00026496.3 NPM3 Nucleoplasmin-3 ENSG00000107833 IPI00026496 NPM3 
K.LSC*QPMLSLDDF
QLQPPVTFR.L 0 0.365 1.35 
IPI00647337.1 _ OTTHUMP00000016411 ENSG00000181524 IPI00647337 _ K.VELC*SFSGYK.I 0.77 0.37 0.95 
IPI00024163.1 POLR3A DNA-directed RNA polymerase III subunit RPC 
POLR
3A 
K.LQQQPGC*TAEET
LEALILK.E 0.79 0.37 1.05 
IPI00759493.3 SUCLG1 succinate-CoA ligase, GDP-forming, alpha su 
SUCL
G1 K.IIC*QGFTGK.Q 0.84 0.375 1.04 
IPI00301994.6 FAHD2B Fumarylacetoacetate hydrolase domain-contai 
FAHD
2B 
K.TFDTFC*PLGPAL
VTK.D 0.735 0.375 0.99 
IPI00025273.1 GART Isoform Long of Trifunctional purine biosynth GART 
K.AFTKPEEAC*SFIL
SADFPALVVK.A 0.81 0.375 1.035 
IPI00016862.1 GSR Isoform Mitochondrial of Glutathione reductase GSR 
K.LGGTC*VNVGCV
PK.K 0.75 0.38 1.01 
IPI00745568.1 TIPRL Uncharacterized protein TIPRL ENSG0000014315 TIPRL 
K.VAC*AEEWQESR.
T 0.795 0.38 1.15 
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IPI00072534.2 UNC45A Isoform 1 of UNC45 homolog A ENSG0000014055 
UNC4
5A 
K.LLAAGVVSAMVC
*MVK.T 0 0.38 0.87 
IPI00012433.2 F8A1 F8A2 F8A3 Factor VIII intron 22 protein ENSG0 F8A1 
R.LVC*PAAYGEPLQ
AAASALGAAVR.L 0.7 0.38 0.915 
IPI00024317.1 GCDH Isoform Long of Glutaryl-CoA dehydrogenase, m GCDH 
R.ASATGMIIMDGV
EVPEENVLPGASSL
GGPFGC*LNNAR.Y 
0.715 0.385 1.005 
IPI00397963.3 _ Uncharacterized protein ENSP00000301828 ENSG0000 _ R.LTEGC*SFR.R 0.735 0.385 0.985 
IPI00552569.1 ERCC6L excision repair protein ERCC6-like ENSG0000 
ERCC
6L 
K.GFGSVEELC*TNS
SLGMEK.S 0.82 0.39 1.135 
IPI00328319.8 RBBP4 Histone-binding protein RBBP4 ENSG0000016252 
RBBP
4 
R.YMPQNPC*IIATK.
T 0.72 0.39 1.04 
IPI00220301.5 PRDX6 Peroxiredoxin-6 ENSG00000117592 IPI00220301 
PRDX
6 
R.DFTPVC*TTELGR.
A 0.94 0.4 1.04 
IPI00297455.4 AKAP8L A-kinase anchor protein 8-like ENSG00000011 
AKAP
8L R.GQC*MSGASR.L 0.865 0.4 1.04 
IPI00301609.8 NEK9 Serine/threonine-protein kinase Nek9 ENSG0000 NEK9 R.LNPAVTC*AGK.G 0.82 0.4 0.985 
IPI00513827.3 ACADM Putative uncharacterized protein DKFZp686M24 
ACAD
M 
R.MTEEPLMC*AYC
VTEPGAGSDVAGIK.
T 
0.38 0.4 0.685 
IPI00144171.2 hCG_2015956 similar to 60S ribosomal protein L7 is 
hCG_2
015956 
K.YGIIC*MEDLIHEI
YTVGK.R 0 0.4 1.06 
IPI00013774.1 HDAC1 Histone deacetylase 1 ENSG00000116478 IPI005 
HDAC
1 
R.FNVGEDC*PVFDG
LFEFCQLSTGGSVA
SAVK.L 
0.65 0.4 0 
IPI00299214.6 TK1 thymidine kinase 1, soluble ENSG00000167900 IP TK1 
K.LFAPQQILQC*SP
AN.- 0.965 0.405 1.11 
IPI00003918.6 RPL4 60S ribosomal protein L4 ENSG00000174444 IPI0 RPL4 
R.SGQGAFGNMC*R.
G 0.76 0.405 0.98 
IPI00011107.2 IDH2 Isocitrate dehydrogenase [NADP], mitochondria IDH2 
K.DLAGC*IHGLSNV
K.L 1.08 0.405 1.185 
IPI00646105.3 PYCRL Pyrroline-5-carboxylate reductase ENSG000001 
PYCR
L 
R.SDVC*TPGGTTIY
GLHALEQGGLR.A 0.71 0.405 0.96 
IPI00164672.6 
DCP1A mRNA-decapping 
enzyme 1A ENSG00000162290 
IPI 
DCP1
A 
K.QHDPYITSIADLT
GQVALYTFC*PK.A 0.9 0.405 0.98 
IPI00216725.2 PHKA1 Uncharacterized protein PHKA1 ENSG0000006717 
PHKA
1 
K.KVEALDEAC*TD
LLSHQK.H 0.56 0.405 0.95 
IPI00640364.2 OTUD5 Isoform 1 of OTU domain-containing protein 5 
OTUD
5 
R.ATSPLVSLYPALE
C*R.A 0.92 0.41 0.97 
IPI00010810.1 ETFA Electron transfer flavoprotein subunit alpha, ETFA 
R.LGGEVSC*LVAGT
K.C 0.91 0.41 1.02 
IPI00007752.1 TUBB2C Tubulin beta-2C chain ENSG00000188229 IPI00 
TUBB
2C 
K.LTTPTYGDLNHL
VSATMSGVTTC*LR.
F 
0.745 0.415 0.985 
IPI00145260.3 C1orf69 Putative transferase C1orf69, mitochondria 
C1orf6
9 
R.VWAVLPSSPEAC*
GAASLQER.A 1.02 0.415 0.965 
IPI00025273.1 GART Isoform Long of Trifunctional purine biosynth GART 
R.SAGVQC*FGPTAE
AAQLESSKR.F 0.83 0.415 1.03 
IPI00456664.1 NIT1 Isoform 4 of Nitrilase homolog 1 ENSG00000158 NIT1 K.IGLAVC*YDMR.F 0.765 0.415 0.995 
IPI00394788.4 AARS2 Probable alanyl-tRNA synthetase, mitochondri 
AARS
2 
K.HSTYDTDLFSPLL
NAIQQGC*R.A 0.83 0.415 1.1 
IPI00296053.3 FH Isoform Mitochondrial of Fumarate hydratase, mi FH 
K.FEALAAHDALVE
LSGAMNTTAC*SLM
K.I 
0.735 0.42 0.985 
IPI00018350.3 MCM5 DNA replication licensing factor MCM5 ENSG000 MCM5 K.C*SPIGVYTSGK.G 0.9 0.42 0.975 
IPI00217952.6 GFPT1 Isoform 1 of Glucosamine--fructose-6-phospha GFPT1 
R.QGRPVVIC*DKED
TETIK.N 0 0.42 1.035 
IPI00848058.1 ACTB Actin, cytoplasmic 2 ENSG00000075624 IPI00021 ACTB K.C*DVDIRK.D 0.825 0.425 1.055 
IPI00024317.1 GCDH Isoform Long of Glutaryl-CoA dehydrogenase, m GCDH 
K.GYGC*AGVSSVA
YGLLAR.E 0.765 0.425 1.2 
IPI00743416.1 IKBKAP inhibitor of kappa light polypeptide gene e 
IKBK
AP 
R.GDGQFFAVSVVC
*PETGAR.K 0.95 0.43 0.83 
234 
 
IPI00292771.4 NUMA1 Isoform 1 of Nuclear mitotic apparatus prote 
NUM
A1 
R.QFC*STQAALQA
MER.E 0.805 0.43 0.905 
IPI00556494.3 MED4 Mediator of RNA polymerase II transcription s MED4 
R.ISASNAVC*APLT
WVPGDPR.R 0 0.43 0.885 
IPI00301421.5 ZC3HC1 Isoform 1 of Nuclear-interacting partner of 
ZC3H
C1 R.LC*SSSSSDTSSR.S 0.925 0.43 1.05 
IPI00007750.1 TUBA4A Tubulin alpha-4A chain ENSG00000127824 IPI0 
TUBA
4A 
K.AYHEQLSVAEITN
AC*FEPANQMVK.C 0.74 0.43 0.98 
IPI00018009.2 EDC3 Enhancer of mRNA-decapping protein 3 ENSG0000 EDC3 
K.SQDVAVSPQQQQ
C*SK.S 0.925 0.43 1.055 
IPI00025273.1 GART Isoform Long of Trifunctional purine biosynth GART 
R.LLEGDGGPNTGG
MGAYC*PAPQVSN
DLLLK.I 
0.805 0.43 1.01 
IPI00550882.2 PYCR1 Pyrroline-5-carboxylate reductase 1 ENSG0000 
PYCR
1 R.C*MTNTPVVVR.E 0.745 0.435 1.04 
IPI00441473.3 PRMT5 Protein arginine N-methyltransferase 5 ENSG0 
PRMT
5 
R.DLNC*VPEIADTL
GAVAK.Q 0.85 0.435 0.965 
IPI00011253.3 RPS3 40S ribosomal protein S3 ENSG00000149273 IPI0 RPS3 K.GC*EVVVSGK.L 0.735 0.435 0.925 
IPI00296337.2 PRKDC Isoform 1 of DNA-dependent protein kinase ca 
PRKD
C 
R.VEQLFQVMNGIL
AQDSAC*SQR.A 0.765 0.44 0.955 
IPI00029485.2 DCTN1 Isoform p150 of Dynactin subunit 1 ENSG00000 
DCTN
1 
K.VTFSC*AAGFGQR
.H 0.87 0.44 0.99 
IPI00748696.1 
AP3S2 44 kDa protein 
ENSG00000157823 IPI00025115 
I 
AP3S2 K.C*NFTGDGK.T 0.91 0.44 1.05 
IPI00218728.4 PAFAH1B1 Isoform 1 of Platelet-activating factor a 
PAFA
H1B1 K.LWDFQGFEC*IR.T 0 0.44 1.07 
IPI00784194.1 SART1 Uncharacterized protein SART1 ENSG0000017546 
SART
1 
R.GLAAALLLC*QN
K.G 0.94 0.44 0.995 
IPI00746165.2 WDR1 Isoform 1 of WD repeat-containing protein 1 E WDR1 
R.MTVDESGQLISC*
SMDDTVR.Y 1.035 0.44 1.025 
IPI00004459.1 
DIMT1L Probable 
dimethyladenosine transferase 
ENSG 
DIMT
1L 
K.TDLPFFDTC*VAN
LPYQISSPFVFK.L 0.6 0.44 0.72 
IPI00787501.1 LOC727737 similar to APG4 autophagy 4 homolog B is 
LOC72
7737 
R.TSVPC*AGATAFP
ADSDR.H 1.005 0.44 0 
IPI00479385.3 ASMTL Uncharacterized protein ASMTL ENSG0000016909 
ASMT
L 
K.LTAC*QVATAFN
LSR.F 0.995 0.445 1.095 
IPI00014177.3 SEPT2 Septin-2 ENSG00000168385 IPI00014177 41519 
R.LTVVDTPGYGDAI
NC*R.D 0.64 0.445 0.915 
IPI00017726.1 HSD17B10 Isoform 1 of 3-hydroxyacyl-CoA dehydrogen 
HSD17
B10 
K.LGNNC*VFAPAD
VTSEKDVQTALALA
K.G 
0.8 0.445 0.935 
IPI00007750.1 TUBA4A Tubulin alpha-4A chain ENSG00000127824 IPI0 
TUBA
4A 
R.AVC*MLSNTTAIA
EAWAR.L 0.755 0.445 0.995 
IPI00218343.4 TUBA1C Tubulin alpha-1C chain ENSG00000167553 IPI0 
TUBA
1C 
K.AYHEQLTVAEITN
AC*FEPANQMVK.C 0.755 0.445 0.98 
IPI00025366.4 CS Citrate synthase, mitochondrial precursor ENSG0 CS R.GFSIPEC*QK.L 0.75 0.445 0.99 
IPI00018206.3 
GOT2 Aspartate 
aminotransferase, mitochondrial 
pre 
GOT2 K.TC*GFDFTGAVEDISK.I 0.795 0.445 1.06 
IPI00398057.1 LOC389342 Uncharacterized protein ENSP00000353659  
LOC38
9342 R.LIPDGC*GVK.Y 0.82 0.45 1.04 
IPI00646512.1 RBBP7 Retinoblastoma binding protein 7 ENSG0000010 
RBBP
7 
R.VHIPNDDAQFDAS
HC*DSDKGEFGGFG
SVTGK.I 
0.925 0.45 0.99 
IPI00219445.1 PSME3 Isoform 2 of Proteasome activator complex su 
PSME
3 
R.LDEC*EEAFQGTK
.V 0.975 0.45 1.04 
IPI00030363.1 ACAT1 Acetyl-CoA acetyltransferase, mitochondrial  
ACAT
1 
K.DGLTDVYNKIHM
GSC*AENTAK.K 0.77 0.45 1.025 
IPI00018931.6 VPS35 Vacuolar protein sorting-associated protein  VPS35 R.TQC*ALAASK.L 0.91 0.45 1.065 
IPI00003918.6 RPL4 60S ribosomal protein L4 ENSG00000174444 IPI0 RPL4 
R.YAIC*SALAASAL
PALVMSK.G 0.695 0.45 0.915 
IPI00163085.2 AMOT Isoform 1 of Angiomotin ENSG00000126016 IPI00 AMOT R.C*LDMEGR.I 0.845 0.455 0.965 
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IPI00007750.1 TUBA4A Tubulin alpha-4A chain ENSG00000127824 IPI0 
TUBA
4A 
K.RSIQFVDWC*PTG
FK.V 0.82 0.455 1.04 
IPI00021435.3 PSMC2 26S protease regulatory subunit 7 ENSG000001 
PSMC
2 R.LC*PNSTGAEIR.S 0.805 0.46 1.025 
IPI00007752.1 TUBB2C Tubulin beta-2C chain ENSG00000188229 IPI00 
TUBB
2C K.NMMAAC*DPR.H 0.78 0.46 1.01 
IPI00218343.4 TUBA1C Tubulin alpha-1C chain ENSG00000167553 IPI0 
TUBA
1C 
R.AVC*MLSNTTAV
AEAWAR.L 0.865 0.465 1.2 
IPI00027107.5 TUFM Tu translation elongation factor, mitochondri TUFM 
K.KGDEC*ELLGHS
K.N 0.74 0.465 0.975 
IPI00397383.2 KIF1B Isoform 4 of Kinesin-like protein KIF1B ENSG KIF1B 
R.ASSPC*PEFEQFQI
VPAVETPYLAR.A 1.06 0.465 0 
IPI00012866.2 
AKT1 RAC-alpha 
serine/threonine-protein kinase 
ENS 
AKT1 K.TFC*GTPEYLAPEVLEDNDYGR.A 0.87 0.47 1.075 
IPI00297579.4 CBX3 LOC653972 Chromobox protein homolog 3 ENSG000 CBX3 
R.LTWHSC*PEDEA
Q.- 0.825 0.47 1.06 
IPI00007752.1 TUBB2C Tubulin beta-2C chain ENSG00000188229 IPI00 
TUBB
2C K.TAVC*DIPPR.G 0.805 0.47 1.025 
IPI00472102.3 
HSPD1 61 kDa protein 
ENSG00000144381 IPI00472102 
I 
HSPD
1 
R.C*IPALDSLTPANE
DQK.I 0.855 0.47 0.99 
IPI00025273.1 GART Isoform Long of Trifunctional purine biosynth GART 
K.ISNTAISISDHTAL
AQFC*K.E 0.79 0.47 1.035 
IPI00646493.1 COPA coatomer protein complex, subunit alpha isofo COPA 
R.MC*TLIDKFDEHD
GPVR.G 0 0.47 1.07 
IPI00107693.4 MED15 Isoform 1 of Mediator of RNA polymerase II t 
MED1
5 
K.QQYLC*QPLLDA
VLANIR.S 1.34 0.475 0.905 
IPI00180675.4 TUBA1A Tubulin alpha-1A chain ENSG00000167552 IPI0 
TUBA
1A 
R.TIQFVDWC*PTGF
K.V 0.825 0.475 1.04 
IPI00019994.3 CXorf15 Gamma-taxilin ENSG00000086712 IPI00019994  
CXorf
15 
R.TDPPDGQQDSEC*
NR.N 0.82 0.475 0.985 
IPI00844388.1 HELLS 103 kDa protein ENSG00000119969 IPI00012073  
HELL
S 
K.C*NGQPVPFQQPK
.H 0 0.475 1.03 
IPI00045051.3 PURB Transcriptional activator protein Pur-beta EN PURB 
R.GGGGGPC*GFQP
ASR.G 0.96 0.48 1.18 
IPI00030363.1 ACAT1 Acetyl-CoA acetyltransferase, mitochondrial  
ACAT
1 
R.QAVLGAGLPISTP
C*TTINK.V 0.82 0.48 1.025 
IPI00024919.3 PRDX3 Thioredoxin-dependent peroxide reductase, mi 
PRDX
3 
K.AFQYVETHGEVC
*PANWTPDSPTIKPS
PAASK.E 
0 0.48 0 
IPI00295851.4 COPB1 Coatomer subunit beta ENSG00000129083 IPI002 
COPB
1 
K.ALSGYC*GFMAA
NLYAR.S 0.98 0.485 1.075 
IPI00184523.1 ARNT Putative uncharacterized protein DKFZp547B061 ARNT 
K.MTAYITELSDMV
PTC*SALAR.K 0.76 0.485 0.85 
IPI00789740.1 GEMIN4 Gem (Nuclear organelle) associated protein  
GEMI
N4 
R.SDPDAC*PTMPLL
AMLLR.G 1.51 0.485 1.43 
IPI00006663.1 ALDH2 Aldehyde dehydrogenase, mitochondrial precur 
ALDH
2 
K.LLC*GGGIAADR.
G 0.83 0.485 1.015 
IPI00157304.1 SSBP3 Isoform 1 of Single-stranded DNA-binding pro SSBP3 R.DTC*EHSSEAK.A 0 0.49 0 
IPI00218728.4 PAFAH1B1 Isoform 1 of Platelet-activating factor a 
PAFA
H1B1 
R.MVRPNQDGTLIA
SC*SNDQTVR.V 0.835 0.49 0.99 
IPI00008982.1 ALDH18A1 Isoform Long of Delta-1-pyrroline-5-carbo 
ALDH
18A1 
K.LGSAVVTRGDEC
*GLALGR.L 0.91 0.495 1.07 
IPI00641743.2 HCFC1 Uncharacterized protein HCFC1 ENSG0000017253 
HCFC
1 R.AC*AAGTPAVIR.I 1.09 0.495 1.03 
IPI00004860.2 RARS Isoform Complexed of Arginyl-tRNA synthetase, RARS 
K.NC*GC*LGASPNL
EQLQEENLK.L 0 0.495 0.98 
IPI00062419.2 SDSL Serine dehydratase-like ENSG00000139410 IPI00 SDSL 
R.MLVEPAC*GAAL
AAIYSGLLR.R 0 0.495 0 
IPI00030363.1 ACAT1 Acetyl-CoA acetyltransferase, mitochondrial  
ACAT
1 
K.QGEYGLASIC*NG
GGGASAMLIQK.L 0.795 0.5 1.03 
IPI00031370.3 TUBB2B Tubulin beta-2B chain ENSG00000137285 IPI00 
TUBB
2B 
K.ESESC*DCLQGFQ
LTHSLGGGTGSGM
GTLLISK.I 
0.725 0.5 0.94 
IPI00455607.3 _ Uncharacterized protein ENSP00000329518 ENSG0000 _ 
R.AQYYHSC*GRES
VIWEITPPALFR.Q 0 0.5 0 
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IPI00011916.1 JTV1 Multisynthetase complex auxiliary component p JTV1 R.VELPTC*MYR.L 0.9 0.505 1.06 
IPI00025178.3 BCAS2 Breast carcinoma amplified sequence 2 ENSG00 
BCAS
2 
K.NDITAWQEC*VN
NSMAQLEHQAVR.I 0.77 0.505 1.02 
IPI00009342.1 IQGAP1 Ras GTPase-activating-like protein IQGAP1 E 
IQGA
P1 
K.QIPAITC*IQSQWR
.G 0 0.505 1.09 
IPI00011107.2 IDH2 Isocitrate dehydrogenase [NADP], mitochondria IDH2 
K.NYDGDVQSDILA
QGFGSLGLMTSVLV
C*PDGK.T 
0 0.505 1.46 
IPI00025366.4 CS Citrate synthase, mitochondrial precursor ENSG0 CS K.LPC*VAAK.I 0.815 0.51 0.96 
IPI00007752.1 TUBB2C Tubulin beta-2C chain ENSG00000188229 IPI00 
TUBB
2C 
K.VSDTVVEPYNAT
LSVHQLVENTDETY
C*IDNEALYDICFR.T 
0.805 0.51 1.01 
IPI00655631.1 
POLD1 DNA polymerase 
ENSG00000062822 IPI00002894 
I 
POLD
1 
R.DNC*PLVANLVT
ASLR.R 0 0.51 1.195 
IPI00025091.3 RPS11 40S ribosomal protein S11 ENSG00000142534 IP RPS11 K.C*PFTGNVSIR.G 0.84 0.51 0.95 
IPI00170877.2 MRPL10 mitochondrial ribosomal protein L10 isoform 
MRPL
10 
R.TVPFLPLLGGC*ID
DTILSR.Q 0 0.51 1.18 
IPI00470610.3 PYCR2 Pyrroline-5-carboxylate reductase 2 ENSG0000 
PYCR
2 
R.SLLINAVEASC*IR
.T 0.815 0.515 1.06 
IPI00295388.2 GLDC Glycine dehydrogenase ENSG00000178445 IPI0074 GLDC 
K.MEDPVC*ENEILA
TLHAISSK.N 0.92 0.515 0.96 
IPI00291419.5 ACAT2 Acetyl-CoA acetyltransferase, cytosolic ENSG 
ACAT
2 
R.QASVGAGIPYSVP
AWSC*QMICGSGLK
.A 
0.91 0.52 0.905 
IPI00790757.1 
DUSP3 23 kDa protein 
ENSG00000108861 IPI00018671 
I 
DUSP
3 
R.EIGPNDGFLAQLC
*QLNDR.L 3.96 0.52 2.34 
IPI00845348.1 
ZRANB2 Putative 
uncharacterized protein 
DKFZp686N0 
ZRAN
B2 K.C*GNVNFAR.R 0.74 0.52 1.015 
IPI00759493.3 SUCLG1 succinate-CoA ligase, GDP-forming, alpha su 
SUCL
G1 
R.LIGPNC*PGVINPG
ECK.I 0.79 0.52 1.07 
IPI00641950.3 GNB2L1 Lung cancer oncogene 7 ENSG00000204628 IPI0 
GNB2
L1 K.LWNTLGVC*K.Y 0.775 0.525 1.01 
IPI00479743.3 POTE2 protein expressed in prostate, ovary, testis POTE2 
K.EKLC*YVALDFE
QEMATAASSSSLEK.
S 
0.85 0.525 1.02 
IPI00787158.1 SORD similar to sorbitol dehydrogenase ENSG0000014 SORD 
R.YNLSPSIFFC*ATP
PDDGNLCR.F 0.8 0.525 1 
IPI00386591.5 C14orf149 Probable proline racemase ENSG0000012679 
C14orf
149 
R.IVLAGC*PEVSGP
TLLAK.R 0 0.53 1.02 
IPI00064765.3 RPL10L 60S ribosomal protein L10-like ENSG00000165 
RPL10
L K.MLSC*AGADR.L 0.675 0.535 0.82 
IPI00022334.1 OAT Ornithine aminotransferase, mitochondrial prec OAT 
K.VLPMNTGVEAGE
TAC*K.L 0.81 0.535 0.935 
IPI00031820.3 FARSA Phenylalanyl-tRNA synthetase alpha chain ENS 
FARS
A 
K.VNLQMVYDSPLC
*R.L 0.835 0.535 1.01 
IPI00787158.1 SORD similar to sorbitol dehydrogenase ENSG0000014 SORD 
R.YC*NTWPVAISM
LASK.S 0.885 0.535 0.975 
IPI00290142.5 CTPS CTP synthase 1 ENSG00000171793 IPI00290142 CTPS 
R.LLETC*SIALVGK.
Y 0.795 0.535 1.065 
IPI00450975.1 
RPS16 RPS16 protein 
ENSG00000105193 IPI00221092 
IP 
RPS16 K.TATAVAHC*K.R 0.925 0.535 1.075 
IPI00291646.2 
MTHFD1L 
methylenetetrahydrofolate 
dehydrogenase (N 
MTHF
D1L R.SSC*SPGGR.T 0.925 0.54 1.045 
IPI00025746.5 ANKRD54 Isoform 1 of Ankyrin repeat domain-contain 
ANKR
D54 R.LDDLC*TR.L 0.81 0.545 1 
IPI00014424.1 EEF1A2 Elongation factor 1-alpha 2 ENSG00000101210 
EEF1A
2 
K.SGDAAIVEMVPG
KPMC*VESFSQYPP
LGR.F 
1.08 0.545 1.18 
IPI00291570.9 CASP2 Isoform ICH-1L of Caspase-2 precursor ENSG00 CASP2 
R.SDMICGYAC*LK.
G 1.19 0.545 1 
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IPI00015911.1 DLD Dihydrolipoyl dehydrogenase, mitochondrial pre DLD 
K.NETLGGTC*LNV
GCIPSK.A 0.885 0.55 0.82 
IPI00018350.3 MCM5 DNA replication licensing factor MCM5 ENSG000 MCM5 K.AIAC*LLFGGSR.K 0.79 0.55 1.01 
IPI00001539.8 ACAA2 3-ketoacyl-CoA thiolase, mitochondrial ENSG0 
ACAA
2 
R.IVGYFVSGC*DPSI
MGIGPVPAISGALK.
K 
0 0.55 0 
IPI00016912.1 TTC1 Tetratricopeptide repeat protein 1 ENSG000001 TTC1 
K.VTDTQEAEC*AG
PPVPDPK.N 1.105 0.555 1.12 
IPI00008240.2 MARS Methionyl-tRNA synthetase, cytoplasmic ENSG00 MARS 
R.LFVSDGVPGC*LP
VLAAAGR.A 0 0.56 0 
IPI00641384.2 SEC16A SEC16 homolog A ENSG00000148396 IPI00641384 
SEC16
A 
R.ANNNAAVAPTTC
*PLQPVTDPFAFSR.
Q 
0.94 0.565 1.06 
IPI00096066.2 SUCLG2 Succinyl-CoA ligase [GDP-forming] beta-chai 
SUCL
G2 
K.IDATQVEVNPFGE
TPEGQVVC*FDAK.I 0.91 0.565 0.94 
IPI00001890.8 
COPG 98 kDa protein 
ENSG00000181789 IPI00001890 
IP 
COPG R.ALC*QITDSTMLQAIER.Y 0.835 0.565 1.15 
IPI00291006.1 MDH2 Malate dehydrogenase, mitochondrial precursor MDH2 K.TIIPLISQC*TPK.V 0.84 0.57 0.98 
IPI00453476.2 _ Uncharacterized protein ENSP00000348237 ENSG0000 _ 
R.YADLTEDQLPSC*
ESLK.D 0.9 0.57 0.985 
IPI00746777.3 ADH5 Alcohol dehydrogenase class-3 ENSG00000197894 ADH5 
K.IDPLAPLDKVCLL
GC*GISTGYGAAVN
TAK.L 
0.71 0.57 1.055 
IPI00220503.9 
DCTN2 dynactin 2 
ENSG00000175203 IPI00220503 
IPI00 
DCTN
2 
R.C*DQDAQNPLSA
GLQGACLMETVELL
QAK.V 
0.795 0.57 0.995 
IPI00025091.3 RPS11 40S ribosomal protein S11 ENSG00000142534 IP RPS11 
R.DVQIGDIVTVGEC
*RPLSK.T 0.84 0.57 1.025 
IPI00029629.3 TRIM25 Tripartite motif-containing protein 25 ENSG 
TRIM2
5 
K.NTVLC*NVVEQF
LQADLAR.E 0.88 0.575 1.06 
IPI00554777.2 ASNS Asparagine synthetase ENSG00000070669 IPI0055 ASNS 
R.IGC*LLSGGLDSSL
VAATLLK.Q 0.845 0.575 0.95 
IPI00641950.3 GNB2L1 Lung cancer oncogene 7 ENSG00000204628 IPI0 
GNB2
L1 
K.AEPPQC*TSLAWS
ADGQTLFAGYTDN
LVR.V 
0.8 0.575 1.09 
IPI00024381.1 CLP1 Pre-mRNA cleavage complex II protein Clp1 ENS CLP1 
K.VGAPTIPDSC*LPL
GMSQEDNQLK.L 0.86 0.58 0.915 
IPI00146935.4 DNM1L Isoform 1 of Dynamin-1-like protein ENSG0000 
DNM1
L 
K.YIETSELC*GGAR.
I 0 0.58 0 
IPI00033025.8 SEPT7 Isoform 1 of Septin-7 ENSG00000122545 IPI008 41524 
K.ADTLTPEEC*QQF
KK.Q 0.87 0.58 1.055 
IPI00141933.3 BUB1B Mitotic checkpoint serine/threonine-protein  
BUB1
B 
K.IPGMTLSSSVCQV
NCC*AR.E 0 0.58 1.06 
IPI00218342.10 MTHFD1 C-1-tetrahydrofolate synthase, cytoplasmic  
MTHF
D1 
K.GC*LELIKETGVPI
AGR.H 0.95 0.58 1.155 
IPI00013214.1 MCM3 DNA replication licensing factor MCM3 ENSG000 MCM3 R.SVHYC*PATK.K 0.935 0.585 1.065 
IPI00784131.1 AARS Uncharacterized protein AARS ENSG00000090861  AARS 
K.AVYTQDC*PLAA
AK.A 0.955 0.585 1.075 
IPI00794575.1 
DNM2 98 kDa protein 
ENSG00000079805 IPI00215974 
IP 
DNM2 
K.LQDAFSSIGQSC*
HLDLPQIAVVGGQS
AGK.S 
0 0.585 0.97 
IPI00641950.3 GNB2L1 Lung cancer oncogene 7 ENSG00000204628 IPI0 
GNB2
L1 
R.FSPNSSNPIIVSC*
GWDK.L 0.825 0.59 0.985 
IPI00029468.1 ACTR1A Alpha-centractin ENSG00000138107 IPI0002946 
ACTR
1A 
R.AC*YLSINPQKDE
TLETEK.A 1.095 0.59 1.09 
IPI00646493.1 COPA coatomer protein complex, subunit alpha isofo COPA 
R.TTYQALPC*LPSM
YGYPNR.N 0 0.59 1.02 
IPI00301058.5 VASP Vasodilator-stimulated phosphoprotein ENSG000 VASP 
K.SSSSVTTSETQPC*
TPSSSDYSDLQR.V 0.985 0.595 1.03 
IPI00152998.3 LRRC40 Leucine-rich repeat-containing protein 40 E 
LRRC
40 R.FLPEFPSC*SLLK.E 0.78 0.595 1.01 
IPI00220158.1 ADD1 Isoform 3 of Alpha-adducin ENSG00000087274 IP ADD1 
K.YSDVEVPASVTG
YSFASDGDSGTC*SP
LR.H 
1.08 0.595 0.95 
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IPI00186290.6 EEF2 Elongation factor 2 ENSG00000167658 IPI001862 EEF2 R.TFC*QLILDPIFK.V 0.885 0.595 1.115 
IPI00018206.3 
GOT2 Aspartate 
aminotransferase, mitochondrial 
pre 
GOT2 K.EYLPIGGLAEFC*K.A 0.91 0.6 1.02 
IPI00028091.3 ACTR3 Actin-like protein 3 ENSG00000115091 IPI0002 
ACTR
3 
K.LGYAGNTEPQFII
PSC*IAIK.E 0.825 0.605 0.93 
IPI00302112.1 MAP2K7 Isoform 2 of Dual specificity mitogen-activ 
MAP2
K7 K.LC*DFGISGR.L 0.89 0.605 1.01 
IPI00022744.5 CSE1L Isoform 1 of Exportin-2 ENSG00000124207 IPI0 CSE1L K.IC*AVGITK.L 0.945 0.605 1.06 
IPI00007750.1 TUBA4A Tubulin alpha-4A chain ENSG00000127824 IPI0 
TUBA
4A K.YMAC*CLLYR.G 0.895 0.605 1.015 
IPI00746806.1 
CTTN CTTN protein 
ENSG00000085733 IPI00029601 
IPI0 
CTTN K.C*ALGWDHQEK.L 1.02 0.605 1.105 
IPI00556451.2 ETFB Isoform 2 of Electron transfer flavoprotein s ETFB 
K.HSMNPFC*EIAVE
EAVR.L 0.92 0.61 0.74 
IPI00646689.1 TXNDC17 Thioredoxin domain-containing protein 17 E 
TXND
C17 
K.DAGGKSWC*PDC
VQAEPVVR.E 1.06 0.61 1.03 
IPI00015956.3 EXOSC3 Exosome complex exonuclease RRP40 ENSG00000 
EXOS
C3 
K.LLAPDC*EIIQEVG
K.L 0.96 0.61 1.11 
IPI00644674.1 NUBP2 Nucleotide-binding protein 2 ENSG00000095906 
NUBP
2 K.ILDATPAC*LP.- 0.855 0.61 0.87 
IPI00005011.1 CNOT2 Isoform 1 of CCR4-NOT transcription complex  
CNOT
2 R.SSPSIIC*MPK.Q 0.81 0.61 0.765 
IPI00796337.1 PCBP2 poly(rC)-binding protein 2 isoform a ENSG000 PCBP2 
R.YSTGSDSASFPHT
TPSMC*LNPDLEGPP
LEAYTIQGQYAIPQP
DLTK.L 
0.975 0.61 1.035 
IPI00010153.5 RPL23 60S ribosomal protein L23 ENSG00000125691 IP RPL23 
R.ISLGLPVGAVINC*
ADNTGAK.N 0.84 0.61 1.01 
IPI00604527.2 TARS2 Threonyl-tRNA synthetase, mitochondrial prec 
TARS
2 
R.LALSTRPSGFLGD
PC*LWDQAEQVLK.
Q 
0 0.61 0.66 
IPI00291006.1 MDH2 Malate dehydrogenase, mitochondrial precursor MDH2 
K.GYLGPEQLPDC*L
K.G 0.51 0.61 0.955 
IPI00011062.1 CPS1 Isoform 1 of Carbamoyl-phosphate synthase [am CPS1 
K.TSAC*FEPSLDYM
VTK.I 0.79 0.61 0 
IPI00177743.5 ZNF318 zinc finger protein 318 ENSG00000171467 IPI 
ZNF31
8 
K.TINSAGLGPSPC*L
PDLVDFVTR.T 0 0.61 0 
IPI00216383.1 RAD51L3 Isoform 5 of DNA repair protein RAD51 homo 
RAD5
1L3 
R.VGLC*PGLTEEMI
QLLR.S 0 0.61 0 
IPI00793696.1 
RPL24 19 kDa protein 
ENSG00000114391 IPI00306332 
I 
RPL24 K.C*ESAFLSK.R 0.905 0.61 1.03 
IPI00646105.3 PYCRL Pyrroline-5-carboxylate reductase ENSG000001 
PYCR
L 
R.AATMSAVEAATC
*R.A 0.78 0.615 1.035 
IPI00018465.1 CCT7 T-complex protein 1 subunit eta ENSG000001356 CCT7 
R.QLC*DNAGFDAT
NILNK.L 0.735 0.615 0.93 
IPI00464979.4 SUCLA2 Isoform 1 of Succinyl-CoA ligase [ADP-formi 
SUCL
A2 
K.YDATMIEINPMVE
DSDGAVLC*MDAK.
I 
0.975 0.615 1.225 
IPI00008240.2 MARS Methionyl-tRNA synthetase, cytoplasmic ENSG00 MARS 
K.VPVLQLDSGNYL
FSTSAIC*R.Y 0.84 0.615 0 
IPI00018206.3 
GOT2 Aspartate 
aminotransferase, mitochondrial 
pre 
GOT2 R.VGAFTMVC*K.D 0.905 0.62 1.025 
IPI00748490.1 AARSD1 Alanyl-tRNA synthetase, class IIc family pr 
AARS
D1 
R.VVNIEGVDSNMC
*CGTHVSNLSDLQV
IK.I 
0.66 0.62 0 
IPI00294739.1 SAMHD1 SAM domain and HD domain-containing protein 
SAMH
D1 R.C*DDSPR.T 0 0.62 0 
IPI00017552.2 MED9 Mediator of RNA polymerase II transcription s MED9 K.SLC*MFEIPKE.- 0 0.62 0.96 
IPI00018206.3 
GOT2 Aspartate 
aminotransferase, mitochondrial 
pre 
GOT2 R.HFIEQGINVC*LCQSYAK.N 0.92 0.62 1.07 
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IPI00106642.4 SDF2L1 Dihydropyrimidinase-like 2 ENSG00000128228  
SDF2L
1 
R.FQLTDC*QIYEVL
SVIR.D 0 0.62 1.225 
IPI00021808.3 HARS Histidyl-tRNA synthetase, cytoplasmic ENSG000 HARS R.TGQPLC*IC.- 0.97 0.625 1.125 
IPI00217442.2 MASK-BP3 EIF4EBP3 MASK-4E-BP3 protein ENSG00000131 
MASK
-BP3 
R.LTSSVSC*ALDEA
AAALTR.M 1.01 0.625 1.215 
IPI00030328.1 SRR Serine racemase ENSG00000167720 IPI00030328 SRR 
K.LEGIPAYIVVPQT
APDC*K.K 1.025 0.625 1.04 
IPI00444329.1 BCKDHA CDNA FLJ45695 fis, clone FEBRA2013570, high 
BCKD
HA 
R.DYPLELFMAQC*
YGNISDLGK.G 0.65 0.625 1.04 
IPI00387130.1 CIAPIN1 Isoform 1 of Anamorsin ENSG00000005194 IPI 
CIAPI
N1 R.AASC*GEGK.K 0.87 0.625 1.005 
IPI00783061.1 PKM2 Uncharacterized protein PKM2 ENSG00000067225  PKM2 
R.GIFPVLC*KDPVQ
EAWAEDVDLR.V 0.935 0.625 1.175 
IPI00641950.3 GNB2L1 Lung cancer oncogene 7 ENSG00000204628 IPI0 
GNB2
L1 
K.HLYTLDGGDIINA
LC*FSPNR.Y 0.92 0.625 1.22 
IPI00026781.2 FASN Fatty acid synthase ENSG00000169710 IPI000267 FASN 
K.AFDTAGNGYC*R.
S 0.96 0.63 1.04 
IPI00069693.4 _ Uncharacterized protein ENSP00000350479 ENSG0000 _ 
R.ALVDGPC*TQVR.
R 0.84 0.63 1.01 
IPI00216298.6 
TXN Thioredoxin 
ENSG00000136810 IPI00552768 
IPI002 
TXN K.C*MPTFQFFK.K 0.7 0.63 1.125 
IPI00478208.2 hCG_2004593 hypothetical protein LOC645296 ENSG000 
hCG_2
004593 
R.INPYMSSPC*HIE
MILTEK.E 0.77 0.63 0.9 
IPI00013485.3 RPS2 40S ribosomal protein S2 ENSG00000140988 IPI0 RPS2 
R.GC*TATLGNFAK.
A 0.93 0.63 1 
IPI00006164.4 ILKAP Integrin-linked kinase-associated serine/thr ILKAP R.FILLAC*DGLFK.V 0.53 0.63 0 
IPI00301107.5 
IPO11 Importin-11 
ENSG00000086200 IPI00783526 
IPI0 
IPO11 R.LKQFLEC*SR.S 0 0.63 0.92 
IPI00784614.1 SEPT9 Isoform 1 of Septin-9 ENSG00000184640 IPI007 41526 
K.LTVIDTPGFGDHI
NNENC*WQPIMK.F 1.165 0.63 0.99 
IPI00219077.4 LTA4H Isoform 1 of Leukotriene A-4 hydrolase ENSG0 
LTA4
H 
R.AILPC*QDTPSVK.
L 0 0.63 0.99 
IPI00020599.1 CALR Calreticulin precursor ENSG00000179218 IPI007 CALR 
K.LFPNSLDQTDMH
GDSEYNIMFGPDIC*
GPGTK.K 
0.52 0.63 0.96 
IPI00028091.3 ACTR3 Actin-like protein 3 ENSG00000115091 IPI0002 
ACTR
3 R.YSYVC*PDLVK.E 1.02 0.635 1.15 
IPI00217030.10 RPS4X 40S ribosomal protein S4, X isoform ENSG0000 RPS4X R.EC*LPLIIFLR.N 0.92 0.635 1.12 
IPI00396627.1 ELAC2 Isoform 1 of Zinc phosphodiesterase ELAC pro 
ELAC
2 
K.VC*FGDFPTMPK.
L 0.955 0.635 1.18 
IPI00186290.6 EEF2 Elongation factor 2 ENSG00000167658 IPI001862 EEF2 
R.YVEPIEDVPC*GNI
VGLVGVDQFLVK.T 0.85 0.635 0.97 
IPI00029091.1 _ Putative nucleoside diphosphate kinase ENSG00000 _ R.GDFC*IQVGR.N 1.265 0.64 0.86 
IPI00396485.3 EEF1A1 Elongation factor 1-alpha 1 ENSG00000156508 
EEF1A
1 
K.PMC*VESFSDYPP
LGR.F 0.885 0.64 1.005 
IPI00852960.1 USP22 Ubiquitin carboxyl-terminal hydrolase 22 ENS USP22 K.C*DDAIITK.A 0 0.64 0 
IPI00398009.2 IPO4 Isoform 2 of Importin-4 ENSG00000196497 IPI00 IPO4 
R.APAALPALC*DLL
ASAADPQIR.Q 0.96 0.65 0.92 
IPI00019755.3 GSTO1 Glutathione transferase omega-1 ENSG00000148 
GSTO
1 R.FC*PFAER.T 1.05 0.65 1.005 
IPI00018235.3 PEF1 Peflin ENSG00000162517 IPI00018235 PEF1 
K.QALVNC*NWSSF
NDETCLMMINMFD
K.T 
0 0.65 0.95 
IPI00419237.3 LAP3 Isoform 1 of Cytosol aminopeptidase ENSG00000 LAP3 
R.SAGAC*TAAAFL
K.E 1.065 0.65 1.005 
IPI00739117.3 BAT2D1 HBxAg transactivated protein 2 ENSG00000117 
BAT2
D1 R.IAC*GPPQAK.L 0.93 0.65 1.07 
IPI00412771.1 CD2AP CD2-associated protein ENSG00000198087 IPI00 
CD2A
P 
K.DTC*YSPKPSVYL
STPSSASK.A 0.965 0.655 1 
IPI00748256.1 PSME1 Uncharacterized protein PSME1 ENSG0000009201 
PSME
1 
K.VDVFREDLC*TK.
T 0.845 0.655 0.99 
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IPI00790530.1 
NUP85 nucleoporin 85 
ENSG00000125450 IPI00790530 
I 
NUP85 R.GC*FSDLDLIDNLGPAMMLSDR.L 0.85 0.655 0.92 
IPI00218606.7 RPS23 40S ribosomal protein S23 ENSG00000186468 IP RPS23 
K.ITAFVPNDGC*LN
FIEENDEVLVAGFG
R.K 
0.925 0.655 1.06 
IPI00001890.8 
COPG 98 kDa protein 
ENSG00000181789 IPI00001890 
IP 
COPG K.ELAPAVSVLQLFC*SSPK.A 0.815 0.655 1.125 
IPI00329260.3 C13orf23 Uncharacterized protein KIAA2032 ENSG0000 
C13orf
23 K.DGEEC*TNEGK.G 0.73 0.66 1.065 
IPI00852816.1 SMARCD1 SWI/SNF-related matrix-associated actin-de 
SMAR
CD1 
R.AEFYFQPWAQEA
VC*R.Y 0 0.66 1.14 
IPI00025273.1 GART Isoform Long of Trifunctional purine biosynth GART 
K.QVLVAPGNAGTA
C*SEK.I 1.005 0.66 0.965 
IPI00220150.4 IDH3G Isocitrate dehydrogenase [NAD] subunit gamma IDH3G 
R.TSLDLYANVIHC*
K.S 1.12 0.66 0 
IPI00005692.1 MRPS12 28S ribosomal protein S12, mitochondrial pr 
MRPS
12 K.GVVLC*TFTR.K 0 0.66 1.32 
IPI00011253.3 RPS3 40S ribosomal protein S3 ENSG00000149273 IPI0 RPS3 
R.GLC*AIAQAESLR.
Y 0.95 0.66 0.98 
IPI00743871.1 INTS7 Uncharacterized protein INTS7 ENSG0000014349 INTS7 
R.IDLLQAFSQLIC*T
CNSLK.T 0 0.66 0 
IPI00298887.5 
STAT3 88 kDa protein 
ENSG00000168610 IPI00298887 
I 
STAT3 R.QQIAC*IGGPPNICLDR.L 0 0.66 0 
IPI00031563.4 C19orf58 Uncharacterized protein C19orf58 ENSG0000 
C19orf
58 R.FHADSVC*K.A 1.05 0.665 1.01 
IPI00027107.5 TUFM Tu translation elongation factor, mitochondri TUFM 
K.GEETPVIVGSALC
*ALEGR.D 0.86 0.665 1.01 
IPI00025746.5 ANKRD54 Isoform 1 of Ankyrin repeat domain-contain 
ANKR
D54 
K.LNILQEGHAQC*L
EAVR.L 1.24 0.67 0.91 
IPI00219217.3 LDHB L-lactate dehydrogenase B chain ENSG000001117 LDHB 
K.GMYGIENEVFLSL
PC*ILNAR.G 0.875 0.67 0.725 
IPI00027251.1 STK38 Serine/threonine-protein kinase 38 ENSG00000 STK38 
K.LSDFGLC*TGLK.
K 0.865 0.67 0.98 
IPI00219160.3 RPL34 60S ribosomal protein L34 ENSG00000109475 IP RPL34 K.SACGVC*PGR.L 0.79 0.67 1.055 
Reverse_IPI00303
343.7 
SCAF1 Splicing factor, 
arginine/serine-rich 19 ENS SCAF1 
K.AAREEGSWSTEE
AGKTGAAQSC*SDA
KSKK.L 
1.23 0.67 0.92 
IPI00303882.2 M6PRBP1 Isoform B of Mannose-6-phosphate receptor- 
M6PR
BP1 
R.VASMPLISSTC*D
MVSAAYASTK.E 0 0.67 1.24 
IPI00257508.4 DPYSL2 Dihydropyrimidinase-related protein 2 ENSG0 
DPYS
L2 
R.GLYDGPVC*EVS
VTPK.T 0.975 0.675 1.135 
IPI00006754.1 WDR68 WD repeat-containing protein 68 ENSG00000136 
WDR6
8 R.VPC*TPVAR.L 0.91 0.675 1.085 
IPI00003881.5 HNRPF Heterogeneous nuclear ribonucleoprotein F EN 
HNRP
F 
R.DLSYC*LSGMYD
HR.Y 0.89 0.68 0.9 
IPI00291646.2 
MTHFD1L 
methylenetetrahydrofolate 
dehydrogenase (N 
MTHF
D1L 
K.IDRYTQQGFGNLP
IC*MAK.T 0 0.68 0.89 
IPI00008453.3 
CORO1C Coronin-1C 
ENSG00000110880 IPI00008453 
IPI0 
CORO
1C K.C*DLISIPK.K 1 0.685 1.03 
IPI00008530.1 RPLP0 60S acidic ribosomal protein P0 ENSG00000089 RPLP0 
R.AGAIAPC*EVTVP
AQNTGLGPEK.T 0.93 0.685 1.055 
IPI00514501.1 C1orf57 Chromosome 1 open reading frame 57 ENSG000 
C1orf5
7 
R.NADC*SSGPGQR.
V 0.9 0.685 0.945 
IPI00013871.1 RRM1 Ribonucleoside-diphosphate reductase large su RRM1 R.DECLMC*GS.- 0.815 0.69 1.03 
IPI00787501.1 LOC727737 similar to APG4 autophagy 4 homolog B is 
LOC72
7737 
K.NFPAIGGTGPTSD
TGWGC*MLR.C 0.955 0.69 1.05 
IPI00100160.3 CAND1 Isoform 1 of Cullin-associated NEDD8-dissoci 
CAND
1 K.NC*IGDFLK.T 0 0.69 1.085 
IPI00018768.1 TSN Translin ENSG00000211460 IPI00018768 TSN K.ETAAAC*VEK.- 0.905 0.69 1.015 
IPI00013871.1 RRM1 Ribonucleoside- RRM1 R.NTAAMVC*SLEN 0.815 0.69 1.03 
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diphosphate reductase large su RDECLMCGS.- 
IPI00303207.3 ABCE1 ATP-binding cassette sub-family E member 1 E 
ABCE
1 R.YC*ANAFK.L 0.845 0.69 1.08 
IPI00152998.3 LRRC40 Leucine-rich repeat-containing protein 40 E 
LRRC
40 
R.DC*GTSVPQGLLK
.A 0.89 0.69 1.13 
IPI00306017.2 C15orf44 Isoform 1 of UPF0464 protein C15orf44 ENS 
C15orf
44 
R.LIDLNNGEGQIFTI
DGPLC*LK.N 0.89 0.7 1.025 
IPI00016802.1 SIRT1 NAD-dependent deacetylase sirtuin-1 ENSG0000 SIRT1 
R.GC*PGAAAAALW
R.E 0 0.7 0.94 
IPI00015911.1 DLD Dihydrolipoyl dehydrogenase, mitochondrial pre DLD 
R.VLGAHILGPGAGE
MVNEAALALEYGA
SC*EDIAR.V 
0 0.7 1.02 
IPI00186290.6 EEF2 Elongation factor 2 ENSG00000167658 IPI001862 EEF2 
R.LMEPIYLVEIQC*P
EQVVGGIYGVLNR.
K 
0.82 0.7 1.11 
IPI00301139.5 MED17 Isoform 1 of Mediator of RNA polymerase II t 
MED1
7 
K.MELLMSALSPC*L
L.- 1.08 0.71 1.04 
IPI00008247.2 ANAPC5 Isoform 1 of Anaphase-promoting complex sub 
ANAP
C5 
K.LIEESC*PQLANS
VQIR.I 0.92 0.71 0.96 
IPI00396086.1 RPS21 8.2 kDa differentiation factor ENSG000001718 RPS21 R.KC*SASNR.I 1.045 0.715 1.02 
IPI00008433.4 RPS5 40S ribosomal protein S5 ENSG00000083845 IPI0 RPS5 K.AQC*PIVER.L 1 0.715 0.995 
IPI00022977.1 CKB Creatine kinase B-type ENSG00000166165 IPI0002 CKB 
K.DYEFMWNPHLG
YILTC*PSNLGTGLR
.A 
0 0.715 0 
IPI00099986.5 FN3KRP Ketosamine-3-kinase ENSG00000141560 IPI0009 
FN3K
RP 
R.ATGHSGGGC*ISQ
GR.S 0.985 0.72 1.035 
IPI00019376.6 SEPT11 Septin-11 ENSG00000138758 IPI00019376 41528 
K.STSQGFC*FNILC
VGETGIGK.S 0.985 0.72 1.065 
IPI00103925.2 IRGQ Immunity-related GTPase family Q protein ENSG IRGQ 
R.TDGEGEDPEC*LG
EGK.M 1.17 0.72 0.96 
IPI00788737.1 
GAPDH 39 kDa protein 
ENSG00000111640 IPI00789134 
I 
GAPD
H 
K.IISNASC*TTNCLA
PLAK.V 1 0.72 1.015 
IPI00011253.3 RPS3 40S ribosomal protein S3 ENSG00000149273 IPI0 RPS3 R.AC*YGVLR.F 0.885 0.72 0.975 
IPI00005780.3 OGT Isoform 3 of UDP-N-acetylglucosamine--peptide  OGT 
K.VMAEANHFIDLS
QIPC*NGK.A 0.98 0.725 0.96 
IPI00419880.6 RPS3A 40S ribosomal protein S3a ENSG00000145425 IP RPS3A R.DKMC*SMVK.K 0.95 0.725 1 
IPI00062839.4 MARS2 Methionyl-tRNA synthetase, mitochondrial pre 
MARS
2 
R.INPSETYPAFC*TT
CFPSEPGLVGPSVR.
A 
0.94 0.725 1.135 
IPI00289773.3 CEBPB CCAAT/enhancer-binding protein beta ENSG0000 
CEBP
B 
K.APPTAC*YAGAA
PAPSQVK.S 0 0.725 1.05 
IPI00096066.2 SUCLG2 Succinyl-CoA ligase [GDP-forming] beta-chai 
SUCL
G2 
R.SC*NGPVLVGSPQ
GGVDIEEVAASNPE
LIFK.E 
0.9 0.73 1.03 
IPI00306290.4 XPOT Uncharacterized protein XPOT ENSG00000184575  XPOT 
R.QASLADC*LNHA
VGFASR.T 0.9 0.73 0 
IPI00146935.4 DNM1L Isoform 1 of Dynamin-1-like protein ENSG0000 
DNM1
L R.IC*YIFHETFGR.T 0 0.73 0 
IPI00026781.2 FASN Fatty acid synthase ENSG00000169710 IPI000267 FASN 
K.LTPGC*EAEAETE
AICFFVQQFTDMEH
NR.V 
0.94 0.735 1.045 
IPI00011631.6 ZW10 Centromere/kinetochore protein zw10 homolog E ZW10 
R.LAPILC*DGTATF
VDLVPGFR.R 0.965 0.735 0.92 
IPI00013871.1 RRM1 Ribonucleoside-diphosphate reductase large su RRM1 
K.IIDINYYPVPEAC*
LSNKR.H 0.86 0.735 0.99 
IPI00465260.4 GARS Glycyl-tRNA synthetase ENSG00000106105 IPI004 GARS R.SCYDLSC*HAR.A 0.6 0.735 1.01 
IPI00018465.1 CCT7 T-complex protein 1 subunit eta ENSG000001356 CCT7 R.YNFFTGC*PK.A 1.22 0.735 0.82 
IPI00005791.1 NDC80 Kinetochore protein Hec1 ENSG00000080986 IPI 
NDC8
0 
K.FNPEAGANC*LV
K.Y 0 0.735 1.15 
IPI00783061.1 PKM2 Uncharacterized protein PKM2 ENSG00000067225  PKM2 
R.AEGSDVANAVLD
GADC*IMLSGETAK. 0.725 0.735 0.955 
242 
 
G 
IPI00329638.10 ZAK Isoform 1 of Mitogen-activated protein kinase  ZAK 
K.FDDLQFFENC*GG
GSFGSVYR.A 0 0.74 0.84 
IPI00007818.3 CPSF3 Cleavage and polyadenylation specificity fac CPSF3 
R.NFNYHILSPC*DL
SNYTDLAMSTVK.Q 0.97 0.74 0.97 
IPI00016580.6 DSN1 Isoform 1 of Kinetochore-associated protein D DSN1 
K.VFDC*MELVMDE
LQGSVK.Q 1.04 0.74 1.14 
IPI00641635.1 
FTO 64 kDa protein 
ENSG00000140718 IPI00028277 
IPI 
FTO K.ANEDAVPLC*MSADFPR.V 0.985 0.74 0.945 
IPI00023919.4 PSMC5 26S protease regulatory subunit 8 ENSG000000 
PSMC
5 
K.FVVDVDKNIDIND
VTPNC*R.V 0.94 0.74 0.94 
IPI00011200.5 PHGDH D-3-phosphoglycerate dehydrogenase ENSG00000 
PHGD
H 
K.NAGNC*LSPAVIV
GLLK.E 0.94 0.745 0.91 
IPI00301051.3 NHLRC2 NHL repeat-containing protein 2 ENSG0000019 
NHLR
C2 
K.AILFSQPLQITDTQ
QGC*IAPVELR.Y 0.965 0.745 0.92 
IPI00004358.4 PYGB Glycogen phosphorylase, brain form ENSG000001 PYGB 
R.LAAC*FLDSMATL
GLAAYGYGIR.Y 0 0.745 0.85 
IPI00002966.1 HSPA4 Heat shock 70 kDa protein 4 ENSG00000170606  
HSPA
4 
R.GC*ALQCAILSPA
FK.V 1.07 0.75 1.085 
IPI00026230.1 HNRPH2 Heterogeneous nuclear ribonucleoprotein H  
HNRP
H2 
R.DLNYC*FSGMSD
HR.Y 0.91 0.75 0.955 
IPI00215719.6 RPL18 60S ribosomal protein L18 ENSG00000063177 IP RPL18 
K.GC*GTVLLSGPR.
K 0.88 0.75 0.96 
IPI00012828.3 ACAA1 3-ketoacyl-CoA thiolase, peroxisomal precurs 
ACAA
1 
R.DC*LIPMGITSEN
VAER.F 0.97 0.75 0 
IPI00643920.2 
TKT Transketolase 
ENSG00000163931 IPI00643920 
IPI0 
TKT R.TVPFC*STFAAFFTR.A 0 0.75 1.01 
IPI00011511.1 CECR5 Isoform 2 of Cat eye syndrome critical regio 
CECR
5 
K.AQELSALLGC*EV
DADQVILSHSPMK.L 1.1 0.755 1.145 
IPI00028091.3 ACTR3 Actin-like protein 3 ENSG00000115091 IPI0002 
ACTR
3 
R.LPACVVDC*GTG
YTK.L 0.945 0.755 1.07 
IPI00844375.1 PSMB2 Proteasome beta 2 subunit variant (Fragment) 
PSMB
2 R.NLADC*LR.S 0.92 0.76 0.985 
IPI00176655.5 _ Uncharacterized protein ENSP00000348430 ENSG0000 _ K.TPC*GEGSK.T 0.99 0.76 1.03 
IPI00641582.1 BAG3 BAG family molecular chaperone regulator 3 EN BAG3 
R.SQSPAASDC*SSSS
SSASLPSSGR.S 1.05 0.76 0 
IPI00013847.4 UQCRC1 Ubiquinol-cytochrome-c reductase complex co 
UQCR
C1 
K.YIYDQC*PAVAG
YGPIEQLPDYNR.I 0 0.76 0.975 
IPI00290566.1 TCP1 T-complex protein 1 subunit alpha ENSG0000012 TCP1 
K.VLC*ELADLQDK
EVGDGTTSVVIIAAE
LLK.N 
1.27 0.76 1.02 
IPI00021926.2 PSMC6 26S protease regulatory subunit S10B ENSG000 
PSMC
6 
K.GC*LLYGPPGTGK
.T 0.71 0.76 0.925 
IPI00219156.7 RPL30 60S ribosomal protein L30 ENSG00000156482 IP RPL30 
R.VC*TLAIIDPGDSD
IIR.S 0.97 0.765 1.075 
IPI00176574.1 LOC284230 Uncharacterized protein ENSP00000351550  
LOC28
4230 R.LECVEPNC*R.S 0.895 0.765 1 
IPI00065671.1 UCK2 Isoform 1 of Uridine-cytidine kinase 2 ENSG00 UCK2 
R.QTNGC*LNGYTPS
R.K 1.04 0.77 1.005 
IPI00020898.1 RPS6KA3 Ribosomal protein S6 kinase alpha-3 ENSG00 
RPS6K
A3 
K.AYSFC*GTVEYM
APEVVNR.R 0.88 0.77 1.08 
IPI00023530.6 CDK5 Cell division protein kinase 5 ENSG0000016488 CDK5 
R.ISAEEALQHPYFS
DFC*PP.- 0.98 0.77 0.98 
IPI00026781.2 FASN Fatty acid synthase ENSG00000169710 IPI000267 FASN 
R.DPETLVGYSMVG
C*QR.A 1.03 0.775 0.945 
IPI00026781.2 FASN Fatty acid synthase ENSG00000169710 IPI000267 FASN 
K.ADEASELAC*PTP
K.E 0.96 0.775 1.11 
IPI00027107.5 TUFM Tu translation elongation factor, mitochondri TUFM 
K.NMITGTAPLDGC*
ILVVAANDGPMPQT
R.E 
0.84 0.775 1.045 
IPI00013214.1 MCM3 DNA replication licensing factor MCM3 ENSG000 MCM3 
R.TLTSC*FLSCVVC
VEGIVTK.C 0 0.775 1.41 
IPI00008994.2 NDRG2 Isoform 1 of Protein NDRG2 ENSG00000165795 I 
NDRG
2 
K.YFLQGMGYMASS
C*MTR.L 0.84 0.78 0.91 
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IPI00291939.1 SMC1A Structural maintenance of chromosomes protei 
SMC1
A 
K.AESLIGVYPEQGD
C*VISK.V 0.88 0.78 1.04 
IPI00220373.4 IDE Insulin-degrading enzyme ENSG00000119912 IPI00 IDE 
R.EMDSC*PVVGEFP
CQNDINLSQAPALP
QPEVIQNMTEFKR.G 
1.12 0.785 1.005 
IPI00383460.7 GRSF1 G-rich RNA sequence binding factor 1 isoform GRSF1 R.YIELFLNSC*PK.G 1.135 0.79 1.115 
IPI00478758.1 C10orf119 Uncharacterized protein C10orf119 ENSG00 
C10orf
119 
R.DASALLDPMEC*T
DTAEEQR.V 1.045 0.79 1.03 
IPI00021840.1 RPS6 40S ribosomal protein S6 ENSG00000137154 IPI0 RPS6 
K.LNISFPATGC*QK.
L 0.965 0.79 0.985 
IPI00375704.1 PSMB5 Putative uncharacterized protein DKFZp686I01 
PSMB
5 
K.KVIEINPYLLGTM
AGGAADC*SFWER.
L 
0.91 0.79 1 
IPI00745793.1 CCNB1 G2/mitotic-specific cyclin-B1 ENSG0000013405 
CCNB
1 R.FMQNNC*VPK.K 1.1 0.79 1.175 
IPI00008422.5 SMARCAD1 Isoform 2 of SWI/SNF-related matrix-assoc 
SMAR
CAD1 
K.NTEMC*NVMMQ
LR.K 1.01 0.795 1.03 
IPI00796337.1 PCBP2 poly(rC)-binding protein 2 isoform a ENSG000 PCBP2 
R.AITIAGIPQSIIEC*
VK.Q 1.015 0.795 1.06 
IPI00301609.8 NEK9 Serine/threonine-protein kinase Nek9 ENSG0000 NEK9 R.LLTFGC*NK.C 1.015 0.8 1.14 
IPI00292753.7 GAPVD1 GTPase activating protein and VPS9 domains  
GAPV
D1 
R.LQELESC*SGLGS
TSDDTDVR.E 1.035 0.8 1.105 
IPI00182533.5 RPL28 60S ribosomal protein L28 ENSG00000108107 IP RPL28 R.NC*SSFLIK.R 0.99 0.8 1.055 
IPI00449197.1 
GMPR2 GMPR2 protein 
ENSG00000100938 IPI00385158 
IP 
GMPR
2 
K.VGIGPGSVC*TTR.
K 1.38 0.8 0.955 
IPI00472102.3 
HSPD1 61 kDa protein 
ENSG00000144381 IPI00472102 
I 
HSPD
1 
K.C*EFQDAYVLLSE
K.K 0.95 0.8 0.985 
IPI00219669.5 CA8 Carbonic anhydrase-related protein ENSG0000017 CA8 
K.GAELVEGC*DGIL
GDNFRPTQPLSDR.V 0.905 0.8 0 
IPI00241841.8 KRT79 keratin 6L ENSG00000185640 IPI00241841 KRT79 
K.KQC*QQLQTAIAE
AEQR.G 0.9 0.8 0 
IPI00018009.2 EDC3 Enhancer of mRNA-decapping protein 3 ENSG0000 EDC3 
K.DLPTSPVDLVINC
*LDCPENVFLR.D 0.935 0.805 0.97 
IPI00003768.1 PES1 Isoform 1 of Pescadillo homolog 1 ENSG0000010 PES1 
K.AGEGTYALDSES
C*MEK.L 0.89 0.805 0.86 
IPI00099996.2 RG9MTD1 RNA (guanine-9-) methyltransferase domain- 
RG9M
TD1 
K.SSVQEEC*VSTISS
SKDEDPLAATR.E 1.02 0.805 0.845 
IPI00216975.1 TPM4 Isoform 2 of Tropomyosin alpha-4 chain ENSG00 TPM4 
K.EENVGLHQTLDQ
TLNELNC*I.- 1.195 0.805 0.94 
IPI00147874.1 NANS Sialic acid synthase ENSG00000095380 IPI00147 NANS 
K.QLLPCEMAC*NE
K.L 0.98 0.81 1.045 
IPI00640703.3 XPO5 Isoform 1 of Exportin-5 ENSG00000124571 IPI00 XPO5 
R.AVMEQIPEIQKDS
LDQFDC*K.L 0.98 0.81 1.07 
IPI00006167.1 PPM1G Protein phosphatase 1G ENSG00000115241 IPI00 
PPM1
G 
R.GTEAGQVGEPGIP
TGEAGPSC*SSASD
KLPR.V 
1.045 0.815 1.005 
IPI00019380.1 NCBP1 Nuclear cap-binding protein subunit 1 ENSG00 
NCBP
1 
K.SAC*SLESNLEGL
AGVLEADLPNYK.S 0 0.815 0 
IPI00025087.1 TP53 Isoform 1 of Cellular tumor antigen p53 ENSG0 TP53 
R.C*SDSDGLAPPQH
LIR.V 0.99 0.82 1.23 
IPI00299524.1 NCAPD2 Condensin complex subunit 1 ENSG00000010292 
NCAP
D2 K.VACC*PLER.C 1.065 0.82 0.97 
IPI00220301.5 PRDX6 Peroxiredoxin-6 ENSG00000117592 IPI00220301 
PRDX
6 
K.DINAYNC*EEPTE
K.L 0.975 0.82 0.995 
IPI00747722.1 GALK1 Uncharacterized protein GALK1 ENSG0000010847 
GALK
1 K.GHALLIDC*R.S 1.03 0.82 0.925 
IPI00448095.3 DCXR L-xylulose reductase ENSG00000169738 IPI00448 DCXR 
R.GVPGAIVNVSSQC
*SQR.A 0.985 0.825 1.27 
IPI00514983.3 HSPH1 Isoform Alpha of Heat shock protein 105 kDa  
HSPH
1 R.C*TPSVISFGSK.N 1.105 0.825 1.04 
IPI00010157.1 MAT2A S-adenosylmethionine synthetase isoform type 
MAT2
A K.VAC*ETVAK.T 0.965 0.825 1.005 
IPI00025273.1 GART Isoform Long of GART R.SGC*KVDLGGFA 0 0.825 1.12 
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Trifunctional purine biosynth GLFDLK.A 
IPI00009668.3 CENPH Centromere protein H ENSG00000153044 IPI0000 
CENP
H 
R.AGGPPQVAGAQA
AC*SEDR.M 1.055 0.83 1.11 
IPI00788737.1 
GAPDH 39 kDa protein 
ENSG00000111640 IPI00789134 
I 
GAPD
H 
R.VPTANVSVVDLT
C*R.L 1 0.83 1 
IPI00304596.3 NONO Non-POU domain-containing octamer-binding pro NONO 
R.C*SEGSFLLTTFPR
PVTVEPMDQLDDEE
GLPEK.L 
1.19 0.83 1.19 
IPI00166130.1 D15Wsu75e DJ347H13.4 protein ENSG00000100418 IPI00 
D15W
su75e 
R.GEAYNLFEHNC*
NTFSNEVAQFLTGR.
K 
0.95 0.83 0.935 
IPI00555734.3 ASRGL1 asparaginase-like 1 protein ENSG00000162174 
ASRG
L1 K.GAQKTDC*QK.N 1.085 0.83 1.05 
IPI00220766.5 GLO1 Lactoylglutathione lyase ENSG00000124767 IPI0 GLO1 K.C*DFPIMK.F 0.91 0.83 0.955 
IPI00016610.2 PCBP1 Poly(rC)-binding protein 1 ENSG00000169564 I PCBP1 
R.AITIAGVPQSVTE
C*VK.Q 0 0.83 0.985 
IPI00026781.2 FASN Fatty acid synthase ENSG00000169710 IPI000267 FASN 
K.AINC*ATSGVVGL
VNCLR.R 1.2 0.835 1.125 
IPI00022228.1 
HDLBP Vigilin 
ENSG00000115677 IPI00022228 
IPI00443 
HDLB
P 
K.AAC*LESAQEPAG
AWGNK.I 1 0.835 0.925 
IPI00021766.4 RTN4 Isoform 1 of Reticulon-4 ENSG00000115310 IPI0 RTN4 
K.YSNSALGHVNC*
TIK.E 0.62 0.835 1.005 
IPI00290566.1 TCP1 T-complex protein 1 subunit alpha ENSG0000012 TCP1 R.SLHDALC*VVK.R 1.075 0.835 0.94 
IPI00607557.1 ELF2 Isoform 5 of ETS-related transcription factor ELF2 
K.IITIPATQLAQC*Q
LQTK.S 0.96 0.835 1.135 
IPI00292771.4 NUMA1 Isoform 1 of Nuclear mitotic apparatus prote 
NUM
A1 
K.APVPSTC*SSTFPE
ELSPPSHQAK.R 0 0.835 0.74 
IPI00556027.1 BAG5 BCL2-associated athanogene 5 isoform a ENSG00 BAG5 
K.TELQGLIGQLDEV
SLEKNPC*IR.E 0.88 0.835 0.99 
IPI00220158.1 ADD1 Isoform 3 of Alpha-adducin ENSG00000087274 IP ADD1 
R.VSMILQSPAFC*E
ELESMIQEQFKK.G 0.94 0.84 0.97 
IPI00290566.1 TCP1 T-complex protein 1 subunit alpha ENSG0000012 TCP1 R.DC*LINAAK.T 0.915 0.84 1.01 
IPI00307755.3 PRKAA2 5-AMP-activated protein kinase catalytic s 
PRKA
A2 
R.TSC*GSPNYAAPE
VISGR.L 1 0.84 1.02 
IPI00221091.9 RPS15A 40S ribosomal protein S15a ENSG00000134419  
RPS15
A K.C*GVISPR.F 0.97 0.84 1.085 
IPI00304742.4 STK10 Uncharacterized protein STK10 ENSG0000007278 STK10 
K.LSEEAEC*PNPSTP
SK.A 0 0.84 0 
IPI00299263.5 ARFGAP3 ADP-ribosylation factor GTPase-activating  
ARFG
AP3 K.LANTC*FNEIEK.Q 1.085 0.845 1.005 
IPI00336008.1 
ALDH5A1 aldehyde 
dehydrogenase 5A1 precursor, 
isof 
ALDH
5A1 
R.NTGQTC*VCSNQF
LVQR.G 1.02 0.845 0.895 
IPI00302673.3 ATPAF1 ATP synthase mitochondrial F1 complex assem 
ATPA
F1 K.C*AQNQNKT.- 1.05 0.845 1 
IPI00018465.1 CCT7 T-complex protein 1 subunit eta ENSG000001356 CCT7 
R.INALTAASEAAC*
LIVSVDETIKNPR.S 0 0.845 0.815 
IPI00163085.2 AMOT Isoform 1 of Angiomotin ENSG00000126016 IPI00 AMOT R.DC*STQTER.G 1.035 0.845 0.97 
IPI00024579.1 RAD18 E3 ubiquitin-protein ligase RAD18 ENSG000000 
RAD1
8 
K.TQCPTCC*VTVTE
PDLK.N 1.085 0.85 0.775 
IPI00748353.1 WDHD1 126 kDa protein ENSG00000198554 IPI00748353  
WDH
D1 
K.NVLSETPAIC*PPQ
NTENQRPK.T 1.03 0.85 1.05 
IPI00024719.1 HAT1 Histone acetyltransferase type B catalytic su HAT1 
K.VDENFDC*VEAD
DVEGK.I 0.97 0.85 1.05 
IPI00644290.1 NDRG3 NDRG family member 3 ENSG00000101079 IPI0021 
NDRG
3 
R.FALNHPELVEGLV
LINVDPC*AK.G 0 0.85 0 
Reverse_IPI00376
572.2 
LOC391722 similar to myosin 
regulatory light chain 
LOC39
1722 
K.CCC*NQSPPSSAS
SVPAMNRNKNVNR
QER.F 
0 0.85 0 
IPI00552897.2 MDC1 Isoform 1 of Mediator of DNA damage checkpoin MDC1 R.C*NVEPVGR.L 0.99 0.85 0.98 
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IPI00025815.2 
TARDBP TDP43 
ENSG00000120948 IPI00025815 
IPI006398 
TARD
BP 
R.VTEDENDEPIEIPS
EDDGTVLLSTVTAQ
FPGAC*GLR.Y 
0 0.85 0.93 
IPI00302688.7 ECHDC1 Isoform 1 of Enoyl-CoA hydratase domain-con 
ECHD
C1 
K.SLGTPEDGMAVC
*MFMQNTLTR.F 0.985 0.855 1.29 
IPI00329321.3 LYRM7 LYR motif-containing protein 7 ENSG000001866 
LYRM
7 
R.KDLLVENVPYC*
DAPTQK.Q 0.96 0.855 0.98 
IPI00022827.1 SLK Isoform 1 of STE20-like serine/threonine-prote SLK 
K.MTGESEC*LNPST
QSR.I 1.03 0.855 0.905 
IPI00410067.1 ZC3HAV1 Isoform 1 of Zinc finger CCCH type antivir 
ZC3H
AV1 
K.NSNVDSSYLESLY
QSC*PR.G 1.135 0.855 0.965 
IPI00013452.8 EPRS glutamyl-prolyl tRNA synthetase ENSG000001366 EPRS 
K.LGVENC*YFPMF
VSQSALEK.E 1 0.855 0.995 
IPI00017963.1 SNRPD2 Small nuclear ribonucleoprotein Sm D2 ENSG0 
SNRP
D2 K.NNTQVLINC*R.N 0.885 0.855 1.01 
IPI00029079.5 GMPS GMP synthase ENSG00000163655 IPI00029079 GMPS K.AC*TTEEDQEK.L 1.145 0.855 0.955 
IPI00479877.4 
ALDH9A1 aldehyde 
dehydrogenase 9A1 
ENSG00000143149 
ALDH
9A1 
K.GALMANFLTQGQ
VC*CNGTR.V 1.045 0.86 1.005 
IPI00455153.2 NFU1 HIRA interacting protein 5 isoform 2 ENSG0000 NFU1 
K.LQGSCTSC*PSSII
TLK.N 1.145 0.86 1.085 
IPI00215610.2 MPP1 55 kDa erythrocyte membrane protein ENSG00000 MPP1 
R.VASMAQSAPSEA
PSC*SPFGK.K 1.075 0.86 1.02 
IPI00010860.1 PSMD9 Isoform p27-L of 26S proteasome non-ATPase r 
PSMD
9 
K.GIGMNEPLVDC*E
GYPR.S 0.95 0.86 0.87 
IPI00220906.4 ACOT2 Isoform 1 of Acyl-coenzyme A thioesterase 2, 
ACOT
2 
K.SEFYANEAC*KR.
L 0.81 0.86 1.065 
IPI00386755.2 ERO1L ERO1-like protein alpha precursor ENSG000001 
ERO1
L 
K.HDDSSDNFC*EA
DDIQSPEAEYVDLL
LNPER.Y 
1.03 0.865 0.95 
IPI00479385.3 ASMTL Uncharacterized protein ASMTL ENSG0000016909 
ASMT
L K.VDASAC*GMER.L 1.105 0.865 1.05 
IPI00001287.1 C20orf72 Uncharacterized protein C20orf72 ENSG0000 
C20orf
72 
R.GVAQTPGSVEED
ALLC*GPVSK.H 1.05 0.865 1.135 
IPI00294008.4 ZWINT ZW10 interactor ENSG00000122952 IPI00646553  
ZWIN
T 
K.LLC*SQLQVADFL
QNILAQEDTAK.G 0.9 0.865 1.025 
IPI00017184.2 EHD1 EH domain-containing protein 1 ENSG0000011004 EHD1 
R.FMC*AQLPNPVL
DSISIIDTPGILSGEK.
Q 
0 0.865 0 
IPI00015141.4 CKMT2 Creatine kinase, sarcomeric mitochondrial pr 
CKMT
2 
R.LGYILTC*PSNLG
TGLR.A 1.06 0.87 1.015 
IPI00090720.4 QRSL1 Glutaminyl-tRNA synthase-like protein 1 ENSG 
QRSL
1 
K.QVQFPVIQLQEL
MDDC*SAVLENEK.
L 
0.825 0.87 0.935 
IPI00550365.2 PCBP3 Poly(RC) binding protein 3 ENSG00000183570 I PCBP3 
R.LVVPASQC*GSLI
GK.G 0.93 0.87 1 
IPI00480131.1 FLNB Uncharacterized protein FLNB ENSG00000136068  FLNB 
R.SSTETC*YSAIPK.
A 0.975 0.87 0.97 
IPI00300371.5 SF3B3 Isoform 1 of Splicing factor 3B subunit 3 EN SF3B3 R.SEHPPLC*GR.D 0 0.87 0.895 
IPI00333763.7 GLRX5 Glutaredoxin-related protein 5 ENSG000001825 
GLRX
5 
K.GTPEQPQC*GFSN
AVVQILR.L 0.95 0.875 1.01 
IPI00374272.3 LOC285636 hypothetical protein LOC285636 ENSG00000 
LOC28
5636 
R.C*PIQLNEGVSFQ
DLDTAK.L 0.905 0.875 1.095 
IPI00639841.2 PECI Peroxisomal 3,2-trans-enoyl-CoA isomerase ENS PECI 
R.WLSDEC*TNAVV
NFLSR.K 0.92 0.875 1.005 
IPI00748935.1 
ELP4 59 kDa protein 
ENSG00000109911 IPI00847770 
IP 
ELP4 K.VEPC*SLTPGYTK.L 1.135 0.875 1.08 
IPI00294536.1 STRAP Serine-threonine kinase receptor-associated  
STRA
P 
K.IGFPETTEEELEEI
ASENSDC*IFPSAPD
VK.A 
0.99 0.875 1.01 
IPI00746351.1 DIS3 Uncharacterized protein DIS3 ENSG00000083520  DIS3 
R.LAC*LSEEGNEIES
GK.I 1.195 0.875 1.21 
IPI00848058.1 ACTB Actin, cytoplasmic 2 ENSG00000075624 IPI00021 ACTB 
R.C*PEALFQPSFLG
MESCGIHETTFNSIM
K.C 
0 0.875 0 
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IPI00012197.1 XTP3TPA XTP3-transactivated gene A protein ENSG000 
XTP3T
PA 
K.YTELPHGAISEDQ
AVGPADIPC*DSTG
QTST.- 
0.995 0.88 1.005 
IPI00514983.3 HSPH1 Isoform Alpha of Heat shock protein 105 kDa  
HSPH
1 
K.LMSSNSTDLPLNI
EC*FMNDKDVSGK.
M 
1.005 0.88 0.935 
IPI00332499.1 NASP nuclear autoantigenic sperm protein isoform 1 NASP 
R.KPTDGASSSNC*V
TDISHLVR.K 0.96 0.88 1.06 
IPI00101652.4 SCLY Selenocysteine lyase ENSG00000132330 IPI00101 SCLY 
R.DAPAPAASQPSGC
*GK.H 1.06 0.88 1.055 
IPI00003814.1 MAP2K6 Isoform 1 of Dual specificity mitogen-activ 
MAP2
K6 
K.AC*ISIGNQNFEV
K.A 0 0.88 1.07 
IPI00021320.2 
MEPCE 7SK snRNA 
methylphosphate capping enzyme 
ENS 
MEPC
E R.SC*FPASLTASR.G 0.78 0.88 1.165 
IPI00007935.4 PDLIM5 PDZ and LIM domain protein 5 ENSG0000016311 
PDLI
M5 
R.QPTVTSVC*SETS
QELAEGQR.R 1.055 0.88 0.945 
IPI00103925.2 IRGQ Immunity-related GTPase family Q protein ENSG IRGQ R.EKC*SAGSQK.A 1.27 0.88 1.15 
IPI00009654.1 TRAPPC1 Trafficking protein particle complex subun 
TRAP
PC1 
K.NPLC*PLGQTVQS
ELFR.S 0 0.88 0 
IPI00027443.5 CARS cysteinyl-tRNA synthetase isoform c ENSG00000 CARS 
R.VQPQWSPPAGTQ
PC*R.L 1.08 0.885 1.09 
IPI00021347.1 UBE2L3 Ubiquitin-conjugating enzyme E2 L3 ENSG0000 
UBE2
L3 
K.GQVC*LPVISAEN
WKPATK.T 0.36 0.885 1.225 
IPI00807364.1 FNBP1L Isoform 1 of Formin-binding protein 1-like  
FNBP1
L 
R.FTSC*VAFFNILNE
LNDYAGQR.E 0 0.885 0 
IPI00658023.1 PTPN11 Isoform 1 of Tyrosine-protein phosphatase n 
PTPN1
1 
K.YSLADQTSGDQS
PLPPCTPTPPC*AEM
R.E 
0.83 0.89 1.02 
IPI00030876.6 
DIAPH1 Diaphanous 1 
ENSG00000131504 IPI00030876 
IP 
DIAP
H1 
K.AGC*AVTSLLASE
LTK.D 0 0.89 0 
IPI00220158.1 ADD1 Isoform 3 of Alpha-adducin ENSG00000087274 IP ADD1 
K.TAGPQSQVLC*G
VVMDR.S 0.935 0.89 1.035 
IPI00011107.2 IDH2 Isocitrate dehydrogenase [NADP], mitochondria IDH2 K.SSGGFVWAC*K.N 0.94 0.89 0.975 
IPI00073602.1 EXOSC6 Exosome complex exonuclease MTR3 ENSG000001 
EXOS
C6 R.RAPPGGC*EER.E 0 0.89 0.81 
IPI00018140.3 SYNCRIP Isoform 1 of Heterogeneous nuclear ribonuc 
SYNC
RIP K.SAFLC*GVMK.T 0.975 0.895 0.995 
IPI00550746.4 NUDC Nuclear migration protein nudC ENSG0000009027 NUDC 
R.WTQTLSELDLAV
PFC*VNFR.L 0.97 0.895 0.96 
IPI00292753.7 GAPVD1 GTPase activating protein and VPS9 domains  
GAPV
D1 
R.FSLC*SDNLEGISE
GPSNR.S 1.05 0.895 1.29 
IPI00169383.3 PGK1 Phosphoglycerate kinase 1 ENSG00000102144 IPI PGK1 
R.GCITIIGGGDTATC
*C*AK.W 0.985 0.895 1.055 
IPI00009949.2 PSMF1 Proteasome inhibitor PI31 subunit ENSG000001 
PSMF
1 
R.QPPWC*DPLGPFV
VGGEDLDPFGPR.R 1.14 0.895 1.005 
IPI00018946.3 PANK4 Pantothenate kinase 4 ENSG00000157881 IPI000 
PANK
4 R.C*FPGVVR.S 0.86 0.895 1.195 
IPI00643920.2 
TKT Transketolase 
ENSG00000163931 IPI00643920 
IPI0 
TKT 
R.MAAISESNINLC*
GSHCGVSIGEDGPS
QMALEDLAMFR.S 
1.095 0.895 0.98 
IPI00013789.5 SMYD5 SET and MYND domain-containing protein 5 ENS 
SMYD
5 R.LFSQFC*NK.T 0.745 0.9 0.77 
IPI00059242.3 SYAP1 Synapse-associated protein 1 ENSG00000169895 
SYAP
1 
K.TQEDEEEISTSPG
VSEFVSDAFDAC*N
LNQEDLRK.E 
0.92 0.9 1.005 
IPI00006181.1 EIF3D Eukaryotic translation initiation factor 3 s EIF3D 
K.FMTPVIQDNPSG
WGPC*AVPEQFR.D 0.86 0.9 1.11 
IPI00103554.1 GATAD2B Transcriptional repressor p66 beta ENSG000 
GATA
D2B K.SC*ASLLR.V 0.98 0.9 1.03 
IPI00059687.1 C18orf25 Isoform 1 of Uncharacterized protein C18o 
C18orf
25 
K.DGVADSTVISSMP
C*LLMELR.R 0.92 0.9 0.995 
IPI00106573.6 C20orf7 hypothetical protein LOC79133 isoform 1 EN 
C20orf
7 
R.NFPLALDLGC*GR
.G 1.06 0.9 1.075 
IPI00016610.2 PCBP1 Poly(rC)-binding protein 1 PCBP1 R.INISEGNC*PER.I 0.995 0.905 1 
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ENSG00000169564 I 
IPI00031680.3 ACBD6 Acyl-CoA-binding domain-containing protein 6 
ACBD
6 
R.DQDGCLPEEVTG
C*K.T 1.1 0.905 1.02 
IPI00174442.2 FAM98A Protein FAM98A ENSG00000119812 IPI00174442  
FAM9
8A R.EKTAC*AINK.V 0.94 0.905 1.045 
IPI00012750.3 RPS25 40S ribosomal protein S25 ENSG00000118181 IP RPS25 K.ATYDKLC*K.E 0.935 0.905 0.985 
IPI00556451.2 ETFB Isoform 2 of Electron transfer flavoprotein s ETFB 
K.EVIAVSCGPAQC*
QETIR.T 1.03 0.905 0.985 
IPI00024993.4 ECHS1 Enoyl-CoA hydratase, mitochondrial precursor 
ECHS
1 
K.AFAAGADIKEMQ
NLSFQDC*YSSK.F 1.01 0.905 1 
IPI00828021.1 HSPA4L Heat shock protein apg-1 ENSG00000164070 IP 
HSPA
4L K.SIDLPIQSSLC*R.Q 1.61 0.905 1.075 
IPI00024661.4 SEC24C Protein transport protein Sec24C ENSG000001 
SEC24
C 
R.APPSSGAPPASTA
QAPC*GQAAYGQF
GQGDVQNGPSSTV
QMQR.L 
0 0.905 1.015 
IPI00472675.2 NUP205 228 kDa protein ENSG00000155561 IPI00783781 
NUP20
5 
R.C*QDVSAGSLQEL
ALLTGIISK.A 0.91 0.91 1.125 
IPI00796199.1 HNRNPL Uncharacterized protein HNRPL ENSG000001048 
HNRN
PL 
K.QPAIMPGQSYGLE
DGSC*SYKDFSESR.
N 
0.865 0.91 1.005 
IPI00642816.2 SRP9 hCG_1781062 Signal recognition particle 9 kDa SRP9 
K.VTDDLVC*LVYK.
T 1.055 0.91 1.06 
IPI00010720.1 CCT5 T-complex protein 1 subunit epsilon ENSG00000 CCT5 K.VVNSC*HR.Q 1 0.91 1.035 
IPI00009010.3 HSPC152 TRM112-like protein ENSG00000173113 IPI000 
HSPC1
52 
R.IC*PVEFNPNFVA
R.M 0.915 0.91 0.97 
IPI00472102.3 
HSPD1 61 kDa protein 
ENSG00000144381 IPI00472102 
I 
HSPD
1 
R.AAVEEGIVLGGG
C*ALLR.C 0.95 0.91 1.02 
IPI00021926.2 PSMC6 26S protease regulatory subunit S10B ENSG000 
PSMC
6 
R.AVASQLDC*NFL
K.V 0.89 0.91 1.095 
IPI00166123.3 TTC5 Tetratricopeptide repeat protein 5 ENSG000001 TTC5 
R.VETPLLLVVNGKP
QGSSSQAVATVASR
PQC*E.- 
0 0.91 0 
IPI00302927.6 CCT4 T-complex protein 1 subunit delta ENSG0000011 CCT4 K.ITGC*ASPGK.T 1.02 0.915 1.055 
IPI00745518.1 MAP4 Microtubule-associated protein 4 isoform 1 va MAP4 
K.NVC*LPPEMEVA
LTEDQVPALK.T 1.12 0.915 1.045 
IPI00797537.1 NUDCD1 NudC domain-containing protein 1 ENSG000001 
NUDC
D1 R.DSAQC*AAIAER.L 1.18 0.915 1.03 
IPI00219103.6 HPCA Neuron-specific calcium-binding protein hippo HPCA 
R.LLQC*DPSSASQF.
- 0.89 0.915 0.87 
IPI00790739.1 ACO2 Aconitase 2, mitochondrial ENSG00000100412 IP ACO2 
R.DLGGIVLANAC*G
PCIGQWDR.K 0.845 0.915 1 
IPI00002966.1 HSPA4 Heat shock 70 kDa protein 4 ENSG00000170606  
HSPA
4 
K.LMSANASDLPLSI
EC*FMNDVDVSGT
MNR.G 
0.98 0.92 1.12 
IPI00103087.2 GEMIN6 Gem-associated protein 6 ENSG00000152147 IP 
GEMI
N6 
K.LMHLFTSGDC*K.
A 0.88 0.92 1.02 
IPI00216682.5 
CNN3 Calponin-3 
ENSG00000117519 IPI00216682 
IPI006 
CNN3 K.C*ASQAGMTAYGTR.R 0.96 0.92 0.97 
IPI00298111.7 SNX6 sorting nexin 6 isoform b ENSG00000129515 IPI SNX6 
R.IGSSLYALGTQDS
TDIC*K.F 1.97 0.92 1.05 
IPI00171856.1 
DOHH Deoxyhypusine 
hydroxylase ENSG00000129932 
IPI 
DOHH R.PAC*LAALQAHADDPER.V 0.93 0.92 1.29 
IPI00032995.1 LANCL2 LanC-like protein 2 ENSG00000132434 IPI0003 
LANC
L2 
R.AFVNPFPDYEAA
AGALLASGAAEETG
C*VRPPATTDEPGLP
FHQDGK.I 
0 0.92 0 
IPI00018146.1 YWHAQ 14-3-3 protein theta ENSG00000134308 IPI0001 
YWH
AQ 
R.DNLTLWTSDSAG
EEC*DAAEGAEN.- 1.05 0.925 0.91 
IPI00021305.1 
CCNH Cyclin-H 
ENSG00000134480 IPI00021305 
IPI00556 
CCNH R.TC*LSQLLDIMK.S 1.13 0.925 1.035 
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IPI00441867.1 PEX19 Isoform 1 of Peroxisomal biogenesis factor 1 PEX19 
R.VGSDMTSQQEFT
SC*LK.E 0.975 0.925 0.99 
IPI00002496.2 GMPPB AMIGO3 GDP-mannose pyrophosphorylase B isofo 
GMPP
B 
R.LC*SGPGIVGNVL
VDPSAR.I 1.025 0.925 1.09 
IPI00456919.2 HUWE1 Isoform 1 of E3 ubiquitin-protein ligase HUW 
HUWE
1 R.DQSAQC*TASK.S 0.85 0.925 1.12 
IPI00397904.6 NUP93 Nuclear pore complex protein Nup93 ENSG00000 NUP93 
K.SSGQSAQLLSHEP
GDPPC*LR.R 1.015 0.925 0.935 
IPI00025491.1 EIF4A1 Eukaryotic initiation factor 4A-I ENSG00000 
EIF4A
1 
K.VVMALGDYMGA
SC*HACIGGTNVR.A 0.91 0.93 1.065 
IPI00008248.3 ANAPC7 Anaphase-promoting complex subunit 7 ENSG00 
ANAP
C7 R.LEDVENLGC*R.L 0.945 0.93 1.17 
IPI00015736.3 UBE1DC1 Ubiquitin-activating enzyme E1 domain-cont 
UBE1
DC1 
R.EGVC*AASLPTTM
GVVAGILVQNVLK.
F 
1.04 0.93 0.975 
IPI00719622.1 RPS28 LOC646195 LOC645899 40S ribosomal protein S2 RPS28 
R.TGSQGQC*TQVR.
V 1.195 0.93 1.07 
IPI00643920.2 
TKT Transketolase 
ENSG00000163931 IPI00643920 
IPI0 
TKT 
K.QAFTDVATGSLG
QGLGAAC*GMAYT
GK.Y 
1.24 0.93 0.985 
IPI00101645.3 
KIAA0828 Putative 
adenosylhomocysteinase 3 
ENSG000 
KIAA0
828 K.FDNLYC*CR.E 1.2 0.93 1.035 
IPI00216746.1 HNRPK Isoform 2 of Heterogeneous nuclear ribonucle 
HNRP
K 
K.IIPTLEEGLQLPSP
TATSQLPLESDAVE
C*LNYQHYK.G 
0.97 0.93 0.99 
IPI00183626.8 PTBP1 polypyrimidine tract-binding protein 1 isofo PTBP1 
K.RGSDELFSTC*VT
NGPFIMSSNSASAA
NGNDSK.K 
1.085 0.93 0.94 
IPI00022977.1 CKB Creatine kinase B-type ENSG00000166165 IPI0002 CKB 
R.FC*TGLTQIETLFK
.S 0.5 0.93 0 
IPI00549467.3 NIT2 Nitrilase family member 2 ENSG00000114021 IPI NIT2 R.VGLGIC*YDMR.F 1.025 0.935 1.005 
IPI00333541.6 
FLNA Filamin-A 
ENSG00000196924 IPI00553169 
IPI0030 
FLNA K.AHVVPC*FDASK.V 0.98 0.935 1.02 
IPI00646361.2 NUP214 Uncharacterized protein NUP214 ENSG00000126 
NUP21
4 
K.VC*ATLPSTVAVT
SVCWSPK.G 0 0.935 1.015 
IPI00021812.2 AHNAK AHNAK nucleoprotein isoform 1 ENSG0000012494 
AHNA
K 
K.LEGDLTGPSVGV
EVPDVELEC*PDAK.
L 
0.84 0.935 1.12 
IPI00008943.3 DDX19B Isoform 1 of ATP-dependent RNA helicase DDX 
DDX1
9B K.VLVTTNVC*AR.G 0.995 0.935 1.01 
IPI00749250.1 
ACTR2 45 kDa protein 
ENSG00000138071 IPI00005159 
I 
ACTR
2 
K.LC*YVGYNIEQEQ
K.L 1.215 0.935 0.98 
IPI00747447.1 
EIF3B 99 kDa protein 
ENSG00000106263 IPI00396370 
I 
EIF3B R.FSHQGVQLIDFSPC*ER.Y 0 0.935 0.93 
IPI00027626.3 CCT6A T-complex protein 1 subunit zeta ENSG0000014 
CCT6
A 
K.NAIDDGC*VVPG
AGAVEVAMAEALI
K.H 
0.92 0.935 0.975 
IPI00306369.3 NSUN2 tRNA ENSG00000037474 IPI00306369 
NSUN
2 
K.DGVC*GPPPSKK.
M 1.07 0.94 1.08 
IPI00041325.1 
NOLA2 H/ACA 
ribonucleoprotein complex 
subunit 2 EN 
NOLA
2 
K.ADPDGPEAQAEA
C*SGER.T 1.08 0.94 1.1 
IPI00470779.2 
TXLNA Alpha-taxilin 
ENSG00000084652 IPI00816089 
IP 
TXLN
A 
R.VTEAPC*YPGAPS
TEASGQTGPQEPTS
AR.A 
1.04 0.94 1.04 
IPI00004839.1 CRKL Crk-like protein ENSG00000099942 IPI00004839 CRKL K.RVPC*AYDK.T 1.065 0.94 1.02 
IPI00298961.3 
XPO1 Exportin-1 
ENSG00000082898 IPI00784388 
IPI002 
XPO1 R.QMSVPGIFNPHEIPEEMC*D.- 0.95 0.94 0.935 
IPI00020454.1 DCK Deoxycytidine kinase ENSG00000156136 IPI000204 DCK 
R.SC*PSFSASSEGTR
.I 0.95 0.94 1.055 
IPI00007682.2 ATP6V1A Vacuolar ATP ATP6 R.VLDALFPCVQGG 0.995 0.94 1.04 
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synthase catalytic subunit A  V1A TTAIPGAFGC*GK.T 
IPI00103467.4 
ALDH1B1 Aldehyde 
dehydrogenase X, mitochondrial 
pr 
ALDH
1B1 K.LLC*GGER.F 0.88 0.94 1.065 
IPI00033030.2 
ADRM1 Protein ADRM1 
ENSG00000130706 IPI00033030 
IP 
ADRM
1 R.VPQC*PSGR.V 0.875 0.945 0.96 
IPI00026138.4 _ Uncharacterized protein ENSP00000371610 ENSG0000 _ 
K.NC*LTNFHGMDL
TR.D 1.03 0.945 0.985 
IPI00018522.4 PRMT1 HMT1 hnRNP methyltransferase-like 2 isoform  
PRMT
1 
K.VIGIEC*SSISDYA
VK.I 1.06 0.945 1.08 
IPI00024993.4 ECHS1 Enoyl-CoA hydratase, mitochondrial precursor 
ECHS
1 
K.ALNALC*DGLIDE
LNQALK.T 1.01 0.945 1.01 
IPI00745345.1 PPP4R2 Protein phosphatase 4 regulatory subunit 2  
PPP4R
2 
K.EVC*PVLDQFLCH
VAK.T 0.97 0.945 0.98 
IPI00450071.5 C1orf19 tRNA-splicing endonuclease subunit Sen15 E 
C1orf1
9 
R.GDSEPTPGC*SGL
GPGGVR.G 0.96 0.945 1.015 
IPI00644079.2 HNRNPU heterogeneous nuclear ribonucleoprotein U i 
HNRN
PU K.MC*LFAGFQR.K 0 0.945 1.85 
IPI00549569.4 ISYNA1 Myo-inositol 1-phosphate synthase A1 ENSG00 
ISYN
A1 
R.FC*EVIPGLNDTA
ENLLR.T 1.075 0.95 1.13 
IPI00294739.1 SAMHD1 SAM domain and HD domain-containing protein 
SAMH
D1 R.VC*EVDNELR.I 1.22 0.95 0 
IPI00384708.2 PDSS2 Isoform 1 of Decaprenyl-diphosphate synthase PDSS2 
R.C*LLSDELSNIAM
QVR.K 0 0.95 0 
IPI00006863.5 SPAG7 Single-stranded nucleic acid binding R3H dom 
SPAG
7 
K.TYGC*VPVANKR.
D 0.975 0.95 0.98 
IPI00398048.1 _ Uncharacterized protein ENSP00000310225 ENSG0000 _ K.C*GFLPGNEK.V 0.925 0.95 0.885 
IPI00000875.6 EEF1G Elongation factor 1-gamma ENSG00000186676 IP EEF1G 
K.AAAPAPEEEMDE
C*EQALAAEPK.A 1 0.95 0.99 
IPI00004534.3 
PFAS 
Phosphoribosylformylglycinamidi
ne synthase EN 
PFAS K.LMWLFGC*PLLLDDVAR.E 0 0.95 0.93 
IPI00007812.1 ATP6V1B2 Vacuolar ATP synthase subunit B, brain is 
ATP6
V1B2 
R.GPVVLAEDFLDIM
GQPINPQC*R.I 0.975 0.95 0.97 
IPI00376199.2 IRF2BP2 interferon regulatory factor 2 binding pro 
IRF2B
P2 R.AHGC*FPEGR.S 1.055 0.95 1.035 
IPI00037599.3 TFCP2 Isoform 1 of Alpha-globin transcription fact TFCP2 
K.IAQLFSISPC*QISQ
IYK.Q 0 0.95 0 
IPI00012535.1 
DNAJA1 DnaJ homolog 
subfamily A member 1 
ENSG00000 
DNAJ
A1 K.GAVEC*CPNCR.G 1 0.955 0.96 
IPI00018783.1 ITPA Inosine triphosphate pyrophosphatase ENSG0000 ITPA 
R.GC*QDFGWDPCF
QPDGYEQTYAEMP
K.A 
0.97 0.955 0.965 
IPI00785096.2 BZW1 similar to basic leucine zipper and W2 domain BZW1 
K.ERFDPTQFQDC*II
QGLTETGTDLEAVA
K.F 
0.995 0.955 0.97 
IPI00217223.1 PAICS Multifunctional protein ADE2 ENSG00000128050 PAICS 
K.C*GETAFIAPQCE
MIPIEWVCR.R 0.955 0.955 0.965 
IPI00018331.3 SNAPAP SNARE-associated protein Snapin ENSG0000014 
SNAP
AP 
R.EQIDNLATELC*R.
I 0 0.955 1.105 
IPI00786942.1 ALDH7A1 similar to antiquitin ENSG00000164904 IPI0 
ALDH
7A1 
K.GSDC*GIVNVNIP
TSGAEIGGAFGGEK.
H 
1.085 0.955 0.945 
IPI00054042.1 GTF2I Isoform 1 of General transcription factor II GTF2I 
R.SILSPGGSC*GPIK.
V 0.94 0.955 0.955 
IPI00023087.1 UBE2T Ubiquitin-conjugating enzyme E2 T ENSG000000 
UBE2
T R.IC*LDVLK.L 1.3 0.955 1.1 
IPI00004534.3 
PFAS 
Phosphoribosylformylglycinamidi
ne synthase EN 
PFAS K.FC*DNSSAIQGK.E 1.06 0.96 1.08 
IPI00219757.13 GSTP1 Glutathione S-transferase P ENSG00000084207  GSTP1 K.ASC*LYGQLPK.F 1.145 0.96 1.02 
IPI00465152.2 SP1 Transcription factor Sp1 ENSG00000185591 IPI00 SP1 
R.SSSTGSSSSTGGG
GQESQPSPLALLAA
TC*SR.I 
0.985 0.96 1 
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IPI00465044.2 RCC2 Protein RCC2 ENSG00000179051 IPI00465044 RCC2 K.AVQDLC*GWR.I 0.945 0.96 0.995 
IPI00549993.3 C10orf97 chromosome 10 open reading frame 97 ENSG0 
C10orf
97 
K.SSPGLSDTIFC*R.
W 1.01 0.96 1.055 
IPI00024673.2 MAPK9 Isoform Alpha-2 of Mitogen-activated protein 
MAPK
9 
R.TAC*TNFMMTPY
VVTR.Y 1.085 0.96 1.005 
IPI00002520.1 
SHMT2 Serine 
hydroxymethyltransferase, 
mitochondri 
SHMT
2 
R.AALEALGSC*LNN
K.Y 1.02 0.96 1.04 
IPI00302925.3 CCT8 Uncharacterized protein CCT8 ENSG00000156261  CCT8 
K.AHEILPNLVC*CS
AK.N 1.15 0.96 0.95 
IPI00748223.1 RABGGTB Uncharacterized protein RABGGTB ENSG000001 
RABG
GTB 
K.KDDYEYC*MSEY
LR.M 1.07 0.96 0 
IPI00217157.5 DDX59 Isoform 1 of Probable ATP-dependent RNA heli 
DDX5
9 K.NLPC*ANVR.Q 1.105 0.965 1.155 
IPI00334775.6 HSP90AB1 85 kDa protein ENSG00000096384 IPI0041467 
HSP90
AB1 
R.VFIMDSC*DELIPE
YLNFIR.G 0.96 0.97 1 
IPI00335449.3 PPP2R1B beta isoform of regulatory subunit A, prot 
PPP2R
1B 
R.LNIISNLDC*VNE
VIGIR.Q 1.01 0.97 1.005 
IPI00029079.5 GMPS GMP synthase ENSG00000163655 IPI00029079 GMPS R.VICAEEPYIC*K.D 0.975 0.97 0.99 
IPI00177965.5 NT5DC1 5-nucleotidase domain-containing protein 1 
NT5D
C1 
K.HFLSDTGMAC*R.
S 1.125 0.97 1.035 
IPI00419237.3 LAP3 Isoform 1 of Cytosol aminopeptidase ENSG00000 LAP3 
R.QVVDC*QLADVN
NIGK.Y 1.03 0.97 1.055 
IPI00019169.3 SH3GL1 SH3-containing GRB2-like protein 1 ENSG0000 
SH3G
L1 
R.EPFDLGEPEQSNG
GFPC*TTAPK.I 0.96 0.97 0.985 
IPI00334159.6 VBP1 Prefoldin subunit 3 ENSG00000155959 IPI003341 VBP1 R.FLLADNLYC*K.A 0.94 0.97 0.975 
IPI00025176.1 SMNDC1 Survival of motor neuron-related-splicing f 
SMND
C1 
K.VGVGTC*GIADKP
MTQYQDTSK.Y 1.045 0.97 1.06 
IPI00020602.1 CSNK2A2 Casein kinase II subunit alpha ENSG000000 
CSNK
2A2 
K.EQSQPC*ADNAV
LSSGLTAAR.- 0.98 0.97 0.97 
IPI00414408.2 LOC646799 similar to zygote arrest 1 ENSG000001891 
LOC64
6799 
R.RPNFQFLEPKYGY
FHCKDC*K.T 1.385 0.97 1.09 
IPI00020898.1 RPS6KA3 Ribosomal protein S6 kinase alpha-3 ENSG00 
RPS6K
A3 
R.AENGLLMTPC*Y
TANFVAPEVLK.R 0.895 0.975 1.035 
IPI00165230.1 DAZAP1 Isoform 1 of DAZ-associated protein 1 ENSG0 
DAZA
P1 R.NIDPKPC*TPR.G 0 0.975 0.995 
IPI00008524.1 PABPC1 Isoform 1 of Polyadenylate-binding protein  
PABP
C1 K.VVC*DENGSK.G 1.02 0.975 0.98 
IPI00641743.2 HCFC1 Uncharacterized protein HCFC1 ENSG0000017253 
HCFC
1 
K.LVIYGGMSGC*R.
L 1.245 0.975 1.17 
IPI00479946.3 
STIP1 STIP1 protein 
ENSG00000168439 IPI00013894 
IP 
STIP1 K.ALDLDSSC*K.E 1.025 0.975 1.045 
IPI00335251.3 DUS1L tRNA-dihydrouridine synthase 1-like ENSG0000 
DUS1
L 
K.AVAIPVFANGNIQ
C*LQDVER.C 1.085 0.98 1.07 
IPI00017617.1 DDX5 Probable ATP-dependent RNA helicase DDX5 ENSG DDX5 R.LIDFLEC*GK.T 0.99 0.98 1.05 
IPI00010240.1 MIF4GD MIF4G domain-containing protein ENSG0000012 
MIF4G
D 
K.VANVIVDHSLQD
C*VFSK.E 0.91 0.98 1.145 
IPI00549389.3 C9orf32 Protein of unknown function DUF858, methyl 
C9orf3
2 
R.IIC*SAGLSLLAEE
R.Q 1.01 0.98 1 
IPI00021329.3 WDR45L WD repeat domain phosphoinositide-interacti 
WDR4
5L 
R.C*NYLALVGGGK.
K 1.045 0.98 1.08 
IPI00792352.1 
RAN 26 kDa protein 
ENSG00000132341 IPI00643041 
IPI 
RAN R.VC*ENIPIVLCGNK.V 1.11 0.98 1.025 
IPI00329679.3 ZWILCH Zwilch ENSG00000174442 IPI00329679 
ZWIL
CH 
R.LNC*AAEDFYSR.
L 0.82 0.98 0.9 
IPI00550852.4 DCTN4 Dynactin subunit 4 ENSG00000132912 IPI005508 
DCTN
4 
R.LLQPDFQPVC*AS
QLYPR.H 1.31 0.98 1.25 
IPI00004461.2 DGUOK Isoform 1 of Deoxyguanosine kinase, mitochon 
DGUO
K 
K.AC*TAQSLGNLL
DMMYR.E 0.97 0.985 1.08 
IPI00008794.1 DFFB Isoform Alpha of DNA fragmentation factor sub DFFB R.VLGSMC*QR.L 1.145 0.985 1.05 
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IPI00746806.1 
CTTN CTTN protein 
ENSG00000085733 IPI00029601 
IPI0 
CTTN K.HC*SQVDSVR.G 1.34 0.985 1.53 
IPI00464979.4 SUCLA2 Isoform 1 of Succinyl-CoA ligase [ADP-formi 
SUCL
A2 R.IC*NQVLVCER.K 0.955 0.985 1.025 
IPI00216694.3 
PLS3 plastin 3 
ENSG00000102024 IPI00848312 
IPI0021 
PLS3 
K.EGIC*ALGGTSEL
SSEGTQHSYSEEEK.
Y 
1.025 0.99 1.015 
IPI00007811.1 CDK4 Cell division protein kinase 4 ENSG0000013544 CDK4 R.LMDVC*ATSR.T 0.81 0.99 0.965 
IPI00013949.1 SGTA Small glutamine-rich tetratricopeptide repeat SGTA R.AIC*IDPAYSK.A 0.945 0.99 0.975 
IPI00334159.6 VBP1 Prefoldin subunit 3 ENSG00000155959 IPI003341 VBP1 
K.DSC*GKGEMATG
NGR.R 1.005 0.99 0.975 
IPI00093057.6 CPOX Coproporphyrinogen III oxidase, mitochondrial CPOX 
K.EGGGGISCVLQD
GC*VFEK.A 0.98 0.99 1.045 
IPI00473014.5 
DSTN Destrin 
ENSG00000125868 IPI00473014 
IPI006432 
DSTN K.LGGSLIVAFEGC*PV.- 1.02 0.99 1.035 
IPI00010219.1 SPC25 Kinetochore protein Spc25 ENSG00000152253 IP SPC25 
K.STDTSC*QMAGL
R.D 1.045 0.99 0.945 
IPI00031647.2 PDCD2L Programmed cell death protein 2-like ENSG00 
PDCD
2L 
R.YSWSGEPLFLTC*
PTSEVTELPACSQC
GGQR.I 
0.97 0.99 0.995 
IPI00018465.1 CCT7 T-complex protein 1 subunit eta ENSG000001356 CCT7 
K.EGTDSSQGIPQLV
SNISAC*QVIAEAVR
.T 
0.965 0.99 0.995 
IPI00470502.2 PPA2 Isoform 2 of Inorganic pyrophosphatase 2, mit PPA2 R.GQPC*SQNYR.L 1.09 0.99 1.125 
IPI00007024.1 FAM96B Protein FAM96B ENSG00000166595 IPI00007024 
FAM9
6B 
R.VAAALENTHLLE
VVNQC*LSAR.S 1.04 0.99 0.76 
IPI00643722.1 ARID1A Isoform 1 of AT-rich interactive domain-con 
ARID1
A 
K.GPADMASQC*WG
AAAAAAAAAAASG
GAQQR.S 
0 0.99 1.23 
IPI00003814.1 MAP2K6 Isoform 1 of Dual specificity mitogen-activ 
MAP2
K6 
K.MC*DFGISGYLVD
SVAK.T 0.955 0.99 0.88 
IPI00005651.3 
IPO13 Importin-13 
ENSG00000117408 IPI00513961 
IPI0 
IPO13 
R.TSLAVECGAVFPL
LEQLLQQPSSPSC*V
R.Q 
0 0.99 0 
IPI00013723.3 PIN1 Peptidyl-prolyl cis-trans isomerase NIMA-inte PIN1 
K.IKSGEEDFESLAS
QFSDC*SSAK.A 1 0.995 0.965 
IPI00298961.3 
XPO1 Exportin-1 
ENSG00000082898 IPI00784388 
IPI002 
XPO1 K.DLLGLC*EQK.R 0.985 0.995 0.975 
IPI00102856.3 SMAP1L Isoform 1 of Stromal membrane-associated pr 
SMAP
1L 
K.STAPVMDLLGLD
APVAC*SIANSK.T 1.105 0.995 0.98 
IPI00016610.2 PCBP1 Poly(rC)-binding protein 1 ENSG00000169564 I PCBP1 
R.LVVPATQC*GSLI
GK.G 1.01 0.995 1.005 
IPI00002214.1 KPNA2 Importin subunit alpha-2 ENSG00000182481 IPI 
KPNA
2 
K.YGAVDPLLALLA
VPDMSSLAC*GYLR
.N 
0.9 0.995 0.95 
IPI00449197.1 
GMPR2 GMPR2 protein 
ENSG00000100938 IPI00385158 
IP 
GMPR
2 
R.VTQQVNPIFSEAC
*.- 0.98 0.995 0.795 
IPI00377005.2 _ Uncharacterized protein ENSP00000340627 ENSG0000 _ K.C*LSAAEEK.Y 1.06 1 0.94 
IPI00007927.3 SMC2 Isoform 1 of Structural maintenance of chromo SMC2 R.FTQC*QNGK.I 1.155 1 0.96 
IPI00293975.4 GPX1 glutathione peroxidase 1 isoform 1 ENSG000001 GPX1 
R.FQTIDIEPDIEALL
SQGPSC*A.- 0.92 1 1.04 
IPI00386122.4 MOBKL3 Isoform 1 of Preimplantation protein 3 ENSG 
MOBK
L3 
R.HTLDGAAC*LLNS
NK.Y 1.02 1 1.02 
IPI00027223.2 IDH1 Isocitrate dehydrogenase [NADP] cytoplasmic E IDH1 K.SEGGFIWAC*K.N 1.02 1 0.995 
IPI00013184.1 
ARD1A N-terminal 
acetyltransferase complex ARD1 
su 
ARD1
A 
K.GNSPPSSGEAC*R.
E 1.005 1 1.06 
IPI00056505.5 NT5C3L Cytosolic 5-nucleotidase NT5C3 K.NSSAC*ENSGYFQ 0.88 1 0 
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III-like protein  L QLEGK.T 
IPI00302925.3 CCT8 Uncharacterized protein CCT8 ENSG00000156261  CCT8 
R.NIQAC*KELAQTT
R.T 0.985 1 0.89 
IPI00180704.3 WDR73 WD repeat protein 73 (Fragment) ENSG00000177 
WDR7
3 
R.LLVTSGLPGC*YL
QVWQVAEDSDVIK.
A 
1.01 1 0.925 
IPI00386189.2 NARG1 Isoform 1 of NMDA receptor-regulated protein 
NARG
1 K.GC*PPVFNTLR.S 0 1 1.08 
IPI00027014.1 DCTN3 Isoform 1 of Dynactin subunit 3 ENSG00000137 
DCTN
3 
K.QFVQWDELLC*Q
LEAATQVKPAEE.- 0 1 1.14 
Reverse_IPI00216
694.3 
PLS3 plastin 3 
ENSG00000102024 IPI00848312 
IPI0021 
PLS3 K.FLEHLEYDC*IFGNSNLDVK.A 1.03 1 1.24 
IPI00012835.1 CTBP1 C-terminal-binding protein 1 ENSG00000159692 CTBP1 
K.SAGDLGIAVCNV
PAASVEETADSTLC
*HILNLYR.R 
0 1 0 
IPI00304071.4 FLJ20920 hypothetical protein LOC80221 ENSG0000016 
FLJ20
920 
R.MVSTPIGGLSYVQ
GC*TK.K 1.005 1.005 1.045 
IPI00291510.3 
IMPDH2 Inosine-5-
monophosphate dehydrogenase 2 
EN 
IMPD
H2 
R.HGFC*GIPITDTGR
.M 0 1.005 0 
IPI00002519.1 SHMT1 Isoform 1 of Serine hydroxymethyltransferase 
SHMT
1 
R.AVLEALGSC*LNN
K.Y 1.61 1.005 1.095 
IPI00257882.7 PEPD Xaa-Pro dipeptidase ENSG00000124299 IPI002578 PEPD 
R.TVEEIEACMAGC*
DK.A 1.185 1.005 1.03 
IPI00009790.1 PFKP 6-phosphofructokinase type C ENSG00000067057  PFKP 
R.LPLMEC*VQMTQ
DVQK.A 1.085 1.005 1.055 
IPI00029534.1 
PPAT 
Amidophosphoribosyltransferase 
precursor ENSG 
PPAT K.C*ELENCQPFVVETLHGK.I 1.005 1.005 1.06 
IPI00177509.4 TRAPPC5 Trafficking protein particle complex subun 
TRAP
PC5 
K.ENSTLNC*ASFTA
GIVEAVLTHSGFPA
K.V 
1.23 1.01 1 
IPI00473014.5 
DSTN Destrin 
ENSG00000125868 IPI00473014 
IPI006432 
DSTN K.C*STPEEIKK.R 1.01 1.01 1.065 
IPI00789101.1 PTGES3 19 kDa protein ENSG00000110958 IPI00015029  
PTGE
S3 
K.HLNEIDLFHC*IDP
NDSK.H 0.995 1.01 1.025 
IPI00030177.2 RBPJ Isoform APCR-2 of Recombining binding protein RBPJ R.IIQFQATPC*PK.E 1.3 1.01 1.135 
IPI00456981.2 RP11-11C5.2 Similar to RIKEN cDNA 2410129H14 ENSG0 
RP11-
11C5.2 
R.LC*EQGINPEALSS
VIK.E 0.73 1.01 1.025 
IPI00024623.3 ACADSB Short/branched chain specific acyl-CoA dehy 
ACAD
SB 
K.VGSFC*LSEAGAG
SDSFALK.T 0.12 1.01 1.03 
IPI00008433.4 RPS5 40S ribosomal protein S5 ENSG00000083845 IPI0 RPS5 
K.TIAEC*LADELIN
AAK.G 1 1.01 0.995 
IPI00021327.3 GRB2 Isoform 1 of Growth factor receptor-bound pro GRB2 
K.VLNEEC*DQNWY
K.A 1.06 1.01 0 
IPI00006113.1 POLR2I DNA-directed RNA polymerase II subunit RPB9 
POLR
2I 
R.NCDYQQEADNSC
*IYVNK.I 0.895 1.01 0.97 
IPI00430812.4 CNBP Zinc finger protein 9 ENSG00000169714 IPI0043 CNBP R.DC*DHADEQK.C 0 1.01 0 
IPI00177008.1 LOC283871 hypothetical protein LOC283871 ENSG00000 
LOC28
3871 K.NNQESDC*VSK.K 1.04 1.015 0.965 
IPI00382470.3 HSP90AA1 heat shock protein 90kDa alpha (cytosolic 
HSP90
AA1 
R.VFIMDNC*EELIPE
YLNFIR.G 0.98 1.015 1.06 
IPI00853598.1 
SEC13 41 kDa protein 
ENSG00000157020 IPI00845335 
I 
SEC13 R.FASGGC*DNLIK.L 1.025 1.015 0.99 
IPI00005648.1 SAFB2 Scaffold attachment factor B2 ENSG0000013025 SAFB2 K.ILDILGETC*K.S 0.97 1.015 0.99 
IPI00554737.3 PPP2R1A Serine/threonine-protein phosphatase 2A 65 
PPP2R
1A K.DC*EAEVR.A 1.08 1.015 1.03 
IPI00011698.3 SAP18 Histone deacetylase complex subunit SAP18 EN SAP18 K.TC*PLLLR.V 1.09 1.015 0.925 
IPI00019903.1 CCDC44 Coiled-coil domain-containing protein 44 EN 
CCDC
44 
K.KLDSLGLCSVSC*
ALEFIPNSK.V 1.17 1.015 1.16 
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IPI00006167.1 PPM1G Protein phosphatase 1G ENSG00000115241 IPI00 
PPM1
G K.C*SGDGVGAPR.L 1.12 1.015 1.085 
IPI00553185.2 CCT3 T-complex protein 1 subunit gamma ENSG0000016 CCT3 
R.TLIQNC*GASTIR.
L 0.945 1.015 0.945 
IPI00023647.4 UBE1L2 Isoform 1 of Ubiquitin-activating enzyme E1 
UBE1
L2 
R.KPNVGC*QQDSE
ELLK.L 1.11 1.02 1.045 
IPI00418471.6 
VIM Vimentin 
ENSG00000026025 IPI00418471 
IPI008276 
VIM R.QVQSLTC*EVDALK.G 0.975 1.02 0.99 
IPI00216951.2 DARS Aspartyl-tRNA synthetase, cytoplasmic ENSG000 DARS 
R.LEYC*EALAMLR.
E 1.02 1.02 1.13 
IPI00218733.5 SOD1 Uncharacterized protein SOD1 ENSG00000142168  SOD1 R.LAC*GVIGIAQ.- 0.955 1.02 1.1 
IPI00020451.2 IMPACT IMPACT protein ENSG00000154059 IPI00020451  
IMPA
CT 
R.STFQAHLAPVVC*
PK.Q 0 1.02 1.065 
IPI00000875.6 EEF1G Elongation factor 1-gamma ENSG00000186676 IP EEF1G 
R.FPEELTQTFMSC*
NLITGMFQR.L 0.87 1.02 1.06 
IPI00100748.3 HSPBP1 Isoform 1 of Hsp70-binding protein 1 ENSG00 
HSPB
P1 
R.LLDRDAC*DTVR.
V 1.02 1.02 1.03 
IPI00015865.6 ADPRHL2 Poly(ADP-ribose) glycohydrolase ARH3 ENSG0 
ADPR
HL2 K.C*RDVFEPAR.A 0.84 1.02 0.95 
IPI00784614.1 SEPT9 Isoform 1 of Septin-9 ENSG00000184640 IPI007 41526 
R.SQEATEAAPSC*V
GDMADTPR.D 1.01 1.025 1.04 
IPI00033132.3 RNF7 Isoform 1 of RING-box protein 2 ENSG000001141 RNF7 R.VQVMDAC*LR.C 1.275 1.025 1.16 
IPI00013452.8 EPRS glutamyl-prolyl tRNA synthetase ENSG000001366 EPRS 
K.LSSC*DSFTSTINE
LNHCLSLR.T 1.135 1.025 0.97 
IPI00744127.1 CSTF2 Uncharacterized protein CSTF2 ENSG0000010181 CSTF2 
K.LC*VQNSPQEAR.
N 1.045 1.025 0.885 
IPI00293564.5 HMGCL Hydroxymethylglutaryl-CoA lyase, mitochondri 
HMGC
L K.VAQATC*KL.- 1.035 1.025 0.97 
IPI00477231.2 MGEA5 Isoform 1 of Bifunctional protein NCOAT ENSG 
MGEA
5 
R.ANSSVVSVNC*K.
G 1.085 1.025 1.09 
IPI00023138.1 RAC3 Ras-related C3 botulinum toxin substrate 3 pr RAC3 R.AVLC*PPPVK.K 1.74 1.025 0.96 
IPI00845436.1 ARF4 similar to ADP-ribosylation factor 4 ENSG0000 ARF4 
K.NIC*FTVWDVGG
QDR.I 1.045 1.025 1.05 
IPI00554737.3 PPP2R1A Serine/threonine-protein phosphatase 2A 65 
PPP2R
1A 
K.DNTIEHLLPLFLA
QLKDEC*PEVR.L 0 1.025 0.94 
IPI00019329.1 DYNLL1 Dynein light chain 1, cytoplasmic ENSG00000 
DYNL
L1 
K.NADMSEEMQQDS
VEC*ATQALEK.Y 1.14 1.025 0.99 
IPI00169383.3 PGK1 Phosphoglycerate kinase 1 ENSG00000102144 IPI PGK1 
R.GCITIIGGGDTATC
*CAK.W 0.96 1.025 0.925 
IPI00788925.1 BCAT2 Branched chain aminotransferase 2, mitochond 
BCAT
2 
R.EVFGSGTAC*QVC
PVHR.I 0 1.03 1.02 
IPI00216008.4 G6PD Isoform Long of Glucose-6-phosphate 1-dehydro G6PD R.TQVC*GILR.E 1.025 1.03 1.01 
IPI00003766.4 ETHE1 ETHE1 protein, mitochondrial precursor ENSG0 
ETHE
1 R.TDFQQGC*AK.T 0.965 1.03 0.945 
IPI00419194.2 IAH1 Isoamyl acetate-hydrolyzing esterase 1 homolo IAH1 
R.VILITPTPLC*ETA
WEEQCIIQGCK.L 1.045 1.03 1.045 
IPI00304935.5 SAAL1 Uncharacterized protein SAAL1 ENSG0000016678 
SAAL
1 
R.VLQNMEQC*QK.
K 1.115 1.03 0.97 
IPI00298961.3 
XPO1 Exportin-1 
ENSG00000082898 IPI00784388 
IPI002 
XPO1 K.LDINLLDNVVNC*LYHGEGAQQR.M 1.07 1.03 1.01 
IPI00033130.3 SAE1 SUMO-activating enzyme subunit 1 ENSG00000142 SAE1 
R.YCFSEMAPVC*A
VVGGILAQEIVK.A 1.15 1.03 0.82 
IPI00025815.2 
TARDBP TDP43 
ENSG00000120948 IPI00025815 
IPI006398 
TARD
BP R.NPVSQC*MR.G 0.92 1.03 1.13 
IPI00019376.6 SEPT11 Septin-11 ENSG00000138758 IPI00019376 41528 
R.QYPWGVVQVENE
NHC*DFVK.L 0.78 1.03 0.955 
IPI00216694.3 
PLS3 plastin 3 
ENSG00000102024 IPI00848312 
IPI0021 
PLS3 K.VDLNSNGFIC*DYELHELFK.E 1.06 1.035 0.995 
IPI00007675.6 DYNC1LI1 Cytoplasmic dynein 1 light intermediate c 
DYNC
1LI1 
R.VGSFGSSPPGLSS
TYTGGPLGNEIASG 0.98 1.035 1.015 
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NGGAAAGDDEDGQ
NLWSC*ILSEVSTR.
S 
IPI00219358.7 MPI Isoform 1 of Mannose-6-phosphate isomerase ENS MPI 
K.GDCVECMAC*SD
NTVR.A 0.62 1.035 0.945 
IPI00442165.1 ZNF346 Isoform 2 of Zinc finger protein 346 ENSG00 
ZNF34
6 
K.NQC*LFTNTQCK.
V 1.31 1.04 0.885 
IPI00003565.1 PSMD10 26S proteasome non-ATPase regulatory subuni 
PSMD
10 
K.GAQVNAVNQNG
C*TPLHYAASK.N 1.02 1.04 1.12 
IPI00001960.4 CLIC4 Chloride intracellular channel protein 4 ENS CLIC4 
K.AGSDGESIGNC*P
FSQR.L 1.065 1.04 1.05 
IPI00289807.3 TRNT1 Isoform 1 of tRNA-nucleotidyltransferase 1,  
TRNT
1 K.YQGEHC*LLK.E 0.955 1.04 1.095 
IPI00011951.2 KIAA0427 Isoform 2 of Uncharacterized protein KIAA 
KIAA0
427 R.VLVC*PIYTCLR.E 0.94 1.04 0.845 
IPI00004795.1 CLNS1A Methylosome subunit pICln ENSG00000074201 I 
CLNS
1A 
R.DRSDC*LGEHLY
VMVNAK.F 1.67 1.04 1.1 
IPI00216805.3 ALDH1A2 Isoform 1 of Retinal dehydrogenase 2 ENSG0 
ALDH
1A2 
K.SPNIIFADADLDY
AVEQAHQGVFFNQ
GQC*CTAGSR.I 
0.97 1.04 1.11 
IPI00032955.1 ZNF313 Zinc finger protein 313 ENSG00000124226 IPI 
ZNF31
3 
R.DC*GGAAQLAGP
AAEADPLGR.F 1.05 1.045 0.92 
IPI00007682.2 ATP6V1A Vacuolar ATP synthase catalytic subunit A  
ATP6
V1A K.WDFTPC*K.N 1.11 1.045 1.075 
IPI00004534.3 
PFAS 
Phosphoribosylformylglycinamidi
ne synthase EN 
PFAS R.IVLVDDREC*PVRR.N 0.98 1.045 1.015 
IPI00302925.3 CCT8 Uncharacterized protein CCT8 ENSG00000156261  CCT8 
K.IAVYSC*PFDGMI
TETK.G 0.99 1.045 0.99 
IPI00186290.6 EEF2 Elongation factor 2 ENSG00000167658 IPI001862 EEF2 K.STLTDSLVC*K.A 0.965 1.045 0.96 
IPI00297779.7 CCT2 T-complex protein 1 subunit beta ENSG00000166 CCT2 
R.SLHDALC*VLAQT
VK.D 0 1.045 1.055 
IPI00045939.4 C10orf22 Uncharacterized protein C10orf22 ENSG0000 
C10orf
22 K.EASSSAC*DLPR.E 0.835 1.045 1.72 
IPI00456803.2 _ Uncharacterized protein ENSP00000368765 ENSG0000 _ 
R.AYCHILLGNYC*V
AVADAK.K 0.99 1.05 0.985 
IPI00395627.3 CACYBP Isoform 1 of Calcyclin-binding protein ENSG 
CACY
BP 
R.WDYLTQVEKEC*
K.E 1.045 1.05 1.015 
IPI00002824.7 CSRP2 Cysteine and glycine-rich protein 2 ENSG0000 CSRP2 R.C*CFLCMVCR.K 1.075 1.05 1.005 
IPI00010896.3 DDAH2 CLIC1 Chloride intracellular channel protein 
DDAH
2 K.IGNC*PFSQR.L 1.07 1.05 1.02 
IPI00005777.1 MAPKAPK3 MAP kinase-activated protein kinase 3 ENS 
MAPK
APK3 
K.QAGSSSASQGC*N
NQ.- 0.94 1.05 1.125 
IPI00060521.1 
FLYWCH2 Putative 
uncharacterized protein 
LOC114984 
FLYW
CH2 
R.TEDSGLAAGPPEA
AGENFAPC*SVAPG
K.S 
1.065 1.05 1.27 
IPI00166873.3 C9orf23 Alba-like protein C9orf23 ENSG00000164967  
C9orf2
3 
R.DPLDPNEC*GYQP
PGAPPGLGSMPSSS
CGPR.S 
1.17 1.05 0.935 
IPI00029266.1 SNRPE Small nuclear ribonucleoprotein E ENSG000001 
SNRP
E 
R.IEGC*IIGFDEYMN
LVLDDAEEIHSK.T 0 1.05 0 
IPI00853009.1 CUGBP1 Isoform 4 of CUG-BP- and ETR-3-like factor  
CUGB
P1 R.GC*AFVTFTTR.A 1.055 1.055 1.18 
IPI00026167.3 NHP2L1 NHP2-like protein 1 ENSG00000100138 IPI0002 
NHP2
L1 
K.KLLDLVQQSC*N
YK.Q 0.985 1.055 1.05 
IPI00647082.1 TBC1D13 TBC1 domain family, member 13 ENSG00000107 
TBC1
D13 
R.LLQDYPITDVC*Q
ILQK.A 1.11 1.055 0.975 
IPI00384180.4 YRDC ischemia/reperfusion inducible protein ENSG00 YRDC 
R.AGAVVAVPTDTL
YGLAC*AASCSAAL
R.A 
0.9 1.055 1.005 
IPI00010157.1 MAT2A S-adenosylmethionine synthetase isoform type 
MAT2
A 
K.TC*NVLVALEQQ
SPDIAQGVHLDR.N 1.105 1.055 1.055 
IPI00419575.6 C7orf20 Protein of unknown function DUF410 family  
C7orf2
0 K.EQNYC*ESR.Y 0.98 1.06 1 
IPI00100213.2 RRM2B Isoform 1 of Ribonucleoside-diphosphate redu 
RRM2
B 
K.IEQEFLTEALPVG
LIGMNC*ILMK.Q 1.005 1.06 0.995 
255 
 
IPI00745613.1 EXOSC4 Uncharacterized protein EXOSC4 ENSG00000178 
EXOS
C4 K.SC*EMGLQLR.Q 0 1.06 0 
IPI00007765.5 HSPA9 Stress-70 protein, mitochondrial precursor E 
HSPA
9 
K.AKC*ELSSSVQTD
INLPYLTMDSSGPK.
H 
1.27 1.06 0 
IPI00009315.6 ACBD3 Golgi resident protein GCP60 ENSG00000182827 
ACBD
3 
K.QVLMGPYNPDTC
*PEVGFFDVLGNDR.
R 
0.945 1.065 1.065 
IPI00007691.1 TRAPPC4 Trafficking protein particle complex subun 
TRAP
PC4 
K.NPFYSLEMPIRC*
ELFDQNLK.L 1.02 1.065 0.935 
IPI00031681.1 CDK2 Cell division protein kinase 2 ENSG0000012337 CDK2 R.APEILLGC*K.Y 0.985 1.065 1.04 
IPI00003783.1 MAP2K2 Dual specificity mitogen-activated protein  
MAP2
K2 
K.LC*DFGVSGQLID
SMANSFVGTR.S 0.985 1.065 0.89 
IPI00010720.1 CCT5 T-complex protein 1 subunit epsilon ENSG00000 CCT5 
R.VVYGGGAAEISC
ALAVSQEADKC*PT
LEQYAMR.A 
0.995 1.065 1.025 
IPI00647082.1 TBC1D13 TBC1 domain family, member 13 ENSG00000107 
TBC1
D13 
K.SLDDSQC*GITYK.
M 1.065 1.07 0.98 
IPI00029997.1 PGLS 6-phosphogluconolactonase ENSG00000130313 IPI PGLS R.AAC*CLAGAR.A 1.1 1.07 1.11 
IPI00290416.3 OLA1 Isoform 1 of Putative GTP-binding protein 9 E OLA1 
K.STFFNVLTNSQAS
AENFPFC*TIDPNES
R.V 
0.985 1.07 1.025 
IPI00025156.4 STUB1 Isoform 1 of STIP1 homology and U box-contai 
STUB
1 R.AQQAC*IEAK.H 1.035 1.07 1 
IPI00646500.1 RPA2 Isoform 3 of Replication protein A 32 kDa sub RPA2 
K.AC*PRPEGLNFQD
LK.N 0 1.07 0.955 
IPI00022442.2 NDUFAB1 Acyl carrier protein, mitochondrial precur 
NDUF
AB1 
K.LMC*PQEIVDYIA
DKK.D 0.89 1.07 1.095 
IPI00008436.4 POLE4 DNA polymerase epsilon subunit 4 ENSG0000011 POLE4 
K.DAYC*CAQQGK.
R 1 1.07 0 
IPI00783852.1 ACTR10 46 kDa protein ENSG00000131966 IPI00783852  
ACTR
10 
R.IPDWC*SLNNPPL
EMMFDVGK.T 1.05 1.075 0.975 
IPI00021290.5 ACLY ATP-citrate synthase ENSG00000131473 IPI00021 ACLY K.FIC*TTSAIQNR.F 1.045 1.075 1.04 
IPI00030363.1 ACAT1 Acetyl-CoA acetyltransferase, mitochondrial  
ACAT
1 K.VC*ASGMK.A 0.85 1.075 1.035 
IPI00828189.1 PCMT1 Isoform 2 of Protein-L-isoaspartate(D-aspart 
PCMT
1 R.MVGC*TGK.V 1.04 1.075 1.02 
IPI00012773.1 MTA1 Isoform Long of Metastasis-associated protein MTA1 R.ALDC*SSSVR.Q 0.985 1.075 1.12 
IPI00299155.5 PSMA4 Proteasome subunit alpha type-4 ENSG00000041 
PSMA
4 
R.YLLQYQEPIPCEQ
LVTALC*DIK.Q 1.045 1.08 1.04 
IPI00155601.1 MACROD1 MACRO domain-containing protein 1 ENSG0000 
MACR
OD1 
K.LEVDAIVNAANSS
LLGGGGVDGC*IHR.
A 
0.95 1.08 0.88 
IPI00658023.1 PTPN11 Isoform 1 of Tyrosine-protein phosphatase n 
PTPN1
1 
K.QGFWEEFETLQQ
QEC*K.L 0.99 1.08 0.99 
IPI00007402.2 IPO7 Uncharacterized protein IPO7 ENSG00000205339  IPO7 
R.GIDQC*IPLFVEAA
LER.L 1.09 1.08 1.095 
IPI00289862.3 SCRN1 Secernin-1 ENSG00000136193 IPI00289862 
SCRN
1 
K.TQSPC*FGDDDPA
KKEPR.F 0.98 1.08 1.055 
IPI00797230.1 
RPL8 32 kDa protein 
ENSG00000161016 IPI00012772 
IP 
RPL8 
K.AQLNIGNVLPVG
TMPEGTIVC*CLEEK
PGDR.G 
1.035 1.08 1.005 
IPI00016443.1 C11orf79 Protein EMI5 homolog, mitochondrial precu 
C11orf
79 
R.GMLENC*ILLSLF
AK.E 0 1.08 0 
IPI00334775.6 HSP90AB1 85 kDa protein ENSG00000096384 IPI0041467 
HSP90
AB1 
R.LVSSPC*CIVTSTY
GWTANMER.I 1.295 1.085 0.925 
IPI00010141.4 POLE3 DNA polymerase epsilon subunit 3 ENSG0000014 POLE3 
R.AASVFVLYATSC*
ANNFAMK.G 0 1.085 0.99 
IPI00029665.8 MMAB Cob ENSG00000139428 IPI00029665 IPI00795427 I 
MMA
B 
K.IQCTLQDVGSALA
TPC*SSAR.E 1.105 1.09 1.1 
IPI00220152.2 BCCIP Isoform 2 of BRCA2 and CDKN1A-interacting pr BCCIP R.TNKPC*GK.C 1.055 1.09 1.08 
IPI00221172.2 C14orf130 Uncharacterized protein C14orf130 ENSG00 
C14orf
130 
K.VEQNSEPC*AGSS
SESDLQTVFK.N 1.12 1.09 0.865 
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IPI00006980.1 C14orf166 Protein C14orf166 ENSG00000087302 IPI000 
C14orf
166 
K.LTALDYHNPAGF
NC*KDETEFR.N 1.05 1.09 1.06 
IPI00411706.1 ESD S-formylglutathione hydrolase ENSG00000139684  ESD 
K.AETGKCPALYWL
SGLTC*TEQNFISK.S 1.045 1.095 0.985 
IPI00022745.1 MVD Diphosphomevalonate decarboxylase ENSG00000167 MVD 
R.DGDPLPSSLSC*K.
V 1.015 1.095 0.855 
IPI00006907.1 C12orf5 Uncharacterized protein C12orf5 ENSG000000 
C12orf
5 
K.AAREEC*PVFTPP
GGETLDQVK.M 1.025 1.095 0.97 
IPI00031519.3 DNMT1 Isoform 1 of DNA (cytosine-5)-methyltransfer 
DNMT
1 K.NQLC*DLETK.L 1.215 1.095 0.995 
IPI00100796.4 CHMP5 Charged multivesicular body protein 5 ENSG00 
CHMP
5 
K.APPPSLTDC*IGTV
DSR.A 1.03 1.1 1.055 
IPI00647082.1 TBC1D13 TBC1 domain family, member 13 ENSG00000107 
TBC1
D13 
R.ELSFSGIPC*EGGL
R.C 1.05 1.1 1.055 
IPI00029079.5 GMPS GMP synthase ENSG00000163655 IPI00029079 GMPS K.TVGVQGDC*R.S 1.07 1.1 0.97 
IPI00410666.1 SCRIB Isoform 3 of Protein LAP4 ENSG00000180900 IP SCRIB 
R.SLEPSPSPGPQEED
GEVALVLLGRPSPG
AVGPEDVALC*SSR.
R 
0 1.1 1.105 
IPI00306159.7 MECR Trans-2-enoyl-CoA reductase, mitochondrial pr MECR R.LALNC*VGGK.S 1.045 1.105 0.99 
IPI00382452.1 CHMP1A Isoform 1 of Charged multivesicular body pr 
CHMP
1A K.NVEC*AR.V 1.03 1.105 1.07 
IPI00220528.6 SNRPF Small nuclear ribonucleoprotein F ENSG000001 
SNRP
F R.C*NNVLYIR.G 1.055 1.105 0.945 
IPI00742681.1 
LSM7 R30783_1 
ENSG00000130332 IPI00007163 
IPI00742 
LSM7 
R.GTSVVLIC*PQDG
MEAIPNPFIQQQDA.
- 
0.97 1.105 0.875 
IPI00029557.3 GRPEL1 GrpE protein homolog 1, mitochondrial precu 
GRPE
L1 
K.ATQC*VPKEEIKD
DNPHLK.N 1.155 1.105 1.11 
IPI00177856.8 C14orf172 Uncharacterized protein C14orf172 ENSG00 
C14orf
172 
R.FCSFSPC*IEQVQR
.T 1.02 1.11 1.035 
IPI00333541.6 
FLNA Filamin-A 
ENSG00000196924 IPI00553169 
IPI0030 
FLNA K.VGTEC*GNQK.V 1.06 1.11 1.05 
IPI00018146.1 YWHAQ 14-3-3 protein theta ENSG00000134308 IPI0001 
YWH
AQ 
R.YLAEVAC*GDDR.
K 1.005 1.11 1.02 
IPI00004534.3 
PFAS 
Phosphoribosylformylglycinamidi
ne synthase EN 
PFAS 
R.GLAPLHWADDDG
NPTEQYPLNPNGSP
GGVAGIC*SCDGR.H 
0.945 1.11 1.025 
IPI00303318.2 FAM49B Protein FAM49B ENSG00000153310 IPI00651701  
FAM4
9B 
K.VLTC*TDLEQGPN
FFLDFENAQPTESEK
.E 
0.91 1.11 0 
IPI00301364.3 SKP1A Isoform 1 of S-phase kinase-associated prote 
SKP1
A R.KENQWC*EEK.- 1.05 1.11 1.045 
IPI00025285.3 FLJ25715 ATP6V1G1 Vacuolar ATP synthase subunit G  
FLJ25
715 
R.GSC*STEVEKETQ
EK.M 1.255 1.11 0 
IPI00030116.1 
PGM3 Isoform 1 of 
Phosphoacetylglucosamine 
mutase  
PGM3 K.QASC*SGDEYR.S 1.32 1.11 0 
IPI00010158.3 CHRAC1 Chromatin accessibility complex protein 1 E 
CHRA
C1 
K.ATELFVQC*LATY
SYR.H 1.11 1.115 0.975 
IPI00221035.3 BTF3 Uncharacterized protein BTF3 ENSG00000145741  BTF3 
R.ARGGC*PGGEAT
LSQPPPR.G 1.1 1.115 1.055 
IPI00006907.1 C12orf5 Uncharacterized protein C12orf5 ENSG000000 
C12orf
5 
K.EADQKEQFSQGS
PSNC*LETSLAEIFPL
GK.N 
0.975 1.115 0.995 
IPI00641181.5 MARCKSL1 MARCKS-related protein ENSG00000175130 IP 
MARC
KSL1 
K.EGGGDSSASSPTE
EEQEQGEIGAC*SDE
GTAQEGK.A 
1.52 1.12 1.23 
IPI00290566.1 TCP1 T-complex protein 1 subunit alpha ENSG0000012 TCP1 R.IC*DDELILIK.N 0.965 1.12 0.995 
IPI00301364.3 SKP1A Isoform 1 of S-phase kinase-associated prote 
SKP1
A K.GLLDVTC*K.T 1.045 1.12 1.08 
IPI00028412.1 
SSSCA1 Sjoegren 
syndrome/scleroderma 
autoantigen 1 
SSSC
A1 
R.MLGETC*ADCGTI
LLQDK.Q 0.935 1.12 1.105 
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IPI00007682.2 ATP6V1A Vacuolar ATP synthase catalytic subunit A  
ATP6
V1A 
K.YSNSDVIIYVGC*
GER.G 1.395 1.12 1.185 
IPI00654865.1 DIP2A Isoform 1 of Disco-interacting protein 2 hom DIP2A 
R.GC*PLEAAPLPAE
VR.E 0 1.12 0 
IPI00022239.7 
METAP1 Methionine 
aminopeptidase 1 
ENSG00000164024 
META
P1 
R.VCETDGC*SSEAK
.L 1.125 1.125 0.95 
IPI00844329.1 HPRT1 Uncharacterized protein HPRT1 ENSG0000016570 
HPRT
1 
K.SYC*NDQSTGDIK
.V 1.065 1.125 1.1 
IPI00015809.1 OSGEP Probable O-sialoglycoprotein endopeptidase E 
OSGE
P 
R.AMAHCGSQEALI
VGGVGC*NVR.L 0 1.125 1.18 
IPI00218782.2 CAPZB Capping protein ENSG00000077549 IPI00026185  
CAPZ
B 
R.QMEKDETVSDC*
SPHIANIGR.L 1.185 1.13 1.105 
IPI00784459.1 CFL1 Uncharacterized protein CFL1 ENSG00000172757  CFL1 
K.HELQANC*YEEV
KDR.C 1.025 1.13 1.1 
IPI00292894.4 
TSR1 TSR1, 20S rRNA 
accumulation ENSG00000167721 
I 
TSR1 R.DTGTVHLNELGNTQNFMLLC*PR.L 0.89 1.13 1.32 
IPI00013212.1 CSK Tyrosine-protein kinase CSK ENSG00000103653 IP CSK R.SVLGGDC*LLK.F 0.94 1.13 1.01 
IPI00032050.4 WBP2 WW domain-binding protein 2 ENSG00000132471 I WBP2 
K.DC*EIKQPVFGAN
YIK.G 1.1 1.13 1.02 
IPI00290566.1 TCP1 T-complex protein 1 subunit alpha ENSG0000012 TCP1 
R.GANDFMC*DEME
R.S 1.09 1.13 0.99 
IPI00456664.1 NIT1 Isoform 4 of Nitrilase homolog 1 ENSG00000158 NIT1 
K.THLC*DVEIPGQG
PMCESNSTMPGPSL
ESPVSTPAGK.I 
1.165 1.13 1.02 
IPI00056314.1 TSR2 Pre-rRNA-processing protein TSR2 homolog ENSG TSR2 
R.AGVC*AALEAWP
ALQIAVENGFGGVH
SQEK.A 
0 1.13 0 
IPI00010244.4 MRPS11 Isoform 1 of 28S ribosomal protein S11, mit 
MRPS
11 
K.ASHNNTQIQVVS
ASNEPLAFASC*GTE
GFR.N 
1.005 1.135 1.1 
IPI00396174.4 CCDC25 Coiled-coil domain-containing protein 25 EN 
CCDC
25 K.ANSIQGC*K.M 1.19 1.135 1.095 
IPI00386189.2 NARG1 Isoform 1 of NMDA receptor-regulated protein 
NARG
1 R.LFNTAVC*ESK.D 0.965 1.135 1.03 
IPI00024670.5 REEP5 Receptor expression-enhancing protein 5 ENSG REEP5 K.NC*MTDLLAK.L 1.06 1.14 0 
IPI00018402.1 TBCE Tubulin-specific chaperone E ENSG00000116957  TBCE R.NCAVSC*AGEK.G 1.11 1.14 1.03 
IPI00152089.3 CXorf38 Isoform 1 of Uncharacterized protein CXorf 
CXorf
38 R.LNC*AEYK.N 1.15 1.145 1.175 
IPI00026328.3 TXNDC12 Thioredoxin domain-containing protein 12 p 
TXND
C12 K.SWC*GACK.A 1.155 1.15 1.08 
IPI00760837.2 FAM98B family with sequence similarity 98, member  
FAM9
8B 
R.INDALSC*EYECR.
R 1.16 1.15 1.165 
IPI00033770.5 ALKBH4 Isoform 1 of Alkylated DNA repair protein a 
ALKB
H4 
R.MGLYPGLEGFRP
VEQCNLDYC*PER.
G 
0 1.15 1.08 
Reverse_IPI00473
118.2 
MATN2 Isoform 1 of Matrilin-2 
precursor ENSG000001 
MATN
2 
K.C*QDHKEELPSGS
PK.T 1.54 1.15 0 
IPI00024013.1 _ Putative ubiquitin-conjugating enzyme E2 D3-like _ 
K.VLLSIC*SLLCDPN
PDDPLVPEIAR.I 0.995 1.155 1.065 
IPI00024990.6 ALDH6A1 Methylmalonate-semialdehyde dehydrogenase  
ALDH
6A1 
R.C*MALSTAVLVG
EAK.K 1.045 1.155 0.9 
IPI00397721.1 BLOC1S3 Biogenesis of lysosome-related organelles  
BLOC
1S3 R.GDLC*ALAER.L 0.975 1.16 0 
IPI00216190.1 GSK3B Isoform 2 of Glycogen synthase kinase-3 beta 
GSK3
B K.LC*DFGSAK.Q 1.105 1.16 1.18 
IPI00514587.1 SARS Uncharacterized protein SARS ENSG00000031698  SARS K.YAGLSTC*FR.Q 1.02 1.165 1.04 
IPI00290279.1 ADK Isoform Long of Adenosine kinase ENSG000001561 ADK 
R.TGC*TFPEKPDFH.
- 1.16 1.165 1.16 
IPI00026216.4 NPEPPS Puromycin-sensitive aminopeptidase ENSG0000 
NPEPP
S R.SKDGVC*VR.V 1.1 1.175 1.09 
IPI00465054.2 THUMPD1 Putative uncharacterized protein 
THUM
PD1 R.C*DAGGPR.Q 1.065 1.18 1.09 
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DKFZp686C 
IPI00742743.1 TP53BP1 Isoform 2 of Tumor suppressor p53-binding  
TP53B
P1 
K.VADPVDSSNLDT
C*GSISQVIEQLPQP
NR.T 
1.065 1.185 1.115 
IPI00643591.5 AP1G1 Adaptor-related protein complex 1, gamma 1 s AP1G1 R.FTC*TVNR.I 1.06 1.185 1.09 
IPI00008433.4 RPS5 40S ribosomal protein S5 ENSG00000083845 IPI0 RPS5 
R.VNQAIWLLC*TG
AR.E 1.09 1.185 0.975 
IPI00306301.2 PDHA1 Mitochondrial PDHA1 ENSG00000131828 IPI00642 
PDHA
1 K.LPCIFIC*ENNR.Y 0 1.185 0.93 
IPI00033494.3 MRLC2 Myosin regulatory light chain ENSG0000011868 
MRLC
2 
R.NAFAC*FDEEATG
TIQEDYLR.E 1.045 1.19 1.06 
IPI00015866.2 ARL2BP Isoform 1 of ADP-ribosylation factor-like p 
ARL2
BP 
R.GLDLSSGLVVTSL
C*K.S 0.995 1.19 1.045 
IPI00028296.1 CAMK1 Calcium/calmodulin-dependent protein kinase  
CAMK
1 
K.MEDPGSVLSTAC*
GTPGYVAPEVLAQK
PYSK.A 
0 1.19 1.08 
IPI00397904.6 NUP93 Nuclear pore complex protein Nup93 ENSG00000 NUP93 
K.LNQVC*FDDDGT
SSPQDR.L 0.94 1.19 0.87 
IPI00045917.3 CRBN Isoform 1 of Protein cereblon ENSG00000113851 CRBN 
K.VQILPEC*VLPST
MSAVQLESLNK.C 0.945 1.195 1.035 
IPI00003394.1 SMN2 SMN1 Isoform SMN of Survival motor neuron pro SMN2 
K.NGDIC*ETSGKPK.
T 1.04 1.2 1.235 
IPI00093057.6 CPOX Coproporphyrinogen III oxidase, mitochondrial CPOX 
R.C*SSFMAPPVTDL
GELR.R 1.21 1.21 0.945 
IPI00218342.10 MTHFD1 C-1-tetrahydrofolate synthase, cytoplasmic  
MTHF
D1 
K.QGFGNLPIC*MAK
.T 1.055 1.215 0.99 
IPI00641950.3 GNB2L1 Lung cancer oncogene 7 ENSG00000204628 IPI0 
GNB2
L1 
R.YWLC*AATGPSIK
.I 0.72 1.22 0 
IPI00329331.6 UGP2 Isoform 1 of UTP--glucose-1-phosphate uridyly UGP2 
K.LNGGLGTSMGC*
K.G 1.135 1.225 1.105 
IPI00019812.1 PPP5C Serine/threonine-protein phosphatase 5 ENSG0 PPP5C 
R.TEC*AEPPRDEPP
ADGALKR.A 0.94 1.23 0 
IPI00645078.1 UBE1 Ubiquitin-activating enzyme E1 ENSG0000013098 UBE1 K.SIPIC*TLK.N 1.175 1.23 1.05 
IPI00024067.4 CLTC Isoform 1 of Clathrin heavy chain 1 ENSG00000 CLTC 
R.IHEGC*EEPATHN
ALAK.I 0 1.23 0 
IPI00086909.6 LOC440917 similar to 14-3-3 protein epsilon ENSG00 
LOC44
0917 
K.LIC*CDILDVLDK.
H 0.965 1.24 1.045 
IPI00550069.3 RNH1 Ribonuclease inhibitor ENSG00000023191 IPI005 RNH1 
R.ELDLSNNC*LGDA
GILQLVESVR.Q 0.97 1.24 0.925 
IPI00290142.5 CTPS CTP synthase 1 ENSG00000171793 IPI00290142 CTPS K.SC*GLHVTSIK.I 0.82 1.24 1.09 
IPI00022796.2 HMG1L1 High-mobility group protein 1-like 1 ENSG00 
HMG1
L1 
K.MSSYAFFVQTC*R
.E 0.985 1.245 0.9 
IPI00293276.10 MIF Macrophage migration inhibitory factor ENSG000 MIF K.LLC*GLLAER.L 1.39 1.25 1 
IPI00328868.3 HS1BP3 HCLS1 binding protein 3 ENSG00000118960 IPI 
HS1BP
3 
K.LFDDPDLGGAIPL
GDSLLLPAAC*ESG
GPTPSLSHR.D 
0 1.25 1.14 
IPI00013219.1 ILK Integrin-linked protein kinase ENSG00000166333 ILK K.FSFQC*PGR.M 0.975 1.26 1.02 
IPI00414858.3 COG3 Isoform 1 of Conserved oligomeric Golgi compl COG3 
R.ELLLGPSIAC*TV
AELTSQNNR.D 0 1.26 1.72 
IPI00291419.5 ACAT2 Acetyl-CoA acetyltransferase, cytosolic ENSG 
ACAT
2 
R.ATVAPEDVSEVIF
GHVLAAGC*GQNP
VR.Q 
1.145 1.27 0.975 
IPI00004363.1 STK39 STE20/SPS1-related proline-alanine-rich prot STK39 
K.TFVGTPC*WMAP
EVMEQVR.G 0 1.27 0 
IPI00784131.1 AARS Uncharacterized protein AARS ENSG00000090861  AARS 
K.NVGC*LQEALQL
ATSFAQLR.L 1.08 1.28 1.02 
IPI00743454.1 ACN9 Uncharacterized protein ACN9 ENSG00000196636  ACN9 K.AC*FGTFLPEEK.L 1.1 1.285 0.96 
IPI00216319.3 YWHAH 14-3-3 protein eta ENSG00000128245 IPI008275 
YWH
AH K.NC*NDFQYESK.V 1.145 1.33 1 
IPI00827583.1 
BSCL2 72 kDa protein 
ENSG00000168000 IPI00045906 
I 
BSCL2 K.EGC*TEVSLLR.V 0 1.34 0.96 
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IPI00220365.5 EIF4G1 EIF4G1 variant protein (Fragment) ENSG00000 
EIF4G
1 
R.LQGINC*GPDFTP
SFANLGR.T 0.985 1.345 1.055 
IPI00148061.3 
LDHAL6A L-lactate 
dehydrogenase A-like 6A 
ENSG0000 
LDHA
L6A 
K.NRVIGSGC*NLDS
AR.F 1.015 1.35 1.015 
IPI00290272.2 POLA2 DNA polymerase subunit alpha B ENSG000000141 
POLA
2 
K.VLGC*PEALTGSY
K.S 1.15 1.35 0.97 
IPI00844329.1 HPRT1 Uncharacterized protein HPRT1 ENSG0000016570 
HPRT
1 
R.SPGVVISDDEPGY
DLDLFC*IPNHYAE
DLER.V 
0.87 1.35 0 
IPI00072534.2 UNC45A Isoform 1 of UNC45 homolog A ENSG0000014055 
UNC4
5A 
R.AIQTVSCLLQGPC
*DAGNR.A 1.22 1.36 1.375 
IPI00646167.2 C14orf142 hypothetical protein LOC84520 ENSG000001 
C14orf
142 
R.VSC*EAPGDGDPF
QGLLSGVAQMK.D 1.085 1.37 0.98 
IPI00011118.2 RRM2 Ribonucleoside-diphosphate reductase M2 subun RRM2 K.LIGMNC*TLMK.Q 1.075 1.37 1.625 
IPI00001636.1 
ATXN10 Ataxin-10 
ENSG00000130638 IPI00385153 
IPI00 
ATXN
10 
K.ETTNIFSNC*GCV
R.A 1.13 1.38 0.995 
IPI00797537.1 NUDCD1 NudC domain-containing protein 1 ENSG000001 
NUDC
D1 
K.FFACAPNYSYAA
LC*ECLR.R 1.18 1.395 0 
IPI00045207.2 BTBD14B BTB/POZ domain-containing protein 14B ENSG 
BTBD
14B 
R.NTLANSC*GTGIR.
S 0 1.41 0 
IPI00456758.4 RPL27A 60S ribosomal protein L27a ENSG00000166441  
RPL27
A 
R.NQSFC*PTVNLDK
.L 0 1.415 1.01 
IPI00002520.1 
SHMT2 Serine 
hydroxymethyltransferase, 
mitochondri 
SHMT
2 K.NTC*PGDR.S 1.085 1.415 1.02 
IPI00000875.6 EEF1G Elongation factor 1-gamma ENSG00000186676 IP EEF1G 
K.VPAFEGDDGFC*
VFESNAIAYYVSNE
ELR.G 
0.76 1.42 0 
IPI00218342.10 MTHFD1 C-1-tetrahydrofolate synthase, cytoplasmic  
MTHF
D1 
R.GDLNDC*FIPCTP
K.G 1.155 1.435 1.04 
IPI00100460.2 DARS2 Aspartyl-tRNA synthetase, mitochondrial prec 
DARS
2 R.LIC*LVTGSPSIR.D 0 1.44 1.1 
IPI00216587.9 RPS8 40S ribosomal protein S8 ENSG00000142937 IPI0 RPS8 
K.NC*IVLIDSTPYR.
Q 1.4 1.47 0.945 
IPI00018352.1 UCHL1 Ubiquitin carboxyl-terminal hydrolase isozym 
UCHL
1 
K.NEAIQAAHDAVA
QEGQC*R.V 1.015 1.475 1.035 
IPI00023234.3 SAE2 SUMO-activating enzyme subunit 2 ENSG00000126 SAE2 
R.VLVVGAGGIGC*E
LLK.N 1.26 1.5 0.99 
IPI00216247.2 
PSMD4 Proteasome 
ENSG00000159352 IPI00853415 
IPI00 
PSMD
4 
R.SNPENNVGLITLA
NDC*EVLTTLTPDT
GR.I 
0.98 1.51 0 
IPI00001636.1 
ATXN10 Ataxin-10 
ENSG00000130638 IPI00385153 
IPI00 
ATXN
10 
R.HAELIASTFVDQC
*K.T 1.2 1.525 1.03 
IPI00465260.4 GARS Glycyl-tRNA synthetase ENSG00000106105 IPI004 GARS 
R.QHFIQEEQILEIDC
*TMLTPEPVLK.T 0 1.58 1 
IPI00217362.2 TPRKB Isoform 3 of TP53RK-binding protein ENSG0000 
TPRK
B 
K.LSSQEESIGTLLD
AIIC*R.M 1.53 1.7 1.54 
IPI00015141.4 CKMT2 Creatine kinase, sarcomeric mitochondrial pr 
CKMT
2 R.GLSLPPAC*TR.A 0 1.71 1.01 
IPI00024915.2 PRDX5 Isoform Mitochondrial of Peroxiredoxin-5, mi 
PRDX
5 
K.ALNVEPDGTGLT
C*SLAPNIISQL.- 1.29 1.78 1.015 
IPI00456898.1 LOC440055 Uncharacterized protein ENSP00000302331  
LOC44
0055 
R.QAHLC*VLASNC
DEPMYVK.L 2.025 1.805 1.065 
IPI00290566.1 TCP1 T-complex protein 1 subunit alpha ENSG0000012 TCP1 
R.SQMESMLISGYAL
NC*VVGSQGMPK.R 0.99 1.825 0.99 
IPI00145260.3 C1orf69 Putative transferase C1orf69, mitochondria 
C1orf6
9 K.GC*YIGQELTAR.T 1.025 1.83 1.045 
IPI00295386.7 CBR1 Carbonyl reductase [NADPH] 1 ENSG00000159228  CBR1 
R.DVC*TELLPLIKP
QGR.V 0 1.86 1.11 
IPI00216587.9 RPS8 40S ribosomal protein S8 ENSG00000142937 IPI0 RPS8 
R.LDVGNFSWGSEC
*CTR.K 1.35 1.9 0 
IPI00024993.4 ECHS1 Enoyl-CoA hydratase, mitochondrial precursor 
ECHS
1 
K.IC*PVETLVEEAIQ
CAEK.I 1.09 1.99 0.925 
IPI00479877.4 ALDH9A1 aldehyde ALDH K.TVC*VEMGDVES 1.235 2.035 1.26 
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dehydrogenase 9A1 
ENSG00000143149 
9A1 AF.- 
IPI00022239.7 
METAP1 Methionine 
aminopeptidase 1 
ENSG00000164024 
META
P1 
K.LGIQGSYFCSQEC
*FK.G 1.425 2.075 0.69 
IPI00306369.3 NSUN2 tRNA ENSG00000037474 IPI00306369 
NSUN
2 
R.MVYSTC*SLNPIE
DEAVIASLLEK.S 1.92 2.245 1.125 
IPI00847579.1 RPS12 ribosomal protein S12 ENSG00000112306 IPI008 RPS12 
R.KVVGCSC*VVVK.
D 1.95 2.265 1.035 
IPI00033130.3 SAE1 SUMO-activating enzyme subunit 1 ENSG00000142 SAE1 K.GNGIVEC*LGPK.- 0 2.42 0.87 
IPI00011118.2 RRM2 Ribonucleoside-diphosphate reductase M2 subun RRM2 
R.EFLFNAIETMPC*
VK.K 1.78 2.76 1.055 
IPI00550069.3 RNH1 Ribonuclease inhibitor ENSG00000023191 IPI005 RNH1 
R.WAELLPLLQQC*
QVVR.L 0 3.01 0 
IPI00306301.2 PDHA1 Mitochondrial PDHA1 ENSG00000131828 IPI00642 
PDHA
1 
K.NFYGGNGIVGAQ
VPLGAGIALAC*K.Y 0 3.05 0 
IPI00550069.3 RNH1 Ribonuclease inhibitor ENSG00000023191 IPI005 RNH1 R.C*KDISSALR.V 1 3.135 0.61 
IPI00002520.1 
SHMT2 Serine 
hydroxymethyltransferase, 
mitochondri 
SHMT
2 
R.GLELIASENFC*SR
.A 0.93 3.575 0 
IPI00550069.3 RNH1 Ribonuclease inhibitor ENSG00000023191 IPI005 RNH1 
R.SNELGDVGVHC*
VLQGLQTPSCK.I 1.41 4.5 1.07 
IPI00550069.3 RNH1 Ribonuclease inhibitor ENSG00000023191 IPI005 RNH1 
K.LSLQNCC*LTGAG
CGVLSSTLR.T 1.36 5.17 1.13 
IPI00015018.1 PPA1 Inorganic pyrophosphatase ENSG00000180817 IPI PPA1 K.C*DPDAAR.A 2.35 7.49 1.02 
IPI00015018.1 PPA1 Inorganic pyrophosphatase ENSG00000180817 IPI PPA1 
K.GISC*MNTTLSES
PFK.C 1.76 9.72 0 
IPI00011200.5 PHGDH D-3-phosphoglycerate dehydrogenase ENSG00000 
PHGD
H 
K.GILVMNTPNGNS
LSAAELTC*GMIMC
LAR.Q 
0 10.535 0 
IPI00395939.3 PITPNB Isoform 2 of Phosphatidylinositol transfer  
PITPN
B 
K.ELANSPDC*PQM
CAYK.L 1.05 16.655 1.215 
 
Table 3A-4. Mass-spectrometry results of global competitive zinc-binding treatment of 
HeLa cell lysates with EDTA and IA-alkyne utilizing the quantitative isotopic Azo-tags. 
Three replicates were performed with the average taken for peptides found in multiple 
runs. A ‘0’ indicates that the peptide was not found in that particular run. Data were 
sorted to present those with the highest R ratio within the EDTA runs (highest increase in 
IA-labeling upon EDTA-treatment). Peptides with an R > 1.50 (1.5-fold increase in IA-
labeling upon EDTA-treatment) are highlighted in grey and represent those cysteines 
most sensitive to EDTA-treatment. 
ipi description symbol sequence EDTA-1 
EDTA-
2 
EDTA-
3 
EDTA-
Avg 
IPI00386119.4 
SF1 Isoform 5 of Splicing 
factor 1 
ENSG00000168066 
SF1 R.SITNTTVC*TK.C 33.2 0 50.9 42.05 
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IPI00015018.1 
PPA1 Inorganic 
pyrophosphatase 
ENSG00000180817 IPI 
PPA1 K.GISC*MNTTLSESPFK.C 34.52 0 48.16 41.34 
IPI00845348.1 
ZRANB2 Putative 
uncharacterized protein 
DKFZp686N0 
ZRAN
B2 
K.C*GNVNFAR.
R 34.75 0 0 34.75 
IPI00009841.4 
EWSR1 CDNA FLJ31747 
fis, clone NT2RI2007377, 
highl 
EWSR
1 
R.AGDWQC*PN
PGCGNQNFAW
R.T 
35.44 0 27.93 31.685 
IPI00845348.1 
ZRANB2 Putative 
uncharacterized protein 
DKFZp686N0 
ZRAN
B2 
R.GLFSANDWQ
C*K.T 24.36 0 0 24.36 
IPI00015018.1 
PPA1 Inorganic 
pyrophosphatase 
ENSG00000180817 IPI 
PPA1 K.C*DPDAAR.A 24.07 0 0 24.07 
IPI00000279.2 ZC3H15 erythropoietin 4 immediate early response E 
ZC3H1
5 
K.SVVC*AFFK.
Q 18.59 0 23.38 20.985 
IPI00302112.1 
MAP2K7 Isoform 2 of 
Dual specificity mitogen-
activ 
MAP2
K7 
R.YQAEINDLEN
LGEMGSGTC*G
QVWK.M 
37.66 0 1.04 19.35 
IPI00430812.4 
CNBP Zinc finger protein 9 
ENSG00000169714 
IPI0043 
CNBP K.TSEVNC*YR.C 15.72 0 0 15.72 
IPI00514501.1 
C1orf57 Chromosome 1 
open reading frame 57 
ENSG000 
C1orf5
7 
R.VC*VIDEIGK.
M 15.56 0 13.86 14.71 
IPI00027107.5 
TUFM Tu translation 
elongation factor, 
mitochondri 
TUFM K.GEETPVIVGSALC*ALEGR.D 12.15 0 14.11 13.13 
IPI00845348.1 
ZRANB2 Putative 
uncharacterized protein 
DKFZp686N0 
ZRAN
B2 
K.TC*SNVNWA
R.R 0 0 13.12 13.12 
IPI00023234.3 
SAE2 SUMO-activating 
enzyme subunit 2 
ENSG00000126 
SAE2 R.VLVVGAGGIGC*ELLK.N 0 0 12.02 12.02 
IPI00027107.5 
TUFM Tu translation 
elongation factor, 
mitochondri 
TUFM 
K.NMITGTAPLD
GC*ILVVAAND
GPMPQTR.E 
0 0 11.48 11.48 
IPI00848058.1 
ACTB Actin, cytoplasmic 2 
ENSG00000075624 
IPI00021 
ACTB K.C*DVDIRK.D 0 10.52 0 10.52 
IPI00011253.3 
RPS3 40S ribosomal 
protein S3 
ENSG00000149273 IPI0 
RPS3 K.GC*EVVVSGK.L 8.84 0 8.82 8.83 
IPI00007765.5 HSPA9 Stress-70 protein, mitochondrial precursor E HSPA9 
K.AKC*ELSSSV
QTDINLPYLTM
DSSGPK.H 
0 0 8.75 8.75 
IPI00432836.2 
RPL37 Uncharacterized 
protein RPL37 
ENSG0000014559 
RPL37 K.THTLC*R.R 0 7.59 0 7.59 
IPI00008433.4 
RPS5 40S ribosomal 
protein S5 
ENSG00000083845 IPI0 
RPS5 K.TIAEC*LADELINAAK.G 6.46 7.68 6.57 7.0975 
IPI00022239.7 
METAP1 Methionine 
aminopeptidase 1 
ENSG00000164024 
META
P1 K.LQC*PTCIK.L 6.95 0 0 6.95 
IPI00004506.3 
KCTD5 BTB/POZ domain-
containing protein KCTD5 
ENSG 
KCTD5 R.C*SAGLGALAQRPGSVSK.W 0 6.73 0 6.73 
IPI00027107.5 
TUFM Tu translation 
elongation factor, 
mitochondri 
TUFM R.HYAHTDC*PGHADYVK.N 0 6.62 0 6.62 
IPI00021840.1 
RPS6 40S ribosomal 
protein S6 
ENSG00000137154 IPI0 
RPS6 K.LNISFPATGC*QK.L 0 7.23 4.74 6.6075 
IPI00479743.3 POTE2 protein expressed in prostate, ovary, testis POTE2 
K.EKLC*YVALD
FEQEMATAASS
SSLEK.S 
3 7.46 8.42 6.585 
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IPI00011253.3 
RPS3 40S ribosomal 
protein S3 
ENSG00000149273 IPI0 
RPS3 R.AC*YGVLR.F 0 0 6.57 6.57 
IPI00217030.10 
RPS4X 40S ribosomal 
protein S4, X isoform 
ENSG0000 
RPS4X R.EC*LPLIIFLR.N 0 6.09 0 6.09 
IPI00022240.3 ISCU Isoform 1 of Iron-sulfur cluster assembly enz ISCU 
K.TFGC*GSAIAS
SSLATEWVK.G 6 0 0 6 
IPI00025091.3 
RPS11 40S ribosomal 
protein S11 
ENSG00000142534 IP 
RPS11 K.NMSVHLSPC*FR.D 0 5.12 0 5.12 
IPI00218606.7 
RPS23 40S ribosomal 
protein S23 
ENSG00000186468 IP 
RPS23 
K.ITAFVPNDGC
*LNFIEENDEVL
VAGFGR.K 
4.07 5.62 4.73 5.01 
IPI00025091.3 
RPS11 40S ribosomal 
protein S11 
ENSG00000142534 IP 
RPS11 R.DVQIGDIVTVGEC*RPLSK.T 4.47 0 5.49 4.98 
IPI00176655.5 
_ Uncharacterized protein 
ENSP00000348430 
ENSG0000 
_ K.TPC*GEGSK.T 4.58 0 4.86 4.72 
IPI00008433.4 
RPS5 40S ribosomal 
protein S5 
ENSG00000083845 IPI0 
RPS5 K.AQC*PIVER.L 4.41 4.86 4.62 4.6875 
IPI00031820.3 
FARSA Phenylalanyl-
tRNA synthetase alpha 
chain ENS 
FARSA K.VNLQMVYDSPLC*R.L 4.61 0 4.63 4.62 
IPI00176574.1 
LOC284230 
Uncharacterized protein 
ENSP00000351550 
LOC28
4230 
R.LECVEPNC*R.
S 4.55 0 4.6 4.575 
IPI00003814.1 
MAP2K6 Isoform 1 of 
Dual specificity mitogen-
activ 
MAP2
K6 
K.TIDAGC*KPY
MAPER.I 4.63 0 4.49 4.56 
IPI00003783.1 MAP2K2 Dual specificity mitogen-activated protein 
MAP2
K2 
K.LC*DFGVSGQ
LIDSMANSFVG
TR.S 
4.35 4.9 4.08 4.5575 
IPI00397963.3 
_ Uncharacterized protein 
ENSP00000301828 
ENSG0000 
_ R.LTEGC*SFR.R 3.66 5.23 4.09 4.5525 
IPI00514501.1 
C1orf57 Chromosome 1 
open reading frame 57 
ENSG000 
C1orf5
7 
R.NADC*SSGPG
QR.V 3.38 6.09 2.48 4.51 
IPI00023073.1 
XRCC3 DNA-repair 
protein XRCC3 
ENSG00000126215 IPI 
XRCC3 R.LSLGC*PVLDALLR.G 0 4.41 3.25 4.12 
IPI00025091.3 
RPS11 40S ribosomal 
protein S11 
ENSG00000142534 IP 
RPS11 K.C*PFTGNVSIR.G 0 4.08 3.95 4.0475 
IPI00008433.4 
RPS5 40S ribosomal 
protein S5 
ENSG00000083845 IPI0 
RPS5 R.VNQAIWLLC*TGAR.E 0.86 0 7.14 4 
IPI00396086.1 
RPS21 8.2 kDa 
differentiation factor 
ENSG000001718 
RPS21 R.KC*SASNR.I 0 4.01 3.7 3.9325 
IPI00218342.10 
MTHFD1 C-1-
tetrahydrofolate synthase, 
cytoplasmic 
MTHF
D1 
K.QGFGNLPIC*
MAK.T 0 0 3.92 3.92 
IPI00746777.3 
ADH5 Alcohol 
dehydrogenase class-3 
ENSG00000197894 
ADH5 
K.IDPLAPLDKV
CLLGC*GISTGY
GAAVNTAK.L 
0 0 3.92 3.92 
IPI00376429.3 
LOC391370 
Uncharacterized protein 
ENSP00000352557 
LOC39
1370 
K.LGEWVGLC*
K.T 3.77 0 4.04 3.905 
IPI00719622.1 
RPS28 LOC646195 
LOC645899 40S ribosomal 
protein S2 
RPS28 R.TGSQGQC*TQVR.V 3.65 0 4.06 3.855 
IPI00216587.9 
RPS8 40S ribosomal 
protein S8 
ENSG00000142937 IPI0 
RPS8 K.NC*IVLIDSTPYR.Q 0 0 3.8 3.8 
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IPI00479877.4 
ALDH9A1 aldehyde 
dehydrogenase 9A1 
ENSG00000143149 
ALDH
9A1 
K.TVC*VEMGD
VESAF.- 3.71 0 0 3.71 
IPI00290142.5 
CTPS CTP synthase 1 
ENSG00000171793 
IPI00290142 
CTPS K.SC*GLHVTSIK.I 0 0 3.63 3.63 
IPI00790530.1 
NUP85 nucleoporin 85 
ENSG00000125450 
IPI00790530 I 
NUP85 
R.GC*FSDLDLID
NLGPAMMLSD
R.L 
5.96 0 1.15 3.555 
Reverse_IPI00376
429.3 
LOC391370 
Uncharacterized protein 
ENSP00000352557 
LOC39
1370 
K.C*LGVWEGL
K.K 3.58 0 3.49 3.535 
IPI00028050.2 EEFSEC Selenocysteine-specific elongation factor E 
EEFSE
C 
K.GMQTQSAEC
*LVIGQIACQK.L 3.42 0 3.37 3.395 
IPI00303207.3 
ABCE1 ATP-binding 
cassette sub-family E 
member 1 E 
ABCE1 R.YC*ANAFK.L 3.51 0 3.17 3.34 
IPI00219160.3 
RPL34 60S ribosomal 
protein L34 
ENSG00000109475 IP 
RPL34 R.AYGGSMC*AK.C 3.32 0 3.32 3.32 
IPI00012750.3 
RPS25 40S ribosomal 
protein S25 
ENSG00000118181 IP 
RPS25 K.ATYDKLC*K.E 3.21 0 0 3.21 
IPI00000875.6 
EEF1G Elongation factor 
1-gamma 
ENSG00000186676 IP 
EEF1G 
R.FPEELTQTFM
SC*NLITGMFQR
.L 
8.93 1.26 0 3.1775 
IPI00055606.2 
FHL1 Isoform 2 of Four 
and a half LIM domains 
prot 
FHL1 K.C*LHPLANETFVAK.D 0 3.04 0 3.04 
IPI00022240.3 ISCU Isoform 1 of Iron-sulfur cluster assembly enz ISCU 
K.NVGTGLVGA
PAC*GDVMK.L 2.85 0 3.17 3.01 
IPI00297779.7 
CCT2 T-complex protein 1 
subunit beta 
ENSG00000166 
CCT2 R.SLHDALC*VLAQTVK.D 0 2.97 0 2.97 
IPI00006164.4 ILKAP Integrin-linked kinase-associated serine/thr ILKAP 
R.FILLAC*DGLF
K.V 0 2.96 2.9 2.945 
IPI00013219.1 ILK Integrin-linked protein kinase ENSG00000166333 ILK K.FSFQC*PGR.M 2.46 3.37 2.39 2.8975 
IPI00644079.2 
HNRNPU heterogeneous 
nuclear ribonucleoprotein 
U i 
HNRN
PU 
R.KAVVVC*PK.
D 0 2.89 0 2.89 
IPI00788737.1 
GAPDH 39 kDa protein 
ENSG00000111640 
IPI00789134 I 
GAPD
H 
R.VPTANVSVV
DLTC*R.L 0 0 2.81 2.81 
IPI00299214.6 
TK1 thymidine kinase 1, 
soluble ENSG00000167900 
IP 
TK1 R.NTMEALPAC*LLR.D 2.59 0 2.9 2.745 
IPI00059764.4 
ZNF428 zinc finger protein 
428 ENSG00000131116 
IPI 
ZNF42
8 
R.LCC*PATAPQ
EAPAPEGR.A 2.71 0 0 2.71 
IPI00140201.3 
PDF COG8 Conserved 
oligomeric Golgi complex 
compon 
PDF R.LEPAGPAC*PEGGR.A 0 0 2.66 2.66 
IPI00470502.2 
PPA2 Isoform 2 of 
Inorganic pyrophosphatase 
2, mit 
PPA2 R.GQPC*SQNYR.L 2.78 0 2.48 2.63 
IPI00419880.6 
RPS3A 40S ribosomal 
protein S3a 
ENSG00000145425 IP 
RPS3A R.DKMC*SMVK.K 2.46 0 2.67 2.565 
IPI00011253.3 
RPS3 40S ribosomal 
protein S3 
ENSG00000149273 IPI0 
RPS3 R.GLC*AIAQAESLR.Y 2.22 2.85 2.32 2.56 
IPI00147874.1 
NANS Sialic acid synthase 
ENSG00000095380 
IPI00147 
NANS K.QLLPCEMAC*NEK.L 0 0 2.56 2.56 
IPI00013485.3 
RPS2 40S ribosomal 
protein S2 
ENSG00000140988 IPI0 
RPS2 R.GC*TATLGNFAK.A 2.19 2.88 2.27 2.555 
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IPI00290279.1 
ADK Isoform Long of 
Adenosine kinase 
ENSG000001561 
ADK R.TGC*TFPEKPDFH.- 0 0 2.48 2.48 
IPI00788737.1 
GAPDH 39 kDa protein 
ENSG00000111640 
IPI00789134 I 
GAPD
H 
K.IISNASC*TTN
CLAPLAK.V 2.25 2.46 2.35 2.38 
IPI00041127.6 
ASF1B Histone chaperone 
ASF1B 
ENSG00000105011 IPI0 
ASF1B K.GLGLPGC*IPGLLPENSMDCI.- 3.56 0 1.19 2.375 
IPI00215719.6 
RPL18 60S ribosomal 
protein L18 
ENSG00000063177 IP 
RPL18 K.GC*GTVLLSGPR.K 0 0 2.36 2.36 
IPI00749250.1 
ACTR2 45 kDa protein 
ENSG00000138071 
IPI00005159 I 
ACTR2 K.LC*YVGYNIEQEQK.L 0 0 2.32 2.32 
IPI00291939.1 
SMC1A Structural 
maintenance of 
chromosomes protei 
SMC1
A 
K.AESLIGVYPE
QGDC*VISK.V 2.41 0 2.18 2.295 
IPI00219160.3 
RPL34 60S ribosomal 
protein L34 
ENSG00000109475 IP 
RPL34 K.SACGVC*PGR.L 2.1 0 2.29 2.195 
IPI00797038.1 
PCK2 mitochondrial 
phosphoenolpyruvate 
carboxykina 
PCK2 R.YVAAAFPSAC*GK.T 2.08 0 2.19 2.135 
IPI00413641.7 
AKR1B1 Aldose reductase 
ENSG00000085662 
IPI0041364 
AKR1
B1 
R.VC*ALLSCTS
HK.D 0 2.11 0 2.11 
IPI00026138.4 
_ Uncharacterized protein 
ENSP00000371610 
ENSG0000 
_ K.NC*LTNFHGMDLTR.D 0 2.03 2.21 2.075 
IPI00783910.1 
KIAA1524 102 kDa protein 
ENSG00000163507 
IPI007839 
KIAA1
524 K.DQIC*DVR.I 2.06 0 0 2.06 
IPI00028296.1 
CAMK1 
Calcium/calmodulin-
dependent protein kinase 
CAMK
1 
R.DC*CVEPGTE
LSPTLPHQL.- 1.7 0 2.39 2.045 
IPI00430622.1 
SPG20 Spartin 
ENSG00000133104 
IPI00480185 IPI00430 
SPG20 K.VSQFLVDGVCTVANC*VGK.E 2.02 0 0 2.02 
IPI00456758.4 
RPL27A 60S ribosomal 
protein L27a 
ENSG00000166441 
RPL27
A 
R.NQSFC*PTVN
LDK.L 2.01 0 0 2.01 
IPI00215919.5 
ARF5 ADP-ribosylation 
factor 5 
ENSG00000004059 IPI 
ARF5 K.NIC*FTVWDVGGQDK.I 1.9 0 2.07 1.985 
IPI00007752.1 
TUBB2C Tubulin beta-2C 
chain ENSG00000188229 
IPI00 
TUBB2
C 
K.NMMAAC*DP
R.H 1.86 2.1 1.86 1.98 
IPI00641950.3 
GNB2L1 Lung cancer 
oncogene 7 
ENSG00000204628 IPI0 
GNB2L
1 
K.VWNLANC*K.
L 1.77 0 2.19 1.98 
IPI00007752.1 
TUBB2C Tubulin beta-2C 
chain ENSG00000188229 
IPI00 
TUBB2
C 
K.VSDTVVEPYN
ATLSVHQLVEN
TDETYC*IDNEA
LYDICFR.T 
2.1 2.04 1.7 1.97 
IPI00007750.1 
TUBA4A Tubulin alpha-
4A chain 
ENSG00000127824 IPI0 
TUBA4
A 
K.AYHEQLSVA
EITNAC*FEPAN
QMVK.C 
1.73 2.21 1.69 1.96 
IPI00007752.1 
TUBB2C Tubulin beta-2C 
chain ENSG00000188229 
IPI00 
TUBB2
C 
K.TAVC*DIPPR.
G 1.79 2.06 1.85 1.94 
IPI00747722.1 
GALK1 Uncharacterized 
protein GALK1 
ENSG0000010847 
GALK
1 
R.AQVCQQAEH
SFAGMPC*GIM
DQFISLMGQK.G 
0 1.93 0 1.93 
IPI00016580.6 
DSN1 Isoform 1 of 
Kinetochore-associated 
protein D 
DSN1 K.VFDC*MELVMDELQGSVK.Q 1.66 0 2.18 1.92 
IPI00655631.1 POLD1 DNA polymerase ENSG00000062822 POLD1 
R.DNC*PLVANL
VTASLR.R 0 0 1.9 1.9 
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IPI00002894 I 
Reverse_IPI00184
021.2 
CRIPAK cysteine-rich 
PAK1 inhibitor 
ENSG0000017997 
CRIPA
K 
R.C*THAPSCEV
HARTILR.A 1.89 0 0 1.89 
IPI00002966.1 
HSPA4 Heat shock 70 kDa 
protein 4 
ENSG00000170606 
HSPA4 R.C*TPACISFGPK.N 0 1.93 1.76 1.8875 
IPI00022442.2 
NDUFAB1 Acyl carrier 
protein, mitochondrial 
precur 
NDUF
AB1 
K.LMC*PQEIVD
YIADKK.D 0 1.88 0 1.88 
IPI00337307.3 HTF9C Isoform 1 of HpaII tiny fragments locus 9c p HTF9C 
R.VIGVELC*PE
AVEDAR.V 1.88 0 0 1.88 
IPI00022334.1 
OAT Ornithine 
aminotransferase, 
mitochondrial prec 
OAT K.VLPMNTGVEAGETAC*K.L 0 0 1.86 1.86 
IPI00027251.1 
STK38 Serine/threonine-
protein kinase 38 
ENSG00000 
STK38 K.LSDFGLC*TGLK.K 0 0 1.86 1.86 
IPI00746351.1 
DIS3 Uncharacterized 
protein DIS3 
ENSG00000083520 
DIS3 R.LAC*LSEEGNEIESGK.I 2.04 0 1.62 1.83 
IPI00848058.1 
ACTB Actin, cytoplasmic 2 
ENSG00000075624 
IPI00021 
ACTB 
R.C*PEALFQPSF
LGMESCGIHET
TFNSIMK.C 
0 1.83 0 1.83 
IPI00305589.3 
PFKFB2 Isoform 1 of 6-
phosphofructo-2-
kinase/fruct 
PFKFB
2 
K.QC*ALVALED
VK.A 1.83 0 0 1.83 
IPI00398057.1 
LOC389342 
Uncharacterized protein 
ENSP00000353659 
LOC38
9342 
K.VDEFPLC*GH
MVSDEYEQLSS
EALEAAR.I 
1.83 0 0 1.83 
IPI00217223.1 
PAICS Multifunctional 
protein ADE2 
ENSG00000128050 
PAICS 
K.C*GETAFIAP
QCEMIPIEWVC
R.R 
0 0 1.82 1.82 
IPI00180675.4 
TUBA1A Tubulin alpha-
1A chain 
ENSG00000167552 IPI0 
TUBA1
A 
K.LADQC*TGLQ
GFLVFHSFGGG
TGSGFTSLLME
R.L 
0 1.81 0 1.81 
IPI00218343.4 
TUBA1C Tubulin alpha-1C 
chain ENSG00000167553 
IPI0 
TUBA1
C 
R.AVC*MLSNTT
AVAEAWAR.L 1.59 1.92 1.79 1.805 
IPI00220766.5 
GLO1 Lactoylglutathione 
lyase ENSG00000124767 
IPI0 
GLO1 K.C*DFPIMK.F 1.67 0 1.94 1.805 
IPI00169383.3 
PGK1 Phosphoglycerate 
kinase 1 
ENSG00000102144 IPI 
PGK1 R.GCITIIGGGDTATC*C*AK.W 0 0 1.8 1.8 
IPI00302925.3 
CCT8 Uncharacterized 
protein CCT8 
ENSG00000156261 
CCT8 K.AHEILPNLVC*CSAK.N 0 1.75 0 1.75 
IPI00182533.5 
RPL28 60S ribosomal 
protein L28 
ENSG00000108107 IP 
RPL28 R.NC*SSFLIK.R 1.72 0 1.77 1.745 
IPI00387130.1 
CIAPIN1 Isoform 1 of 
Anamorsin 
ENSG00000005194 IPI 
CIAPI
N1 
R.CASC*PYLGM
PAFKPGEK.V 0 1.74 0 1.74 
IPI00396627.1 
ELAC2 Isoform 1 of Zinc 
phosphodiesterase ELAC 
pro 
ELAC2 K.VVYSGDTMPC*EALVR.M 1.74 0 0 1.74 
IPI00007750.1 
TUBA4A Tubulin alpha-
4A chain 
ENSG00000127824 IPI0 
TUBA4
A 
R.AVC*MLSNTT
AIAEAWAR.L 1.57 1.9 1.56 1.7325 
IPI00010153.5 
RPL23 60S ribosomal 
protein L23 
ENSG00000125691 IP 
RPL23 
R.ISLGLPVGAVI
NC*ADNTGAK.
N 
0 1.77 1.6 1.7275 
IPI00218343.4 
TUBA1C Tubulin alpha-1C 
chain ENSG00000167553 
IPI0 
TUBA1
C 
K.AYHEQLTVA
EITNAC*FEPAN
QMVK.C 
1.71 0 1.74 1.725 
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IPI00453476.2 
_ Uncharacterized protein 
ENSP00000348237 
ENSG0000 
_ R.YADLTEDQLPSC*ESLK.D 0 0 1.71 1.71 
IPI00180675.4 
TUBA1A Tubulin alpha-
1A chain 
ENSG00000167552 IPI0 
TUBA1
A 
R.TIQFVDWC*P
TGFK.V 1.53 1.88 1.54 1.7075 
IPI00514587.1 
SARS Uncharacterized 
protein SARS 
ENSG00000031698 
SARS R.TIC*AILENYQTEK.G 1.77 0 1.6 1.685 
IPI00301609.8 
NEK9 Serine/threonine-
protein kinase Nek9 
ENSG0000 
NEK9 R.LNPAVTC*AGK.G 0 0 1.68 1.68 
IPI00010720.1 
CCT5 T-complex protein 1 
subunit epsilon 
ENSG00000 
CCT5 K.IAILTC*PFEPPKPK.T 0 1.68 0 1.68 
IPI00552897.2 
MDC1 Isoform 1 of 
Mediator of DNA damage 
checkpoin 
MDC1 R.C*NVEPVGR.L 1.67 0 0 1.67 
IPI00641635.1 
FTO 64 kDa protein 
ENSG00000140718 
IPI00028277 IPI 
FTO K.ANEDAVPLC*MSADFPR.V 0.98 0 2.33 1.655 
IPI00514587.1 
SARS Uncharacterized 
protein SARS 
ENSG00000031698 
SARS K.YAGLSTC*FR.Q 1.57 1.72 1.6 1.6525 
IPI00163085.2 
AMOT Isoform 1 of 
Angiomotin 
ENSG00000126016 IPI00 
AMOT 
R.QGNC*QPTNV
SEYNAAALMEL
LR.E 
1.69 0 1.61 1.65 
IPI00219103.6 
HPCA Neuron-specific 
calcium-binding protein 
hippo 
HPCA R.LLQC*DPSSASQF.- 1.5 0 1.77 1.635 
IPI00220158.1 
ADD1 Isoform 3 of Alpha-
adducin 
ENSG00000087274 IP 
ADD1 
K.YSDVEVPASV
TGYSFASDGDS
GTC*SPLR.H 
1.99 0 1.26 1.625 
IPI00789740.1 
GEMIN4 Gem (Nuclear 
organelle) associated 
protein 
GEMI
N4 
R.SDPDAC*PTM
PLLAMLLR.G 0 0 1.62 1.62 
IPI00552569.1 
ERCC6L excision repair 
protein ERCC6-like 
ENSG0000 
ERCC6
L 
K.GFGSVEELC*
TNSSLGMEK.S 0 0 1.61 1.61 
Reverse_IPI00479
998.1 
ZNF267 Zinc finger protein 
267 ENSG00000185947 
IPI 
ZNF26
7 
R.HQTLC*SSRSF
VKGCEK.C 1.61 0 0 1.61 
IPI00152089.3 
CXorf38 Isoform 1 of 
Uncharacterized protein 
CXorf 
CXorf3
8 R.LNC*AEYK.N 0 1.72 1.27 1.6075 
IPI00788737.1 
GAPDH 39 kDa protein 
ENSG00000111640 
IPI00789134 I 
GAPD
H 
K.IISNASC*TTN
C*LAPLAK.V 0 1.6 0 1.6 
IPI00031517.1 
MCM6 DNA replication 
licensing factor MCM6 
ENSG000 
MCM6 R.LGFSEYC*R.I 1.6 0 0 1.6 
IPI00297455.4 
AKAP8L A-kinase anchor 
protein 8-like 
ENSG00000011 
AKAP8
L 
R.GQC*MSGASR
.L 1.79 0 1.37 1.58 
IPI00790739.1 
ACO2 Aconitase 2, 
mitochondrial 
ENSG00000100412 IP 
ACO2 R.VGLIGSC*TNSSYEDMGR.S 0 0 1.58 1.58 
IPI00641950.3 
GNB2L1 Lung cancer 
oncogene 7 
ENSG00000204628 IPI0 
GNB2L
1 
R.FSPNSSNPIIVS
C*GWDK.L 1.42 0 1.73 1.575 
IPI00216085.3 
COX6B1 Cytochrome c 
oxidase subunit VIb 
isoform 1 
COX6
B1 
R.VYQSLC*PTS
WVTDWDEQR.A 1.57 0 0 1.57 
IPI00387130.1 
CIAPIN1 Isoform 1 of 
Anamorsin 
ENSG00000005194 IPI 
CIAPI
N1 
K.NC*TCGLAEE
LEK.E 1.55 0 0 1.55 
IPI00007750.1 
TUBA4A Tubulin alpha-
4A chain 
ENSG00000127824 IPI0 
TUBA4
A 
K.YMAC*CLLY
R.G 1.35 1.7 1.45 1.55 
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IPI00028296.1 
CAMK1 
Calcium/calmodulin-
dependent protein kinase 
CAMK
1 
K.MEDPGSVLST
AC*GTPGYVAP
EVLAQKPYSK.A 
1.36 0 1.71 1.535 
IPI00018931.6 VPS35 Vacuolar protein sorting-associated protein VPS35 
R.TQC*ALAASK
.L 1.53 0 0 1.53 
IPI00742682.1 TPR nuclear pore complex-associated protein TPR EN TPR R.RDC*QEQAK.I 1.53 0 0 1.53 
IPI00007750.1 
TUBA4A Tubulin alpha-
4A chain 
ENSG00000127824 IPI0 
TUBA4
A 
K.RSIQFVDWC*
PTGFK.V 1.41 1.64 1.42 1.5275 
IPI00787961.1 
ZNF703 similar to zinc 
finger protein 703 
ENSG0000 
ZNF70
3 
K.SPLALLAQTC
*SQIGKPDPPPSS
K.L 
0 1.52 0 1.52 
IPI00852960.1 USP22 Ubiquitin carboxyl-terminal hydrolase 22 ENS USP22 K.C*DDAIITK.A 1.52 0 0 1.52 
IPI00396485.3 
EEF1A1 Elongation factor 
1-alpha 1 
ENSG00000156508 
EEF1A
1 
K.PMC*VESFSD
YPPLGR.F 1.4 1.61 1.45 1.5175 
IPI00024381.1 
CLP1 Pre-mRNA cleavage 
complex II protein Clp1 
ENS 
CLP1 
K.VGAPTIPDSC*
LPLGMSQEDNQ
LK.L 
1.4 0 1.63 1.515 
IPI00387130.1 
CIAPIN1 Isoform 1 of 
Anamorsin 
ENSG00000005194 IPI 
CIAPI
N1 
K.SAC*GNCYLG
DAFR.C 1.4 0 1.61 1.505 
IPI00641950.3 
GNB2L1 Lung cancer 
oncogene 7 
ENSG00000204628 IPI0 
GNB2L
1 
K.LWNTLGVC*
K.Y 1.57 0 1.43 1.5 
IPI00011951.2 
KIAA0427 Isoform 2 of 
Uncharacterized protein 
KIAA 
KIAA0
427 
R.VLVC*PIYTCL
R.E 0 0 1.5 1.5 
IPI00005692.1 
MRPS12 28S ribosomal 
protein S12, mitochondrial 
pr 
MRPS1
2 
K.GVVLC*TFTR.
K 0 0 1.5 1.5 
IPI00011118.2 
RRM2 Ribonucleoside-
diphosphate reductase M2 
subun 
RRM2 R.EFLFNAIETMPC*VK.K 0 0 1.49 1.49 
IPI00220150.4 
IDH3G Isocitrate 
dehydrogenase [NAD] 
subunit gamma 
IDH3G R.TSLDLYANVIHC*K.S 0 0 1.49 1.49 
IPI00792352.1 
RAN 26 kDa protein 
ENSG00000132341 
IPI00643041 IPI 
RAN R.VC*ENIPIVLCGNK.V 1.45 0 1.53 1.49 
IPI00103142.1 
NUDCD2 NudC domain-
containing protein 2 
ENSG000001 
NUDC
D2 
R.DAANC*WTS
LLESEYAADPW
VQDQMQR.K 
1.48 0 0 1.48 
IPI00015736.3 
UBE1DC1 Ubiquitin-
activating enzyme E1 
domain-cont 
UBE1D
C1 
R.EGVC*AASLP
TTMGVVAGILV
QNVLK.F 
0 1.48 1.46 1.475 
IPI00093057.6 
CPOX 
Coproporphyrinogen III 
oxidase, mitochondrial 
CPOX R.C*SSFMAPPVTDLGELR.R 1.79 0 1.15 1.47 
IPI00021277.1 
NUBP1 Nucleotide-binding 
protein 1 
ENSG00000103274 
NUBP1 
K.NC*DKGQSFF
IDAPDSPATLAY
R.S 
0 0 1.47 1.47 
IPI00012433.2 
F8A1 F8A2 F8A3 Factor 
VIII intron 22 protein 
ENSG0 
F8A1 
R.LVC*PAAYGE
PLQAAASALGA
AVR.L 
1.47 0 0 1.47 
IPI00216190.1 
GSK3B Isoform 2 of 
Glycogen synthase kinase-3 
beta 
GSK3B K.LC*DFGSAK.Q 1.18 1.68 1.32 1.465 
IPI00021435.3 
PSMC2 26S protease 
regulatory subunit 7 
ENSG000001 
PSMC2 R.LC*PNSTGAEIR.S 1.41 0 1.52 1.465 
IPI00387130.1 
CIAPIN1 Isoform 1 of 
Anamorsin 
ENSG00000005194 IPI 
CIAPI
N1 
R.AASC*GEGK.
K 1.47 0 1.41 1.44 
IPI00645078.1 
UBE1 Ubiquitin-activating 
enzyme E1 
ENSG0000013098 
UBE1 K.SIPIC*TLK.N 1.36 1.42 1.54 1.435 
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IPI00333541.6 
FLNA Filamin-A 
ENSG00000196924 
IPI00553169 IPI0030 
FLNA K.VGTEC*GNQK.V 1.93 0 0.93 1.43 
IPI00029629.3 
TRIM25 Tripartite motif-
containing protein 25 
ENSG 
TRIM2
5 
K.NTVLC*NVVE
QFLQADLAR.E 0 0 1.43 1.43 
IPI00007611.1 
ATP5O ATP synthase 
subunit O, mitochondrial 
precur 
ATP5O 
R.GEVPC*TVTS
ASPLEEATLSEL
K.T 
1.43 0 0 1.43 
IPI00477231.2 
MGEA5 Isoform 1 of 
Bifunctional protein 
NCOAT ENSG 
MGEA
5 
R.ANSSVVSVNC
*K.G 1.23 1.62 1.24 1.4275 
IPI00166130.1 
D15Wsu75e DJ347H13.4 
protein ENSG00000100418 
IPI00 
D15Ws
u75e 
R.GEAYNLFEHN
C*NTFSNEVAQ
FLTGR.K 
0 1.53 1.09 1.42 
IPI00299214.6 
TK1 thymidine kinase 1, 
soluble ENSG00000167900 
IP 
TK1 K.LFAPQQILQC*SPAN.- 0 1.52 1.12 1.42 
IPI00784131.1 
AARS Uncharacterized 
protein AARS 
ENSG00000090861 
AARS K.AVYTQDC*PLAAAK.A 0 0 1.42 1.42 
IPI00216230.3 TMPO Lamina-associated polypeptide 2 isoform alpha TMPO 
K.SGIQPLC*PER
.S 1.34 0 1.5 1.42 
IPI00306708.3 PBK Lymphokine-activated killer T-cell-originated PBK 
K.SVLC*STPTIN
IPASPFMQK.L 0 1.42 0 1.42 
IPI00103925.2 
IRGQ Immunity-related 
GTPase family Q protein 
ENSG 
IRGQ R.EKC*SAGSQK.A 1.42 0 0 1.42 
IPI00024623.3 
ACADSB Short/branched 
chain specific acyl-CoA 
dehy 
ACAD
SB 
K.VGSFC*LSEA
GAGSDSFALK.T 1.25 0 1.57 1.41 
IPI00301609.8 
NEK9 Serine/threonine-
protein kinase Nek9 
ENSG0000 
NEK9 R.TFDATNPLNLC*VK.I 1.4 0 1.42 1.41 
IPI00216047.3 
SMARCC2 Isoform 1 of 
SWI/SNF-related matrix-
associ 
SMAR
CC2 
K.SLVQNNCLSR
PNIFLC*PEIEPK.
L 
0 1.41 0 1.41 
IPI00024623.3 
ACADSB Short/branched 
chain specific acyl-CoA 
dehy 
ACAD
SB 
R.ASSTC*PLTFE
NVK.V 1.41 0 0 1.41 
IPI00024403.1 
CPNE3 Copine-3 
ENSG00000085719 
IPI00024403 IPI0074 
CPNE3 K.NC*LNPQFSK.T 2.16 1.18 1.08 1.4 
IPI00398057.1 
LOC389342 
Uncharacterized protein 
ENSP00000353659 
LOC38
9342 
R.LIPDGC*GVK.
Y 0 1.43 1.31 1.4 
IPI00007102.3 
GLOD4 Uncharacterized 
protein C17orf25 
ENSG0000016 
GLOD
4 
K.AAC*NGPYD
GK.W 0 0 1.4 1.4 
IPI00644079.2 
HNRNPU heterogeneous 
nuclear ribonucleoprotein 
U i 
HNRN
PU 
K.MC*LFAGFQR
.K 0 1.4 0 1.4 
IPI00472102.3 
HSPD1 61 kDa protein 
ENSG00000144381 
IPI00472102 I 
HSPD1 R.AAVEEGIVLGGGC*ALLR.C 1.27 1.53 1.25 1.395 
IPI00163085.2 
AMOT Isoform 1 of 
Angiomotin 
ENSG00000126016 IPI00 
AMOT R.C*LDMEGR.I 0 0 1.39 1.39 
IPI00641743.2 
HCFC1 Uncharacterized 
protein HCFC1 
ENSG0000017253 
HCFC1 K.TC*LPGFPGAPCAIK.I 0 1.39 0 1.39 
IPI00217952.6 
GFPT1 Isoform 1 of 
Glucosamine--fructose-6-
phospha 
GFPT1 R.VDSTTC*LFPVEEK.A 0 0 1.38 1.38 
IPI00760837.2 
FAM98B family with 
sequence similarity 98, 
member 
FAM98
B 
R.INDALSC*EY
ECR.R 1.38 0 0 1.38 
IPI00398048.1 _ Uncharacterized protein ENSP00000310225 _ 
K.C*GFLPGNEK.
V 1.25 1.59 1.08 1.3775 
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ENSG0000 
IPI00020729.1 
IRS4 insulin receptor 
substrate 4 
ENSG00000133124 
IRS4 
R.GSGGGQGSN
GQGSSSHSSGG
NQC*SGEGQGS
R.G 
1.7 0 1.04 1.37 
IPI00444329.1 
BCKDHA CDNA 
FLJ45695 fis, clone 
FEBRA2013570, high 
BCKD
HA 
R.DYPLELFMAQ
C*YGNISDLGK.
G 
1.34 0 1.4 1.37 
IPI00107693.4 
MED15 Isoform 1 of 
Mediator of RNA 
polymerase II t 
MED15 K.QQYLC*QPLLDAVLANIR.S 0 1.46 1.08 1.365 
IPI00008248.3 
ANAPC7 Anaphase-
promoting complex subunit 
7 ENSG00 
ANAP
C7 
R.LEDVENLGC*
R.L 1.47 0 1.26 1.365 
IPI00020578.2 
ARAF ARAF protein 
ENSG00000078061 
IPI00020578 IPI0 
ARAF R.TQADELPAC*LLSAAR.L 0 0 1.36 1.36 
IPI00790937.1 
NMD3 Protein NMD3 
homolog 
ENSG00000169251 
IPI00790 
NMD3 K.MVEFLQCTVPC*R.Y 0 0 1.36 1.36 
IPI00298935.4 JMJD1B Isoform 1 of JmjC domain-containing histone 
JMJD1
B 
K.NLFFQC*MSQ
TLPTSNYFTTVS
ESLADDSSSR.D 
0 0 1.36 1.36 
IPI00026781.2 
FASN Fatty acid synthase 
ENSG00000169710 
IPI000267 
FASN R.LGMLSPEGTC*K.A 1.36 0 1.35 1.355 
IPI00554737.3 PPP2R1A Serine/threonine-protein phosphatase 2A 65 
PPP2R
1A K.DC*EAEVR.A 1.54 0 1.16 1.35 
IPI00017726.1 
HSD17B10 Isoform 1 of 3-
hydroxyacyl-CoA 
dehydrogen 
HSD17
B10 
K.LGNNC*VFAP
ADVTSEKDVQT
ALALAK.G 
0 0 1.35 1.35 
IPI00790757.1 
DUSP3 23 kDa protein 
ENSG00000108861 
IPI00018671 I 
DUSP3 R.EIGPNDGFLAQLC*QLNDR.L 0 0 1.35 1.35 
IPI00477802.1 
TCEAL1 Isoform 2 of 
Transcription elongation 
facto 
TCEAL
1 
K.DLFEGRPPME
QPPC*GVGK.H 0 0 1.35 1.35 
IPI00414858.3 
COG3 Isoform 1 of 
Conserved oligomeric 
Golgi compl 
COG3 
R.ELLLGPSIAC*
TVAELTSQNNR.
D 
1.17 1.4 0 1.3425 
IPI00018465.1 
CCT7 T-complex protein 1 
subunit eta 
ENSG000001356 
CCT7 R.QLC*DNAGFDATNILNK.L 1.36 0 1.32 1.34 
IPI00026492.3 
GCAT 2-amino-3-
ketobutyrate coenzyme A 
ligase, mit 
GCAT 
R.LVATDGAFS
MDGDIAPLQEIC
*CLASR.Y 
1.34 0 0 1.34 
IPI00023530.6 CDK5 Cell division protein kinase 5 ENSG0000016488 CDK5 
R.ISAEEALQHP
YFSDFC*PP.- 1.45 0 1.23 1.34 
IPI00423156.1 
CHEK2 Isoform 9 of 
Serine/threonine-protein 
kinase 
CHEK2 K.TLGSGAC*GEVK.L 1.8 1.05 1.44 1.335 
IPI00031370.3 
TUBB2B Tubulin beta-2B 
chain ENSG00000137285 
IPI00 
TUBB2
B 
K.ESESC*DCLQ
GFQLTHSLGGG
TGSGMGTLLIS
K.I 
0 0 1.33 1.33 
IPI00006167.1 
PPM1G Protein 
phosphatase 1G 
ENSG00000115241 IPI00 
PPM1G K.C*SGDGVGAPR.L 0 0 1.33 1.33 
IPI00296337.2 
PRKDC Isoform 1 of 
DNA-dependent protein 
kinase ca 
PRKD
C 
R.VEQLFQVMN
GILAQDSAC*SQ
R.A 
1.33 0 0 1.33 
IPI00145260.3 
C1orf69 Putative 
transferase C1orf69, 
mitochondria 
C1orf6
9 
R.VWAVLPSSPE
AC*GAASLQER.
A 
1.32 0 1.33 1.325 
IPI00103467.4 
ALDH1B1 Aldehyde 
dehydrogenase X, 
mitochondrial pr 
ALDH
1B1 K.LLC*GGER.F 1.16 0 1.49 1.325 
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IPI00021320.2 
MEPCE 7SK snRNA 
methylphosphate capping 
enzyme ENS 
MEPC
E 
R.SC*FPASLTAS
R.G 1.15 0 1.5 1.325 
IPI00335449.3 PPP2R1B beta isoform of regulatory subunit A, prot 
PPP2R
1B 
R.LNIISNLDC*V
NEVIGIR.Q 1.17 1.52 1.08 1.3225 
IPI00025273.1 
GART Isoform Long of 
Trifunctional purine 
biosynth 
GART R.SGC*KVDLGGFAGLFDLK.A 1.32 0 0 1.32 
IPI00456919.2 
HUWE1 Isoform 1 of E3 
ubiquitin-protein ligase 
HUW 
HUWE
1 
R.DQSAQC*TAS
K.S 1.24 0 1.4 1.32 
IPI00845436.1 
ARF4 similar to ADP-
ribosylation factor 4 
ENSG0000 
ARF4 K.NIC*FTVWDVGGQDR.I 1.34 0 1.29 1.315 
IPI00011631.6 
ZW10 
Centromere/kinetochore 
protein zw10 homolog E 
ZW10 
R.LAPILC*DGT
ATFVDLVPGFR.
R 
0 1.35 1.19 1.31 
IPI00008943.3 
DDX19B Isoform 1 of 
ATP-dependent RNA 
helicase DDX 
DDX19
B 
K.VLVTTNVC*A
R.G 1.33 0 1.29 1.31 
IPI00307755.3 PRKAA2 5-AMP-activated protein kinase catalytic s 
PRKA
A2 
R.TSC*GSPNYA
APEVISGR.L 0 0 1.31 1.31 
IPI00306017.2 
C15orf44 Isoform 1 of 
UPF0464 protein C15orf44 
ENS 
C15orf
44 
R.LIDLNNGEGQ
IFTIDGPLC*LK.
N 
1.04 0 1.58 1.31 
IPI00646500.1 
RPA2 Isoform 3 of 
Replication protein A 32 
kDa sub 
RPA2 K.AC*PRPEGLNFQDLK.N 0 1.31 0 1.31 
IPI00170877.2 
MRPL10 mitochondrial 
ribosomal protein L10 
isoform 
MRPL1
0 
R.TVPFLPLLGG
C*IDDTILSR.Q 0 1.31 0 1.31 
IPI00397721.1 BLOC1S3 Biogenesis of lysosome-related organelles 
BLOC1
S3 
R.GDLC*ALAER
.L 1.31 0 0 1.31 
IPI00465260.4 
GARS Glycyl-tRNA 
synthetase 
ENSG00000106105 IPI004 
GARS R.SCYDLSC*HAR.A 1.33 0 1.28 1.305 
IPI00021277.1 
NUBP1 Nucleotide-binding 
protein 1 
ENSG00000103274 
NUBP1 
R.LC*ASGAGAT
PDTAIEEIKEK.
M 
1.26 0 1.35 1.305 
IPI00016610.2 
PCBP1 Poly(rC)-binding 
protein 1 
ENSG00000169564 I 
PCBP1 R.LVVPATQC*GSLIGK.G 0 1.34 1.19 1.3025 
IPI00100748.3 
HSPBP1 Isoform 1 of 
Hsp70-binding protein 1 
ENSG00 
HSPBP
1 
R.LLDRDAC*DT
VR.V 0 1.3 0 1.3 
IPI00719725.1 
SAPS3 Isoform 5 of SAPS 
domain family member 3 
ENS 
SAPS3 K.C*AAPRPPSSSPEQR.T 0 1.3 0 1.3 
IPI00021435.3 
PSMC2 26S protease 
regulatory subunit 7 
ENSG000001 
PSMC2 R.SVC*TEAGMFAIR.A 1.3 0 0 1.3 
IPI00647655.1 
POLA1 Uncharacterized 
protein POLA1 
ENSG0000010186 
POLA1 R.YIFDAEC*ALEK.L 1.3 0 0 1.3 
IPI00064765.3 
RPL10L 60S ribosomal 
protein L10-like 
ENSG00000165 
RPL10
L 
K.MLSC*AGAD
R.L 1.16 1.46 1.11 1.2975 
IPI00007402.2 
IPO7 Uncharacterized 
protein IPO7 
ENSG00000205339 
IPO7 R.GIDQC*IPLFVEAALER.L 1.25 1.39 1.16 1.2975 
IPI00785096.2 
BZW1 similar to basic 
leucine zipper and W2 
domain 
BZW1 
K.ERFDPTQFQD
C*IIQGLTETGT
DLEAVAK.F 
1.14 1.42 1.21 1.2975 
IPI00024670.5 
REEP5 Receptor 
expression-enhancing 
protein 5 ENSG 
REEP5 K.NC*MTDLLAK.L 1.08 0 1.51 1.295 
Reverse_IPI00102
425.1 
P15RS Cyclin-dependent 
kinase inhibitor-related pr P15RS 
K.KC*SEDTESS
VHK.F 1.42 0 1.16 1.29 
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IPI00019903.1 
CCDC44 Coiled-coil 
domain-containing protein 
44 EN 
CCDC4
4 
K.KLDSLGLCSV
SC*ALEFIPNSK.
V 
1.27 0 1.31 1.29 
IPI00021347.1 
UBE2L3 Ubiquitin-
conjugating enzyme E2 L3 
ENSG0000 
UBE2L
3 
K.GQVC*LPVIS
AENWKPATK.T 0 1.29 0 1.29 
IPI00174962.2 
MICALL1 MICAL-like 
protein 1 
ENSG00000100139 IPI00 
MICAL
L1 
R.GSSGPQPAKP
C*SGATPTPLLL
VGDR.S 
0 1.29 0 1.29 
IPI00397904.6 
NUP93 Nuclear pore 
complex protein Nup93 
ENSG00000 
NUP93 K.LNQVC*FDDDGTSSPQDR.L 1.29 0 0 1.29 
IPI00641743.2 
HCFC1 Uncharacterized 
protein HCFC1 
ENSG0000017253 
HCFC1 R.VAGINAC*GR.G 1.27 1.35 1.17 1.285 
IPI00028412.1 
SSSCA1 Sjoegren 
syndrome/scleroderma 
autoantigen 1 
SSSCA
1 
R.MLGETC*ADC
GTILLQDK.Q 1.23 0 1.34 1.285 
IPI00793696.1 
RPL24 19 kDa protein 
ENSG00000114391 
IPI00306332 I 
RPL24 K.C*ESAFLSK.R 1.21 1.37 1.18 1.2825 
IPI00011118.2 
RRM2 Ribonucleoside-
diphosphate reductase M2 
subun 
RRM2 K.LIGMNC*TLMK.Q 0 0 1.28 1.28 
IPI00146935.4 
DNM1L Isoform 1 of 
Dynamin-1-like protein 
ENSG0000 
DNM1
L 
K.YIETSELC*GG
AR.I 1.28 0 0 1.28 
IPI00012197.1 
XTP3TPA XTP3-
transactivated gene A 
protein ENSG000 
XTP3T
PA 
K.YTELPHGAIS
EDQAVGPADIP
C*DSTGQTST.- 
1.36 0 1.19 1.275 
IPI00018465.1 
CCT7 T-complex protein 1 
subunit eta 
ENSG000001356 
CCT7 
K.EGTDSSQGIP
QLVSNISAC*QV
IAEAVR.T 
1.28 0 1.27 1.275 
IPI00030363.1 
ACAT1 Acetyl-CoA 
acetyltransferase, 
mitochondrial 
ACAT1 
K.DGLTDVYNKI
HMGSC*AENTA
K.K 
1.06 1.4 1.23 1.2725 
IPI00023138.1 
RAC3 Ras-related C3 
botulinum toxin substrate 3 
pr 
RAC3 R.AVLC*PPPVK.K 0 0 1.27 1.27 
IPI00024097.3 
TES Isoform 1 of Testin 
ENSG00000135269 
IPI0002409 
TES 
K.SEALGVGDV
KLPC*EMDAQG
PK.Q 
0 0 1.27 1.27 
IPI00745518.1 
MAP4 Microtubule-
associated protein 4 
isoform 1 va 
MAP4 
K.KKPC*SETSQI
EDTPSSKPTLLA
NGGHGVEGSDT
TGSPTEFLEEK.
M 
0 1.27 0 1.27 
IPI00025815.2 
TARDBP TDP43 
ENSG00000120948 
IPI00025815 IPI006398 
TARD
BP 
R.NPVSQC*MR.
G 1.27 0 0 1.27 
IPI00549189.4 
THOP1 Thimet 
oligopeptidase 
ENSG00000172009 IPI005 
THOP1 K.GLQVGGC*EPEPQVC.- 1.27 0 0 1.27 
IPI00550191.2 
C9orf78 Uncharacterized 
protein C9orf78 
ENSG000001 
C9orf7
8 
K.NAEDC*LYEL
PENIR.V 1.27 0 0 1.27 
IPI00011107.2 
IDH2 Isocitrate 
dehydrogenase [NADP], 
mitochondria 
IDH2 K.SSGGFVWAC*K.N 1.14 1.34 1.23 1.2625 
IPI00290566.1 
TCP1 T-complex protein 1 
subunit alpha 
ENSG0000012 
TCP1 R.DC*LINAAK.T 1.33 0 1.19 1.26 
IPI00096066.2 
SUCLG2 Succinyl-CoA 
ligase [GDP-forming] beta-
chai 
SUCL
G2 
R.SC*NGPVLVG
SPQGGVDIEEV
AASNPELIFK.E 
1.31 0 1.21 1.26 
IPI00550365.2 
PCBP3 Poly(RC) binding 
protein 3 
ENSG00000183570 I 
PCBP3 R.LVVPASQC*GSLIGK.G 0 1.27 1.23 1.26 
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IPI00555957.1 
_ Heat shock protein 90Ad 
ENSG00000205100 
IPI00555 
_ R.DLIMDNC*EELIPEYLNFIR.G 0 0 1.26 1.26 
IPI00030363.1 
ACAT1 Acetyl-CoA 
acetyltransferase, 
mitochondrial 
ACAT1 R.QAVLGAGLPISTPC*TTINK.V 0 1.25 1.29 1.26 
IPI00411570.2 
RANGAP1 KIAA1835 
protein (Fragment) 
ENSG0000010040 
RANG
AP1 
K.ALAPLLLAFV
TKPNSALESC*S
FAR.H 
0 1.26 0 1.26 
IPI00302925.3 
CCT8 Uncharacterized 
protein CCT8 
ENSG00000156261 
CCT8 K.IAVYSC*PFDGMITETK.G 1.19 1.35 1.14 1.2575 
IPI00478758.1 
C10orf119 Uncharacterized 
protein C10orf119 
ENSG00 
C10orf
119 
R.DASALLDPME
C*TDTAEEQR.V 1.29 0 1.21 1.25 
IPI00003918.6 
RPL4 60S ribosomal 
protein L4 
ENSG00000174444 IPI0 
RPL4 R.SGQGAFGNMC*R.G 1.27 0 1.23 1.25 
IPI00033030.2 
ADRM1 Protein ADRM1 
ENSG00000130706 
IPI00033030 IP 
ADRM
1 R.VPQC*PSGR.V 0 0 1.25 1.25 
IPI00301364.3 
SKP1A Isoform 1 of S-
phase kinase-associated 
prote 
SKP1A R.KENQWC*EEK.- 1.16 0 1.34 1.25 
IPI00418794.1 
ENOSF1 Enolase 
superfamily member 1 
ENSG0000013219 
ENOSF
1 
K.ALQFLQIDSC
*R.L 1.13 0 1.37 1.25 
IPI00513791.2 
DOCK7 Isoform 1 of 
Dedicator of cytokinesis 
protei 
DOCK
7 
K.AVLPVTC*HR
.D 0 1.25 0 1.25 
IPI00000874.1 
PRDX1 Peroxiredoxin-1 
ENSG00000117450 
IPI00000874 
PRDX1 
K.HGEVC*PAG
WKPGSDTIKPD
VQK.S 
0 1.25 0 1.25 
IPI00296589.3 
ITPK1 ITPK1 protein 
(Fragment) 
ENSG00000100605 IPI 
ITPK1 
R.LGC*NAGVSP
SFQQHCVASLA
TK.A 
0 1.25 0 1.25 
IPI00154451.6 
MMS19 Isoform 1 of 
MMS19-like protein 
ENSG00000155 
MMS1
9 
R.YHPLSSC*LT
AR.L 0 1.25 0 1.25 
IPI00027228.1 
PET112L Probable 
glutamyl-tRNA(Gln) 
amidotransfera 
PET11
2L 
R.AGVGLLEVV
LEPDMSC*GEE
AATAVR.E 
1.25 0 0 1.25 
IPI00025273.1 
GART Isoform Long of 
Trifunctional purine 
biosynth 
GART 
K.SSLQYSSPAP
DGC*GDQTLGD
LLLTPTR.I 
1.25 0 0 1.25 
IPI00441867.1 
PEX19 Isoform 1 of 
Peroxisomal biogenesis 
factor 1 
PEX19 R.VGSDMTSQQEFTSC*LK.E 1.34 0 1.15 1.245 
IPI00002520.1 
SHMT2 Serine 
hydroxymethyltransferase, 
mitochondri 
SHMT
2 
R.AALEALGSC*
LNNK.Y 0 0 1.24 1.24 
IPI00026940.2 
NUP50 Nucleoporin 50 
kDa ENSG00000093000 
IPI000269 
NUP50 K.AC*VGNAYHK.Q 0 1.24 0 1.24 
IPI00152151.4 
FAM122B Isoform 3 of 
Protein FAM122B 
ENSG000001565 
FAM12
2B 
K.GSATAESPVA
C*SNSCSSFILM
DDLSPK.- 
1.24 0 0 1.24 
IPI00332499.1 
NASP nuclear 
autoantigenic sperm protein 
isoform 1 
NASP 
R.KPTDGASSSN
C*VTDISHLVR.
K 
0 1.31 1.02 1.2375 
IPI00186290.6 
EEF2 Elongation factor 2 
ENSG00000167658 
IPI001862 
EEF2 K.STLTDSLVC*K.A 1.25 1.26 1.18 1.2375 
IPI00025491.1 
EIF4A1 Eukaryotic 
initiation factor 4A-I 
ENSG00000 
EIF4A1 
K.VVMALGDY
MGASC*HACIG
GTNVR.A 
0 1.35 0.89 1.235 
IPI00015262.10 
CNN2 Calponin-2 
ENSG00000064666 
IPI00015262 IPI003 
CNN2 K.AGQC*VIGLQMGTNK.C 1.4 1.05 1.44 1.235 
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IPI00643591.5 
AP1G1 Adaptor-related 
protein complex 1, gamma 
1 s 
AP1G1 R.FTC*TVNR.I 1.19 0 1.28 1.235 
IPI00377005.2 
_ Uncharacterized protein 
ENSP00000340627 
ENSG0000 
_ K.C*LSAAEEK.Y 1.2 1.39 0.95 1.2325 
IPI00102425.1 P15RS Cyclin-dependent kinase inhibitor-related pr P15RS 
K.HVSSETDESC
*KK.H 1.29 0 1.17 1.23 
IPI00293564.5 
HMGCL 
Hydroxymethylglutaryl-
CoA lyase, mitochondri 
HMGC
L K.VAQATC*KL.- 1.25 0 1.21 1.23 
IPI00005511.1 
PHF5A PHD finger-like 
domain-containing protein 
5A 
PHF5A R.ICDEC*NYGSYQGR.C 0 0 1.23 1.23 
IPI00657888.1 
GMPPA Uncharacterized 
protein GMPPA 
ENSG0000014459 
GMPP
A 
K.LLPAITILGC*
R.V 0 1.23 0 1.23 
IPI00376351.2 
METTL2B METTL2A 
Isoform 1 of 
Methyltransferase-lik 
METT
L2B 
K.ISDLEIC*ADE
FPGSSATYR.I 1.23 0 0 1.23 
IPI00013214.1 
MCM3 DNA replication 
licensing factor MCM3 
ENSG000 
MCM3 R.SVHYC*PATK.K 0 1.19 1.34 1.2275 
IPI00550746.4 
NUDC Nuclear migration 
protein nudC 
ENSG0000009027 
NUDC R.WTQTLSELDLAVPFC*VNFR.L 0 1.28 1.06 1.225 
IPI00745613.1 
EXOSC4 Uncharacterized 
protein EXOSC4 
ENSG00000178 
EXOS
C4 
K.SC*EMGLQLR
.Q 1.39 0 1.06 1.225 
IPI00742743.1 
TP53BP1 Isoform 2 of 
Tumor suppressor p53-
binding 
TP53B
P1 
K.VADPVDSSNL
DTC*GSISQVIE
QLPQPNR.T 
1.19 0 1.26 1.225 
IPI00009668.3 
CENPH Centromere 
protein H 
ENSG00000153044 
IPI0000 
CENP
H 
R.AGGPPQVAG
AQAAC*SEDR.
M 
1.12 1.35 1.06 1.22 
IPI00016912.1 
TTC1 Tetratricopeptide 
repeat protein 1 
ENSG000001 
TTC1 K.VTDTQEAEC*AGPPVPDPK.N 1.25 0 1.19 1.22 
IPI00641384.2 
SEC16A SEC16 homolog 
A ENSG00000148396 
IPI00641384 
SEC16
A 
R.ANNNAAVAP
TTC*PLQPVTDP
FAFSR.Q 
0 0 1.22 1.22 
IPI00003814.1 
MAP2K6 Isoform 1 of 
Dual specificity mitogen-
activ 
MAP2
K6 
K.AC*ISIGNQNF
EVK.A 0 0 1.22 1.22 
IPI00456981.2 
RP11-11C5.2 Similar to 
RIKEN cDNA 
2410129H14 ENSG0 
RP11-
11C5.2 
R.LC*EQGINPE
ALSSVIK.E 0 0 1.22 1.22 
IPI00796337.1 
PCBP2 poly(rC)-binding 
protein 2 isoform a 
ENSG000 
PCBP2 R.AITIAGIPQSIIEC*VK.Q 0 0 1.22 1.22 
IPI00556594.2 
ZCCHC8 Isoform 1 of Zinc 
finger CCHC domain-
contai 
ZCCH
C8 
R.IFGSIPMQAC*
QQK.D 0 0 1.22 1.22 
IPI00827583.1 
BSCL2 72 kDa protein 
ENSG00000168000 
IPI00045906 I 
BSCL2 K.EGC*TEVSLLR.V 1.22 0 0 1.22 
IPI00641582.1 
BAG3 BAG family 
molecular chaperone 
regulator 3 EN 
BAG3 
R.SQSPAASDC*
SSSSSSASLPSSG
R.S 
1.22 0 0 1.22 
IPI00030116.1 
PGM3 Isoform 1 of 
Phosphoacetylglucosamine 
mutase 
PGM3 K.QASC*SGDEYR.S 1.22 0 0 1.22 
IPI00029665.8 
MMAB Cob 
ENSG00000139428 
IPI00029665 IPI00795427 
I 
MMAB 
K.IQCTLQDVGS
ALATPC*SSAR.
E 
1.23 1.26 1.11 1.215 
IPI00333541.6 FLNA Filamin-A ENSG00000196924 FLNA 
K.AHVVPC*FDA
SK.V 0 1.28 1.02 1.215 
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IPI00553169 IPI0030 
IPI00012773.1 
MTA1 Isoform Long of 
Metastasis-associated 
protein 
MTA1 R.ALDC*SSSVR.Q 1.19 0 1.24 1.215 
IPI00844329.1 
HPRT1 Uncharacterized 
protein HPRT1 
ENSG0000016570 
HPRT1 K.SYC*NDQSTGDIK.V 1.05 1.44 0.91 1.21 
IPI00216975.1 
TPM4 Isoform 2 of 
Tropomyosin alpha-4 chain 
ENSG00 
TPM4 K.EENVGLHQTLDQTLNELNC*I.- 1.23 0 1.19 1.21 
IPI00297579.4 
CBX3 LOC653972 
Chromobox protein 
homolog 3 ENSG000 
CBX3 R.LTWHSC*PEDEAQ.- 1.22 0 1.2 1.21 
IPI00607557.1 ELF2 Isoform 5 of ETS-related transcription factor ELF2 
K.IITIPATQLAQ
C*QLQTK.S 0 0 1.21 1.21 
IPI00292753.7 
GAPVD1 GTPase 
activating protein and 
VPS9 domains 
GAPV
D1 
R.LQELESC*SG
LGSTSDDTDVR.
E 
0 0 1.21 1.21 
IPI00003027.1 
GEMIN7 Gem-associated 
protein 7 
ENSG00000142252 IP 
GEMI
N7 
R.RAPLRPEVPEI
QEC*PIAQESLE
SQEQR.A 
0 1.21 0 1.21 
IPI00643920.2 
TKT Transketolase 
ENSG00000163931 
IPI00643920 IPI0 
TKT 
K.QAFTDVATGS
LGQGLGAAC*G
MAYTGK.Y 
1.21 0 0 1.21 
IPI00021786.1 RAF1 RAF proto-oncogene serine/threonine-protein k RAF1 
K.DAVFDGSSC*
ISPTIVQQFGYQ
R.R 
1.21 0 0 1.21 
IPI00033132.3 
RNF7 Isoform 1 of RING-
box protein 2 
ENSG000001141 
RNF7 R.VQVMDAC*LR.C 1.1 1.37 0.98 1.205 
IPI00018768.1 
TSN Translin 
ENSG00000211460 
IPI00018768 
TSN K.ETAAAC*VEK.- 1.23 0 1.18 1.205 
IPI00470610.3 
PYCR2 Pyrroline-5-
carboxylate reductase 2 
ENSG0000 
PYCR2 R.SLLINAVEASC*IR.T 1.16 0 1.25 1.205 
IPI00029079.5 
GMPS GMP synthase 
ENSG00000163655 
IPI00029079 
GMPS K.TVGVQGDC*R.S 1.09 0 1.32 1.205 
IPI00217442.2 
MASK-BP3 EIF4EBP3 
MASK-4E-BP3 protein 
ENSG00000131 
MASK-
BP3 
R.LTSSVSC*AL
DEAAAALTR.M 1.26 0 1.14 1.2 
IPI00292753.7 
GAPVD1 GTPase 
activating protein and 
VPS9 domains 
GAPV
D1 
R.FSLC*SDNLE
GISEGPSNR.S 1.25 0 1.15 1.2 
IPI00290566.1 
TCP1 T-complex protein 1 
subunit alpha 
ENSG0000012 
TCP1 R.SLHDALC*VVK.R 0 0 1.2 1.2 
IPI00290571.3 
FBXO30 F-box only 
protein 30 
ENSG00000118496 IPI00 
FBXO3
0 
R.SFGVQPC*VS
TVLVEPAR.N 0 0 1.2 1.2 
IPI00000104.1 
RNGTT Isoform 1 of 
mRNA-capping enzyme 
ENSG0000011 
RNGT
T 
R.NKPFFDIC*TS
R.K 0 1.2 0 1.2 
IPI00012828.3 
ACAA1 3-ketoacyl-CoA 
thiolase, peroxisomal 
precurs 
ACAA
1 
R.DC*LIPMGITS
ENVAER.F 1.2 0 0 1.2 
IPI00020454.1 
DCK Deoxycytidine kinase 
ENSG00000156136 
IPI000204 
DCK K.QLC*EDWEVVPEPVAR.W 1.2 0 0 1.2 
IPI00008422.5 
SMARCAD1 Isoform 2 of 
SWI/SNF-related matrix-
assoc 
SMAR
CAD1 
R.VLGC*ILSELK
.Q 1.2 0 0 1.2 
IPI00022744.5 
CSE1L Isoform 1 of 
Exportin-2 
ENSG00000124207 IPI0 
CSE1L K.IC*AVGITK.L 1.2 0 1.19 1.195 
IPI00374316.4 C6orf115 similar to Protein C6orf115 ENSG000001463 
C6orf1
15 
K.C*ANLFEALV
GTLK.A 0 1.22 1.1 1.19 
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IPI00294536.1 STRAP Serine-threonine kinase receptor-associated STRAP 
K.IGFPETTEEEL
EEIASENSDC*IF
PSAPDVK.A 
1.12 1.25 1.14 1.19 
IPI00015262.10 
CNN2 Calponin-2 
ENSG00000064666 
IPI00015262 IPI003 
CNN2 
K.YCPQGTVAD
GAPSGTGDC*P
DPGEVPEYPPY
YQEEAGY.- 
1.22 0 1.16 1.19 
IPI00013871.1 
RRM1 Ribonucleoside-
diphosphate reductase large 
su 
RRM1 K.IIDINYYPVPEAC*LSNKR.H 0 0 1.19 1.19 
IPI00219445.1 
PSME3 Isoform 2 of 
Proteasome activator 
complex su 
PSME3 R.LDEC*EEAFQGTK.V 1.17 0 1.21 1.19 
IPI00013452.8 
EPRS glutamyl-prolyl 
tRNA synthetase 
ENSG000001366 
EPRS K.LGVENC*YFPMFVSQSALEK.E 1.04 0 1.34 1.19 
IPI00004534.3 
PFAS 
Phosphoribosylformylglyci
namidine synthase EN 
PFAS K.LMWLFGC*PLLLDDVAR.E 0 1.19 0 1.19 
IPI00333541.6 
FLNA Filamin-A 
ENSG00000196924 
IPI00553169 IPI0030 
FLNA K.ATC*APQHGAPGPGPADASK.V 0 1.19 0 1.19 
IPI00013830.1 
SNW1 SNW domain-
containing protein 1 
ENSG000001006 
SNW1 K.IPPC*ISNWK.N 0 1.19 0 1.19 
IPI00003766.4 
ETHE1 ETHE1 protein, 
mitochondrial precursor 
ENSG0 
ETHE1 R.QMFEPVSC*TFTYLLGDR.E 0 1.19 0 1.19 
IPI00005104.1 
CHUK ERLIN1 Inhibitor 
of nuclear factor kappa-B 
ki 
CHUK R.SLSDC*VNYIVQDSK.I 1.19 0 0 1.19 
IPI00019400.1 
TPMT Thiopurine S-
methyltransferase 
ENSG0000013736 
TPMT K.C*YADTMFSLLGK.K 1.19 0 0 1.19 
IPI00473014.5 
DSTN Destrin 
ENSG00000125868 
IPI00473014 IPI006432 
DSTN K.C*STPEEIKK.R 1.18 1.3 0.97 1.1875 
IPI00411706.1 
ESD S-formylglutathione 
hydrolase 
ENSG00000139684 
ESD 
K.AETGKCPALY
WLSGLTC*TEQ
NFISK.S 
0 1.19 1.18 1.1875 
IPI00220301.5 
PRDX6 Peroxiredoxin-6 
ENSG00000117592 
IPI00220301 
PRDX6 R.DFTPVC*TTELGR.A 1.19 0 1.18 1.185 
IPI00641743.2 
HCFC1 Uncharacterized 
protein HCFC1 
ENSG0000017253 
HCFC1 R.AC*AAGTPAVIR.I 1.05 0 1.32 1.185 
IPI00410067.1 
ZC3HAV1 Isoform 1 of 
Zinc finger CCCH type 
antivir 
ZC3HA
V1 
K.NSNVDSSYLE
SLYQSC*PR.G 1.11 0 1.25 1.18 
IPI00019755.3 
GSTO1 Glutathione 
transferase omega-1 
ENSG00000148 
GSTO1 R.FC*PFAER.T 1.4 1.17 0.98 1.18 
IPI00024719.1 
HAT1 Histone 
acetyltransferase type B 
catalytic su 
HAT1 K.VDENFDC*VEADDVEGK.I 1.21 0 1.15 1.18 
IPI00184523.1 
ARNT Putative 
uncharacterized protein 
DKFZp547B061 
ARNT 
K.MTAYITELSD
MVPTC*SALAR.
K 
0 0 1.18 1.18 
IPI00011698.3 
SAP18 Histone deacetylase 
complex subunit SAP18 
EN 
SAP18 K.TC*PLLLR.V 0 0 1.18 1.18 
IPI00141561.3 
COG1 Conserved 
oligomeric Golgi complex 
component 
COG1 K.AQAISPC*VQNFCSALDSK.L 0 0 1.18 1.18 
IPI00009010.3 
HSPC152 TRM112-like 
protein ENSG00000173113 
IPI000 
HSPC1
52 
R.IC*PVEFNPNF
VAR.M 0 0 1.18 1.18 
IPI00291006.1 MDH2 Malate dehydrogenase, MDH2 
K.TIIPLISQC*TP
K.V 0 0 1.18 1.18 
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mitochondrial precursor 
IPI00739117.3 
BAT2D1 HBxAg 
transactivated protein 2 
ENSG00000117 
BAT2D
1 
R.IAC*GPPQAK.
L 0 0 1.18 1.18 
IPI00220152.2 
BCCIP Isoform 2 of 
BRCA2 and CDKN1A-
interacting pr 
BCCIP R.TNKPC*GK.C 0 0 1.18 1.18 
IPI00010219.1 
SPC25 Kinetochore protein 
Spc25 ENSG00000152253 
IP 
SPC25 K.STDTSC*QMAGLR.D 1.17 0 1.19 1.18 
IPI00018350.3 
MCM5 DNA replication 
licensing factor MCM5 
ENSG000 
MCM5 K.C*SPIGVYTSGK.G 1.18 0 0 1.18 
IPI00005777.1 
MAPKAPK3 MAP kinase-
activated protein kinase 3 
ENS 
MAPK
APK3 
K.ETTQNALQTP
C*YTPYYVAPE
VLGPEK.Y 
1.18 0 0 1.18 
IPI00030774.2 
TBCD Isoform 4 of 
Tubulin-specific chaperone 
D ENS 
TBCD 
K.AGAPDEAVC
GENVSQIYC*AL
LGCMDDYTTDS
R.G 
1.18 0 0 1.18 
IPI00419237.3 
LAP3 Isoform 1 of Cytosol 
aminopeptidase 
ENSG00000 
LAP3 R.SAGAC*TAAAFLK.E 1.06 1.3 1.05 1.1775 
IPI00008524.1 
PABPC1 Isoform 1 of 
Polyadenylate-binding 
protein 
PABPC
1 
K.VVC*DENGSK
.G 1.35 0 1 1.175 
IPI00644674.1 
NUBP2 Nucleotide-binding 
protein 2 
ENSG00000095906 
NUBP2 K.ILDATPAC*LP.- 1.25 0 1.1 1.175 
IPI00030363.1 
ACAT1 Acetyl-CoA 
acetyltransferase, 
mitochondrial 
ACAT1 
K.QGEYGLASIC
*NGGGGASAML
IQK.L 
1.06 1.26 1.12 1.175 
IPI00007682.2 ATP6V1A Vacuolar ATP synthase catalytic subunit A 
ATP6V
1A K.WDFTPC*K.N 1.4 0 0.95 1.175 
IPI00020898.1 
RPS6KA3 Ribosomal 
protein S6 kinase alpha-3 
ENSG00 
RPS6K
A3 
R.AENGLLMTPC
*YTANFVAPEV
LK.R 
1.21 0 1.14 1.175 
IPI00024993.4 
ECHS1 Enoyl-CoA 
hydratase, mitochondrial 
precursor 
ECHS1 K.ALNALC*DGLIDELNQALK.T 1.11 1.25 1.08 1.1725 
IPI00013184.1 
ARD1A N-terminal 
acetyltransferase complex 
ARD1 su 
ARD1
A 
K.GNSPPSSGEA
C*R.E 0 1.17 1.17 1.17 
IPI00796337.1 
PCBP2 poly(rC)-binding 
protein 2 isoform a 
ENSG000 
PCBP2 
R.YSTGSDSASF
PHTTPSMC*LNP
DLEGPPLEAYTI
QGQYAIPQPDL
TK.L 
0 0 1.17 1.17 
IPI00024673.2 
MAPK9 Isoform Alpha-2 
of Mitogen-activated 
protein 
MAPK
9 
R.TAC*TNFMM
TPYVVTR.Y 0 0 1.17 1.17 
IPI00216951.2 
DARS Aspartyl-tRNA 
synthetase, cytoplasmic 
ENSG000 
DARS R.LEYC*EALAMLR.E 0 0 1.17 1.17 
IPI00479946.3 
STIP1 STIP1 protein 
ENSG00000168439 
IPI00013894 IP 
STIP1 K.ALDLDSSC*K.E 1.12 0 1.22 1.17 
IPI00550917.3 
TWF2 Twinfilin-2 
ENSG00000212130 
IPI00550917 
TWF2 K.HLSSC*AAPAPLTSAER.E 0 1.17 0 1.17 
IPI00017726.1 
HSD17B10 Isoform 1 of 3-
hydroxyacyl-CoA 
dehydrogen 
HSD17
B10 
K.VC*NFLASQV
PFPSR.L 0 1.17 0 1.17 
IPI00419237.3 
LAP3 Isoform 1 of Cytosol 
aminopeptidase 
ENSG00000 
LAP3 R.QVVDC*QLADVNNIGK.Y 1.23 0 1.1 1.165 
IPI00658023.1 PTPN11 Isoform 1 of Tyrosine-protein 
PTPN1
1 
K.QGFWEEFETL
QQQEC*K.L 1.23 0 1.1 1.165 
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phosphatase n 
IPI00639841.2 
PECI Peroxisomal 3,2-
trans-enoyl-CoA isomerase 
ENS 
PECI R.WLSDEC*TNAVVNFLSR.K 1.15 1.2 1.11 1.165 
IPI00093057.6 
CPOX 
Coproporphyrinogen III 
oxidase, mitochondrial 
CPOX K.EGGGGISCVLQDGC*VFEK.A 1.21 0 1.12 1.165 
IPI00008530.1 
RPLP0 60S acidic 
ribosomal protein P0 
ENSG00000089 
RPLP0 
R.AGAIAPC*EV
TVPAQNTGLGP
EK.T 
1.16 0 1.17 1.165 
IPI00218733.5 
SOD1 Uncharacterized 
protein SOD1 
ENSG00000142168 
SOD1 R.LAC*GVIGIAQ.- 1.1 0 1.23 1.165 
IPI00026216.4 
NPEPPS Puromycin-
sensitive aminopeptidase 
ENSG0000 
NPEPP
S 
R.SKDGVC*VR.
V 1.16 1.24 1.01 1.1625 
IPI00007811.1 CDK4 Cell division protein kinase 4 ENSG0000013544 CDK4 
R.LMDVC*ATSR
.T 1.11 1.26 1.02 1.1625 
IPI00008453.3 
CORO1C Coronin-1C 
ENSG00000110880 
IPI00008453 IPI0 
CORO
1C K.C*DLISIPK.K 0 1.2 1.04 1.16 
IPI00006907.1 
C12orf5 Uncharacterized 
protein C12orf5 
ENSG000000 
C12orf
5 
K.EADQKEQFSQ
GSPSNC*LETSL
AEIFPLGK.N 
1.06 1.25 1.08 1.16 
IPI00099996.2 
RG9MTD1 RNA (guanine-
9-) methyltransferase 
domain- 
RG9M
TD1 
K.SSVQEEC*VS
TISSSKDEDPLA
ATR.E 
1.11 0 1.21 1.16 
IPI00025176.1 
SMNDC1 Survival of 
motor neuron-related-
splicing f 
SMND
C1 
K.VGVGTC*GIA
DKPMTQYQDTS
K.Y 
1.17 0 1.15 1.16 
IPI00395939.3 
PITPNB Isoform 2 of 
Phosphatidylinositol 
transfer 
PITPN
B 
K.ELANSPDC*P
QMCAYK.L 1.17 0 1.15 1.16 
IPI00010720.1 
CCT5 T-complex protein 1 
subunit epsilon 
ENSG00000 
CCT5 K.VVNSC*HR.Q 0 0 1.16 1.16 
IPI00006754.1 
WDR68 WD repeat-
containing protein 68 
ENSG00000136 
WDR6
8 R.VPC*TPVAR.L 0 0 1.16 1.16 
IPI00100160.3 
CAND1 Isoform 1 of 
Cullin-associated NEDD8-
dissoci 
CAND
1 K.NC*IGDFLK.T 0 0 1.16 1.16 
IPI00301609.8 
NEK9 Serine/threonine-
protein kinase Nek9 
ENSG0000 
NEK9 R.LLTFGC*NK.C 0 0 1.16 1.16 
IPI00009949.2 
PSMF1 Proteasome 
inhibitor PI31 subunit 
ENSG000001 
PSMF1 
R.QPPWC*DPLG
PFVVGGEDLDP
FGPR.R 
0 1.16 0 1.16 
IPI00377005.2 
_ Uncharacterized protein 
ENSP00000340627 
ENSG0000 
_ K.EEHLC*TQR.M 1.16 0 0 1.16 
IPI00045939.4 
C10orf22 Uncharacterized 
protein C10orf22 
ENSG0000 
C10orf
22 
K.EASSSAC*DL
PR.E 1.16 0 0 1.16 
IPI00007927.3 
SMC2 Isoform 1 of 
Structural maintenance of 
chromo 
SMC2 R.FTQC*QNGK.I 1.32 0 0.99 1.155 
IPI00647082.1 
TBC1D13 TBC1 domain 
family, member 13 
ENSG00000107 
TBC1D
13 
R.LLQDYPITDV
C*QILQK.A 1.06 1.23 1.1 1.155 
IPI00018146.1 
YWHAQ 14-3-3 protein 
theta ENSG00000134308 
IPI0001 
YWHA
Q 
R.YLAEVAC*GD
DR.K 1.17 0 1.14 1.155 
IPI00016610.2 
PCBP1 Poly(rC)-binding 
protein 1 
ENSG00000169564 I 
PCBP1 R.INISEGNC*PER.I 1.09 1.2 1.12 1.1525 
IPI00293975.4 GPX1 glutathione peroxidase 1 isoform 1 GPX1 
R.FQTIDIEPDIE
ALLSQGPSC*A.- 1.18 1.2 1.02 1.15 
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ENSG000001 
IPI00301364.3 
SKP1A Isoform 1 of S-
phase kinase-associated 
prote 
SKP1A K.GLLDVTC*K.T 1.19 0 1.11 1.15 
IPI00472675.2 
NUP205 228 kDa protein 
ENSG00000155561 
IPI00783781 
NUP20
5 
R.C*QDVSAGSL
QELALLTGIISK.
A 
1.16 0 1.14 1.15 
IPI00021766.4 
RTN4 Isoform 1 of 
Reticulon-4 
ENSG00000115310 IPI0 
RTN4 K.YSNSALGHVNC*TIK.E 0 0 1.15 1.15 
IPI00295851.4 
COPB1 Coatomer subunit 
beta ENSG00000129083 
IPI002 
COPB1 K.ALSGYC*GFMAANLYAR.S 0 0 1.15 1.15 
IPI00002496.2 
GMPPB AMIGO3 GDP-
mannose 
pyrophosphorylase B isofo 
GMPP
B 
R.LC*SGPGIVG
NVLVDPSAR.I 0 0 1.15 1.15 
IPI00005791.1 
NDC80 Kinetochore 
protein Hec1 
ENSG00000080986 IPI 
NDC80 K.FNPEAGANC*LVK.Y 0 0 1.15 1.15 
IPI00021812.2 
AHNAK AHNAK 
nucleoprotein isoform 1 
ENSG0000012494 
AHNA
K 
K.LEGDLTGPSV
GVEVPDVELEC
*PDAK.L 
0 0 1.15 1.15 
IPI00746806.1 
CTTN CTTN protein 
ENSG00000085733 
IPI00029601 IPI0 
CTTN K.HC*SQVDSVR.G 0 0 1.15 1.15 
IPI00473014.5 
DSTN Destrin 
ENSG00000125868 
IPI00473014 IPI006432 
DSTN K.LGGSLIVAFEGC*PV.- 1.14 0 1.16 1.15 
IPI00072534.2 
UNC45A Isoform 1 of 
UNC45 homolog A 
ENSG0000014055 
UNC45
A 
K.LLAAGVVSA
MVC*MVK.T 0 1.15 0 1.15 
IPI00554824.1 
SGOL1 Isoform 1 of 
Shugoshin-like 1 
ENSG0000012981 
SGOL1 R.SFIAAPC*QIITNTSTLLK.N 0 1.15 0 1.15 
IPI00018009.2 
EDC3 Enhancer of mRNA-
decapping protein 3 
ENSG0000 
EDC3 K.SQDVAVSPQQQQC*SK.S 1.15 0 0 1.15 
IPI00456919.2 
HUWE1 Isoform 1 of E3 
ubiquitin-protein ligase 
HUW 
HUWE
1 
R.AQC*ETLSPD
GLPEEQPQTTK.
L 
1.15 0 0 1.15 
IPI00018352.1 
UCHL1 Ubiquitin 
carboxyl-terminal 
hydrolase isozym 
UCHL1 
K.NEAIQAAHD
AVAQEGQC*R.
V 
1.06 1.24 1.05 1.1475 
IPI00257508.4 
DPYSL2 
Dihydropyrimidinase-
related protein 2 ENSG0 
DPYSL
2 
R.GLYDGPVC*E
VSVTPK.T 1.18 0 1.11 1.145 
IPI00298111.7 
SNX6 sorting nexin 6 
isoform b 
ENSG00000129515 IPI 
SNX6 R.IGSSLYALGTQDSTDIC*K.F 1.17 0 1.12 1.145 
IPI00299214.6 
TK1 thymidine kinase 1, 
soluble ENSG00000167900 
IP 
TK1 R.YSSSFC*THDR.N 1.14 0 1.15 1.145 
IPI00022796.2 
HMG1L1 High-mobility 
group protein 1-like 1 
ENSG00 
HMG1
L1 
K.MSSYAFFVQT
C*R.E 1.12 0 1.17 1.145 
IPI00013871.1 
RRM1 Ribonucleoside-
diphosphate reductase large 
su 
RRM1 
R.NTAAMVC*SL
ENRDECLMCGS
.- 
1.02 0 1.27 1.145 
IPI00007682.2 ATP6V1A Vacuolar ATP synthase catalytic subunit A 
ATP6V
1A 
R.VLDALFPCVQ
GGTTAIPGAFG
C*GK.T 
0 1.09 1.31 1.145 
IPI00030328.1 
SRR Serine racemase 
ENSG00000167720 
IPI00030328 
SRR K.LEGIPAYIVVPQTAPDC*K.K 1.06 0 1.22 1.14 
IPI00304417.6 
IDH3B Isocitrate 
dehydrogenase [NAD] 
subunit beta, 
IDH3B K.LGDGLFLQC*CEEVAELYPK.I 0.96 0 1.32 1.14 
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IPI00103925.2 
IRGQ Immunity-related 
GTPase family Q protein 
ENSG 
IRGQ R.TDGEGEDPEC*LGEGK.M 0 0 1.14 1.14 
IPI00478208.2 
hCG_2004593 hypothetical 
protein LOC645296 
ENSG000 
hCG_2
004593 
R.INPYMSSPC*
HIEMILTEK.E 0 0 1.14 1.14 
IPI00031680.3 
ACBD6 Acyl-CoA-binding 
domain-containing protein 
6 
ACBD
6 
R.DQDGCLPEEV
TGC*K.T 0 0 1.14 1.14 
IPI00555734.3 
ASRGL1 asparaginase-like 
1 protein 
ENSG00000162174 
ASRG
L1 
K.GAQKTDC*Q
K.N 0 0 1.14 1.14 
IPI00450071.5 
C1orf19 tRNA-splicing 
endonuclease subunit 
Sen15 E 
C1orf1
9 
R.GDSEPTPGC*
SGLGPGGVR.G 0 0 1.14 1.14 
IPI00027443.5 
CARS cysteinyl-tRNA 
synthetase isoform c 
ENSG00000 
CARS R.VQPQWSPPAGTQPC*R.L 0 0 1.14 1.14 
IPI00152998.3 
LRRC40 Leucine-rich 
repeat-containing protein 
40 E 
LRRC4
0 
R.FLPEFPSC*SL
LK.E 0 0 1.14 1.14 
IPI00334683.1 
GAMT guanidinoacetate 
N-methyltransferase 
isoform 
GAMT 
K.VQEAPIDEHW
IIEC*NDGVFQR.
L 
0 0 1.14 1.14 
IPI00003881.5 
HNRPF Heterogeneous 
nuclear ribonucleoprotein F 
EN 
HNRPF R.DLSYC*LSGMYDHR.Y 1.13 0 1.15 1.14 
IPI00830108.1 
ZRF1 Isoform 1 of DnaJ 
homolog subfamily C 
member 
ZRF1 R.LELASLQC*LNETLTSCTK.E 1.13 0 1.15 1.14 
IPI00480131.1 
FLNB Uncharacterized 
protein FLNB 
ENSG00000136068 
FLNB R.SSTETC*YSAIPK.A 1.14 0 0 1.14 
IPI00290416.3 
OLA1 Isoform 1 of 
Putative GTP-binding 
protein 9 E 
OLA1 
K.STFFNVLTNS
QASAENFPFC*T
IDPNESR.V 
1.12 1.21 1.01 1.1375 
IPI00216298.6 
TXN Thioredoxin 
ENSG00000136810 
IPI00552768 IPI002 
TXN K.C*MPTFQFFK.K 0 1.15 1.1 1.1375 
IPI00029079.5 
GMPS GMP synthase 
ENSG00000163655 
IPI00029079 
GMPS R.VICAEEPYIC*K.D 1.18 0 1.09 1.135 
IPI00020602.1 CSNK2A2 Casein kinase II subunit alpha ENSG000000 
CSNK2
A2 
K.EQSQPC*ADN
AVLSSGLTAAR.
- 
1.1 0 1.17 1.135 
IPI00031647.2 
PDCD2L Programmed cell 
death protein 2-like 
ENSG00 
PDCD2
L 
R.YSWSGEPLFL
TC*PTSEVTELP
ACSQCGGQR.I 
1.01 0 1.26 1.135 
IPI00018402.1 
TBCE Tubulin-specific 
chaperone E 
ENSG00000116957 
TBCE R.NCAVSC*AGEK.G 1.3 1.12 0.99 1.1325 
IPI00006863.5 
SPAG7 Single-stranded 
nucleic acid binding R3H 
dom 
SPAG7 K.TYGC*VPVANKR.D 0 1.17 1.02 1.1325 
IPI00303318.2 
FAM49B Protein FAM49B 
ENSG00000153310 
IPI00651701 
FAM49
B 
K.VLTC*TDLEQ
GPNFFLDFENA
QPTESEK.E 
1.25 0 1.01 1.13 
IPI00022228.1 
HDLBP Vigilin 
ENSG00000115677 
IPI00022228 IPI00443 
HDLB
P 
K.AAC*LESAQE
PAGAWGNK.I 1.16 0 1.1 1.13 
IPI00008982.1 
ALDH18A1 Isoform Long 
of Delta-1-pyrroline-5-
carbo 
ALDH
18A1 
K.LGSAVVTRG
DEC*GLALGR.L 1.13 0 1.13 1.13 
IPI00294008.4 
ZWINT ZW10 interactor 
ENSG00000122952 
IPI00646553 
ZWINT 
K.LLC*SQLQVA
DFLQNILAQED
TAK.G 
0 0 1.13 1.13 
IPI00004534.3 
PFAS 
Phosphoribosylformylglyci
namidine synthase EN 
PFAS R.IVLVDDREC*PVRR.N 0 0 1.13 1.13 
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IPI00023087.1 
UBE2T Ubiquitin-
conjugating enzyme E2 T 
ENSG000000 
UBE2T R.IC*LDVLK.L 0 0 1.13 1.13 
IPI00291646.2 
MTHFD1L 
methylenetetrahydrofolate 
dehydrogenase (N 
MTHF
D1L R.SSC*SPGGR.T 1.11 0 1.15 1.13 
IPI00022827.1 SLK Isoform 1 of STE20-like serine/threonine-prote SLK 
K.MTGESEC*LN
PSTQSR.I 1.09 0 1.17 1.13 
IPI00174390.3 2-PDE 2-phosphodiesterase ENSG00000174840 IPI001 2-PDE 
K.SRPNASGGAA
C*SGPGPEPAVF
CEPVVK.L 
0 1.13 0 1.13 
IPI00056505.5 NT5C3L Cytosolic 5-nucleotidase III-like protein 
NT5C3
L 
K.NSSAC*ENSG
YFQQLEGK.T 1.13 0 0 1.13 
IPI00025273.1 
GART Isoform Long of 
Trifunctional purine 
biosynth 
GART K.QVLVAPGNAGTAC*SEK.I 1.13 1.08 1.22 1.1275 
IPI00298961.3 
XPO1 Exportin-1 
ENSG00000082898 
IPI00784388 IPI002 
XPO1 K.DLLGLC*EQK.R 1.23 0 1.02 1.125 
IPI00334775.6 
HSP90AB1 85 kDa protein 
ENSG00000096384 
IPI0041467 
HSP90
AB1 
R.LVSSPC*CIVT
STYGWTANME
R.I 
1.16 0 1.09 1.125 
IPI00215610.2 
MPP1 55 kDa erythrocyte 
membrane protein 
ENSG00000 
MPP1 
R.VASMAQSAPS
EAPSC*SPFGK.
K 
1.15 0 1.1 1.125 
IPI00418471.6 
VIM Vimentin 
ENSG00000026025 
IPI00418471 IPI008276 
VIM R.QVQSLTC*EVDALK.G 1.15 0 1.1 1.125 
IPI00828189.1 
PCMT1 Isoform 2 of 
Protein-L-isoaspartate(D-
aspart 
PCMT1 R.MVGC*TGK.V 1.15 0 1.1 1.125 
IPI00647082.1 
TBC1D13 TBC1 domain 
family, member 13 
ENSG00000107 
TBC1D
13 
K.SLDDSQC*GI
TYK.M 1.14 0 1.11 1.125 
IPI00014177.3 
SEPT2 Septin-2 
ENSG00000168385 
IPI00014177 
41519 R.LTVVDTPGYGDAINC*R.D 1.14 0 1.11 1.125 
IPI00334159.6 
VBP1 Prefoldin subunit 3 
ENSG00000155959 
IPI003341 
VBP1 R.FLLADNLYC*K.A 1.12 0 1.13 1.125 
IPI00045207.2 
BTBD14B BTB/POZ 
domain-containing protein 
14B ENSG 
BTBD1
4B 
R.NTLANSC*GT
GIR.S 1.11 0 1.14 1.125 
IPI00060521.1 
FLYWCH2 Putative 
uncharacterized protein 
LOC114984 
FLYW
CH2 
R.TEDSGLAAGP
PEAAGENFAPC
*SVAPGK.S 
1.06 0 1.19 1.125 
IPI00021290.5 
ACLY ATP-citrate 
synthase 
ENSG00000131473 
IPI00021 
ACLY K.FIC*TTSAIQNR.F 1.1 1.16 1.07 1.1225 
IPI00220528.6 
SNRPF Small nuclear 
ribonucleoprotein F 
ENSG000001 
SNRPF R.C*NNVLYIR.G 1.08 1.19 1.02 1.12 
IPI00020454.1 
DCK Deoxycytidine kinase 
ENSG00000156136 
IPI000204 
DCK R.SC*PSFSASSEGTR.I 1.17 0 1.07 1.12 
IPI00005777.1 
MAPKAPK3 MAP kinase-
activated protein kinase 3 
ENS 
MAPK
APK3 
K.QAGSSSASQG
C*NNQ.- 1.16 0 1.08 1.12 
IPI00844388.1 
HELLS 103 kDa protein 
ENSG00000119969 
IPI00012073 
HELLS K.ILENSEDSSPEC*LF.- 1.14 0 1.1 1.12 
IPI00384180.4 
YRDC 
ischemia/reperfusion 
inducible protein ENSG00 
YRDC 
R.AGAVVAVPT
DTLYGLAC*AA
SCSAALR.A 
1.14 0 1.1 1.12 
IPI00221172.2 
C14orf130 Uncharacterized 
protein C14orf130 
ENSG00 
C14orf
130 
K.VEQNSEPC*A
GSSSESDLQTVF
K.N 
0 0 1.12 1.12 
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IPI00008422.5 
SMARCAD1 Isoform 2 of 
SWI/SNF-related matrix-
assoc 
SMAR
CAD1 
K.NTEMC*NVM
MQLR.K 0 0 1.12 1.12 
IPI00061623.1 SGTB Small glutamine-rich tetratricopeptide repeat SGTB 
K.ISPEDTHLAV
SQPLTEMFTSSF
C*K.N 
0 0 1.12 1.12 
IPI00025087.1 TP53 Isoform 1 of Cellular tumor antigen p53 ENSG0 TP53 
R.C*SDSDGLAP
PQHLIR.V 0 0 1.12 1.12 
IPI00024403.1 
CPNE3 Copine-3 
ENSG00000085719 
IPI00024403 IPI0074 
CPNE3 
K.EALAQC*VLA
EIPQQVVGYFN
TYK.L 
0 0 1.12 1.12 
IPI00022977.1 
CKB Creatine kinase B-
type ENSG00000166165 
IPI0002 
CKB 
K.DYEFMWNPH
LGYILTC*PSNL
GTGLR.A 
0 1.12 0 1.12 
IPI00456803.2 
_ Uncharacterized protein 
ENSP00000368765 
ENSG0000 
_ R.AYCHILLGNYC*VAVADAK.K 0 1.17 0.97 1.12 
IPI00549389.3 
C9orf32 Protein of 
unknown function 
DUF858, methyl 
C9orf3
2 
R.IIC*SAGLSLL
AEER.Q 1.05 1.17 1.08 1.1175 
IPI00018783.1 
ITPA Inosine triphosphate 
pyrophosphatase 
ENSG0000 
ITPA 
R.GC*QDFGWD
PCFQPDGYEQT
YAEMPK.A 
1.11 0 1.12 1.115 
IPI00148061.3 
LDHAL6A L-lactate 
dehydrogenase A-like 6A 
ENSG0000 
LDHA
L6A 
K.NRVIGSGC*N
LDSAR.F 1.17 0 1.06 1.115 
IPI00021329.3 
WDR45L WD repeat 
domain phosphoinositide-
interacti 
WDR4
5L 
R.C*NYLALVGG
GK.K 1.14 0 1.09 1.115 
IPI00549993.3 
C10orf97 chromosome 10 
open reading frame 97 
ENSG0 
C10orf
97 
K.SSPGLSDTIFC
*R.W 1.13 0 1.1 1.115 
IPI00059687.1 
C18orf25 Isoform 1 of 
Uncharacterized protein 
C18o 
C18orf
25 
K.DGVADSTVIS
SMPC*LLMELR.
R 
1.13 0 1.1 1.115 
IPI00011200.5 
PHGDH D-3-
phosphoglycerate 
dehydrogenase 
ENSG00000 
PHGD
H 
K.VLISDSLDPC*
CR.K 1.13 0 1.1 1.115 
IPI00054042.1 
GTF2I Isoform 1 of 
General transcription factor 
II 
GTF2I R.SILSPGGSC*GPIK.V 1.1 0 1.13 1.115 
IPI00797537.1 
NUDCD1 NudC domain-
containing protein 1 
ENSG000001 
NUDC
D1 
R.DSAQC*AAIA
ER.L 1.09 0 1.14 1.115 
IPI00220158.1 
ADD1 Isoform 3 of Alpha-
adducin 
ENSG00000087274 IP 
ADD1 K.TAGPQSQVLC*GVVMDR.S 1.08 0 1.15 1.115 
IPI00010141.4 
POLE3 DNA polymerase 
epsilon subunit 3 
ENSG0000014 
POLE3 
R.AASVFVLYAT
SC*ANNFAMK.
G 
0 0 1.11 1.11 
IPI00748935.1 
ELP4 59 kDa protein 
ENSG00000109911 
IPI00847770 IP 
ELP4 K.VEPC*SLTPGYTK.L 0 0 1.11 1.11 
IPI00030876.6 
DIAPH1 Diaphanous 1 
ENSG00000131504 
IPI00030876 IP 
DIAPH
1 
K.AGC*AVTSLL
ASELTK.D 0 0 1.11 1.11 
IPI00291510.3 
IMPDH2 Inosine-5-
monophosphate 
dehydrogenase 2 EN 
IMPDH
2 
R.HGFC*GIPITD
TGR.M 0 1.11 0 1.11 
IPI00004928.1 
EGLN1 Isoform 1 of Egl 
nine homolog 1 
ENSG00000135 
EGLN1 K.AKPPADPAAAASPC*R.A 0 1.11 0 1.11 
IPI00296441.5 
ADA Adenosine deaminase 
ENSG00000196839 
IPI0029644 
ADA K.FDYYMPAIAGC*R.E 1.11 0 0 1.11 
IPI00032995.1 
LANCL2 LanC-like protein 
2 ENSG00000132434 
IPI0003 
LANC
L2 
R.SVVC*QESDL
PDELLYGR.A 1.11 0 0 1.11 
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IPI00382470.3 
HSP90AA1 heat shock 
protein 90kDa alpha 
(cytosolic 
HSP90
AA1 
R.VFIMDNC*EE
LIPEYLNFIR.G 0.98 1.23 1 1.11 
IPI00550069.3 
RNH1 Ribonuclease 
inhibitor 
ENSG00000023191 IPI005 
RNH1 
R.ELDLSNNC*L
GDAGILQLVES
VR.Q 
1.14 0 1.08 1.11 
IPI00021808.3 
HARS Histidyl-tRNA 
synthetase, cytoplasmic 
ENSG000 
HARS R.TGQPLC*IC.- 1.14 0 1.08 1.11 
IPI00015141.4 
CKMT2 Creatine kinase, 
sarcomeric mitochondrial 
pr 
CKMT
2 
R.LGYILTC*PSN
LGTGLR.A 0 1.17 0.92 1.1075 
IPI00010896.3 
DDAH2 CLIC1 Chloride 
intracellular channel 
protein 
DDAH
2 
K.IGNC*PFSQR.
L 1.38 1.04 0.97 1.1075 
IPI00647337.1 
_ OTTHUMP00000016411 
ENSG00000181524 
IPI00647337 
_ K.VELC*SFSGYK.I 1.16 0 1.05 1.105 
IPI00026781.2 
FASN Fatty acid synthase 
ENSG00000169710 
IPI000267 
FASN K.ADEASELAC*PTPK.E 1.09 0 1.12 1.105 
IPI00301421.5 
ZC3HC1 Isoform 1 of 
Nuclear-interacting partner 
of 
ZC3HC
1 
R.LC*SSSSSDTS
SR.S 1.02 0 1.19 1.105 
IPI00334775.6 
HSP90AB1 85 kDa protein 
ENSG00000096384 
IPI0041467 
HSP90
AB1 
R.VFIMDSC*DE
LIPEYLNFIR.G 1.09 1.14 1.04 1.1025 
IPI00008531.1 
RCOR1 REST corepressor 
1 ENSG00000089902 
IPI000085 
RCOR1 
R.GRNNAAASA
SAAAASAAASA
AC*ASPAATAA
SGAAASSASAA
AASAAAAPNNG
QNK.S 
1.1 1.23 0.84 1.1 
IPI00257882.7 
PEPD Xaa-Pro dipeptidase 
ENSG00000124299 
IPI002578 
PEPD R.TVEEIEACMAGC*DK.A 1.21 0 0.99 1.1 
IPI00449197.1 
GMPR2 GMPR2 protein 
ENSG00000100938 
IPI00385158 IP 
GMPR
2 
R.VTQQVNPIFS
EAC*.- 1.13 0 1.07 1.1 
IPI00220158.1 
ADD1 Isoform 3 of Alpha-
adducin 
ENSG00000087274 IP 
ADD1 
R.VSMILQSPAF
C*EELESMIQEQ
FKK.G 
0 0 1.1 1.1 
IPI00550882.2 
PYCR1 Pyrroline-5-
carboxylate reductase 1 
ENSG0000 
PYCR1 R.C*MTNTPVVVR.E 0 0 1.1 1.1 
IPI00852816.1 
SMARCD1 SWI/SNF-
related matrix-associated 
actin-de 
SMAR
CD1 
R.AEFYFQPWA
QEAVC*R.Y 0 0 1.1 1.1 
IPI00787501.1 
LOC727737 similar to 
APG4 autophagy 4 
homolog B is 
LOC72
7737 
K.NFPAIGGTGP
TSDTGWGC*ML
R.C 
0 0 1.1 1.1 
IPI00641743.2 
HCFC1 Uncharacterized 
protein HCFC1 
ENSG0000017253 
HCFC1 K.LVIYGGMSGC*R.L 0 0 1.1 1.1 
IPI00020898.1 
RPS6KA3 Ribosomal 
protein S6 kinase alpha-3 
ENSG00 
RPS6K
A3 
K.AYSFC*GTVE
YMAPEVVNR.R 0 0 1.1 1.1 
IPI00154645.7 
TBC1D15 Isoform 1 of 
TBC1 domain family 
member 15 
TBC1D
15 
R.NDSPTQIPVSS
DVC*R.L 1.1 0 0 1.1 
IPI00514510.1 
ANXA7 annexin VII 
isoform 2 
ENSG00000138279 IPI005 
ANXA
7 
R.LGTDESC*FN
MILATR.S 1.11 0 1.08 1.095 
IPI00019169.3 
SH3GL1 SH3-containing 
GRB2-like protein 1 
ENSG0000 
SH3GL
1 
R.EPFDLGEPEQ
SNGGFPC*TTAP
K.I 
1.08 0 1.11 1.095 
IPI00329321.3 
LYRM7 LYR motif-
containing protein 7 
ENSG000001866 
LYRM
7 
R.KDLLVENVPY
C*DAPTQK.Q 1.05 0 1.14 1.095 
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IPI00216682.5 
CNN3 Calponin-3 
ENSG00000117519 
IPI00216682 IPI006 
CNN3 K.C*ASQAGMTAYGTR.R 1.04 0 1.15 1.095 
IPI00086909.6 
LOC440917 similar to 14-
3-3 protein epsilon 
ENSG00 
LOC44
0917 
K.LIC*CDILDVL
DK.H 1.11 0 1.07 1.09 
IPI00219217.3 
LDHB L-lactate 
dehydrogenase B chain 
ENSG000001117 
LDHB K.GMYGIENEVFLSLPC*ILNAR.G 0 0 1.09 1.09 
IPI00301051.3 
NHLRC2 NHL repeat-
containing protein 2 
ENSG0000019 
NHLR
C2 
K.AILFSQPLQIT
DTQQGC*IAPVE
LR.Y 
0 0 1.09 1.09 
IPI00177965.5 
NT5DC1 5-nucleotidase 
domain-containing protein 
1 
NT5DC
1 
K.HFLSDTGMA
C*R.S 0 0 1.09 1.09 
IPI00015866.2 
ARL2BP Isoform 1 of 
ADP-ribosylation factor-
like p 
ARL2B
P 
R.GLDLSSGLVV
TSLC*K.S 0 0 1.09 1.09 
IPI00030177.2 
RBPJ Isoform APCR-2 of 
Recombining binding 
protein 
RBPJ R.IIQFQATPC*PK.E 0 0 1.09 1.09 
IPI00010157.1 
MAT2A S-
adenosylmethionine 
synthetase isoform type 
MAT2
A 
K.VAC*ETVAK.
T 1.07 0 1.11 1.09 
IPI00145260.3 
C1orf69 Putative 
transferase C1orf69, 
mitochondria 
C1orf6
9 
K.GC*YIGQELT
AR.T 1.06 0 1.12 1.09 
IPI00554737.3 PPP2R1A Serine/threonine-protein phosphatase 2A 65 
PPP2R
1A 
K.DNTIEHLLPLF
LAQLKDEC*PE
VR.L 
0 1.09 0 1.09 
IPI00020729.1 
IRS4 insulin receptor 
substrate 4 
ENSG00000133124 
IRS4 R.GGQGSNGQGSGGNQC*SR.D 1.09 0 0 1.09 
IPI00303962.3 
PPCDC Isoform 1 of 
Phosphopantothenoylcystei
ne dec 
PPCDC 
K.LVC*GDEGLG
AMAEVGTIVDK
.V 
1.09 0 0 1.09 
IPI00025156.4 STUB1 Isoform 1 of STIP1 homology and U box-contai STUB1 
R.AQQAC*IEAK.
H 1.14 0 1.04 1.09 
IPI00465044.2 
RCC2 Protein RCC2 
ENSG00000179051 
IPI00465044 
RCC2 K.AVQDLC*GWR.I 1.13 0 1.05 1.09 
IPI00182757.9 
KIAA1967 
Uncharacterized protein 
KIAA1967 ENSG0000 
KIAA1
967 
R.GEASEDLC*E
MALDPELLLLR.
D 
1.13 0 1.05 1.09 
IPI00025746.5 
ANKRD54 Isoform 1 of 
Ankyrin repeat domain-
contain 
ANKR
D54 R.LDDLC*TR.L 1.02 0 1.16 1.09 
IPI00640364.2 
OTUD5 Isoform 1 of OTU 
domain-containing protein 
5 
OTUD
5 
R.ATSPLVSLYP
ALEC*R.A 1.02 0 1.16 1.09 
IPI00479385.3 
ASMTL Uncharacterized 
protein ASMTL 
ENSG0000016909 
ASMT
L 
K.VDASAC*GM
ER.L 0 1.12 0.99 1.0875 
IPI00465152.2 
SP1 Transcription factor 
Sp1 ENSG00000185591 
IPI00 
SP1 
R.SSSTGSSSSTG
GGGQESQPSPL
ALLAATC*SR.I 
1.14 0 1.03 1.085 
IPI00853598.1 
SEC13 41 kDa protein 
ENSG00000157020 
IPI00845335 I 
SEC13 R.FASGGC*DNLIK.L 1.02 1.14 1.04 1.085 
IPI00012866.2 
AKT1 RAC-alpha 
serine/threonine-protein 
kinase ENS 
AKT1 
K.TFC*GTPEYL
APEVLEDNDYG
R.A 
1.1 0 1.07 1.085 
IPI00298961.3 
XPO1 Exportin-1 
ENSG00000082898 
IPI00784388 IPI002 
XPO1 
K.LDINLLDNVV
NC*LYHGEGAQ
QR.M 
1.08 1.09 1.08 1.085 
IPI00030363.1 
ACAT1 Acetyl-CoA 
acetyltransferase, 
mitochondrial 
ACAT1 K.VC*ASGMK.A 1.09 1.08 1.09 1.085 
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IPI00748696.1 
AP3S2 44 kDa protein 
ENSG00000157823 
IPI00025115 I 
AP3S2 K.C*NFTGDGK.T 1.07 0 1.1 1.085 
IPI00103554.1 
GATAD2B Transcriptional 
repressor p66 beta 
ENSG000 
GATA
D2B K.SC*ASLLR.V 1.07 0 1.1 1.085 
IPI00102856.3 
SMAP1L Isoform 1 of 
Stromal membrane-
associated pr 
SMAP1
L 
K.STAPVMDLL
GLDAPVAC*SIA
NSK.T 
1.12 1.09 1.03 1.0825 
IPI00748256.1 
PSME1 Uncharacterized 
protein PSME1 
ENSG0000009201 
PSME1 K.VDVFREDLC*TK.T 0 0 1.08 1.08 
IPI00745345.1 
PPP4R2 Protein 
phosphatase 4 regulatory 
subunit 2 
PPP4R
2 
K.EVC*PVLDQF
LCHVAK.T 0 0 1.08 1.08 
IPI00025366.4 
CS Citrate synthase, 
mitochondrial precursor 
ENSG0 
CS K.LPC*VAAK.I 0 0 1.08 1.08 
IPI00002824.7 
CSRP2 Cysteine and 
glycine-rich protein 2 
ENSG0000 
CSRP2 R.C*GDSVYAAEK.I 0 0 1.08 1.08 
IPI00101652.4 
SCLY Selenocysteine lyase 
ENSG00000132330 
IPI00101 
SCLY R.DAPAPAASQPSGC*GK.H 0 0 1.08 1.08 
IPI00789101.1 
PTGES3 19 kDa protein 
ENSG00000110958 
IPI00015029 
PTGES
3 
K.HLNEIDLFHC
*IDPNDSK.H 0 0 1.08 1.08 
IPI00018955.1 ZNF174 Isoform 1 of Zinc finger protein 174 ENSG00 
ZNF17
4 
R.LQHLGHQPTR
SAKKPYKC*DD
CGK.S 
0 1.08 0 1.08 
IPI00021327.3 GRB2 Isoform 1 of Growth factor receptor-bound pro GRB2 
K.VLNEEC*DQN
WYK.A 1.08 0 0 1.08 
IPI00026781.2 
FASN Fatty acid synthase 
ENSG00000169710 
IPI000267 
FASN K.AINC*ATSGVVGLVNCLR.R 0 1.1 1.01 1.0775 
IPI00386189.2 
NARG1 Isoform 1 of 
NMDA receptor-regulated 
protein 
NARG
1 
R.LFNTAVC*ES
K.D 1.18 1.03 1.07 1.0775 
IPI00005011.1 
CNOT2 Isoform 1 of 
CCR4-NOT transcription 
complex 
CNOT2 R.SSPSIIC*MPK.Q 1.04 0 1.11 1.075 
IPI00018146.1 
YWHAQ 14-3-3 protein 
theta ENSG00000134308 
IPI0001 
YWHA
Q 
R.DNLTLWTSDS
AGEEC*DAAEG
AEN.- 
1.15 0 1 1.075 
IPI00658023.1 
PTPN11 Isoform 1 of 
Tyrosine-protein 
phosphatase n 
PTPN1
1 
K.YSLADQTSGD
QSPLPPCTPTPP
C*AEMR.E 
1.08 0 1.06 1.07 
IPI00298308.6 
ALDH1L2 Aldehyde 
dehydrogenase family 1 
member L2 
ALDH
1L2 
K.SPLIIFNDC*E
LDK.T 0 0 1.07 1.07 
IPI00448751.2 
KIAA1598 Isoform 3 of 
Shootin-1 
ENSG00000187164 IP 
KIAA1
598 
K.VTFQPPSSIGC
*R.K 0 0 1.07 1.07 
IPI00033130.3 
SAE1 SUMO-activating 
enzyme subunit 1 
ENSG00000142 
SAE1 
R.YCFSEMAPVC
*AVVGGILAQEI
VK.A 
1.02 0 1.12 1.07 
IPI00025178.3 
BCAS2 Breast carcinoma 
amplified sequence 2 
ENSG00 
BCAS2 
K.NDITAWQEC*
VNNSMAQLEH
QAVR.I 
1.07 0 0 1.07 
IPI00162563.5 
RNF40 Isoform 1 of E3 
ubiquitin-protein ligase 
BRE 
RNF40 R.LTCPC*CNTR.K 1.07 0 0 1.07 
IPI00177509.4 
TRAPPC5 Trafficking 
protein particle complex 
subun 
TRAPP
C5 
K.ENSTLNC*AS
FTAGIVEAVLT
HSGFPAK.V 
0 1.13 0.88 1.0675 
IPI00786942.1 
ALDH7A1 similar to 
antiquitin 
ENSG00000164904 IPI0 
ALDH
7A1 
K.GSDC*GIVNV
NIPTSGAEIGGA
FGGEK.H 
1.16 0 0.97 1.065 
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IPI00007694.4 
PPME1 Isoform 1 of 
Protein phosphatase 
methylester 
PPME1 R.FAEPIGGFQC*VFPGC.- 1.16 0 0.97 1.065 
IPI00013949.1 SGTA Small glutamine-rich tetratricopeptide repeat SGTA 
R.AIC*IDPAYSK
.A 1.09 0 1.04 1.065 
IPI00032050.4 
WBP2 WW domain-
binding protein 2 
ENSG00000132471 I 
WBP2 K.DC*EIKQPVFGANYIK.G 1.09 0 1.04 1.065 
IPI00090720.4 
QRSL1 Glutaminyl-tRNA 
synthase-like protein 1 
ENSG 
QRSL1 
K.QVQFPVIQLQ
ELMDDC*SAVL
ENEK.L 
1.04 0 1.09 1.065 
IPI00152998.3 
LRRC40 Leucine-rich 
repeat-containing protein 
40 E 
LRRC4
0 
R.DC*GTSVPQG
LLK.A 1.03 0 1.1 1.065 
IPI00549189.4 
THOP1 Thimet 
oligopeptidase 
ENSG00000172009 IPI005 
THOP1 
-
.MKPPAAC*AG
DMADAASPCSV
VNDLR.W 
0 0 1.06 1.06 
IPI00386122.4 
MOBKL3 Isoform 1 of 
Preimplantation protein 3 
ENSG 
MOBK
L3 
R.HTLDGAAC*L
LNSNK.Y 0 0 1.06 1.06 
IPI00742743.1 
TP53BP1 Isoform 2 of 
Tumor suppressor p53-
binding 
TP53B
P1 
K.TMSVLSCIC*
EAR.Q 0 0 1.06 1.06 
IPI00216319.3 
YWHAH 14-3-3 protein eta 
ENSG00000128245 
IPI008275 
YWHA
H 
K.NC*NDFQYES
K.V 0 0 1.06 1.06 
IPI00784131.1 
AARS Uncharacterized 
protein AARS 
ENSG00000090861 
AARS K.NVGC*LQEALQLATSFAQLR.L 0 1.06 0 1.06 
IPI00030781.1 STAT1 Isoform Alpha of Signal transducer and activ STAT1 
R.NLSFFLTPPC*
AR.W 0 1.06 0 1.06 
IPI00337397.1 
NUP98 Isoform 5 of 
Nuclear pore complex 
protein Nu 
NUP98 K.FTSGAFLSPSVSVQEC*R.T 1.06 0 0 1.06 
IPI00008794.1 
DFFB Isoform Alpha of 
DNA fragmentation factor 
sub 
DFFB R.VLGSMC*QR.L 0 1.06 1.05 1.0575 
IPI00290566.1 
TCP1 T-complex protein 1 
subunit alpha 
ENSG0000012 
TCP1 R.IC*DDELILIK.N 1.08 0 1.03 1.055 
IPI00219757.13 
GSTP1 Glutathione S-
transferase P 
ENSG00000084207 
GSTP1 K.ASC*LYGQLPK.F 1.08 0 1.03 1.055 
IPI00646512.1 
RBBP7 Retinoblastoma 
binding protein 7 
ENSG0000010 
RBBP7 
R.VHIPNDDAQF
DASHC*DSDKG
EFGGFGSVTGK.
I 
1.04 0 1.07 1.055 
IPI00027223.2 
IDH1 Isocitrate 
dehydrogenase [NADP] 
cytoplasmic E 
IDH1 K.SEGGFIWAC*K.N 1.04 0 1.07 1.055 
IPI00000875.6 
EEF1G Elongation factor 
1-gamma 
ENSG00000186676 IP 
EEF1G 
K.AAAPAPEEE
MDEC*EQALAA
EPK.A 
1.12 0.99 1.12 1.055 
IPI00019812.1 
PPP5C Serine/threonine-
protein phosphatase 5 
ENSG0 
PPP5C R.TEC*AEPPRDEPPADGALKR.A 1.13 0 0.98 1.055 
IPI00004839.1 
CRKL Crk-like protein 
ENSG00000099942 
IPI00004839 
CRKL K.RVPC*AYDK.T 0.91 1.16 0.99 1.055 
IPI00011200.5 
PHGDH D-3-
phosphoglycerate 
dehydrogenase 
ENSG00000 
PHGD
H 
K.NAGNC*LSPA
VIVGLLK.E 0 1.1 0.91 1.0525 
IPI00784614.1 
SEPT9 Isoform 1 of Septin-
9 ENSG00000184640 
IPI007 
41526 
R.SQEATEAAPS
C*VGDMADTPR
.D 
1.18 0 0.92 1.05 
IPI00301263.2 CAD CAD protein ENSG00000084774 CAD 
K.AQILVLTYPLI
GNYGIPPDEMD 0 1.07 0.99 1.05 
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IPI00301263 EFGLC*K.W 
IPI00646361.2 
NUP214 Uncharacterized 
protein NUP214 
ENSG00000126 
NUP21
4 
K.VC*ATLPSTV
AVTSVCWSPK.
G 
1.07 0 1.03 1.05 
IPI00183626.8 PTBP1 polypyrimidine tract-binding protein 1 isofo PTBP1 
K.RGSDELFSTC
*VTNGPFIMSSN
SASAANGNDSK
.K 
1.06 0 1.04 1.05 
IPI00550069.3 
RNH1 Ribonuclease 
inhibitor 
ENSG00000023191 IPI005 
RNH1 
R.SNELGDVGV
HC*VLQGLQTP
SCK.I 
0 0 1.05 1.05 
IPI00304935.5 
SAAL1 Uncharacterized 
protein SAAL1 
ENSG0000016678 
SAAL1 R.VLQNMEQC*QK.K 0 0 1.05 1.05 
IPI00154451.6 
MMS19 Isoform 1 of 
MMS19-like protein 
ENSG00000155 
MMS1
9 
R.LMGLLSDPEL
GPAAADGFSLL
MSDC*TDVLTR.
A 
0 0 1.05 1.05 
IPI00291570.9 
CASP2 Isoform ICH-1L of 
Caspase-2 precursor 
ENSG00 
CASP2 R.SDMICGYAC*LK.G 0.98 0 1.12 1.05 
IPI00304596.3 
NONO Non-POU domain-
containing octamer-binding 
pro 
NONO R.FAC*HSASLTVR.N 0 1.05 0 1.05 
IPI00022745.1 
MVD 
Diphosphomevalonate 
decarboxylase 
ENSG00000167 
MVD R.DGDPLPSSLSC*K.V 1.05 0 0 1.05 
IPI00010860.1 
PSMD9 Isoform p27-L of 
26S proteasome non-
ATPase r 
PSMD9 K.GIGMNEPLVDC*EGYPR.S 1.05 0 0 1.05 
IPI00157304.1 SSBP3 Isoform 1 of Single-stranded DNA-binding pro SSBP3 
R.DTC*EHSSEA
K.A 1.05 0 0 1.05 
IPI00103247.1 
HNRPLL Isoform 1 of 
Heterogeneous nuclear 
ribonucl 
HNRP
LL 
R.GLC*ESVVEA
DLVEALEK.F 1.05 0 0 1.05 
IPI00744127.1 
CSTF2 Uncharacterized 
protein CSTF2 
ENSG0000010181 
CSTF2 K.LC*VQNSPQEAR.N 0.97 1.03 1.16 1.0475 
IPI00745518.1 
MAP4 Microtubule-
associated protein 4 
isoform 1 va 
MAP4 
K.NVC*LPPEME
VALTEDQVPAL
K.T 
1.17 0 0.92 1.045 
IPI00642816.2 SRP9 hCG_1781062 Signal recognition particle 9 kDa SRP9 
K.VTDDLVC*LV
YK.T 1.1 0 0.99 1.045 
IPI00100796.4 
CHMP5 Charged 
multivesicular body protein 
5 ENSG00 
CHMP
5 
K.APPPSLTDC*I
GTVDSR.A 1.06 0 1.03 1.045 
IPI00742681.1 
LSM7 R30783_1 
ENSG00000130332 
IPI00007163 IPI00742 
LSM7 
R.GTSVVLIC*PQ
DGMEAIPNPFIQ
QQDA.- 
1.01 0 1.08 1.045 
IPI00302112.1 
MAP2K7 Isoform 2 of 
Dual specificity mitogen-
activ 
MAP2
K7 
K.LC*DFGISGR.
L 1.01 0 1.08 1.045 
IPI00290272.2 
POLA2 DNA polymerase 
subunit alpha B 
ENSG000000141 
POLA2 K.VLGC*PEALTGSYK.S 1 0 1.09 1.045 
IPI00009790.1 
PFKP 6-
phosphofructokinase type C 
ENSG00000067057 
PFKP R.LPLMEC*VQMTQDVQK.A 1.07 0 1.01 1.04 
IPI00024990.6 
ALDH6A1 
Methylmalonate-
semialdehyde 
dehydrogenase 
ALDH
6A1 
R.C*MALSTAVL
VGEAK.K 1.06 0 1.02 1.04 
IPI00018235.3 
PEF1 Peflin 
ENSG00000162517 
IPI00018235 
PEF1 
K.QALVNC*NW
SSFNDETCLMM
INMFDK.T 
0 0 1.04 1.04 
IPI00005648.1 SAFB2 Scaffold attachment factor B2 SAFB2 
K.ILDILGETC*K
.S 0 0 1.04 1.04 
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ENSG0000013025 
IPI00072534.2 
UNC45A Isoform 1 of 
UNC45 homolog A 
ENSG0000014055 
UNC45
A 
R.AIQTVSCLLQ
GPC*DAGNR.A 0 0 1.04 1.04 
IPI00026230.1 
HNRPH2 Heterogeneous 
nuclear ribonucleoprotein 
H 
HNRP
H2 
R.DLNYC*FSGM
SDHR.Y 1.02 0 1.06 1.04 
IPI00011916.1 
JTV1 Multisynthetase 
complex auxiliary 
component p 
JTV1 R.VELPTC*MYR.L 1.01 0 1.07 1.04 
IPI00020451.2 
IMPACT IMPACT protein 
ENSG00000154059 
IPI00020451 
IMPAC
T 
R.STFQAHLAPV
VC*PK.Q 0 1.04 0 1.04 
Reverse_IPI00376
572.2 
LOC391722 similar to 
myosin regulatory light 
chain 
LOC39
1722 
K.CCC*NQSPPS
SASSVPAMNRN
KNVNRQER.F 
0 1.04 0 1.04 
IPI00302112.1 
MAP2K7 Isoform 2 of 
Dual specificity mitogen-
activ 
MAP2
K7 
R.SAGC*AAYM
APER.I 1.04 0 0 1.04 
IPI00025285.3 
FLJ25715 ATP6V1G1 
Vacuolar ATP synthase 
subunit G 
FLJ257
15 
R.GSC*STEVEK
ETQEK.M 1.04 0 0 1.04 
IPI00221035.3 
BTF3 Uncharacterized 
protein BTF3 
ENSG00000145741 
BTF3 R.ARGGC*PGGEATLSQPPPR.G 0 1.03 1.06 1.0375 
IPI00334159.6 
VBP1 Prefoldin subunit 3 
ENSG00000155959 
IPI003341 
VBP1 K.DSC*GKGEMATGNGR.R 1.02 0 1.05 1.035 
IPI00220301.5 
PRDX6 Peroxiredoxin-6 
ENSG00000117592 
IPI00220301 
PRDX6 K.DINAYNC*EEPTEK.L 1 0 1.07 1.035 
IPI00018009.2 
EDC3 Enhancer of mRNA-
decapping protein 3 
ENSG0000 
EDC3 
K.DLPTSPVDLV
INC*LDCPENVF
LR.D 
1 1.09 0.95 1.0325 
IPI00001287.1 
C20orf72 Uncharacterized 
protein C20orf72 
ENSG0000 
C20orf
72 
R.GVAQTPGSVE
EDALLC*GPVS
K.H 
1.04 0 1.02 1.03 
IPI00012535.1 
DNAJA1 DnaJ homolog 
subfamily A member 1 
ENSG00000 
DNAJ
A1 
K.GAVEC*CPNC
R.G 0 0 1.03 1.03 
IPI00298961.3 
XPO1 Exportin-1 
ENSG00000082898 
IPI00784388 IPI002 
XPO1 R.QMSVPGIFNPHEIPEEMC*D.- 0 0 1.03 1.03 
IPI00103087.2 
GEMIN6 Gem-associated 
protein 6 
ENSG00000152147 IP 
GEMI
N6 
K.LMHLFTSGDC
*K.A 0 0 1.03 1.03 
IPI00008982.1 
ALDH18A1 Isoform Long 
of Delta-1-pyrroline-5-
carbo 
ALDH
18A1 
K.CEYPAAC*NA
LETLLIHR.D 0 0 1.03 1.03 
IPI00023547.1 MAPK10 Isoform Alpha-2 of Mitogen-activated protei 
MAPK
10 
K.VIEQLGTPC*P
EFMK.K 1.03 0 0 1.03 
IPI00305383.1 
UQCRC2 Ubiquinol-
cytochrome-c reductase 
complex co 
UQCR
C2 
R.NALANPLYC*
PDYR.I 1.03 0 0 1.03 
IPI00549467.3 
NIT2 Nitrilase family 
member 2 
ENSG00000114021 IPI 
NIT2 R.VGLGIC*YDMR.F 0.92 1.14 0.91 1.0275 
IPI00026167.3 
NHP2L1 NHP2-like 
protein 1 
ENSG00000100138 
IPI0002 
NHP2L
1 
K.KLLDLVQQSC
*NYK.Q 0.93 1.11 0.95 1.025 
IPI00013789.5 
SMYD5 SET and MYND 
domain-containing protein 
5 ENS 
SMYD
5 R.LFSQFC*NK.T 1.1 0 0.95 1.025 
IPI00299155.5 
PSMA4 Proteasome 
subunit alpha type-4 
ENSG00000041 
PSMA4 
R.YLLQYQEPIP
CEQLVTALC*DI
K.Q 
1.08 0 0.97 1.025 
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IPI00001960.4 
CLIC4 Chloride 
intracellular channel 
protein 4 ENS 
CLIC4 K.AGSDGESIGNC*PFSQR.L 0.98 1.07 0.98 1.025 
IPI00329331.6 
UGP2 Isoform 1 of UTP--
glucose-1-phosphate 
uridyly 
UGP2 K.LNGGLGTSMGC*K.G 1.03 0 1.02 1.025 
IPI00002214.1 
KPNA2 Importin subunit 
alpha-2 
ENSG00000182481 IPI 
KPNA2 
R.TDC*SPIQFES
AWALTNIASGT
SEQTK.A 
1.03 0 1.02 1.025 
IPI00013212.1 
CSK Tyrosine-protein 
kinase CSK 
ENSG00000103653 IP 
CSK R.SVLGGDC*LLK.F 1.02 0 1.03 1.025 
IPI00396174.4 
CCDC25 Coiled-coil 
domain-containing protein 
25 EN 
CCDC2
5 
K.ANSIQGC*K.
M 1.11 1.01 0.96 1.0225 
IPI00292771.4 
NUMA1 Isoform 1 of 
Nuclear mitotic apparatus 
prote 
NUMA
1 
R.QFC*STQAAL
QAMER.E 1.11 0 0.93 1.02 
IPI00006167.1 
PPM1G Protein 
phosphatase 1G 
ENSG00000115241 IPI00 
PPM1G 
R.GTEAGQVGEP
GIPTGEAGPSC*
SSASDKLPR.V 
1.06 0 0.98 1.02 
IPI00017799.5 
TXN2 Thioredoxin, 
mitochondrial precursor 
ENSG0000 
TXN2 
R.VVNSETPVVV
DFHAQWC*GPC
K.I 
0 0 1.02 1.02 
IPI00015956.3 
EXOSC3 Exosome 
complex exonuclease 
RRP40 ENSG00000 
EXOS
C3 
K.LLAPDC*EIIQ
EVGK.L 1.01 0 1.03 1.02 
IPI00010240.1 
MIF4GD MIF4G domain-
containing protein 
ENSG0000012 
MIF4G
D 
K.VANVIVDHSL
QDC*VFSK.E 1 0 1.04 1.02 
IPI00745568.1 
TIPRL Uncharacterized 
protein TIPRL 
ENSG0000014315 
TIPRL K.VAC*AEEWQESR.T 0.98 0 1.06 1.02 
IPI00170916.1 
NECAP1 Isoform 1 of 
Adaptin ear-binding coat-
assoc 
NECA
P1 
K.LC*IGNITNK.
K 1.02 0 0 1.02 
IPI00655704.1 
PDK1 Mitochondrial 
pyruvate dehydrogenase 
kinase i 
PDK1 K.QFLDFGSVNAC*EK.T 1.02 0 0 1.02 
IPI00302673.3 
ATPAF1 ATP synthase 
mitochondrial F1 complex 
assem 
ATPAF
1 
K.C*AQNQNKT.
- 0.91 1 1.16 1.0175 
IPI00470779.2 
TXLNA Alpha-taxilin 
ENSG00000084652 
IPI00816089 IP 
TXLN
A 
R.VTEAPC*YPG
APSTEASGQTG
PQEPTSAR.A 
1.05 0 0.98 1.015 
IPI00031681.1 CDK2 Cell division protein kinase 2 ENSG0000012337 CDK2 
R.APEILLGC*K.
Y 0.98 0 1.05 1.015 
IPI00009542.1 
MAGED2 Isoform 1 of 
Melanoma-associated 
antigen D2 
MAGE
D2 
R.MGIGLGSENA
AGPC*NWDEAD
IGPWAK.A 
0.9 0 1.13 1.015 
IPI00216746.1 
HNRPK Isoform 2 of 
Heterogeneous nuclear 
ribonucle 
HNRP
K 
K.IIPTLEEGLQL
PSPTATSQLPLE
SDAVEC*LNYQ
HYK.G 
0 1.01 1.02 1.0125 
IPI00023785.6 
DDX17 DEAD box 
polypeptide 17 isoform 1 
ENSG000001 
DDX17 R.TTSSANNPNLMYQDEC*DR.R 1.13 0 0.89 1.01 
IPI00479877.4 
ALDH9A1 aldehyde 
dehydrogenase 9A1 
ENSG00000143149 
ALDH
9A1 
K.GALMANFLT
QGQVC*CNGTR
.V 
0 1.03 0.95 1.01 
IPI00021305.1 
CCNH Cyclin-H 
ENSG00000134480 
IPI00021305 IPI00556 
CCNH R.TC*LSQLLDIMK.S 1.01 0 1.01 1.01 
IPI00015911.1 
DLD Dihydrolipoyl 
dehydrogenase, 
mitochondrial pre 
DLD K.NETLGGTC*LNVGCIPSK.A 0 0 1.01 1.01 
IPI00025746.5 
ANKRD54 Isoform 1 of 
Ankyrin repeat domain-
contain 
ANKR
D54 
K.LNILQEGHAQ
C*LEAVR.L 0 0 1.01 1.01 
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IPI00008994.2 
NDRG2 Isoform 1 of 
Protein NDRG2 
ENSG00000165795 I 
NDRG
2 
K.YFLQGMGYM
ASSC*MTR.L 0 0 1.01 1.01 
IPI00220373.4 
IDE Insulin-degrading 
enzyme 
ENSG00000119912 IPI00 
IDE 
R.EMDSC*PVVG
EFPCQNDINLSQ
APALPQPEVIQN
MTEFKR.G 
0 0 1.01 1.01 
IPI00024317.1 
GCDH Isoform Long of 
Glutaryl-CoA 
dehydrogenase, m 
GCDH K.GYGC*AGVSSVAYGLLAR.E 0 0 1.01 1.01 
IPI00292894.4 
TSR1 TSR1, 20S rRNA 
accumulation 
ENSG00000167721 I 
TSR1 
R.DTGTVHLNEL
GNTQNFMLLC*
PR.L 
0 0 1.01 1.01 
IPI00001636.1 
ATXN10 Ataxin-10 
ENSG00000130638 
IPI00385153 IPI00 
ATXN
10 
R.HAELIASTFV
DQC*K.T 1 0 1.02 1.01 
IPI00029534.1 
PPAT 
Amidophosphoribosyltransf
erase precursor ENSG 
PPAT K.C*ELENCQPFVVETLHGK.I 0.98 0 1.04 1.01 
IPI00844375.1 PSMB2 Proteasome beta 2 subunit variant (Fragment) PSMB2 R.NLADC*LR.S 0.96 0 1.06 1.01 
IPI00007935.4 
PDLIM5 PDZ and LIM 
domain protein 5 
ENSG0000016311 
PDLIM
5 
R.QPTVTSVC*S
ETSQELAEGQR.
R 
1.01 0 0 1.01 
IPI00220991.2 
AP2B1 Putative 
uncharacterized protein 
DKFZp781K07 
AP2B1 K.DC*EDPNPLIR.A 1.01 0 0 1.01 
IPI00004461.2 
DGUOK Isoform 1 of 
Deoxyguanosine kinase, 
mitochon 
DGUO
K 
K.AC*TAQSLGN
LLDMMYR.E 0 1.03 0.93 1.005 
IPI00514983.3 HSPH1 Isoform Alpha of Heat shock protein 105 kDa HSPH1 
R.C*TPSVISFGS
K.N 0.97 0 1.04 1.005 
IPI00301139.5 
MED17 Isoform 1 of 
Mediator of RNA 
polymerase II t 
MED17 K.MELLMSALSPC*LL.- 0.94 0 1.07 1.005 
IPI00009315.6 
ACBD3 Golgi resident 
protein GCP60 
ENSG00000182827 
ACBD
3 
K.QVLMGPYNP
DTC*PEVGFFD
VLGNDR.R 
1.08 0 0.92 1 
IPI00646167.2 
C14orf142 hypothetical 
protein LOC84520 
ENSG000001 
C14orf
142 
R.VSC*EAPGDG
DPFQGLLSGVA
QMK.D 
1.07 0 0.93 1 
IPI00013871.1 
RRM1 Ribonucleoside-
diphosphate reductase large 
su 
RRM1 R.DECLMC*GS.- 1.03 0 0.97 1 
IPI00556494.3 
MED4 Mediator of RNA 
polymerase II transcription 
s 
MED4 R.ISASNAVC*APLTWVPGDPR.R 0 0 1 1 
IPI00007818.3 
CPSF3 Cleavage and 
polyadenylation specificity 
fac 
CPSF3 
R.NFNYHILSPC*
DLSNYTDLAMS
TVK.Q 
0 0 1 1 
IPI00007074.5 
YARS Tyrosyl-tRNA 
synthetase, cytoplasmic 
ENSG0000 
YARS K.AFC*EPGNVENNGVLSFIK.H 0 0 1 1 
IPI00217157.5 
DDX59 Isoform 1 of 
Probable ATP-dependent 
RNA heli 
DDX59 K.NLPC*ANVR.Q 0 0 1 1 
IPI00001539.8 
ACAA2 3-ketoacyl-CoA 
thiolase, mitochondrial 
ENSG0 
ACAA
2 
R.LC*GSGFQSIV
NGCQEICVK.E 0.97 0 1.03 1 
IPI00647082.1 
TBC1D13 TBC1 domain 
family, member 13 
ENSG00000107 
TBC1D
13 
R.ELSFSGIPC*E
GGLR.C 0.96 0 1.04 1 
IPI00219025.3 
GLRX Glutaredoxin-1 
ENSG00000173221 
IPI00219025 
GLRX K.VVVFIKPTC*PYCR.R 0 1 0 1 
IPI00294739.1 
SAMHD1 SAM domain 
and HD domain-containing 
protein 
SAMH
D1 R.C*DDSPR.T 1 0 0 1 
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IPI00018206.3 
GOT2 Aspartate 
aminotransferase, 
mitochondrial pre 
GOT2 R.VGAFTMVC*K.D 1.23 0 0.76 0.995 
IPI00101600.5 
CWF19L1 CWF19-like 1, 
cell cycle control 
ENSG00000 
CWF19
L1 
K.QILAPVEESA
C*QFFFDLNEK.
Q 
1.04 0 0.95 0.995 
IPI00216298.6 
TXN Thioredoxin 
ENSG00000136810 
IPI00552768 IPI002 
TXN K.LVVVDFSATWC*GPCK.M 0 1.01 0.94 0.9925 
IPI00029997.1 
PGLS 6-
phosphogluconolactonase 
ENSG00000130313 IPI 
PGLS R.AAC*CLAGAR.A 0.98 1.04 0.9 0.99 
IPI00419194.2 
IAH1 Isoamyl acetate-
hydrolyzing esterase 1 
homolo 
IAH1 
R.VILITPTPLC*E
TAWEEQCIIQG
CK.L 
0 1 0.96 0.99 
IPI00004534.3 
PFAS 
Phosphoribosylformylglyci
namidine synthase EN 
PFAS 
R.GLAPLHWAD
DDGNPTEQYPL
NPNGSPGGVAG
IC*SCDGR.H 
0 0 0.99 0.99 
IPI00024317.1 
GCDH Isoform Long of 
Glutaryl-CoA 
dehydrogenase, m 
GCDH 
R.ASATGMIIMD
GVEVPEENVLP
GASSLGGPFGC*
LNNAR.Y 
0 0 0.99 0.99 
IPI00045917.3 
CRBN Isoform 1 of Protein 
cereblon 
ENSG00000113851 
CRBN 
K.VQILPEC*VLP
STMSAVQLESL
NK.C 
0 0 0.99 0.99 
IPI00329638.10 
ZAK Isoform 1 of 
Mitogen-activated protein 
kinase 
ZAK 
K.FDDLQFFENC
*GGGSFGSVYR.
A 
0 0 0.99 0.99 
IPI00743454.1 
ACN9 Uncharacterized 
protein ACN9 
ENSG00000196636 
ACN9 K.AC*FGTFLPEEK.L 0.9 0 1.08 0.99 
IPI00008436.4 
POLE4 DNA polymerase 
epsilon subunit 4 
ENSG0000011 
POLE4 K.DAYC*CAQQGK.R 0.99 0 0 0.99 
IPI00456919.2 
HUWE1 Isoform 1 of E3 
ubiquitin-protein ligase 
HUW 
HUWE
1 
K.ACSPCSSQSSS
SGIC*TDFWDLL
VK.L 
0.99 0 0 0.99 
IPI00010438.2 
SNAP23 Isoform SNAP-
23a of Synaptosomal-
associated 
SNAP2
3 
K.TTWGDGGEN
SPC*NVVSK.Q 0.99 0 0 0.99 
IPI00003766.4 
ETHE1 ETHE1 protein, 
mitochondrial precursor 
ENSG0 
ETHE1 R.TDFQQGC*AK.T 0.89 1.07 0.92 0.9875 
IPI00018522.4 
PRMT1 HMT1 hnRNP 
methyltransferase-like 2 
isoform 
PRMT1 K.VIGIEC*SSISDYAVK.I 0.98 1 0.97 0.9875 
IPI00026337.1 
RANBP3 Isoform 1 of 
Ran-binding protein 3 
ENSG0000 
RANB
P3 
K.ALSQTVPSSG
TNGVSLPADC*
TGAVPAASPDT
AAWR.S 
1.11 0 0.86 0.985 
IPI00024579.1 
RAD18 E3 ubiquitin-
protein ligase RAD18 
ENSG000000 
RAD18 K.TQCPTCC*VTVTEPDLK.N 1.06 0 0.91 0.985 
IPI00016862.1 
GSR Isoform 
Mitochondrial of 
Glutathione reductase 
GSR K.LGGTC*VNVGCVPK.K 1.16 0 0.81 0.985 
IPI00019376.6 
SEPT11 Septin-11 
ENSG00000138758 
IPI00019376 
41528 K.STSQGFC*FNILCVGETGIGK.S 1 0 0.97 0.985 
IPI00155601.1 
MACROD1 MACRO 
domain-containing protein 
1 ENSG0000 
MACR
OD1 
K.LEVDAIVNAA
NSSLLGGGGVD
GC*IHR.A 
0 0 0.98 0.98 
IPI00023647.4 
UBE1L2 Isoform 1 of 
Ubiquitin-activating 
enzyme E1 
UBE1L
2 
R.KPNVGC*QQ
DSEELLK.L 0 0 0.98 0.98 
IPI00796199.1 
HNRNPL Uncharacterized 
protein HNRPL 
ENSG000001048 
HNRN
PL 
K.QPAIMPGQSY
GLEDGSC*SYK
DFSESR.N 
0 0 0.98 0.98 
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IPI00017617.1 
DDX5 Probable ATP-
dependent RNA helicase 
DDX5 ENSG 
DDX5 R.LIDFLEC*GK.T 0 0 0.98 0.98 
IPI00748490.1 
AARSD1 Alanyl-tRNA 
synthetase, class IIc family 
pr 
AARS
D1 
R.VVNIEGVDSN
MC*CGTHVSNL
SDLQVIK.I 
0 0 0.98 0.98 
IPI00007675.6 
DYNC1LI1 Cytoplasmic 
dynein 1 light intermediate 
c 
DYNC
1LI1 
R.VGSFGSSPPG
LSSTYTGGPLG
NEIASGNGGAA
AGDDEDGQNL
WSC*ILSEVSTR.
S 
0.93 0 1.03 0.98 
IPI00396627.1 
ELAC2 Isoform 1 of Zinc 
phosphodiesterase ELAC 
pro 
ELAC2 K.VC*FGDFPTMPK.L 0.98 0 0 0.98 
IPI00783852.1 
ACTR10 46 kDa protein 
ENSG00000131966 
IPI00783852 
ACTR1
0 
R.IPDWC*SLNN
PPLEMMFDVGK
.T 
1.04 0 0.91 0.975 
IPI00374272.3 
LOC285636 hypothetical 
protein LOC285636 
ENSG00000 
LOC28
5636 
R.C*PIQLNEGVS
FQDLDTAK.L 0.97 0 0.98 0.975 
IPI00177008.1 
LOC283871 hypothetical 
protein LOC283871 
ENSG00000 
LOC28
3871 
K.NNQESDC*VS
K.K 0.93 0.99 0.98 0.9725 
IPI00100213.2 
RRM2B Isoform 1 of 
Ribonucleoside-
diphosphate redu 
RRM2
B 
K.IEQEFLTEALP
VGLIGMNC*IL
MK.Q 
0 0 0.97 0.97 
IPI00019640.1 
VRK1 Serine/threonine-
protein kinase VRK1 
ENSG0000 
VRK1 
K.VGLPIGQGGF
GC*IYLADMNS
SESVGSDAPCV
VK.V 
0 0 0.97 0.97 
IPI00291510.3 
IMPDH2 Inosine-5-
monophosphate 
dehydrogenase 2 EN 
IMPDH
2 
R.VGMGSGSIC*I
TQEVLACGRPQ
ATAVYK.V 
0 0.97 0 0.97 
IPI00006907.1 
C12orf5 Uncharacterized 
protein C12orf5 
ENSG000000 
C12orf
5 
K.AAREEC*PVF
TPPGGETLDQV
K.M 
0.96 0 0.97 0.965 
IPI00026781.2 
FASN Fatty acid synthase 
ENSG00000169710 
IPI000267 
FASN 
K.LTPGC*EAEA
ETEAICFFVQQF
TDMEHNR.V 
0 0.94 1.04 0.965 
IPI00646689.1 
TXNDC17 Thioredoxin 
domain-containing protein 
17 E 
TXND
C17 
K.DAGGKSWC*
PDCVQAEPVVR.
E 
0.97 0 0.95 0.96 
IPI00455153.2 
NFU1 HIRA interacting 
protein 5 isoform 2 
ENSG0000 
NFU1 K.LQGSCTSC*PSSIITLK.N 0.97 0 0.95 0.96 
IPI00032900.1 
BOLA1 BolA-like protein 
1 ENSG00000178096 
IPI00032 
BOLA1 
R.VCLC*QGSAG
SGAIGPVEAAIR.
T 
0 0 0.96 0.96 
IPI00045051.3 
PURB Transcriptional 
activator protein Pur-beta 
EN 
PURB R.GGGGGPC*GFQPASR.G 0 0 0.96 0.96 
IPI00003768.1 
PES1 Isoform 1 of 
Pescadillo homolog 1 
ENSG0000010 
PES1 K.AGEGTYALDSESC*MEK.L 0 0 0.96 0.96 
IPI00336008.1 
ALDH5A1 aldehyde 
dehydrogenase 5A1 
precursor, isof 
ALDH
5A1 
R.NTGQTC*VCS
NQFLVQR.G 0.95 0 0.97 0.96 
IPI00298547.3 
PARK7 Protein DJ-1 
ENSG00000116288 
IPI00298547 
PARK7 
K.GLIAAIC*AGP
TALLAHEIGFGS
K.V 
0 0.96 0 0.96 
IPI00007752.1 
TUBB2C Tubulin beta-2C 
chain ENSG00000188229 
IPI00 
TUBB2
C 
K.LTTPTYGDLN
HLVSATMSGVT
TC*LR.F 
0 0.97 0.92 0.9575 
IPI00031563.4 
C19orf58 Uncharacterized 
protein C19orf58 
ENSG0000 
C19orf
58 
R.FHADSVC*K.
A 0.91 1 0.92 0.9575 
IPI00026328.3 TXNDC12 Thioredoxin domain-containing protein 
TXND
C12 K.SWC*GACK.A 0.99 0 0.92 0.955 
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12 p 
IPI00013452.8 
EPRS glutamyl-prolyl 
tRNA synthetase 
ENSG000001366 
EPRS 
K.LSSC*DSFTST
INELNHCLSLR.
T 
0.91 0 1 0.955 
IPI00041325.1 
NOLA2 H/ACA 
ribonucleoprotein complex 
subunit 2 EN 
NOLA
2 
K.ADPDGPEAQ
AEAC*SGER.T 0.97 0 0.94 0.955 
IPI00220503.9 
DCTN2 dynactin 2 
ENSG00000175203 
IPI00220503 IPI00 
DCTN2 
R.C*DQDAQNPL
SAGLQGACLME
TVELLQAK.V 
0.82 0.96 1.08 0.955 
IPI00218782.2 
CAPZB Capping protein 
ENSG00000077549 
IPI00026185 
CAPZB 
R.QMEKDETVS
DC*SPHIANIGR.
L 
1.12 0 0.78 0.95 
IPI00304071.4 
FLJ20920 hypothetical 
protein LOC80221 
ENSG0000016 
FLJ209
20 
R.MVSTPIGGLS
YVQGC*TK.K 0.99 0 0.91 0.95 
IPI00301058.5 
VASP Vasodilator-
stimulated phosphoprotein 
ENSG000 
VASP 
K.SSSSVTTSETQ
PC*TPSSSDYSD
LQR.V 
0.99 0 0.91 0.95 
IPI00299263.5 
ARFGAP3 ADP-
ribosylation factor GTPase-
activating 
ARFG
AP3 
R.LGMGFGNC*
R.S 0 0 0.95 0.95 
IPI00797537.1 
NUDCD1 NudC domain-
containing protein 1 
ENSG000001 
NUDC
D1 
K.FFACAPNYSY
AALC*ECLR.R 0 0 0.95 0.95 
IPI00019380.1 
NCBP1 Nuclear cap-
binding protein subunit 1 
ENSG00 
NCBP1 
K.SAC*SLESNL
EGLAGVLEADL
PNYK.S 
0 0.95 0 0.95 
IPI00439415.6 
EIF4B eukaryotic 
translation initiation factor 
4B 
EIF4B 
K.SLENETLNKE
EDC*HSPTSKPP
KPDQPLK.V 
0 0.95 0 0.95 
IPI00746806.1 
CTTN CTTN protein 
ENSG00000085733 
IPI00029601 IPI0 
CTTN K.C*ALGWDHQEK.L 0.95 0 0 0.95 
IPI00031519.3 DNMT1 Isoform 1 of DNA (cytosine-5)-methyltransfer 
DNMT
1 
K.NQLC*DLETK
.L 0.95 0 0 0.95 
IPI00386755.2 
ERO1L ERO1-like protein 
alpha precursor 
ENSG000001 
ERO1L 
K.HDDSSDNFC*
EADDIQSPEAEY
VDLLLNPER.Y 
0.96 0 0.93 0.945 
IPI00479385.3 
ASMTL Uncharacterized 
protein ASMTL 
ENSG0000016909 
ASMT
L 
K.LTAC*QVATA
FNLSR.F 0 0 0.94 0.94 
IPI00796038.1 
ARL6IP4 OGFOD2 SRp25 
nuclear protein isoform 1 
ENS 
ARL6I
P4 
R.GDC*LAFQM
R.A 0 0 0.94 0.94 
IPI00216230.3 TMPO Lamina-associated polypeptide 2 isoform alpha TMPO 
K.VDDEILGFISE
ATPLGGIQAAST
ESC*NQQLDLA
LCR.A 
0 0 0.94 0.94 
IPI00016458.2 
L2HGDH Isoform 1 of L-
2-hydroxyglutarate 
dehydroge 
L2HG
DH 
K.AC*FLGATVK
.Y 0.94 0 0 0.94 
IPI00029091.1 
_ Putative nucleoside 
diphosphate kinase 
ENSG00000 
_ R.GDFC*IQVGR.N 0 0 0.93 0.93 
IPI00302688.7 
ECHDC1 Isoform 1 of 
Enoyl-CoA hydratase 
domain-con 
ECHD
C1 
K.SLGTPEDGM
AVC*MFMQNTL
TR.F 
0 0 0.93 0.93 
Reverse_IPI00418
790.3 
EML5 echinoderm 
microtubule associated 
protein lik 
EML5 
K.VGC*SVLKNP
QYLDWSIDFIR.
D 
0 0 0.93 0.93 
IPI00398009.2 
IPO4 Isoform 2 of 
Importin-4 
ENSG00000196497 IPI00 
IPO4 K.LC*PQLMPMLEEALR.S 0.93 0 0 0.93 
IPI00032955.1 
ZNF313 Zinc finger protein 
313 ENSG00000124226 
IPI 
ZNF31
3 
R.DC*GGAAQL
AGPAAEADPLG
R.F 
1.03 0 0.83 0.93 
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IPI00556451.2 
ETFB Isoform 2 of 
Electron transfer 
flavoprotein s 
ETFB K.HSMNPFC*EIAVEEAVR.L 0.94 0 0.92 0.93 
IPI00299524.1 
NCAPD2 Condensin 
complex subunit 1 
ENSG00000010292 
NCAP
D2 K.VACC*PLER.C 0.94 0 0.92 0.93 
IPI00018331.3 
SNAPAP SNARE-
associated protein Snapin 
ENSG0000014 
SNAP
AP 
R.EQIDNLATEL
C*R.I 0.94 0 0.92 0.93 
IPI00333763.7 
GLRX5 Glutaredoxin-
related protein 5 
ENSG000001825 
GLRX5 K.GTPEQPQC*GFSNAVVQILR.L 0.94 0 0.92 0.93 
IPI00784459.1 
CFL1 Uncharacterized 
protein CFL1 
ENSG00000172757 
CFL1 K.HELQANC*YEEVKDR.C 0.91 0.94 0.9 0.9225 
IPI00101645.3 
KIAA0828 Putative 
adenosylhomocysteinase 3 
ENSG000 
KIAA0
828 
K.FDNLYC*CR.
E 0 0 0.92 0.92 
IPI00748353.1 
WDHD1 126 kDa protein 
ENSG00000198554 
IPI00748353 
WDHD
1 
K.NVLSETPAIC*
PPQNTENQRPK.
T 
0 0 0.92 0.92 
IPI00382452.1 
CHMP1A Isoform 1 of 
Charged multivesicular 
body pr 
CHMP
1A K.NVEC*AR.V 0 0 0.92 0.92 
IPI00384708.2 
PDSS2 Isoform 1 of 
Decaprenyl-diphosphate 
synthase 
PDSS2 R.C*LLSDELSNIAMQVR.K 0 0 0.92 0.92 
IPI00073602.1 
EXOSC6 Exosome 
complex exonuclease 
MTR3 ENSG000001 
EXOS
C6 
R.RAPPGGC*EE
R.E 0 0.92 0 0.92 
IPI00797038.1 
PCK2 mitochondrial 
phosphoenolpyruvate 
carboxykina 
PCK2 
R.QC*PIMDPAW
EAPEGVPIDAIIF
GGR.R 
0.92 0 0 0.92 
IPI00024915.2 
PRDX5 Isoform 
Mitochondrial of 
Peroxiredoxin-5, mi 
PRDX5 
K.ALNVEPDGT
GLTC*SLAPNIIS
QL.- 
0.78 1.02 0.85 0.9175 
IPI00099986.5 
FN3KRP Ketosamine-3-
kinase ENSG00000141560 
IPI0009 
FN3KR
P 
R.ATGHSGGGC*
ISQGR.S 0 0.93 0.86 0.9125 
IPI00291419.5 
ACAT2 Acetyl-CoA 
acetyltransferase, cytosolic 
ENSG 
ACAT2 
R.QASVGAGIPY
SVPAWSC*QMI
CGSGLK.A 
0 0 0.91 0.91 
IPI00788879.2 
TBC1D23 Isoform 1 of 
TBC1 domain family 
member 23 
TBC1D
23 
K.FLENTPSSLNI
EDIEDLFSLAQY
YC*SK.T 
0 0 0.91 0.91 
IPI00828021.1 
HSPA4L Heat shock 
protein apg-1 
ENSG00000164070 IP 
HSPA4
L 
K.LMSANASDLP
LNIEC*FMNDL
DVSSK.M 
0.99 0 0.83 0.91 
IPI00014589.1 
CLTB Isoform Brain of 
Clathrin light chain B 
ENSG0 
CLTB K.VAQLC*DFNPK.S 0 0 0.9 0.9 
IPI00306369.3 
NSUN2 tRNA 
ENSG00000037474 
IPI00306369 
NSUN2 K.DGVC*GPPPSKK.M 0 0 0.9 0.9 
IPI00028091.3 
ACTR3 Actin-like protein 
3 ENSG00000115091 
IPI0002 
ACTR3 R.YSYVC*PDLVK.E 0 0 0.9 0.9 
IPI00335251.3 
DUS1L tRNA-
dihydrouridine synthase 1-
like ENSG0000 
DUS1L 
K.AVAIPVFANG
NIQC*LQDVER.
C 
0 0 0.9 0.9 
IPI00412771.1 
CD2AP CD2-associated 
protein ENSG00000198087 
IPI00 
CD2AP 
K.DTC*YSPKPS
VYLSTPSSASK.
A 
0.76 0 1.04 0.9 
IPI00386755.2 
ERO1L ERO1-like protein 
alpha precursor 
ENSG000001 
ERO1L 
K.RPLNPLASGQ
GTSEENTFYSW
LEGLC*VEK.R 
0 0.9 0 0.9 
IPI00174442.2 
FAM98A Protein FAM98A 
ENSG00000119812 
IPI00174442 
FAM98
A 
R.EKTAC*AINK.
V 0.9 0 0 0.9 
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IPI00303439.1 
SMARCB1 CDNA 
FLJ13963 fis, clone 
Y79AA1001299, hig 
SMAR
CB1 
R.NTGDADQWC
*PLLETLTDAE
MEK.K 
0.9 0 0 0.9 
IPI00013871.1 
RRM1 Ribonucleoside-
diphosphate reductase large 
su 
RRM1 
R.VETNQDWSL
MC*PNECPGLD
EVWGEEFEK.L 
0.9 0 0 0.9 
IPI00026216.4 
NPEPPS Puromycin-
sensitive aminopeptidase 
ENSG0000 
NPEPP
S K.NSC*SSSR.Q 0.96 0 0.84 0.9 
IPI00065671.1 
UCK2 Isoform 1 of 
Uridine-cytidine kinase 2 
ENSG00 
UCK2 R.QTNGC*LNGYTPSR.K 0.9 0 0.89 0.895 
IPI00007691.1 
TRAPPC4 Trafficking 
protein particle complex 
subun 
TRAPP
C4 
K.NPFYSLEMPI
RC*ELFDQNLK.
L 
0.8 0 0.99 0.895 
IPI00299263.5 
ARFGAP3 ADP-
ribosylation factor GTPase-
activating 
ARFG
AP3 
K.LANTC*FNEIE
K.Q 0 0 0.89 0.89 
IPI00383460.7 
GRSF1 G-rich RNA 
sequence binding factor 1 
isoform 
GRSF1 R.YIELFLNSC*PK.G 0 0 0.88 0.88 
IPI00013774.1 
HDAC1 Histone 
deacetylase 1 
ENSG00000116478 IPI005 
HDAC
1 
K.VMEMFQPSA
VVLQC*GSDSL
SGDR.L 
0 0 0.88 0.88 
IPI00456898.1 
LOC440055 
Uncharacterized protein 
ENSP00000302331 
LOC44
0055 
R.QAHLC*VLAS
NCDEPMYVK.L 0.88 0 0 0.88 
IPI00743416.1 IKBKAP inhibitor of kappa light polypeptide gene e 
IKBKA
P 
R.GDGQFFAVSV
VC*PETGAR.K 0.9 0 0.85 0.875 
IPI00002966.1 
HSPA4 Heat shock 70 kDa 
protein 4 
ENSG00000170606 
HSPA4 
K.LMSANASDLP
LSIEC*FMNDVD
VSGTMNR.G 
0.89 0 0.86 0.875 
IPI00219156.7 
RPL30 60S ribosomal 
protein L30 
ENSG00000156482 IP 
RPL30 R.VC*TLAIIDPGDSDIIR.S 0.75 0 1 0.875 
IPI00028091.3 
ACTR3 Actin-like protein 
3 ENSG00000115091 
IPI0002 
ACTR3 K.LGYAGNTEPQFIIPSC*IAIK.E 0 0 0.87 0.87 
IPI00646105.3 
PYCRL Pyrroline-5-
carboxylate reductase 
ENSG000001 
PYCRL R.AATMSAVEAATC*R.A 0 0 0.87 0.87 
IPI00296053.3 FH Isoform Mitochondrial of Fumarate hydratase, mi FH 
K.FEALAAHDA
LVELSGAMNTT
AC*SLMK.I 
0 0 0.87 0.87 
IPI00022239.7 
METAP1 Methionine 
aminopeptidase 1 
ENSG00000164024 
META
P1 
K.LGIQGSYFCS
QEC*FK.G 0.86 0 0.88 0.87 
IPI00009146.4 
TRAFD1 TRAF-type zinc 
finger domain-containing 
pro 
TRAF
D1 
R.STSGPRPGCQ
PSSPC*VPK.L 0 0.87 0 0.87 
IPI00168009.1 
NUDT16L1 Isoform 2 of 
Protein syndesmos 
ENSG000001 
NUDT
16L1 
R.VLGLGLGC*L
R.L 0 0.87 0 0.87 
IPI00216694.3 
PLS3 plastin 3 
ENSG00000102024 
IPI00848312 IPI0021 
PLS3 
K.EGIC*ALGGT
SELSSEGTQHSY
SEEEK.Y 
0.91 0 0.82 0.865 
IPI00001636.1 
ATXN10 Ataxin-10 
ENSG00000130638 
IPI00385153 IPI00 
ATXN
10 
K.ETTNIFSNC*G
CVR.A 0.79 0 0.94 0.865 
IPI00289807.3 
TRNT1 Isoform 1 of 
tRNA-
nucleotidyltransferase 1, 
TRNT1 K.YQGEHC*LLK.E 0 0.7 1.35 0.8625 
IPI00069693.4 
_ Uncharacterized protein 
ENSP00000350479 
ENSG0000 
_ R.ALVDGPC*TQVR.R 0.91 0 0.81 0.86 
IPI00549569.4 
ISYNA1 Myo-inositol 1-
phosphate synthase A1 
ENSG00 
ISYNA
1 
R.FC*EVIPGLND
TAENLLR.T 0 0 0.86 0.86 
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IPI00294739.1 
SAMHD1 SAM domain 
and HD domain-containing 
protein 
SAMH
D1 
R.VC*EVDNELR
.I 0 0 0.86 0.86 
IPI00004534.3 
PFAS 
Phosphoribosylformylglyci
namidine synthase EN 
PFAS K.FC*DNSSAIQGK.E 0.89 0 0.79 0.84 
IPI00002966.1 
HSPA4 Heat shock 70 kDa 
protein 4 
ENSG00000170606 
HSPA4 R.GC*ALQCAILSPAFK.V 0 0 0.84 0.84 
IPI00018272.3 
PNPO Pyridoxine-5-
phosphate oxidase 
ENSG000001084 
PNPO K.KLPEEEAEC*YFHSRPK.S 0 0.84 0 0.84 
IPI00240909.1 
hCG_15200 
Uncharacterized protein 
ENSP00000343276 
hCG_1
5200 K.TC*FSPNR.V 0 0.84 0 0.84 
IPI00465054.2 
THUMPD1 Putative 
uncharacterized protein 
DKFZp686C 
THUM
PD1 R.C*DAGGPR.Q 0.93 0.76 0.9 0.8375 
IPI00008454.1 
DNAJB11 DnaJ homolog 
subfamily B member 11 
precurs 
DNAJB
11 
R.FQMTQEVVC
DEC*PNVK.L 0.94 0 0.71 0.825 
IPI00644290.1 
NDRG3 NDRG family 
member 3 
ENSG00000101079 
IPI0021 
NDRG
3 
R.FALNHPELVE
GLVLINVDPC*A
K.G 
0 0.81 0 0.81 
IPI00029485.2 
DCTN1 Isoform p150 of 
Dynactin subunit 1 
ENSG00000 
DCTN1 K.VTFSC*AAGFGQR.H 1 0 0.61 0.805 
IPI00456664.1 NIT1 Isoform 4 of Nitrilase homolog 1 ENSG00000158 NIT1 
K.IGLAVC*YDM
R.F 1.02 0.67 0.86 0.805 
IPI00003565.1 
PSMD10 26S proteasome 
non-ATPase regulatory 
subuni 
PSMD1
0 
K.GAQVNAVNQ
NGC*TPLHYAA
SK.N 
0 0 0.8 0.8 
IPI00026781.2 
FASN Fatty acid synthase 
ENSG00000169710 
IPI000267 
FASN K.AFDTAGNGYC*R.S 0 0 0.79 0.79 
IPI00183626.8 PTBP1 polypyrimidine tract-binding protein 1 isofo PTBP1 
K.LSLDGQNIYN
AC*CTLR.I 0 0 0.78 0.78 
IPI00010244.4 MRPS11 Isoform 1 of 28S ribosomal protein S11, mit 
MRPS1
1 
K.ASHNNTQIQV
VSASNEPLAFAS
C*GTEGFR.N 
0 0 0.77 0.77 
IPI00002214.1 
KPNA2 Importin subunit 
alpha-2 
ENSG00000182481 IPI 
KPNA2 
K.YGAVDPLLA
LLAVPDMSSLA
C*GYLR.N 
0 0.77 0 0.77 
IPI00216008.4 
G6PD Isoform Long of 
Glucose-6-phosphate 1-
dehydro 
G6PD R.TQVC*GILR.E 0.75 0 0.75 0.75 
IPI00514983.3 HSPH1 Isoform Alpha of Heat shock protein 105 kDa HSPH1 
K.LMSSNSTDLP
LNIEC*FMNDK
DVSGK.M 
0 0 0.75 0.75 
IPI00002824.7 
CSRP2 Cysteine and 
glycine-rich protein 2 
ENSG0000 
CSRP2 R.C*CFLCMVCR.K 0 0.77 0.68 0.7475 
IPI00853009.1 
CUGBP1 Isoform 4 of 
CUG-BP- and ETR-3-like 
factor 
CUGB
P1 
R.GC*AFVTFTT
R.A 0 0 0.74 0.74 
IPI00641181.5 
MARCKSL1 MARCKS-
related protein 
ENSG00000175130 IP 
MARC
KSL1 
K.EGGGDSSASS
PTEEEQEQGEIG
AC*SDEGTAQE
GK.A 
0 0 0.74 0.74 
IPI00852960.1 USP22 Ubiquitin carboxyl-terminal hydrolase 22 ENS USP22 
K.ITSNC*TIGLR.
G 0.68 0 0.78 0.73 
IPI00006504.3 EIF2B3 Isoform 1 of Translation initiation factor EIF2B3 
K.EANTLNLAPY
DAC*WNACR.G 0.73 0 0 0.73 
IPI00018140.3 
SYNCRIP Isoform 1 of 
Heterogeneous nuclear 
ribonuc 
SYNC
RIP 
K.SAFLC*GVMK
.T 0.72 0 0.73 0.725 
IPI00010158.3 CHRAC1 Chromatin accessibility complex 
CHRA
C1 
K.ATELFVQC*L
ATYSYR.H 0 0 0.72 0.72 
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protein 1 E 
IPI00018206.3 
GOT2 Aspartate 
aminotransferase, 
mitochondrial pre 
GOT2 K.EYLPIGGLAEFC*K.A 0 0 0.71 0.71 
IPI00419575.6 
C7orf20 Protein of 
unknown function DUF410 
family 
C7orf2
0 
K.EQNYC*ESR.
Y 0 0 0.7 0.7 
IPI00033494.3 
MRLC2 Myosin regulatory 
light chain 
ENSG0000011868 
MRLC
2 
R.NAFAC*FDEE
ATGTIQEDYLR.
E 
0.62 0 0.78 0.7 
IPI00013723.3 PIN1 Peptidyl-prolyl cis-trans isomerase NIMA-inte PIN1 
K.IKSGEEDFESL
ASQFSDC*SSAK
.A 
0.9 0.47 0.95 0.6975 
IPI00306159.7 MECR Trans-2-enoyl-CoA reductase, mitochondrial pr MECR 
R.LALNC*VGGK
.S 0.69 0 0.7 0.695 
IPI00442165.1 ZNF346 Isoform 2 of Zinc finger protein 346 ENSG00 
ZNF34
6 
K.NQC*LFTNTQ
CK.V 0.94 0 0.44 0.69 
IPI00419237.3 
LAP3 Isoform 1 of Cytosol 
aminopeptidase 
ENSG00000 
LAP3 R.LILADALC*YAHTFNPK.V 0.69 0 0 0.69 
IPI00152432.2 GPT2 Isoform 1 of Alanine aminotransferase 2 ENSG0 GPT2 
K.LLEETGIC*V
VPGSGFGQR.E 0.71 0 0.66 0.685 
IPI00788925.1 
BCAT2 Branched chain 
aminotransferase 2, 
mitochond 
BCAT2 R.EVFGSGTAC*QVCPVHR.I 0 0 0.68 0.68 
IPI00011107.2 
IDH2 Isocitrate 
dehydrogenase [NADP], 
mitochondria 
IDH2 K.DLAGC*IHGLSNVK.L 0.67 0 0 0.67 
IPI00005780.3 OGT Isoform 3 of UDP-N-acetylglucosamine--peptide OGT 
K.VMAEANHFI
DLSQIPC*NGK.
A 
0 0 0.62 0.62 
IPI00177856.8 
C14orf172 Uncharacterized 
protein C14orf172 
ENSG00 
C14orf
172 
R.FCSFSPC*IEQ
VQR.T 0.65 0 0.54 0.595 
IPI00302927.6 
CCT4 T-complex protein 1 
subunit delta 
ENSG0000011 
CCT4 K.ITGC*ASPGK.T 0.57 0 0 0.57 
IPI00022239.7 
METAP1 Methionine 
aminopeptidase 1 
ENSG00000164024 
META
P1 
R.VCETDGC*SS
EAK.L 0.54 0 0.58 0.56 
IPI00448095.3 
DCXR L-xylulose 
reductase 
ENSG00000169738 
IPI00448 
DCXR R.GVPGAIVNVSSQC*SQR.A 0.46 0.51 0.47 0.4875 
IPI00029557.3 
GRPEL1 GrpE protein 
homolog 1, mitochondrial 
precu 
GRPEL
1 
K.ATQC*VPKEE
IKDDNPHLK.N 0 0.34 0 0.34 
IPI00024013.1 
_ Putative ubiquitin-
conjugating enzyme E2 D3-
like 
_ 
K.VLLSIC*SLLC
DPNPDDPLVPEI
AR.I 
0 0.17 0.23 0.185 
IPI00216694.3 
PLS3 plastin 3 
ENSG00000102024 
IPI00848312 IPI0021 
PLS3 K.VDLNSNGFIC*DYELHELFK.E 0.12 0 0.09 0.105 
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Appendix III 
Protein gels 
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Figure 2A-1. Apoptotic, NJP2-treated, HeLa lysates were subjected to either click 
chemistry or PS-Rh labeling, followed by in-gel fluorescence analysis.  
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Figure 3A-1. Zn2+-affinity gels. HeLa lysates were treated with increasing concentrations 
of Zn2+, followed by NJP14 and underwent in-gel fluorescence analysis. 
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Figure 4A-1. Competitive in-gel fluorescence platform of PDI C53A and C397A 
administered RB-11-ca.  
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Figure 4A-2. Competitive in-gel fluorescence platform of PDI C53A and C397A 
administered 16F16.  
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Figure 4A-3. Competitive in-gel fluorescence platform of PDI C53A and C397A 
administered NJP15.  
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Figure 4A-4. Competitive in-gel fluorescence platform of PDI C53A and C397A 
administered SMC-9.  
